<SEC-DOCUMENT>0001193125-18-022393.txt : 20180129
<SEC-HEADER>0001193125-18-022393.hdr.sgml : 20180129
<ACCEPTANCE-DATETIME>20180129061306
ACCESSION NUMBER:		0001193125-18-022393
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20180129
DATE AS OF CHANGE:		20180129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			resTORbio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222373
		FILM NUMBER:		18553421

	BUSINESS ADDRESS:	
		STREET 1:		501 BOYLSTON STREET
		STREET 2:		SUITE 6102
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		501 BOYLSTON STREET
		STREET 2:		SUITE 6102
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d475892d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424(b)(4)<BR>Registration No. 333-22237 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PROSPECTUS </U></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>5,666,667 Shares
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g92q50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This is resTORbio,
Inc.&#146;s initial public offering. We are selling&nbsp;5,666,667&nbsp;shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The public offering price for our
common stock is $15.00 per share. Currently, no public market exists for the shares. Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol &#147;TORC.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>We are an &#147;emerging growth company&#148; under federal securities laws and are subject to reduced public company disclosure standards.
See &#147;Summary&#151;Implications of Being an Emerging Growth Company.&#148; </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman"><B>Investing in the common stock involves risks that
are described in the &#147;<A HREF="#toc475892_2">Risk&nbsp;Factors</A>&#148; section beginning on page 11 of this prospectus. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:34.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:18.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$85,000,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5,950,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$13.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$79,050,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We refer you to &#147;Underwriting&#148; beginning on page&nbsp;172 of this prospectus for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders, including certain affiliates of our directors, have indicated an interest in purchasing an aggregate of
up to $35&nbsp;million of shares of our common stock in this offering at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more,
less or no shares in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, less or no shares in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters may also exercise their option to purchase up to an additional&nbsp;850,000 shares from us, at the public offering price,
less underwriting discounts and commissions, for 30 days after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares will be ready for delivery on or about&nbsp;January 30, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top"><B>BofA&nbsp;Merrill&nbsp;Lynch</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Leerink Partners</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:18pt; font-family:Times New Roman" ALIGN="right"><B>Evercore ISI</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Wedbush PacGrow </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this
prospectus is&nbsp;January 25, 2018. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_1">Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_3">Special Note Regarding Forward-Looking Statements and Industry
Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_8">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of
 Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_12">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_13">Transactions with Related Persons</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_15">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_16">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_17">Material U.S. Federal Income and Estate Tax Considerations for <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_18">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_21">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc475892_22">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide you with any information or to make any
representations other than those contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. Neither we nor the underwriters take
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales
are permitted. The information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock. Our business,
financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For investors outside the United States: We
have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside
the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_1"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights, and is qualified in its entirety by, the more detailed information and financial statements included elsewhere in
this prospectus. This summary does not contain all of the information that may be important to you. You should read and carefully consider the entire prospectus, especially our financial statements and the notes thereto appearing at the end of this
prospectus and the &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus, before deciding to invest in our common stock. Except as otherwise
indicated herein or as the context otherwise requires, references in this prospectus to &#147;resTORbio,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to resTORbio,&nbsp;Inc. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Our lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled
trial, the potential to treat multiple diseases of aging for which there are no approved therapies. The decline in immune function that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases, including
respiratory tract infections, or RTIs, that significantly contribute to morbidity and mortality in the elderly. Our approach focuses on the mechanistic target of rapamycin, or mTOR, pathway, an evolutionarily conserved pathway that regulates aging,
and specifically on selective inhibition of the target of rapamycin complex 1, or TORC1. Our initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR
inhibitors such as everolimus&#151;as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunotherapy program designed to improve immune function and thereby reduce the incidence of RTIs in the elderly
regardless of the causative pathogen. We licensed the worldwide rights to our TORC1 program, including RTB101 alone or in combination with everolimus or other mTOR inhibitors, from Novartis International Pharmaceutical Ltd., or Novartis, in March
2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our TORC1 immunotherapy approach is supported by a randomized, placebo-controlled Phase 2a clinical trial in 264 elderly subjects
that provided statistically significant and clinically meaningful results. This trial demonstrated that treatment with RTB101 alone and in combination with everolimus can enhance the ability of the aging immune system to fight infectious pathogens
and consequently reduce the incidence of all infections, including RTIs in elderly subjects. Six weeks of treatment with RTB101 alone and in combination with everolimus met a prespecified endpoint of reducing the incidence of infections by 33% and
38%, respectively, during a period of one year following initiation of therapy. We are evaluating RTB101 alone and in combination with everolimus in a Phase 2b clinical trial for the reduction in the incidence of RTIs in the elderly and expect to
report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in the second half of 2018. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Product Pipeline </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes key information about our product candidates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g16r29.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Other infections include those that the elderly are at increased risk of contracting, such as urinary tract infections. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">For heart failure with preserved ejection fraction, autophagy-related neurodegenerative diseases and certain other infections, we may be required to file an investigational new drug application, or IND, prior to
initiating Phase&nbsp;2 clinical trials. We expect to have the ability to initiate these Phase 2 clinical trials without the need to conduct prior Phase 1 clinical trials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also have a follow-on TORC1 inhibitor program at discovery stage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect market exclusivity for RTB101 alone and in combination with everolimus until at least 2031 in the United States, 2032 in major
European markets, and 2030 in Japan, and additional pending patent applications may prolong the exclusivity of these product candidates up to 2036. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>TORC1 Inhibition for Improving Immune Function in the Elderly </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Recent scientific findings, including those published in the scientific journals Cell, Nature and Science suggest that aging and aging-related
conditions, such as immunosenescence, are attributable not only to random cellular wear and tear, but also to specific intra-cellular signaling pathways, including the mTOR pathway. mTOR is a protein kinase that signals via two multiprotein
complexes, known as TORC1 and TORC2. TORC1 inhibition has been observed to prolong lifespan, enhance immune function, ameliorate heart failure, enhance memory and mobility and delay the onset of aging-related diseases in multiple animal studies.
Specifically with respect to enhanced immune function, TORC1 inhibition was observed in preclinical studies to rejuvenate blood, or hematopoietic, stem cell function, increase infection-fighting white blood cell production and enhance
antibody-mediated, or adaptive, immunity. On the other hand, TORC2 inhibition has been observed to decrease lifespan in preclinical studies and cause unwanted side effects of hyperlipidemia and hyperglycemia in certain animals and humans. Therefore,
based on these observations and data from the Phase 2a clinical trial, we believe our TORC1 program is well-suited to improve immune function and counteract immunosenescence in the elderly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>High Unmet Need for Addressing Respiratory Tract Infections in the Elderly </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The reduced ability of elderly patients to effectively detect and fight infections is most commonly manifested in their susceptibility to RTIs
and the negative effects such infections have on their overall health. According to the U.S. Census Bureau, RTIs are the fifth leading cause of death in people age 85 and over and the </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
seventh leading cause of death in people age 65 and over, and result in high healthcare burdens and costs for the elderly population and the healthcare system. The majority of RTIs are caused by
viruses for which there are no approved therapies. Despite this, antibiotics, which are ineffective against viruses, are often prescribed indiscriminately to treat RTIs, which may cause side effects related to antibiotic use and contribute to the
growing global problem of antibiotic resistance. As the elderly represent the fastest growing population in the world as a whole, we believe there is significant unmet medical need for innovative therapeutic options for reducing the incidence of
RTIs by enhancing the function of the aging immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our TORC1 Program for Addressing Respiratory Tract Infections in the Elderly
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe our approach to addressing RTIs in the elderly possesses several clinical and commercial advantages. Our TORC1 program
offers an immunotherapy approach that has the potential to address a broad range of viral, and potentially bacterial, pathogens. Statistically significant and clinically meaningful reductions in RTI incidence were observed in the Phase 2a clinical
trial that evaluated RTB101 alone and in combination with everolimus. We believe the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">risk-to-benefit</FONT></FONT> ratio of our program is well-suited to the elderly due to the
following observations: our oral product candidates were well-tolerated in elderly subjects and none of the participants in the active treatment arms experienced a serious adverse event that was related to the study drug, and the doses being
investigated in our ongoing Phase 2b clinical trial are 60 to 240 times lower than maximum tolerated doses established in prior clinical trials for other indications. Based on communications, including those during a high-level policy meeting, with
the U.S. Food and Drug Administration, or FDA, to date, we believe a reduction in the incidence of RTIs has the potential to be a clinically relevant endpoint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are conducting a randomized, double-blinded, placebo-controlled Phase 2b clinical trial to assess the safety, tolerability and efficacy of
16 weeks of treatment with RTB101 alone or in combination with everolimus as compared to placebo in elderly patients without unstable medical conditions but who are at increased risk of <FONT STYLE="white-space:nowrap">RTI-related</FONT> morbidity
or mortality. Elderly patients at increased risk of <FONT STYLE="white-space:nowrap">RTI-associated</FONT> morbidity and mortality are defined as subjects who are 85 years of age or older or subjects 65 years of age or older with asthma, chronic
obstructive pulmonary disease, chronic bronchitis, Type 2 diabetes mellitus, congestive heart failure, an emergency room visit or hospitalization for an RTI within the past 12 months, or who are current smokers. We are conducting the trial in two
parts across two hemispheres. The first part was conducted during the winter cold and flu season in the southern hemisphere. Following an interim analysis that we conducted in October 2017, we commenced the second part during the winter cold and flu
season in the United States in the fourth quarter of 2017. We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in the second half of 2018. The primary endpoint of the trial is to assess the potential of RTB101
alone or in combination with everolimus to decrease the percentage of subjects with RTIs compared to placebo during the <FONT STYLE="white-space:nowrap">16-week</FONT> administration period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the results from the ongoing Phase 2b clinical trial are positive, we intend to conduct two Phase 3 pivotal clinical trials across two
hemispheres. The Phase 3 clinical program is expected to start in the southern hemisphere in the first half of 2019 at the beginning of the winter cold and flu season and run through the second quarter of 2020. If our Phase 3 clinical trials are
successful, we anticipate filing a New Drug Application, or NDA, with the FDA in 2020, and a Marketing Authorization Application, or MAA, with the European Medicines Agency, or EMA, in 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Potential Indications for Our TORC1 Program </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may evaluate RTB101 alone or in combination with everolimus or other drugs for the treatment of additional indications, such as heart
failure with preserved ejection fraction, urinary tract infections, Huntington&#146;s disease and Parkinson&#146;s disease. We plan to initiate at least one Phase&nbsp;2 proof of concept study in 2018. We expect to select indications based on strong
scientific rationale, preclinical or clinical data, unmet medical need and other relevant considerations. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Company Management and Investors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We were founded by Chen Schor, who serves as our President and Chief Executive Officer, Joan Mannick, M.D., who serves as our Chief Medical
Officer, and PureTech Health LLC, or PureTech Health, an affiliate of PureTech Health plc, an advanced clinical-stage biopharma company. Dr.&nbsp;Mannick led the TORC1 clinical program at Novartis Institutes for Biomedical Research, Inc., or NIBR,
prior to our <FONT STYLE="white-space:nowrap">in-licensing</FONT> of the program. PureTech Health currently provides us with certain business services pursuant to a business services, personnel and information management agreement. In addition, we
currently share administrative resources with PureTech Health, including legal, accounting and human resources support, computer and telecommunications systems and other office infrastructure pursuant to the agreement. PureTech Health has also
assisted with our market research efforts, including conducting a market survey in the United States prior to our initiation of our ongoing Phase 2b clinical trial of RTB101 alone and in combination with everolimus. We were a subsidiary of PureTech
Health until the closing of our Series B financing in November 2017. Based on the number of shares outstanding as of December 31, 2017 and after giving effect to the sale of 5,666,667&nbsp;shares in this offering (without giving effect to any
potential purchases by PureTech Health of shares of our common stock in this offering), PureTech Health will beneficially own shares representing approximately 35.2% of our outstanding common stock. In addition, PureTech Health has appointed two
directors to our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our management team includes veterans in drug development and discovery, with executive experience
in leading global pharmaceutical companies. We are supported by investors that include both private equity venture capital funds and public healthcare investment funds. Our investors include OrbiMed Advisors, Fidelity Management &amp; Research
Company, Rock Springs Capital, Quan Capital and Nest Bio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our goal is to be a leading biopharmaceutical company focused on treating aging-related diseases. We strive to maintain a leadership position
in the TORC1 inhibitor class of pharmaceutical products. The key elements of our strategy to achieve this goal include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Rapidly advance our TORC1 program as immunotherapy for reducing the incidence of RTIs in elderly subjects; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Develop our TORC1 program for additional indications; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Commercialize our product candidates in the United States and potentially collaborate with others globally to maximize their commercial value; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Maintain and grow a robust intellectual property portfolio in the field of TORC1 inhibition for aging-related diseases; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates that enhance our global leadership position. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus
summary. These risks include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a limited operating history, have incurred significant operating losses since inception, expect to incur significant and increasing losses for the foreseeable future, will need substantial additional funding and
may never achieve or maintain profitability; investors may lose their entire investment; </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our business has no history of commercialization and depends virtually entirely upon the success of RTB101 alone or in combination with everolimus, which is still under clinical development. If we are unable to obtain
regulatory approval for or successfully commercialize RTB101, our business would be materially harmed. Even if we receive regulatory approval to market product candidates, the market may not be receptive to our product candidates upon their
commercial introduction, which will prevent us from becoming profitable; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant
negative consequences following regulatory approval, if any; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may be subject to additional risks because we are administering RTB101 in combination with other mTOR inhibitors, such as everolimus; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we fail to develop RTB101 alone or in combination with an mTOR inhibitor for additional therapies or develop other product candidates, we may be unable to grow our business; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Use of third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our product candidates or products, or necessary quantities at an acceptable cost;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our commercial success depends on our ability to protect our intellectual property and proprietary technology; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We depend heavily on our executive officers and principal consultants and the loss of their services could materially harm our business; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Concentration of ownership of our common stock may prevent new investors in this offering from influencing significant corporate decisions. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Corporate Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the State of Delaware on July&nbsp;5, 2016 under the name resTORbio,&nbsp;Inc. Our executive offices are located at 500 Boylston Street, 12th floor, Boston, Massachusetts 02116, and our telephone number is (617) <FONT
STYLE="white-space:nowrap">482-2333.</FONT> Our website address is <I>www.restorbio.com</I>. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this
prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In this prospectus, unless otherwise stated or the context otherwise requires,
references to &#147;resTORbio,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references refer to resTORbio, Inc. resTORbio and other trademarks or service marks of resTORbio appearing in this prospectus
are the property of resTORbio. The other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to
without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their
rights thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion of revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
We may remain an emerging growth company for up to five years, or until such earlier time as we have more than $1.07&nbsp;billion in annual revenue, the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is more than $700.0&nbsp;million or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. For so long as we remain an emerging
growth company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">only two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; disclosure; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure about our executive compensation arrangements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation or golden parachute arrangements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exemption from new or revised financial accounting standards until they would apply to private companies and from compliance with any new requirements adopted by the Public Company Accounting Oversight Board
requiring mandatory audit firm rotation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In particular, in this prospectus, we have not included all of the executive
compensation-related information that would be required if we were not an emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.
We are considering whether to &#147;opt out&#148; of the exemption for the delayed adoption of certain accounting standards and thereby be subject to the same new or revised accounting standards as other public companies that are not emerging growth
companies. If we do elect to &#147;opt out&#148; of this exemption, such election is irrevocable. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>5,666,667&nbsp;shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately following this offering </P></TD>
<TD>27,196,315&nbsp;shares (28,046,315&nbsp;shares if the underwriters exercise their option to purchase additional shares of common stock in full) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>The underwriters have the option to purchase an additional 850,000&nbsp;shares of common stock. The underwriters may exercise this option at any time within 30 days from the date of this prospectus. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $77.6&nbsp;million, or approximately $89.4&nbsp;million if
the underwriters exercise their option to purchase additional shares from us in full. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the development of RTB101, alone and in combination with everolimus, for RTIs and other indications,
and our TORC1 follow-on candidate and other pipeline candidates, and the remainder, if any, for working capital and general corporate purposes. See the &#147;Use of Proceeds&#148; section in this prospectus for a more complete description of the
intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;TORC&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders, including certain affiliates of our directors, have indicated an
interest in purchasing an aggregate of up to $35&nbsp;million of shares of our common stock in this offering at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the
underwriters may determine to sell more, less or no shares in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, less or no shares in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on 5,659,089&nbsp;shares of our common stock
outstanding as of January 16, 2018 and 15,870,559 additional shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering excludes: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">306,988&nbsp;shares of our common stock issuable upon the exercise of stock options outstanding as of January&nbsp;16,&nbsp;2018, at a weighted average exercise price of $7.63 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,559,021 additional shares of our common stock available for future issuance under our 2017 stock incentive plan, which will no longer be available for future issuance following this offering; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,475,290&nbsp;additional shares of our common stock that will become available for future issuance under our
2018 stock incentive plan and our 2018 employee stock purchase plan, each effective </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
upon the effectiveness of the registration statement of which this prospectus forms a part, and from which we intend to grant options to purchase an aggregate of 331,310 shares of common stock to
certain of our officers upon the pricing of this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information in this
prospectus assumes or gives effect to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise of the outstanding options described above; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no exercise by the underwriters of their option to purchase up to&nbsp;850,000 additional shares of our common stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 15,870,559&nbsp;shares of our common stock upon the closing of this offering; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1.2804</FONT></FONT> reverse split of our common stock effected on&nbsp;January 12, 2018; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amendment and restatement of our certificate of incorporation and the amendment and restatement of our bylaws upon the closing of this offering. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following tables summarize our financial data as of the dates and for the periods indicated. The statements of operations data for the
period from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and the nine months ended September&nbsp;30, 2017 and the balance sheet data as of September&nbsp;30, 2017 have been derived from our audited financial statements included
elsewhere in this prospectus. The statement of operations data for the period from July&nbsp;5, 2016 (inception) through September&nbsp;30, 2016 have been derived from our unaudited financial statements included elsewhere in this prospectus and have
been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal, recurring adjustments, necessary for a fair statement of the financial
information in those statements. Our historical results from any prior period are not necessarily indicative of results to be expected in any future period, and our interim period results are not necessarily indicative of results to be expected for
a full year or any other interim period. The summary financial data below should be read in conjunction with the sections entitled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; and our financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>July 5, 2016</B><br><B>(inception)</B><br><B>through</B><br><B>December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>July 5, 2016</B><br><B>(inception)</B><br><B>through</B><br><B>September&nbsp;30,</B><br><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine Months<BR>Ended<BR>September&nbsp;30,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares used in computing net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,978,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,919,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,839,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares used in computing pro forma net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,230,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Notes 2 and 12 in the notes to our financial statements included elsewhere in this prospectus for an explanation of the calculation of our basic and diluted net loss per share, the weighted-average common shares
used in computing basic and diluted net loss per share, basic and diluted pro forma net loss per share and the weighted-average common shares used in computing basic and diluted pro forma net loss per share. The information presented in this table
does not give effect to the sale and issuance of our Series&nbsp;A preferred stock in October 2017 and Series&nbsp;B preferred stock in November 2017. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of</B><br><B>September 30, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro<BR>Forma<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro<BR>Forma As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Pro forma amounts give effect to (i)&nbsp;the sale and issuance of 7,763,975 shares of our Series A preferred stock in October 2017 for aggregate net proceeds of $15.0&nbsp;million, (ii) the sale and issuance of
4,792,716 shares of our Series B preferred stock in November 2017 for aggregate net proceeds of $39.9&nbsp;million and (iii)&nbsp;the automatic conversion of all of our outstanding shares of preferred stock into an aggregate of 15,870,559 shares of
common stock upon the closing of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Pro forma as adjusted amounts reflect pro forma adjustments described in footnote (2)&nbsp;as well as the sale of 5,666,667&nbsp;shares of our common stock in this offering at the initial public offering price of $15.00
per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together
with all other information in this prospectus, including our financial statements and related notes and &#147;Management&#146;s Discussion and Analysis of Results of Operations and Financial Condition,&#148; before investing in our common stock. Any
of the risk factors we describe below could adversely affect our business, financial condition or results of operations. The market price of our common stock could decline if one or more of these risks or uncertainties actually occur, causing you to
lose all or part of your investment in our common stock. The risks and uncertainties we describe below are not the only ones we face. Additional risks and uncertainties that we currently do not know about or that we currently believe to be
immaterial may also impair our business. Certain statements below are forward-looking statements. See &#147;Special Note Regarding Forward-Looking Statements and Industry Data&#148; in this prospectus. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future, and
we may never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a limited operating
history. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an
acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research
and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception in July 2016. We have devoted substantially all of our financial resources and
efforts to research and development, including preclinical studies and our clinical trials. Our financial condition and operating results, including net losses, may fluctuate significantly from quarter to quarter and year to year. Accordingly, you
should not rely upon the results of any quarterly or annual periods as indications of future operating performance. Additionally, net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#146;
equity and working capital. For the period from July&nbsp;5, 2016 (inception) to December&nbsp;31, 2016, we reported a net loss of $1,000. For the nine months ended September&nbsp;30, 2017, we reported a net loss of $10.7&nbsp;million. As of
September&nbsp;30, 2017, we had an accumulated deficit of $10.7&nbsp;million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and
seek regulatory approvals for, RTB101, alone or in combination with everolimus, and other product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We anticipate that our
expenses will increase substantially if and as we: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to develop and conduct clinical trials for our lead product candidate, RTB101, alone and in combination with everolimus; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate and continue research, preclinical and clinical development efforts for any current or future product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek to identify additional product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek regulatory approvals for RTB101, alone or in combination with everolimus, or any other product candidates that successfully complete clinical development, if any; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the future to commercialize various products for which we may obtain regulatory approval, if any;
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the manufacture of larger quantities of RTB101 alone or in fixed dose combination with everolimus for clinical development and, potentially, commercialization; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire and retain additional personnel, such as clinical, quality control, scientific and commercial personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and help us comply with our obligations as a public company; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add equipment and physical infrastructure to support our research and development; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue
unless and until we are, or any future collaborator is, able to obtain regulatory approval for, and successfully commercialize, RTB101, alone or in combination with everolimus, or any other product candidates. Successful commercialization will
require achievement of key milestones, including demonstrating safety and efficacy in clinical trials, obtaining regulatory, including marketing, approval for these product candidates, manufacturing, marketing and selling those products for which
we, or any of our future collaborators, may obtain regulatory approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks
associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues, the extent of any further losses or if or when we might achieve profitability. We and any future collaborators may never succeed
in these activities and, even if we do, or any future collaborators do, we may never generate revenues that are large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase
profitability on a quarterly or annual basis. Additionally, our expenses could increase if we are required by the U.S. Food and Drug Administration, or FDA, or any comparable foreign regulatory authority to perform studies in addition to those
currently expected, or if there are any delays in completing our clinical trials or the development of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
failure to become and remain profitable would depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. If we continue to suffer
losses as we have in the past, investors may not receive any return on their investment and may lose their entire investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our company has a
limited operating history and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We were formed in July 2016 and commenced research and development operations in March 2017. Our operations to date have been limited to
organizing, staffing and financing our company, raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> our technology and conducting research and development activities for our product candidates. We have not yet demonstrated an
ability to obtain regulatory approvals, manufacture a commercial-scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Accordingly, you
should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in clinical development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make
about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business
objectives. We will eventually need to transition from a company with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our
product discovery and development programs or commercialization efforts. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our operations have required substantial amounts of cash
since inception. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. For the foreseeable future, we expect to
continue to rely on additional financing to achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">From July&nbsp;5, 2016 (inception) to December&nbsp;31,
2016, we did not use any cash for our operating activities, and in the nine months ended September&nbsp;30, 2017, we used $6.0&nbsp;million in net cash for our operating activities, substantially all of which related to research and development
activities. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we initiate new clinical trials of, initiate new research and preclinical development efforts for and seek regulatory approval
for, RTB101, alone or in combination with everolimus, or any product candidates that we develop or acquire, if any. In addition, if we obtain regulatory approval for RTB101, alone or in combination with everolimus, or any other product candidates,
we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Some of these expenses may be incurred in advance of regulatory approval, and could be substantial. Furthermore, following
the completion of this offering, we expect to incur significant additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we
are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering, together with our existing cash, to fund the development of RTB101, alone and in
combination with everolimus, for RTIs and other indications, and of our TORC1 follow-on candidate and other pipeline candidates, and the remainder, if any, for working capital and general corporate purposes. We will be required to expend significant
funds in order to advance the development of RTB101 alone and in combination with everolimus, as well as other product candidates we may seek to develop or acquire. In addition, while we may seek one or more collaborators for future development of
RTB101 alone and in combination with everolimus for one or more additional indications beyond immunosenescence or in geographies outside of the United States, Europe and key territories, we may not be able to enter into a collaboration for RTB101 or
any other product candidates for such indications or in such geographies on suitable terms, on a timely basis or at all. In any event, the net proceeds of this offering and our existing cash will not be sufficient to fund all of the efforts that we
plan to undertake or to fund the completion of development of RTB101 alone or in combination with everolimus, including activities related to the development of RTB101, alone and in combination with everolimus, for RTIs and other indications, and
the development of our TORC1 follow-on candidate and other pipeline candidates. Accordingly, we will be required to obtain substantial additional funding through public or private equity offerings, debt financings, collaborations and licensing
arrangements or other sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no
committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our
product candidates or other research and development initiatives. Any of our current or future license agreements may also be terminated if we are unable to meet the payment or other obligations under the agreements. We could be required to seek
collaborators for product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to product candidates in
markets where we otherwise would seek to pursue development or commercialization ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds from this offering, together with our existing cash and
cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements through 2020, including the completion of our ongoing Phase 2b clinical trial of RTB101 alone or in combination with everolimus, the completion of a
subsequent pivotal Phase 3 clinical program, assuming a successful outcome in our Phase 2b clinical trial of RTB101 alone or in combination with everolimus, and the filing of an NDA with the FDA, assuming a successful outcome in our Phase 3 clinical
program. Our estimate may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly
faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements, both short- and long-term, will depend on many factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, RTB101, alone or in combination with everolimus, and any future product candidates;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to enter into, and the terms and timing of, any collaborations, licensing or other arrangements on favorable terms, if at all; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of future product candidates that we pursue and their development requirements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and costs of seeking regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if approved, the costs of commercialization activities for RTB101, alone or in combination with everolimus, or any other product candidate that receives regulatory approval to the extent such costs are not the
responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to receipt of regulatory approval, revenue, if any, received from commercial sales of RTB101, alone or in combination with everolimus, or any future product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other products, product candidates or technologies; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our headcount growth and associated costs as we expand our research and development and establish a commercial infrastructure; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property
rights, including milestone and royalty payments and patent prosecution fees that we are obligated to pay pursuant to our license agreement; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights including enforcing and defending intellectual property related claims; and
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of operating as a public company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our
stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase in connection with our planned operations. Unless and until we can generate a substantial amount of revenue
from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. In addition, we may
seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of common stock, convertible
securities or other equity securities, your ownership interest may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a common
stockholder. In addition, debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making
capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our
management and may divert a disproportionate amount of their attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our management&#146;s ability to
oversee the development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations or marketing, distribution or
licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional
funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market
ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain
limitations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017, we had federal and state net operating loss carryforwards of $7.5&nbsp;million and
$7.4&nbsp;million, respectively, which begin to expire in various amounts in 2036. As of September&nbsp;30, 2017, we also had federal research and development tax credit carryforwards of $0.1&nbsp;million, which begin to expire in 2037. These net
operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a
corporation that undergoes an &#147;ownership change&#148; is subject to limitations on its ability to utilize its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating losses or tax credits, or NOLs or credits, to offset future taxable
income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#146;s stock increases its ownership by more
than 50 percentage points over its lowest ownership percentage within a specified testing period. Our existing NOLs or credits may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change in connection
with or after this offering, our ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an
ownership change under Sections 382 and 383 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. If we determine that an ownership change has
occurred and our ability to use our historical NOLs or credits is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U. S. federal and state
taxable income. As described above under &#147;Risk Factors&#151;Risks Related to our Financial Position and Need for Additional Capital,&#148; we have incurred significant net losses since our inception and anticipate that we will continue to incur
significant losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOL or credit carryforwards that are subject to limitation by Sections
382 and 383 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The U.S. government has recently enacted comprehensive tax legislation that includes significant changes to the taxation of business entities.
These changes include, among others, a permanent reduction to the corporate income tax rate. Notwithstanding the reduction in the corporate income tax rate, the overall impact of this tax reform is uncertain, and our business and financial condition
could be adversely affected. This prospectus does not discuss any such tax legislation or the manner in which it might affect purchasers of our common stock. We urge our stockholders to consult with their legal and tax advisors with respect to any
such legislation and the potential tax consequences of investing in our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery, Development and Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business depends virtually entirely upon the success of RTB101 alone or in combination with everolimus. If we are unable to obtain regulatory
approval for or successfully commercialize RTB101, alone or in combination with everolimus, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale and are investing the majority of our efforts and financial resources in the development of
our lead product candidate, RTB101, either alone or in combination with everolimus. Successful continued development and ultimate regulatory approval of RTB101, alone or in combination with everolimus, for the treatment of aging-related diseases,
including our lead indication, reducing the incidence of respiratory tract infections, or RTIs, is critical to the future success of our business. We will need to raise sufficient funds for, and successfully enroll and complete, our clinical
development program for RTB101, alone or in combination with everolimus, to treat RTIs and possibly other aging-related diseases. The future regulatory and commercial success of this product candidate is subject to a number of risks, including the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not have sufficient financial and other resources to initiate or complete the necessary clinical trials for RTB101, alone or in combination with everolimus; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to obtain adequate evidence of clinical efficacy and safety for RTB101, alone or in combination with everolimus, or to obtain regulatory approval of RTB101, alone or in combination with everolimus,
for reducing the incidence of RTIs or other indications; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">even if RTB101 monotherapy succeeds in its clinical development and is approved for one or more targeted indications, there can be no assurance that the RTB101+everolimus combination therapy would be developed
successfully and approved, and vice versa; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to maintain an acceptable safety profile for RTB101 alone or in combination with everolimus, even if approved; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we do not know the degree to which RTB101 alone or in combination with everolimus will have market uptake as a therapy by patients, the medical community or third-party payors, among others, if approved;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in our clinical programs, we may experience variability in the response of subjects to treatment, the need to adjust clinical trial procedures and the need for additional clinical trial sites, which could delay our
clinical trial progress; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our clinical trials may not meet the level of statistical significance required by the FDA, the European Medicines Agency, or EMA, or comparable foreign regulatory bodies for regulatory approval for
reducing the incidence of RTIs or for other indications; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may have difficulty enrolling subjects in trials if, for instance, a current or future effective standard of care limits the desire of patients, physicians, or regulatory agencies to participate in or support
clinical trials, or if patients choose to participate in the trials of other sponsors&#146; product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patients in our clinical trials may die or suffer other adverse effects for reasons that may or may not be related to RTB101, which could delay or prevent further clinical development; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the requirements implemented by regulatory agencies may change at any time; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or foreign regulatory agencies may require efficacy endpoints for a future clinical trial for reducing the incidence of RTIs that differ from the endpoints of our current or future trials, which may require
us to conduct additional clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the mechanism of action of RTB101, alone or in combination with everolimus, is complex and we cannot guarantee the degree to which it will translate into a medical benefit in any indications; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitor products including generic products may be developed to reduce the incidence of RTIs that may have similar or better safety and efficacy or lower costs than RTB101 alone or in combination with everolimus;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which we may obtain regulatory approval; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our contract manufacturers may not be able to manufacture RTB101, everolimus, the fixed dose combination of RTB101 with everolimus or other future product candidates at the appropriate quality or sufficient
quantities to support further clinical development and/or commercialization; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our investigational drug products or manufacturing processes may be considered by regulatory authorities, such as the FDA or EMA, to be unsuitable for continued development and/or commercialization; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may observe unexpected toxicities in preclinical safety or efficacy animal studies that delay, limit or prevent further clinical development; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intellectual property may not be patentable, valid or enforceable; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to obtain, maintain, defend, protect or enforce our patents, our trade secrets, regulatory exclusivities and other intellectual property rights, both in the United States and internationally,
including those that we have licensed under our license agreement with Novartis. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of these risks are beyond our
control, including the risks related to clinical development, the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any future collaborator. If we are unable to
develop, receive regulatory approval for, or successfully commercialize RTB101 alone or in combination with everolimus, or if we experience delays as a result of any of these risks or otherwise, our business could be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, of the large number of drugs in development in the pharmaceutical industry, only a small percentage result in the submission of
an NDA to the FDA and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval for RTB101, alone or in combination with everolimus, any such approval may be subject to limitations on the indicated uses or
patient populations for which we may market the product. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, we cannot assure you that we will successfully develop or commercialize RTB101,
alone or in combination with everolimus, for RTIs or any other indications. If we or any of our future collaborators are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize RTB101, alone or in
combination with everolimus, for RTIs or any other indications, we may not be able to generate sufficient revenue to continue our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have
no experience as a company in obtaining regulatory approval for a drug. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a company, we have never obtained regulatory approval
for, or commercialized, a drug. It is possible that the FDA may refuse to accept any or all of our planned NDAs for substantive review or may conclude after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
review of our data that our application is insufficient to obtain regulatory approval for any current or future product candidates. If the FDA does not approve any of our planned NDAs, it may
require that we conduct additional costly clinical, nonclinical or manufacturing validation studies before it will reconsider our applications. Depending on the extent of these or any other <FONT STYLE="white-space:nowrap">FDA-required</FONT>
studies, approval of any NDA or other application that we submit may be significantly delayed, possibly for several years, or may require us to expend more resources than we have available. Any failure or delay in obtaining regulatory approvals
would prevent us from commercializing RTB101 alone or in combination with everolimus or any other product candidate, generating revenues and achieving and sustaining profitability. It is also possible that additional studies, if performed and
completed, may not be considered sufficient by the FDA to approve any NDA or other application that we submit. If any of these outcomes occur, we may be forced to abandon the development of our product candidates, which would materially adversely
affect our business and could potentially cause us to cease operations. We face similar risks for our applications in foreign jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
depend on the successful initiation and completion of clinical trials for RTB101 alone or in combination with everolimus. The positive clinical results, if any, obtained in prior or ongoing clinical trials may not be predictive of future results or
repeated in later-stage clinical trials. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval for the sale of RTB101, alone or in combination
with everolimus, or any other potential product candidate, we must conduct additional clinical trials to demonstrate safety and efficacy in humans. The regulatory requirements for demonstrating efficacy and safety for obtaining approval for reducing
the incidence of RTIs or other indications with RTB101 alone or in combination with everolimus may differ. We have not completed the clinical trials necessary to support an application for approval to market RTB101 alone or in combination with
everolimus. Successful completion of such clinical trials is a prerequisite to submitting an NDA to the FDA and, consequently, the ultimate approval and commercial marketing of RTB101 alone or in combination with everolimus or any other potential
product candidate. A failure of one or more clinical trials can occur at any stage of testing. We need to complete our ongoing Phase 2b clinical trial of RTB101 alone and in combination with everolimus, and subsequently the requisite Phase 3
clinical trials prior to a submission for regulatory approval. We have conducted limited safety studies in humans to date and have only recently commenced our Phase 2b clinical program to assess the safety, tolerability and efficacy of RTB101, alone
or in combination with everolimus, in elderly patients. Additional toxicity and metabolism studies may be required by the FDA or other regulatory agencies. A number of companies in the pharmaceutical and biotechnology industries, including those
with greater resources and experience than us, have suffered significant setbacks in late stage clinical development, even after seeing promising results in earlier clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may experience a number of unforeseen events during, or as a result of, clinical trials for RTB101, alone or in combination with
everolimus, or any other potential product candidate that could adversely affect the costs, timing, or successful completion of our clinical trials, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or other comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators, and/or institutional review boards or other reviewing bodies may not authorize us or our investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific
trial site; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly
among different CROs and trial sites; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical trials of RTB101, alone or in combination with everolimus, or any other potential product candidate may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct
additional clinical trials or abandon product development programs; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of subjects or patients required for clinical trials of RTB101, alone or in combination with everolimus, or any other potential product candidate may be larger than we anticipate, enrollment in these clinical
trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical
trials at a higher rate than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us
in a timely manner, or at all; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might have to suspend or terminate clinical trials of RTB101, alone or in combination with everolimus, or any other potential product candidate for various reasons, including a finding that the subjects are being
exposed to unacceptable health risks; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may have to amend clinical trial protocol submitted to regulatory authorities or conduct additional studies to reflect changes in regulatory requirements or guidance, which we may be required to resubmit to an
Institutional Review Board, or IRB, and regulatory authorities for <FONT STYLE="white-space:nowrap">re-examination;</FONT> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators, institutional review boards or data monitoring committees may require or recommend that we or our investigators suspend or terminate clinical research for various reasons, including safety signals or
noncompliance with regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of clinical trials of RTB101, alone or in combination with everolimus, or any other potential product candidate may be greater than we anticipate; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators, institutional review boards or other reviewing bodies may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we enter into
agreement for clinical and commercial supplies, or the supply or quality of RTB101, everolimus or the fixed dose combination of RTB101 and everolimus or any other potential product candidate or other materials necessary to conduct clinical trials of
our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner rendering our clinical data insufficient for approval; and
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">RTB101, alone or in combination with everolimus, or any other potential product candidate may have undesirable side effects or other unexpected characteristics. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Regulators, institutional review boards of the institutions in which clinical trials are being conducted or data monitoring committees may
suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the
FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions
or lack of adequate funding to continue the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Negative or inconclusive results from our ongoing clinical trial of RTB101
alone and in combination with everolimus, or any other clinical trial or preclinical studies in animals that we conduct, could mandate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
repeated or additional clinical trials. We do not know whether any clinical trials that we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market
RTB101, alone or in combination with everolimus, or any other potential product candidate. If later stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for RTB101, alone or in combination with
everolimus, or any other potential product candidate may be adversely impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Clinical trials must be conducted in accordance with the
laws and regulations of the FDA, EMA and regulations and other applicable regulatory authorities&#146; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs at the medical institutions
where the clinical trials are conducted. In addition, clinical trials must be conducted with supplies of our product candidates produced under current good manufacturing practice, or cGMP, requirements and other regulations. Furthermore, we rely on
CROs, and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators
and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the
study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both. In addition, clinical trials that are conducted in countries
outside the United States and EU may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> and <FONT
STYLE="white-space:nowrap">non-EU</FONT> CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA or the EMA, and different standards of diagnosis, screening and medical care. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to additional risks because we are administering RTB101 in combination with other mTOR inhibitors, such as everolimus. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are evaluating RTB101 in combination with other mTOR inhibitors. For example, in our ongoing Phase 2b clinical trial, we are assessing the
safety, tolerability and efficacy of RTB101 alone and in combination with everolimus. The use of RTB101 in combination with other compounds may subject us to risks that we would not face if RTB101 were being administered as a monotherapy. For
example, the other mTOR inhibitors, including everolimus, may have safety issues that are improperly attributed to RTB101 or the administration of RTB101 with such other therapies may result in safety issues that such other therapies or RTB101 would
not have when used alone. In addition, other mTOR inhibitors with which we may administer RTB101, such as everolimus, could be removed from the market and thus be unavailable for testing or commercial use concomitantly with RTB101. The outcome and
cost of developing a product candidate to be used with other compounds is difficult to predict and dependent on a number of factors that are outside our reasonable control. If we experience efficacy or safety issues in our clinical trials in which
RTB101 is being administered with everolimus, we may not receive regulatory approval for RTB101, which could prevent us from ever generating revenue or achieving profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive products may reduce or eliminate the commercial opportunity for RTB101, alone or in combination with everolimus. If our competitors develop
technologies or product candidates more rapidly than we do, or their technologies are more effective or safer than ours, our ability to develop and successfully commercialize RTB101 alone or in combination with everolimus may be adversely affected.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The clinical and commercial landscape for aging-related diseases is highly competitive and subject to rapid and significant
technological change. New data from competitors&#146; product candidates continue to emerge. It is possible that these data may alter the current standard of care, completely precluding us from further developing RTB101, alone or in combination with
everolimus, for RTIs or other aging-related diseases. Further, it is possible that we may initiate a clinical trial or trials for RTB101, alone or in combination with everolimus, or any other potential product candidate only to find that data from
competing products make it impossible for us to complete enrollment in clinical trials, resulting in our inability to submit applications for regulatory approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with regulatory agencies. Even if RTB101 were approved, alone or in combination with everolimus, it may have limited sales due to competition in the specific indications approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Competitive therapeutic treatments for aging-related diseases, including RTIs, include those that are currently in development and any new
treatments that enter the market. We believe that a significant number of product candidates are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop
product candidates. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. We consider Navitor
Pharma to be our most direct competitor in developing novel therapeutics targeting the TORC1 mechanism of action. Additionally, we are also aware of other companies, including Calico and Unity, which are seeking to develop treatments to prevent or
treat aging-related diseases through biological pathways that may be unrelated to mTOR inhibition. Similarly, there are several other companies, such as PrEP BioPharm, Virion Health and Innavac, which are pursuing broad-spectrum prophylactic and
therapeutic treatments in RTIs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of our competitors have greater financial, technical, manufacturing, marketing, sales and supply
resources, and human resources or experience than us and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products.
Accordingly, our competitors may be more successful than we may be in obtaining regulatory approval for therapies and achieving widespread market acceptance. Our competitors&#146; products may be more effective, or more effectively marketed and
sold, than any product candidate we may commercialize and may render our therapies obsolete or <FONT STYLE="white-space:nowrap">non-competitive</FONT> before we can recover development and commercialization expenses. If RTB101, alone or in
combination with everolimus, is approved for the indications we are currently pursuing, it could compete with a range of therapeutic treatments that are in development. In addition, our competitors may succeed in developing, acquiring or licensing
technologies and drug products that are more effective or less costly than RTB101 alone or in combination with everolimus or any other product candidates that we are currently developing or that we may develop, which could render our product
candidates obsolete and noncompetitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we obtain approval for RTB101, alone or in combination with everolimus, or any other future
product candidate, we may face competition based on many different factors, including the efficacy, safety and tolerability of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for these
products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Existing and future competing products could present superior treatment alternatives, including being more
effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing
our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. Mergers and acquisitions in the pharmaceutical and biotechnology industries
may result in even more resources being concentrated among a small number of competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also compete with other clinical stage
companies and institutions for clinical trial participants, which could reduce our ability to recruit participants for our clinical trials. Delay in recruiting clinical trial participants could adversely affect our ability to bring a product to
market prior to our competitors. Further, research and discoveries by others may result in breakthroughs that render our product candidates obsolete even before they begin to generate any revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, our competitors may obtain patent protection, regulatory exclusivities, or FDA approval and commercialize products more rapidly
than we do, which may impact future approvals or sales of any of our product candidates that receive regulatory approval. If the FDA approves the commercial sale of RTB101, alone or in combination with everolimus, or any other product candidate, we
will also be competing with respect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing capabilities and manufacturing efficiency. We expect competition among products will be based on product efficacy and safety, the timing and scope of regulatory approvals, availability
of supply, marketing and sales capabilities, product price, reimbursement coverage by government and private third-party payers, regulatory exclusivities and patent position. Our profitability and financial position will suffer if our product
candidates receive regulatory approval, but cannot compete effectively in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly
greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the
pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites, as well as in acquiring
technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, regulatory authorities&#146; assessment of the data and
results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency funding, staffing and leadership. We
cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects. For example, average review times at the FDA for regulatory approval applications can be affected by a variety of
factors, including budget and funding levels and statutory, regulatory and policy changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA, EMA and
comparable foreign authorities are lengthy, time consuming and inherently unpredictable. If clinical trials of RTB101, alone or in combination with everolimus, fail to satisfactorily demonstrate safety and efficacy to the FDA or other regulators, or
do not otherwise produce favorable results, we, or any future collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of RTB101 alone or in combination
with everolimus. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, and any future collaborators, are not permitted to commercialize, market, promote or sell any product
candidate in the United States without obtaining regulatory approval from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements. The time required to obtain approval by the FDA, EMA and comparable foreign authorities
is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the
type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. To date, we have not submitted an NDA to the FDA or similar drug approval
submissions to comparable foreign regulatory authorities for RTB101, alone or in combination with everolimus, or any other product candidate. We, and any future collaborators, must complete additional preclinical or nonclinical studies and clinical
trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome.
We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of RTB101 alone or in combination with everolimus or other drugs is susceptible to the risk of failure inherent
at any stage of development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of adverse events that are severe or medically or commercially unacceptable, failure to comply with
protocols or applicable regulatory requirements, and determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or is not approvable. It is possible that even if RTB101, alone or in
combination with everolimus, or any other product candidate has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the seasonal and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
geographical RTI rates and size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an
apparent positive effect of RTB101, alone or in combination with everolimus, or any other product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of or
intolerability caused by RTB101, everolimus or any other product candidate, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any inability to successfully complete preclinical and clinical development could result in additional costs to us, or any future
collaborators. Moreover, if we, or any future collaborators, are required to conduct additional clinical trials or other testing of RTB101, alone or in combination with everolimus, or any other product candidate beyond the trials and testing that we
or they contemplate, if we or they are unable to successfully complete clinical trials of our product candidates or other testing or the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or there are
unacceptable safety concerns associated with our product candidates, we, or any future collaborators may: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur additional unplanned costs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining regulatory approval for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain regulatory approval at all; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing or other requirements; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be required to remove the product from the market after obtaining regulatory approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
failure to successfully initiate and complete clinical trials of RTB101, alone or in combination with everolimus, or any other product candidate and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market RTB101,
alone or in combination with everolimus, or any other product candidate would significantly harm our business. Our product candidate development costs will also increase if we experience delays in testing or regulatory approvals and we may be
required to obtain additional funds to complete clinical trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure our trials after they have begun.
Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to
successfully commercialize our product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of
RTB101 alone or in combination with everolimus or any other product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause undesirable side effects or have
other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by RTB101, alone or in combination with everolimus, or any other product candidate could cause us or
regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Results of our clinical trials
could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. In clinical trials of RTB101, alone or in combination with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
everolimus, to date, there were no observed study drug-related serious adverse events in the Phase 2a clinical trial except in the placebo arm. The majority of observed study-drug related adverse
events were mild or moderate in severity, transient and resolved without stopping the study drug. However, there can be no guarantee that we would observe a similar tolerability profile of RTB101, alone or in combination with everolimus, in our
ongoing Phase 2b clinical trial or in future clinical trials. Many compounds that initially showed promise in clinical or earlier stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the
compound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If unacceptable side effects arise in the development of our product candidates, we, the FDA or comparable foreign regulatory
authorities, the IRBs, or independent ethics committees at the institutions in which our trials are conducted, or the Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory
authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-emergent side effects that are deemed to be treatment-related could also affect subject recruitment or the
ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical
personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our
product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical
trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to
identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the
following adverse consequences could occur: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw their approval of the product, seize the product, or seek an injunction against its manufacture or distribution; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we, or any future collaborators, may need to recall the product, or be required to change the way the product is administered or conduct additional clinical trials, develop a surveillance program; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require one or more post-market studies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, such as a &#147;black box&#148; warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other
communications containing warnings or other safety information about the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we, or any future collaborators, could be sued and held liable for harm caused to patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the product may become less competitive; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any of these events could harm our business and operations, and could negatively impact our
stock price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to develop and commercialize RTB101, alone or in combination with everolimus, for additional indications or fail to
discover, develop and commercialize other product candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although the development and commercialization of RTB101 alone or in combination with everolimus for RTIs is our primary focus, as part of our
longer-term growth strategy, we may evaluate RTB101, alone or in combination with everolimus, in other indications and develop other product candidates. We intend to evaluate internal opportunities from RTB101, alone or in combination with
everolimus, or other product candidates from our TORC1 program, and also may choose to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other product candidates as well as commercial products to treat patients suffering from other
disorders with significant unmet medical needs and limited treatment options. These other product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials and
approval by the FDA and/or applicable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be
shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, successfully commercialized or widely
accepted in the marketplace or be more effective than other commercially available alternatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research programs to identify product
candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield
product candidates for clinical development for many reasons, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the research methodology used may not be successful in identifying potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitors may develop alternatives that render our product candidates obsolete; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates that we develop may nevertheless be covered by third parties&#146; patents or other exclusive rights; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in identifying and developing additional product candidates, our potential for growth and achieving our strategic
objectives may be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our preclinical programs may not produce new product candidates that are suitable for clinical trials or that can be
successfully commercialized or generate revenue through collaborations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We must successfully complete preclinical testing for our
preclinical programs, including our TORC1 <FONT STYLE="white-space:nowrap">follow-on</FONT> program, which may include demonstrating activity and comprehensive studies to show the lack of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
toxicity and other adverse effects in established animal models, before commencing clinical trials for any product candidate. Many pharmaceutical products do not successfully complete preclinical
testing and, even if preclinical testing is successfully completed, may fail in clinical trials. In addition, there can be no assurance that positive results from preclinical studies will be predictive of results obtained from subsequent preclinical
studies or clinical trials. Many pharmaceutical candidates are not suitable for manufacture on the scale or of the quality required for clinical trials or commercialization. Some pharmaceutical candidates that initially seem suitable may later be
found to be insufficiently stable or may generate toxic impurities over time. We also cannot be certain that any product candidates that do advance into clinical trials will successfully demonstrate safety and efficacy in clinical trials. Even if we
achieve positive results in early preclinical studies or clinical trials, they may not be predictive of the results in later trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend
our resources to pursue a particular product candidate or indication and forgo the opportunity to capitalize on product candidates or indications that may ultimately be more profitable or for which there is a greater likelihood of success.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we intend to focus on developing product candidates for specific
indications that we identify as most likely to succeed, in terms of both their potential for regulatory approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other
indications that may prove to have greater commercial potential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our resource allocation decisions may cause us to fail to capitalize on
viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do
not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it
would have been more advantageous for us to retain sole development and commercialization rights to the product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the FDA or comparable
foreign regulatory authorities approve generic versions of RTB101, alone or in combination with everolimus, or any other product candidate of ours that receives regulatory approval, or such authorities do not grant our products appropriate periods
of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity before approving generic versions of such products, the sales of such products could be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Once an NDA is approved, the product covered thereby becomes a &#147;listed drug&#148; in the FDA&#146;s publication, &#147;Approved Drug
Products with Therapeutic Equivalence Evaluations,&#148; or the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. In
support of an ANDA, a generic manufacturer generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration, conditions of use and labeling as the reference listed drug and that the generic
version is bioequivalent to the reference listed drug, meaning, in part, that it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and
companies that produce generic products are generally able to offer them at lower prices. Moreover, many states allow or require substitution of therapeutically equivalent generic drugs at the pharmacy level even if the branded drug is prescribed.
Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug may be lost to the generic product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may not approve an ANDA for a generic product until any applicable period of <FONT STYLE="white-space:nowrap">non-patent</FONT>
exclusivity for the reference listed drug has expired. The Federal Food, Drug, and Cosmetic Act, or FDCA, provides a period of five years of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for a new drug containing a new chemical
entity, or NCE. Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification that a patent covering
the listed drug is invalid, unenforceable or will not be infringed by the generic product, in which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
case the applicant may submit its application four years following approval of the listed drug. It is unclear whether the FDA will treat the active ingredients in our product candidates as NCEs
and, therefore, afford them five years of NCE data exclusivity if they are approved. If any product we develop does not receive five years of NCE exclusivity, the FDA may approve generic versions of such product three years after its date of
approval, subject to the requirement that the ANDA applicant certifies to any patents listed for our products in the Orange Book. Three year exclusivity is given to a drug if it contains an active moiety that has previously been approved, and the
NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the NDA. If approved, manufacturers may seek to
launch these generic products following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Competition that our products, if approved, may face from generic versions of our products could negatively impact our future revenue,
profitability and cash flows and substantially limit our ability to obtain a return on our investments in those product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter
difficulties enrolling patients in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials
in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the patient eligibility criteria defined in the protocol; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size of the patient population required for analysis of the trial&#146;s primary endpoints; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proximity of patients to study sites; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design of the trial; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new
drugs that may be approved for the indications that we are investigating; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain patient consents; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our
product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors.
Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our
clinical trials in such clinical trial site. In addition, because we intend to investigate our product candidates during the winter cold and flu season, this timing requirement may further limit the available pool of clinical trial subjects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to
abandon one or more clinical trials altogether. Delays in patient enrollment may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result in increased costs, affect the timing or outcome of the planned clinical trials, product candidate development and approval process and jeopardize our ability to seek and obtain the
regulatory approval required to commence product sales and generate revenue, which could prevent completion of these trials, adversely affect our ability to advance the development of our product candidates, cause the value of our company to decline
and limit our ability to obtain additional financing if needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ingredients, excipients and other materials necessary to manufacture RTB101 or
everolimus may not be available on commercially reasonable terms, or at all, which may adversely affect the development and commercialization of RTB101, alone or in combination with everolimus. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We and our third-party manufacturers must obtain from other third-party suppliers the active pharmaceutical ingredients, excipients and
primary and secondary packaging materials necessary for our contract manufacturers to produce RTB101 or everolimus for our clinical trials and, to the extent approved or commercialized, for commercial distribution. There is no guarantee that we
would be able to enter into all the necessary agreements with third-party suppliers that we require for the supply of such materials on commercially reasonable terms or at all. Even if we were able to secure such agreements or guarantees, our
suppliers may be unable or choose not to provide us the ingredients, excipients or materials in a timely manner or in the quantities required. If we or our third-party manufacturers are unable to obtain the quantities of these ingredients,
excipients or materials that are necessary for the manufacture of commercial supplies of RTB101 or everolimus, our ability to generate revenue from the sale of RTB101 alone or in combination with everolimus would be materially and adversely
affected. Further, if we or our third-party manufacturers are unable to obtain active pharmaceutical ingredients, excipients and materials as necessary for our clinical trials or for the manufacture of commercial supplies of our product candidates,
if approved, potential regulatory approval or commercialization would be delayed, which would materially and adversely affect our ability to generate revenue from the sale of our product candidates. As a result of these and other factors, the cost
of manufacturing drug material may not support continued development or commercialization or may materially reduce revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if RTB101, alone
or in combination with everolimus, or any other product candidate of ours receives regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary
for commercial success, in which case we may not generate significant revenues or become profitable. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have never commercialized
a product, and even if RTB101, alone or in combination with everolimus, or any other product candidate of ours is approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to gain sufficient market acceptance
by physicians, patients, third-party payors and others in the medical community. The market for therapies targeting aging-related diseases with an immunotherapy is novel, and physicians may be reluctant to adopt novel therapies. In addition,
patients and their physicians may not desire to add RTB101, alone or in combination with everolimus, even if approved, to their existing prophylactic treatment regime. For example, physicians are often reluctant to switch their patients from
existing prophylactics for RTIs even when new and potentially more effective or convenient alternatives enter the market. Further, patients often acclimate to the treatment regime that they are currently taking and do not want to switch unless their
physicians recommend switching products or they are required to switch due to lack of coverage and reimbursement. In addition, even if we are able to demonstrate our product candidates&#146; safety and efficacy to the FDA and other regulators,
safety or efficacy concerns in the medical community may hinder market acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Efforts to educate the medical community and
third-party payors on the benefits of our product candidates may require significant resources, including management time and financial resources, and may not be successful. If RTB101, alone or in combination with everolimus, or any other product
candidate is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety of the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential advantages of the product compared to competitive therapies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the product is recommended under physician prophylactic guidelines; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the product&#146;s convenience and ease of administration compared to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the willingness of the target patient population to try, and of physicians to prescribe, the product; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings, including distribution or use restrictions contained in the product&#146;s approved labeling; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the strength of sales, marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the standard of care for the targeted indications for the product; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability and adequacy of coverage and reimbursement from government payors, managed care plans and other third-party payors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any failure by RTB101 alone or in combination with everolimus or any other product candidate of ours that obtains regulatory approval to
achieve market acceptance or commercial success would adversely affect our business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we, or any future collaborators, are able to
commercialize any product candidate that we, or they, develop, the product may become subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, any of which could harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Patients who are provided medical treatment for their conditions generally rely on third party payors to reimburse all or part of the costs
associated with their treatment. Therefore, our ability, and the ability of any future collaborators to commercialize any of our product candidates will depend in part on the extent to which coverage and reimbursement for these products and related
treatments will be available from third-party payors including government health administration authorities and private health coverage insurers. Third-party payors decide which medications they will cover and establish reimbursement levels. We
cannot be certain that coverage will be available and reimbursement will be adequate for RTB101, alone or in combination with everolimus, or any of our other product candidates. Also, we cannot be certain that reimbursement policies will not reduce
the demand for, or the price paid for, our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If coverage and reimbursement are not available, or reimbursement is available only
to limited levels, we, or any future collaborators, may be limited in our ability to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investment. In the United States, no uniform policy of coverage and
reimbursement for products exists among third-party payors and coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that
will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Regulatory approvals,
pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or
product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we, or any future collaborators, might obtain
regulatory approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, which may negatively impact the revenues we are able to generate from the sale of the product in that
country. Adverse pricing limitations may hinder our ability or the ability of any future collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other
third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications, which could affect our ability or that of any future collaborators to sell our product candidates profitably. These
payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of any future collaborators, or may not be sufficient to allow our products, if any, to be marketed on a
competitive basis. Cost-control initiatives could cause us, or any future collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenues. If the prices for our products,
if any, decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability will suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the
indications for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including
research, development, manufacture, sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement
levels already set for lower cost drugs or may be incorporated into existing payments for other services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, increasingly,
third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging prices. We cannot be sure that coverage will be available for any product candidate that we, or any future
collaborator, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of
drugs from one country to another. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for any of our product candidates for which we, or any future collaborator, obtain regulatory
approval could significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us or any of our future collaborators could divert our resources and attention, cause us incur substantial
liabilities and limit commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are exposed to potential product liability and professional
indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently, we have no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products that have been approved for commercial sale; however, the current and future use of our product candidates by us and any collaborators in clinical trials, and the sale of these product
candidates, if approved, in the future, may expose us to liability claims. We face an inherent risk of product liability lawsuits related to the use of our product candidates in elderly patients and will face an even greater risk if product
candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our partners by participants enrolled in our clinical trials, patients, health care providers, pharmaceutical
companies, our collaborators or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities or be required to limit
commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for any of our future approved products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of clinical trial sites or entire trial programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant litigation costs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to, or costly settlements with, patients or other claimants; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls or a change in the indications for which they may be used; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversion of management and scientific resources from our business operations; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although the clinical trial process is
designed to identify and assess potential side effects, clinical development does not always fully characterize the safety and efficacy profile of a new medicine, and it is always possible that a drug, even after regulatory approval, may exhibit
unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or after approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify
known potential adverse effects and patients who should not use our product candidates. If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our
products. We could be adversely affected if we are subject to negative publicity associated with illness or other adverse effects resulting from patients&#146; use or misuse of our products or any similar products distributed by other companies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we maintain product liability insurance coverage in the amount of up to $10.0&nbsp;million in the aggregate, including clinical
trial liability, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our
insurance coverage if we commercialize any product that receives regulatory approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to maintain sufficient insurance coverage at an acceptable cost or to
otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could harm our business, financial condition, results of operations and
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing, sales or distribution infrastructure. If we are unable to develop our
sales, marketing and distribution capability on our own or through collaborations with marketing partners, we will not be successful in commercializing our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently have no marketing, sales or distribution capabilities. If RTB101, alone or in combination with everolimus, is approved for RTIs,
we intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize the approved product in key territories, which will require substantial additional resources. Some or all of
these costs may be incurred in advance of any approval of RTB101, alone or in combination with everolimus. Any failure or delay in the development of our or third parties&#146; internal sales, marketing and distribution capabilities would adversely
impact the commercialization of RTB101, alone or in combination with everolimus, and other future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Factors that may
inhibit our efforts to commercialize our products on our own include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any future products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;&nbsp;and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">With respect to our existing and future product candidates, we may choose to collaborate with third parties that have direct sales forces and
established distribution systems to serve as an alternative to our own sales force and distribution systems. Our product revenue may be lower than if we directly marketed or sold our products, if approved. In addition, any revenue we receive will
depend in whole or in part upon the efforts of these third parties, which may not be successful and are generally not within our control. If we are not successful in commercializing any approved products, our future product revenue will suffer and
we may incur significant additional losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we do not establish sales and marketing capabilities successfully, either on our own or in
collaboration with third parties, we will not be successful in commercializing our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we, or any future collaborators,
experience any of a number of possible unforeseen events in connection with clinical trials of RTB101, alone or in combination with everolimus, or any other product candidate, potential clinical development, regulatory approval or commercialization
of our product candidates could be delayed or prevented. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, or any future collaborators, may experience numerous unforeseen
events during, or as a result of, clinical trials that could delay or prevent clinical development, regulatory approval or commercialization of our product candidates, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our product candidates may produce unfavorable or inconclusive results; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators may require us or any future collaborators, to conduct additional clinical trials or abandon product development programs; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of patients required for clinical trials of our product candidates may be larger than we, or any future collaborators anticipate, patient enrollment in these clinical trials may be slower than we, or any
future collaborators, may anticipate or participants may drop out of these clinical trials at a higher rate than we, or any future collaborators, anticipate; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of planned clinical trials of our product candidates may be greater than we anticipate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our third-party contractors or those of any future collaborators, including those manufacturing our product candidates or components or ingredients thereof or conducting clinical trials on our behalf or on behalf of any
future collaborators, may fail to comply with regulatory requirements or meet their contractual obligations to us or any future collaborators in a timely manner or at all; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators, IRBs or independent ethics committees may not authorize us, any future collaborators or our or their investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching or failure to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patients who enroll in a clinical trial may misrepresent their eligibility to do so or may otherwise not comply with the clinical trial protocol, resulting in the need to drop the patients from the clinical trial,
increase the needed enrollment size for the clinical trial or extend the clinical trial&#146;s duration; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, suspension or termination of clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or
other unexpected characteristics of the product candidate; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators, IRBs or independent ethics committees may require that we, or any future collaborators, or our or their investigators suspend or terminate clinical research for various reasons, including noncompliance with
regulatory requirements or their standards of conduct, a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate or findings of undesirable
effects caused by a chemically or mechanistically similar product or product candidate. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Further, conducting clinical trials
in foreign countries, as we have done and plan to do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to
clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign
countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Product development costs for us, or any future collaborators, will increase if we, or they, experience delays in testing or
pursuing regulatory approvals and we, or they, may be required to obtain additional funds to complete clinical trials and prepare for possible commercialization of our product candidates. We do not know whether any preclinical studies or clinical
trials will begin as planned, will need to be restructured, or will be completed on schedule or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we, or any future collaborators, may have the
exclusive right to commercialize our product candidates or allow our competitors, or the competitors of any future collaborators, to bring products to market before we, or any future collaborators, do and impair our ability, or the ability of any
future collaborators, to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that lead to clinical trial delays may ultimately lead to the denial of regulatory
approval of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of preclinical studies and early clinical trials may not be predictive of results of future
clinical trials, and such results do not guarantee approval of a product candidate by regulatory authorities. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The outcome of
preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials do not necessarily predict success in the results of completed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier
development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well
advanced. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have
nonetheless failed to obtain regulatory approval for their product candidates. Even if we complete clinical development of RTB101 alone or in combination with everolimus for RTIs or any other indication, there can be no assurance that the FDA, EMA,
or other regulatory authorities will approve RTB101 alone or in combination with everolimus for marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In some instances, there can
be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the
patient populations, changes in and adherence to the dosing regimen and other clinical trial procedures and the rate of dropout among clinical trial participants. If we fail to receive positive results in clinical trials of our product candidates,
the development timeline and regulatory approval and commercialization prospects for our most advanced product candidate, and, correspondingly, our business and financial prospects would be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval and Marketing of Our Product Candidates and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process for product candidates is expensive, time
consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of RTB101 alone or in combination with everolimus or any other product candidate. As a result, we cannot predict when or if,
and in which territories, we, or any future collaborators, will obtain regulatory approval to commercialize a product candidate. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to extensive
regulation by the FDA and comparable foreign regulatory authorities. We, and any future collaborators, are not permitted to market RTB101, alone or in combination with everolimus, or any other product candidate in the United States or in other
countries until we, or they, receive approval of an NDA from the FDA or regulatory approval from applicable regulatory authorities outside the United States. RTB101 is in clinical development and is subject to the risks of failure inherent in drug
development. We have not submitted an application for or received regulatory approval for RTB101, alone or in combination with everolimus, or any other product candidate in the United States or in any other jurisdiction. We have limited experience
in conducting and managing the clinical trials necessary to obtain regulatory approvals, including obtaining FDA approval of an NDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
process of obtaining regulatory approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the
type, complexity and novelty of the product candidates involved. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to
establish the product candidate&#146;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory
authorities. The FDA or other regulatory authorities may determine that RTB101, alone or in combination with everolimus, or any other product candidates are not safe and effective, only moderately effective or have undesirable or unintended side
effects, toxicities or other characteristics that preclude our obtaining regulatory approval or prevent or limit commercial use. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that
render the approved product not commercially viable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, changes in regulatory approval policies during the development period, changes
in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have
substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of
the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate. Any regulatory approval we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or
post-approval commitments that render the approved product not commercially viable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our clinical
trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other
regulatory authority. The FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other
regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our
marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any delay in obtaining or failure to obtain required approvals could negatively impact our ability or that of any future collaborators to
generate revenue from the particular product candidate, which likely would result in significant harm to our business and adversely impact our stock price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to obtain regulatory approval in foreign jurisdictions would prevent our product candidates from being marketed abroad, and any approval we
are granted for RTB101, alone or in combination with everolimus, or any of our other product candidates in the United States would not assure approval of product candidates in foreign jurisdictions. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding clinical trial design, safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory
approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in
significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming and could delay or prevent introduction of RTB101, alone or in combination with everolimus,
or any of our other product candidates in those countries. We do not have experience in obtaining regulatory approval in international markets. If we or our partners fail to comply with regulatory requirements or to obtain and maintain required
approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Additionally, on June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to
as Brexit. On March&nbsp;29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. Since a significant proportion of the regulatory framework in the United Kingdom is derived
from European Union directives and regulations, the referendum could materially impact the regulatory regime with respect to the approval of our product candidates in the United Kingdom or the European Union. Any delay in obtaining, or an inability
to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the European Union and restrict our ability to generate revenue and achieve and
sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our product candidates, which could significantly and materially harm
our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we, or any future collaborators, obtain regulatory approvals for our product candidates, the
terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, which could impair our ability to generate revenue. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Once regulatory approval has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive
regulation. We, and any future collaborators, must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain regulatory approval. Promotional communications with respect to
prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#146;s approved labeling. Thus, we and any future collaborators will not be able to promote any products we
develop for indications or uses for which they are not approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers of approved products and those
manufacturers&#146; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMPs, which include requirements
relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, any future collaborators and their contract manufacturers could be
subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMPs. Despite our efforts to inspect and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory
inspection by FDA or other authorities to be not in compliance with cGMP regulations, which may result in shutdown of the third-party vendor or invalidation of drug product lots or processes. In some cases, a product recall may be warranted or
required, which would materially affect our ability to supply and market our drug products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Accordingly, assuming we, or any future
collaborators, receive regulatory approval for one or more of our product candidates, we, and any future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance,
including manufacturing, production, product surveillance and quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we, and any future collaborators, are not able to
comply with post-approval regulatory requirements, we, and any future collaborators, could have the regulatory approvals for our products withdrawn by regulatory authorities and our, or any future collaborators&#146;, ability to market any future
products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to extensive government regulation and the failure to comply with these regulations may have a material adverse effect on our operations
and business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Both before and after approval of any product, we and our suppliers, contract manufacturers and clinical
investigators are subject to extensive regulation by governmental authorities in the United States and other countries, covering, among other things, testing, manufacturing, quality control, clinical trials, post-marketing studies, labeling,
advertising, promotion, distribution, import and export, governmental pricing, price reporting and rebate requirements. Failure to comply with applicable requirements could result in one or more of the following actions: warning or untitled letters;
unanticipated expenditures; delays in approval or refusal to approve a product candidate; voluntary product recall; product seizure; interruption of manufacturing or clinical trials; operating or marketing restrictions; injunctions; criminal
prosecution and civil or criminal penalties including fines and other monetary penalties; exclusion from federal health care programs such as Medicare and Medicaid; adverse publicity; and disruptions to our business. Further, government
investigations into potential violations of these laws would require us to expend considerable resources and face adverse publicity and the potential disruption of our business even if we are ultimately found not to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Obtaining FDA approval of our product candidates requires substantial time, effort and financial resources and may be subject to both expected
and unforeseen delays, and there can be no assurance that any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval will be granted for any of our product candidates on a timely basis, if at all. The FDA may decide that our data are insufficient for approval of our product candidates and require
additional preclinical, clinical or other studies or additional work related to chemistry, manufacturing and controls. In addition, we, the FDA, IRBs or independent ethics committees may suspend or terminate human clinical trials at any time on
various grounds, including a finding that the patients are or would be exposed to an unacceptable health risk or because of the way in which the investigators on which we rely carry out the trials. If we are required to conduct additional trials or
to conduct other testing of our product candidates beyond that which we currently contemplate for regulatory approval, if we are unable to complete successfully our clinical trials or other testing, or if the results of these and other trials or
tests fail to demonstrate efficacy or raise safety concerns, we may face substantial additional expenses, be delayed in obtaining regulatory approval for our product candidates or may never obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are also required to comply with extensive governmental regulatory requirements after a product has received marketing authorization.
Governing regulatory authorities may require post-marketing studies that may negatively impact the commercial viability of a product. Once on the market, a product may become associated with previously undetected adverse effects and/or may
experience manufacturing or other commercial difficulties. As a result of any of these or other problems, a product&#146;s regulatory approval could be withdrawn, which could harm our business and operating results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any of our product candidates for which we, or any future collaborators, obtain regulatory approval in the future will be subject to ongoing obligations
and continued regulatory review, which may result in significant additional expense. If approved, our product candidates could be subject to post-marketing restrictions or withdrawal from the market and we, or any future collaborators, may be
subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any of our product candidates for which we, or any future collaborators, obtain regulatory approval, as well as the manufacturing processes,
post-approval studies, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing requirements of and review by the FDA, EMA and other regulatory authorities. These requirements include
submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents,
requirements regarding the distribution of samples to physicians and recordkeeping. We and our contract manufacturers will also be subject to user fees and periodic inspection by the FDA, EMA and other regulatory authorities to monitor compliance
with these requirements and the terms of any product approval we may obtain. Even if regulatory approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to
the conditions of approval, including the requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA, EMA and
other regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely
regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA
imposes stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we, or any future collaborators, do not market any of our product candidates for which we, or they, receive
regulatory approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing if it is alleged that we are doing so. Violation of the FDCA and
other statutes relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws, including the False
Claims Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown adverse events or other problems with our
products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the manufacturing of such products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the labeling or marketing of such products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on product distribution or use; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to conduct post-marketing studies or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of the products from the market; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending applications or supplements to approved applications that we submit; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall of products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on coverage by third-party payors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, restitution or disgorgement of profits or revenues; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exclusion from federal health care programs such as Medicare and Medicaid; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to permit the import or export of products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The efforts of the Administration to
pursue regulatory reform may limit FDA&#146;s ability to engage in oversight and implementation activities in the normal course, and that could negatively impact our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United
States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of executive orders, that
could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of
marketing applications. On January&nbsp;30, 2017, President Trump issued an executive order, applicable to all executive agencies, including the FDA, that requires that for each notice of proposed rulemaking or final regulation to be issued in
fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;two-for-one&#148;</FONT></FONT> provisions. This executive order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the
2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the executive order requires agencies to identify regulations to offset any incremental cost of a new
regulation. In interim guidance issued by the Office of Information and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Regulatory Affairs within OMB on February&nbsp;2, 2017, the administration indicates that the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;two-for-one&#148;</FONT></FONT> provisions may apply not only to agency regulations, but also to significant agency guidance documents, and on September&nbsp;8, 2017, the FDA
published notices in the Federal Register soliciting broad public comment to identify regulations that could be modified in compliance with these Executive Orders. It is difficult to predict how these requirements will be implemented, and the extent
to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business may be
negatively impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback,
fraud and abuse, privacy and transparency and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished
profits and future earnings. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third party payors will play a primary role in the
recommendation and prescription of any products for which we obtain regulatory approval. Our future arrangements with third party payors, healthcare providers and physicians may expose us to broadly applicable fraud and abuse and other healthcare
laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain regulatory approval.
These include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Anti-Kickback Statute</B>&#151;The federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or
indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare
program such as Medicare and Medicaid. A person or entity can be found guilty of violating the federal Anti-Kickback Statute without actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In
addition, the government may assert that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money
penalties statute; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>False Claims Act</B>&#151;The federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things,
knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal healthcare program; making a false statement or record material to a false or fraudulent claim or an obligation to pay money to the federal
government; or avoiding, decreasing or concealing an obligation to pay money to the federal government. A claim that includes items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the
False Claims Act.. Potential liability for violating the False Claims Act includes mandatory treble damages and significant <FONT STYLE="white-space:nowrap">per-claim</FONT> penalties; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>HIPAA</B>&#151;The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false
statements relating to healthcare matters. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, HIPAA
and, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations on covered entities and their business associates, including mandatory contractual terms and
technical safeguards, with respect to maintaining the privacy, security and transmission of individually identifiable health information; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Transparency Requirements</B>&#151;Federal laws require applicable manufacturers of covered drugs to report
payments and other transfers of value to physicians, including doctors, dentists, optometrists, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
podiatrists and chiropractors, and teaching hospitals, as well as information regarding ownership and investment interests held by the physicians described above and their immediate family
members; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Analogous State and Foreign Laws</B>&#151;Analogous state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, can apply to our business practices, including but not
limited to research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third party payors and are generally broad and are enforced
by many different federal and state agencies as well as through private actions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some state laws require pharmaceutical
companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from
each other in significant ways and often are not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties, and our business generally, will comply with applicable healthcare laws
and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable
fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. Defending against any such actions can be costly,
time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other
healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement,
purchase, supply, order or use of medicinal products is generally not permitted in the countries that form part of the European Union. Some European Union Member States, like the United Kingdom, through the United Kingdom Bribery Act 2010, have
enacted laws explicitly prohibiting the provision of these type of benefits and advantages. Infringements of these laws can result in substantial fines and imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain European Union Member States (e.g., France or Belgium) must be publically disclosed. Moreover,
agreements with physicians often must be the subject of prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member
States. These requirements are provided in the European Union Member State national laws, industry codes (e.g. the European Federation of Pharmaceutical Industries and Associations Disclosure and Healthcare Professionals Codes) or professional codes
of conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The collection and processing of personal data &#150; including health data &#150; in the European Union is currently governed by the
provisions of the Data Protection Directive, as implemented into national laws by the European Union Member States. The new European Union-wide General Data Protection Regulation, or GDPR, entered into force in May 2016 and will become applicable on
May&nbsp;25, 2018, replacing the current data </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protection laws of each European Union Member State. The GDPR will implement more stringent operational requirements for processors and controllers of personal data, including, for example,
expanded disclosures about how personal information is to be used, limitations on retention of information, increased requirements pertaining to health data and pseudonymised (i.e., key-coded) data, mandatory data breach notification requirements
and higher standards for controllers to demonstrate that they have obtained valid consent for certain data processing activities. The GDPR provides that European Union Member States may make their own further laws and regulations in relation to the
processing of genetic, biometric or health data, which could result in differences between Member States, limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. We are
also subject to evolving and strict rules on the transfer of personal data out of the European Union to the United States. Failure to comply with European Union data protection laws may result in fines (for example, of up to &#128;20,000,000 or up
to 4% of the total worldwide annual turnover of the preceding financial year (whichever is higher) under the GDPR) and other administrative penalties, which may be onerous and adversely affect our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain regulatory approval of
and commercialize our product candidates and affect the prices we, or they, may obtain. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States and foreign
jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any product candidates for which we obtain regulatory approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in additional
reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March&nbsp;2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and
Education Reconciliation Act, or collectively the ACA. Among the provisions of the ACA of potential importance to our business and our product candidates are the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, <FONT STYLE="white-space:nowrap">non-deductible</FONT> fee on any entity that manufactures or imports specified branded prescription products and biologic products; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for products that are inhaled, infused, instilled, implanted or injected; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off
negotiated prices of applicable brand products to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient products to be covered under Medicare Part&nbsp;D; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new requirements to report certain financial arrangements with physicians and teaching hospitals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new requirement to annually report product samples that manufacturers and distributors provide to physicians; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes to the Medicare program to reduce expenditures by the program that could result in reduced payments for prescription
products; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August&nbsp;2011, the Budget Control Act
of 2011, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April&nbsp;2013 and will remain in effect through 2025 unless additional Congressional action is taken. The
American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws
may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product
candidate is prescribed or used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">With the new Administration and Congress, there will likely be additional administrative or legislative
changes, including modification, repeal, or replacement of all, or certain provisions of, the ACA. In January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, or the Budget Resolution, that authorizes the implementation of
legislation that would repeal portions of the ACA. The Budget Resolution is not a law, however, it is widely viewed as the first step toward the passage of legislation that would repeal certain aspects of the ACA. Further, on January&nbsp;20, 2017,
President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or
regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At the same time, Congress has focused on additional legislative changes, including in particular repeal and replacement of certain provisions
of the ACA. It remains to be seen, however, whether new legislation reforming, repealing or replacing the ACA will be enacted and, if so, precisely what the new legislation will provide and what impact it will have on the availability of healthcare
and containing or lowering the cost of healthcare. It is possible that these reform, repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance coverage or in individuals having
insurance coverage with less generous benefits. It is also possible that some ACA provisions that generally are not favorable for the research-based pharmaceutical industry could also be repealed along with ACA coverage expansion provisions. At this
point, healthcare reform and its impacts on us are highly uncertain in many respects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The costs of prescription pharmaceuticals in the
United States has also been the subject of considerable discussion in the United States, and members of Congress and the Administration have stated that they will address such costs through new legislative and administrative measures. There have
been several U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition,
individual states have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain
product access, and to encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The pricing of prescription pharmaceuticals is
also subject to governmental control outside the United States. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a product. To obtain reimbursement or
pricing approval in some countries, we may be required to conduct a clinical trial that compares the <FONT STYLE="white-space:nowrap">cost-effectiveness</FONT> of our product candidates to other available therapies. If reimbursement of our products
is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governments outside the United States may impose strict price controls, which may adversely affect our revenues, if any. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In some countries, including Member States of the European Union, the pricing of prescription drugs is subject to governmental control.
Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition,
there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations,
and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced
countries, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain
reimbursement or pricing approval, which is time-consuming and costly. We cannot be sure that such prices and reimbursement will be acceptable to us or our strategic partners. Publication of discounts by third-party payors or authorities may lead to
further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues
from sales by us or our strategic partners and the potential profitability of any of our product candidates in those countries would be negatively affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain
products outside of the United States and require us to develop and implement costly compliance programs. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we further expand
our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S.
individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign
entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books
and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the
FCPA presents particular challenges in the pharmaceutical industry, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with
clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with
certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United
States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit
our growth potential and increase our development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business practices may
result in substantial civil and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of
the FCPA&#146;s accounting provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws
and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and
flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk
of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our
resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this
insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
commercial success depends on our ability to protect our intellectual property and proprietary technology. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our commercial success
depends in large part on our ability to obtain and maintain intellectual property rights protection through patents, trademarks, and trade secrets in the United States and other countries with respect to our proprietary product candidates. If we do
not adequately protect our intellectual property rights, competitors may be able to erode, negate or preempt any competitive advantage we may have, which could harm our business and ability to achieve profitability. To protect our proprietary
position, we have patent applications and may file other patent applications in the United States or abroad related to our product candidates that are important to our business; we may also license or purchase patent applications filed by others.
The patent application and approval process is expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Agreements through which we license patent rights may not give us control over patent
prosecution or maintenance, so that we may not be able to control which claims or arguments are presented, how claims are amended, and may not be able to secure, maintain, or successfully enforce necessary or desirable patent protection from those
patent rights. We have not had and do not have primary control over patent prosecution and maintenance for certain of the patents and patent applications we license, and therefore cannot guarantee that these patents and applications will be
prosecuted or maintained in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and
regulations or will result in valid and enforceable patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the scope of the patent protection we or our licensors obtain is not
sufficiently broad, we may not be able to prevent others from developing and commercializing technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be
unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our licensed patents have, or that any of our pending owned
or licensed patent applications that mature into issued patents will include, claims with a scope sufficient to protect our proprietary platform or otherwise provide any competitive advantage, nor can we assure you that our licenses are or will
remain in force. Other parties have developed or may develop technologies that may be related or competitive with our approach, and may have filed or may file patent applications and may have been issued or may be issued patents with claims that
overlap or conflict with our patent applications, either by claiming the same compounds, formulations or methods or by claiming subject matter that could dominate our patent position. In addition, the laws of foreign countries may not protect our
rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed. Various extensions may be available;
however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or
shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to our product candidates. In
addition, the patent portfolio licensed to us is, or may be, licensed to third parties, such as outside our field, and such third parties may have certain enforcement rights. Thus, patents licensed to us could be put at risk of being invalidated or
interpreted narrowly in litigation filed by or against another licensee or in administrative proceedings brought by or against another licensee in response to such litigation or for other reasons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if they are unchallenged, our owned and licensed patents and pending patent applications, if issued, may not provide us with any
meaningful protection or prevent competitors from designing around our patent claims to circumvent our patents by developing similar or alternative technologies or therapeutics in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. For
example, a third party may develop a competitive therapy that provides benefits similar to one or more of our product candidates but falls outside the scope of our patent protection or license rights. If the patent protection provided by the patents
and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected, which would harm
our business. Currently, a significant portion of our patents and patent applications are <FONT STYLE="white-space:nowrap">in-licensed,</FONT> though similar risks would apply to any patents or patent applications that we now own or may own or <FONT
STYLE="white-space:nowrap">in-license</FONT> in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, or any future partners, collaborators, or licensees, may fail to identify
patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future,
for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our partners, collaborators, licensees, or licensors, whether current </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees, or
licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or
enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from
third parties, which may have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies
carries uncertainty. In addition, the determination of patent rights with respect to pharmaceutical compounds commonly involves complex legal and factual questions, which are dependent upon the current legal and intellectual property context, extant
legal precedent and interpretations of the law by individuals. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are characterized by uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a
patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file&nbsp;a patent application is generally entitled to the patent. However, prior to March&nbsp;16, 2013, in the United States,
the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are not published until
18&nbsp;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of
such inventions. Similarly, we cannot be certain that parties from whom we do or may license or purchase patent rights were the first to make relevant claimed inventions, or were the first to file for patent protection for them. If third parties
have filed prior patent applications on inventions claimed in our patents or applications that were filed on or before March&nbsp;15, 2013, an interference proceeding in the United States can be initiated by such third parties to determine who was
the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such prior applications after March&nbsp;15, 2013, a derivation proceeding in the United States can be initiated by such
third parties to determine whether our invention was derived from theirs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, because the issuance of a patent is not conclusive as
to its inventorship, scope, validity or enforceability, our patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. There is no assurance that all of the potentially relevant prior
art relating to our patents and patent applications has been found. If such prior art exists, it may be used to invalidate a patent, or may prevent a patent from issuing from a pending patent application. For example, such patent filings may be
subject to a third-party submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or to other patent offices around the world. Alternately or additionally, we may become involved in post-grant review procedures, oppositions,
derivation proceedings, <I>ex parte</I> reexaminations, <I>inter partes</I> review, supplemental examinations, or interference proceedings or challenges in district court, in the United States or in various foreign patent offices, including both
national and regional, challenging patents or patent applications in which we have rights, including patents on which we rely to protect our business. An adverse determination in any such challenges may result in loss of the patent or in patent or
patent application claims being narrowed, invalidated or held unenforceable, in whole or in part, or in denial of the patent application or loss or reduction in the scope of one or more claims of the patent or patent application, any of which could
limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the
development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pending and future patent applications may not result in patents being issued that protect our business, in whole or in part, or which
effectively prevent others from commercializing competitive products. Competitors may also be able to design around our patents. Changes in either the patent laws or interpretation of the patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our
rights to the same extent or in the same manner as the laws of the United States. For example, patent laws in various jurisdictions, including significant commercial markets such as Europe, restrict the patentability of methods of treatment of the
human body more than United States law does. If these developments were to occur, they could have a material adverse effect on our ability to generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future
development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which
noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than
would otherwise have been the case; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patent applications may not result in any patents being issued; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patents that may be issued or <FONT STYLE="white-space:nowrap">in-licensed</FONT> may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive
advantage; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our competitors, many of whom have substantially greater resources and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere
with or eliminate our ability to make, use, and sell our potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove
successful, as a matter of public policy regarding worldwide health concerns; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product
candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Issued patents that we have or may obtain or license may not provide us with any meaningful protection, prevent
competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a
<FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Our competitors may also seek approval to market their own products similar to or otherwise competitive with our products. Alternatively, our competitors may seek to market generic
versions of any approved products by submitting ANDAs to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both,
including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid or unenforceable, or that our competitors are competing in a <FONT
STYLE="white-space:nowrap">non-infringing</FONT> manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we rely on the protection of our trade secrets and proprietary, unpatented <FONT STYLE="white-space:nowrap">know-how.</FONT>
Although we have taken steps to protect our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> including entering into confidentiality agreements with third parties, and confidential information and invention assignment
agreements with employees, consultants, collaborators, vendors, and advisors, we cannot provide any assurances that all such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently. It is possible that technology relevant to our
business will be independently developed by a person who is not a party to such a confidentiality or invention assignment agreement. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by
consultants, collaborators, vendors, advisors, former employees and current employees. Furthermore, if the parties to our confidentiality agreements breach or violate the terms of these agreement, we may not have adequate remedies for any such
breach or violation, and we could lose our trade secrets as a consequence of such breaches or violations. Our trade secrets could otherwise become known or be independently discovered by our competitors. Additionally, if the steps taken to maintain
our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary <FONT
STYLE="white-space:nowrap">know-how,</FONT> our business may be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on intellectual property licensed from third parties and
termination of any of these licenses could result in the loss of significant rights, which would harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March
2017, we entered into a license agreement with Novartis, or the Novartis License, pursuant to which we were granted an exclusive, field-restricted, worldwide license to certain intellectual property rights owned or controlled by Novartis, including
patents, patent applications, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property, to develop, commercialize and sell one or more therapeutic products comprising RTB101 or RTB101 and everolimus
in a fixed dose combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are dependent on these patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary
technology, licensed from Novartis. Any termination of this license, or a finding that such intellectual property lacks legal effect, could result in the loss of significant rights and could harm our ability to commercialize any product candidates.
See the section entitled &#147;Business&#151;Intellectual Property&#148; for additional information regarding our license agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Disputes may also arise between us and our licensor, our licensor and its licensors, or us and third parties that <FONT
STYLE="white-space:nowrap">co-own</FONT> intellectual property with our licensor or its licensors, regarding intellectual property subject to a license agreement, including those relating to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights, if any, granted under the license agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether our licensor or its licensor had the right to grant the license agreement; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property without their authorization; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right to sublicense patent and other rights to third parties under collaborative development relationships; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether we are complying with our obligations with respect to the use of the licensed technology in relation to our development and commercialization of product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our involvement in the prosecution of the licensed patents and our licensors&#146; overall patent enforcement strategy; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the allocation of ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of intellectual property by our licensors and by us and our partners; and
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amounts of royalties, milestones or other payments due under the license agreement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we have licensed prevent or impair our ability
to maintain our current licensing arrangements on acceptable terms, or are insufficient to provide us the necessary rights to use the intellectual property, we may be unable to successfully develop and commercialize the affected product candidates.
If we or any such licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Novartis may partially terminate the license agreement with respect to everolimus if we fail or cease for three years to use commercially
reasonable efforts to research, develop and commercialize a product using everolimus, provided that our license related to RTB101 and Novartis&#146;s license to our improvements related to everolimus will continue. Additionally, either party may
terminate the Novartis License if the other party commits a material breach and fails to cure such breach within 60 days after written notice. If Novartis unilaterally terminates the Novartis License, the research and development of RTB101 or RTB101
and everolimus in a fixed dose combination would be suspended, and we may be unable to research, develop and license future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
may be required to pay certain milestones and royalties under our&nbsp;license&nbsp;agreements with&nbsp;third-party licensors. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our current and future license agreements, we may be required to pay milestones and royalties based on our revenues from sales of our
products utilizing the technologies licensed or sublicensed from Novartis or other licensors and these royalty payments could adversely affect the overall profitability for us of any products that we may seek to commercialize. In order to maintain
our&nbsp;license&nbsp;rights under current and future license&nbsp;agreements, we may need to meet certain specified milestones, subject to certain cure provisions, in the development of our product candidates and in the raising of funding. In
addition, these agreements may contain diligence milestones and we may not be successful in meeting all of the milestones in the future on a timely basis or at all, which could result in termination of our rights under such agreements. We may need
to outsource and rely on&nbsp;third parties&nbsp;for many aspects of the clinical development, sales and marketing of our products covered under our current and future license&nbsp;agreements. Delay or failure by these&nbsp;third parties&nbsp;could
adversely affect the continuation of our&nbsp;license&nbsp;agreements with their third-party licensors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is difficult and costly to protect our
intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our commercial success
will depend in part on obtaining and maintaining patent protection and trade secret protection for the use, formulation and structure of our products and product candidates, the methods used to manufacture them, the related therapeutic targets and
associated methods of treatment as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our products and product candidates from unauthorized making, using, selling, offering to sell or
importing by third parties is dependent on the extent to which we have rights under valid and enforceable patents that cover these activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent positions of pharmaceutical, biotechnology and other life sciences companies can be highly uncertain and involve complex legal and
factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Further,
the determination that a patent application or patent claim meets all of the requirements for patentability is a subjective determination based on the application of law and jurisprudence. The ultimate determination by the USPTO or by a court or
other trier of fact in the United States, or corresponding foreign national patent offices or courts, on whether a claim meets all requirements of patentability cannot be assured. Although we have conducted searches for third-party publications,
patents and other information that may affect the patentability of claims in our various patent applications and patents, we cannot be certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of claims
that may be allowed or enforced in our owned patents or patent applications, in our licensed patents or patent applications or in third-party patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We cannot provide assurances that any of our patent applications will be found to be
patentable, including over our own or our licensors&#146; prior art publications or patent literature, or will issue as patents. Neither can we make assurances as to the scope of any claims that may issue from our pending and future patent
applications nor to the outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability of our patents and patent applications in the United States or foreign jurisdictions. Any such
challenge, if successful, could limit patent protection for our products and product candidates and/or materially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to generate sufficient data to support full patent applications that protect the entire breadth of developments in one or more of our programs; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the patent(s) claims will have sufficient scope to protect our technology, provide us with a basis
for commercially viable products or provide us with any competitive advantages; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if our pending applications issue as patents, they may be challenged by third parties as not infringed, invalid or unenforceable under United States or foreign laws; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if issued, the patents under which we hold rights may not be valid or enforceable; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not successfully commercialize RTB101, alone or in combination with everolimus, if approved, before our relevant patents expire; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be the first to make the inventions covered by each of our patents and pending patent applications; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not develop additional proprietary technologies or product candidates that are separately patentable. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, to the extent that we are unable to obtain and maintain patent protection for one of our products or product candidates or in the
event that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of a product or product candidate for <FONT STYLE="white-space:nowrap">follow-on</FONT> indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also may rely on trade secrets to protect our technologies or products, especially where we do not believe patent protection is appropriate
or obtainable. Also, we cannot provide any assurances that any of our licensed patents have claims with a scope sufficient to protect our technology or otherwise provide any competitive advantage, nor can we assure you that our licenses are or will
remain in full force or effect, in which case we would similarly rely on trade secrets. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors,
outside scientific collaborators and other advisers may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and
time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and <FONT
STYLE="white-space:nowrap">know-how.</FONT> Notably, proprietary technology protected by a trade secret does not preempt the patenting of independently developed equivalent technology, even if such equivalent technology is invented subsequent to the
technology protected by a trade secret. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid
to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental patent
agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in which
<FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such a circumstance, competitors
may be able to enter the market earlier than otherwise would be the case. Under the terms of some of our current and future licenses, we may not have the ability to maintain patents or prosecute patent applications in the portfolio, and may
therefore have to rely on third parties to comply with these requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on
our products for an adequate amount of time. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Given the amount of time required for the development, testing and regulatory review
of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we
are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved
indication (or any additional indications approved during the period of extension). We might not be granted an extension because of, for example, failure to apply within applicable periods, failure to apply prior to the expiration of relevant
patents or otherwise failure to satisfy any of the numerous applicable requirements. Moreover, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not
agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to obtain approval of competing
products following our patent expiration by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. If this were to occur, it could have a material adverse effect on our ability to generate
revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our commercial success is heavily
dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Recent
wide-ranging patent reform legislation in the United States, including the Leahy-Smith America Invents Act, or the America Invents Act, could increase those uncertainties and costs. The America Invents Act was signed into law on September&nbsp;16,
2011, and many of the substantive changes became effective on March&nbsp;16, 2013. The America Invents Act reforms United States patent law in part by changing the U.S. patent system from a &#147;first to invent&#148; system to a &#147;first
inventor to file&#148; system, expanding the definition of prior art, and developing a post-grant review system. This legislation changes United States patent law in a way that may weaken our ability to obtain patent protection in the United States
for those applications filed after March&nbsp;16, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Further, the America Invents Act created new procedures to challenge the validity
of issued patents in the United States, including post-grant review and <I>inter partes</I> review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a
patent with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an effective filing date of March&nbsp;16, 2013 or later, a petition for post-grant review can be filed by a third party in a nine month window from issuance of the patent. A petition for
<I>inter partes</I> review can be filed immediately following the issuance of a patent if the patent has an effective filing date prior to March&nbsp;16, 2013. A petition for <I>inter partes</I> review can be filed after the nine month period for
filing a post-grant review petition has expired for a patent with an effective filing date of March&nbsp;16, 2013 or later. Post-grant review proceedings can be brought on any ground of invalidity, whereas <I>inter partes</I> review proceedings can
only raise an invalidity challenge based on published prior art and patents. These adversarial actions at the USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts, and use a lower
burden of proof than used in litigation in U.S. federal courts. Therefore, it is generally considered easier for a competitor or third party to have a U.S. patent invalidated in a USPTO post-grant review or <I>inter partes</I> review proceeding than
invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party in such a USPTO proceeding, there is no guarantee that we or our licensors or collaborators will be successful in defending the patent, which
may result in a loss of the challenged patent right to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, recent court rulings in cases such as <I>Association for
Molecular Pathology v. Myriad Genetics,</I><I></I><I>&nbsp;Inc., BRCA1-</I><I></I><I>&nbsp;&amp; BRCA2-Based Hereditary Cancer Test Patent Litigation, and Promega Corp.</I><I></I><I>&nbsp;v. Life Technologies Corp.</I> have narrowed the scope of
patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has
created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the
laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to enforce our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, enforcing and defending patents on our product candidates in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing
countries; thus, even in countries where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign
intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Many companies have encountered
significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including India, China and other developing countries, do not favor the enforcement of patents and
other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws
under which a patent owner must grant licenses to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside the United States and Europe or from selling or importing products
made from our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop and market their own products and, further, may export
otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Agreements through which we license patent rights may
not give us sufficient rights to permit us to pursue enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents (or control of such enforcement or defense) of such patent rights in all relevant
jurisdictions as requirements may vary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights, whether or not successful, could result in
substantial costs and divert our efforts and resources from other aspects of our business. Moreover, such proceedings could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and
could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Furthermore, while we intend to protect our
intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products, if approved. Accordingly, our efforts to
protect our intellectual property rights in such countries may be inadequate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Others may challenge inventorship or claim an ownership interest in
our intellectual property which could expose it to litigation and have a significant adverse effect on its prospects. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A third
party or former employee or collaborator may claim an ownership interest in one or more of our or our licensors&#146; patents or other proprietary or intellectual property rights. A third party could bring legal actions against us and seek monetary
damages and/or enjoin clinical testing, manufacturing and marketing of the affected product or products. While we are presently unaware of any claims or assertions by third-parties with respect to our patents or other intellectual property, we
cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. If we become involved in any litigation, it could consume a substantial portion of our resources, and cause a significant
diversion of effort by our technical and management personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are sued for infringing intellectual property rights of third parties, such
litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing the
intellectual property and other proprietary rights of third parties. Third parties may have U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issued patents and pending patent applications relating to compounds, methods of manufacturing
compounds and/or methods of use for the treatment of the disease indications for which we are developing our product candidates. If any third-party patents or patent applications are found to cover our product candidates or their methods of use or
manufacture, we may not be free to manufacture or market our product candidates as planned without obtaining a license, which may not be available on commercially reasonable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party
to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our products candidates, including interference and post-grant proceedings before the USPTO. There may be third-party patents
or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture of our product candidates. We cannot guarantee that any of our patent searches or analyses
including, but not limited to, the identification of relevant patents, the scope of patent claims or the expiration of relevant patents are complete or thorough, nor can we be certain that we have identified each and every patent and pending
application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. Because patent applications can take many years to issue, there may be currently pending patent
applications which may later result in issued patents that our product candidates may be accused of infringing. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.
Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise in the future. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately
quantified in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of
use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always uniform. If we were sued for patent infringement, we would need to demonstrate that
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our product candidates, products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do
this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these
proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we may
not have sufficient resources to bring these actions to a successful conclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are found to infringe a third party&#146;s
intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third
party in order to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate or product. If we were required to obtain a license to continue to manufacture or market the affected product, we
may be required to pay substantial royalties or grant cross-licenses to our patents. We cannot, however, assure you that any such license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a
product, or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights, Further, the outcome of intellectual property litigation is subject to
uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of
experts as to technical facts upon which experts may reasonably disagree. Furthermore, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to compete successfully in the
commercial marketplace. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from
commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar
negative impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims by third parties asserting that our employees or we have misappropriated their
intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of our current and former
employees and our licensors&#146; current and former employees, including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential
competitors. Some of these employees, including members of our senior management, may have executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements, or
similar agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be
subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in
defending any such claims, in addition to paying monetary damages, we may sustain damages or lose key personnel, valuable intellectual property rights or the personnel&#146;s work product, which could hamper or prevent commercialization of our
technology, which could materially affect our commercial development efforts. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or
products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or
against us related to the ownership of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful
in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management and scientific personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and
unsuccessful. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter
infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived
infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding,
there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the
validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the
invention. An adverse outcome in a litigation or proceeding involving one or more of our patents could limit our ability to assert those patents against those parties or other competitors, and may curtail or preclude our ability to exclude third
parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have
asserted trademark infringement has superior rights to the trademarks in question. In this case, we could ultimately be forced to cease use of such trademarks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only
monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it
could adversely affect the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are
concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Additionally, for certain of our existing and future <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, we may not have the
right to bring suit for infringement and may have to rely on third parties to enforce these rights for us. If we cannot or choose not to take action against those we believe infringe our intellectual property rights, we may have difficulty competing
in certain markets where such potential infringers conduct their business, and our commercialization efforts may suffer as a result. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our
trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We
rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners
or customers in our markets of interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks.
Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use for our products in the United States must be approved by the FDA, regardless of
whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our
proposed product names, we may be required to expend significant additional resources in an effort to identify a usable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be
acceptable to the FDA. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may not be able to obtain regulatory
approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not independently conduct clinical trials of any of our product candidates. We have relied upon and plan to continue to rely on third
parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct these clinical trials and expect to rely on these third parties to conduct clinical trials of any
other product candidate that we develop. Any of these third parties may terminate their engagements with us under certain circumstances. We may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In
addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Further, although our reliance on these third parties for clinical development activities limits our control over these
activities, we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. For example, notwithstanding the obligations of a CRO for a
trial of one of our product candidates, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with
requirements, commonly referred to as Good Clinical Practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and
confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and IRBs. If we or our third-party contractors fail to comply with
applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which would delay the regulatory approval process.
We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. We are also required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored
database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under
our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. These contractors may also have relationships with other commercial entities, including our
competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties, including clinical investigators,
do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in obtaining, regulatory approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In
such an event, our financial results and the commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our
distributors could delay clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our use of third parties to manufacture our product candidates and products which we are studying in combination with our product candidates may
increase the risk that we will not have sufficient quantities of our product candidates, products, or necessary quantities of such materials on time or at an acceptable cost. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates, and we
lack the resources and the capabilities to do so. As a result, we currently rely on third parties for the manufacture and supply of the active pharmaceutical ingredients, or API, in our product candidates. Our current strategy is to outsource all
manufacturing of our product candidates to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently engage one third-party manufacturer to provide the active
pharmaceutical ingredient, or API, and four other third-party manufacturers to provide services for the final drug product formulation of RTB101 that is being used in our clinical trials. Although we believe that there are several potential
alternative manufacturers who could manufacture RTB101 and everolimus, we may incur added costs and delays in identifying and qualifying any such replacement. In addition, we typically order raw materials and services on a purchase order basis and
do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial manufacturer. There is no assurance that we will be able to timely secure needed supply arrangements on satisfactory terms, or at all. Our failure to
secure these arrangements as needed could have a material adverse effect on our ability to complete the development of our product candidates or, to commercialize them, if approved. We may be unable to conclude agreements for commercial supply with
third-party manufacturers, or may be unable to do so on acceptable terms. There may be difficulties in scaling up to commercial quantities and formulation of RTB101, alone or in combination with everolimus, and the costs of manufacturing could be
prohibitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party
manufacturers entails additional risks, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on third-parties for manufacturing process development, regulatory compliance and quality assurance;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement
between us; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations on supply availability resulting from capacity and scheduling constraints of third-parties; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible breach of manufacturing agreements by third-parties because of factors beyond our control; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible termination or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of the manufacturing agreements by the third-party, at a time that is costly or inconvenient to us; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possible misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how.</FONT> </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we do not maintain our key manufacturing relationships, we may fail to find replacement manufacturers or develop our own manufacturing
capabilities, which could delay or impair our ability to obtain regulatory approval for our products. If we do find replacement manufacturers, we may not be able to enter into agreements with them on terms and conditions favorable to us and there
could be a substantial delay before new facilities could be qualified and registered with the FDA and other foreign regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved by any regulatory agency, we intend to utilize arrangements with third-party contract
manufacturers for the commercial production of those products. This process is difficult and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under
cGMPs that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on
us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly
affect supplies of our product candidates. The facilities used by our contract manufacturers to manufacture our product candidates must be evaluated by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We do
not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and
the strict regulatory requirements of the FDA or others, we may not be able to secure and/or maintain regulatory approval for our product manufactured at these facilities. In addition, we have no control over the ability of our contract
manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA finds deficiencies or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates
or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.
Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any
failure to comply with cGMP requirements or other FDA, EMA and comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop our product candidates and market our products, if approved.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA and other foreign regulatory authorities require manufacturers to register manufacturing facilities. The FDA and corresponding
foreign regulators also inspect these facilities to confirm compliance with cGMPs. Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor
may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA, EMA and comparable foreign regulatory requirements could adversely affect our clinical research activities and
our ability to develop our product candidates and market our products following approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any third-party manufacturer of our product candidates
is unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture the product may increase and commercialization may be delayed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of RTB101,
alone or in combination with everolimus, or any other product candidates that we may develop, our third party manufacturer will be required to increase its production and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
optimize its manufacturing processes while maintaining the quality of the product. The transition to larger scale production could prove difficult. In addition, if our third party manufacturer is
not able to optimize its manufacturing process to increase the product yield for our product candidates, or if it is unable to produce increased amounts of our product candidates while maintaining the quality of the product, then we may not be able
to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need to maintain licenses for active ingredients from third parties to develop and commercialize some of our product candidates, which could
increase our development costs and delay our ability to commercialize those product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Should we decide to use active
pharmaceutical ingredients in any of our product candidates that are proprietary to one or more third parties, we would need to maintain licenses to those active ingredients from those third parties. If we are unable to gain or continue to access
rights to these active ingredients prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these programs by either accessing or developing alternate active
ingredients, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to gain or maintain continued access rights to the desired active ingredients on commercially reasonable terms or
develop suitable alternate active ingredients, we may not be able to commercialize product candidates from these programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of third parties to
conduct testing of our product candidates in tissues or animals may increase the risk that we will have unsuitable or invalidated data for regulatory submissions and approval. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently do not own or operate laboratory facilities in which to conduct preclinical testing of our product candidates in tissues or
animals. Preclinical studies regulated by FDA, EMA and most other health authorities are governed by Good Laboratory Practices, or GLP. Additionally, studies involving animals may be subject to further regulation by institutional, private or
government animal welfare authorities that may vary by territory. Studies involving human tissues may also be subject to institutional and government human subject privacy policies that may vary by territory. Third party vendors conducting tissue
and/or animal studies on our behalf may be found to be in violation of one or more of these regulations or policies and may be subject to closure, censure or other penalties. In some cases, these penalties could materially impact the performance,
availability, or validity of studies conducted on our behalf. Even in the absence of violations resulting in penalties, regulatory and other authorities may refuse to authorize the conduct or to accept the results of studies for regulatory or
ethical reasons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the
event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other
agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from claims relating to the products, processes or
services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our exercise of rights under the agreement. With respect to our commercial agreements, we indemnify our vendors from
any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage, our
business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage or the indemnification obligation exceeds the applicable insurance coverage and does not have other assets available to indemnify us, our business, financial condition and results of
operations could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to establish collaborations and, if we are not able to establish them on commercially
reasonable terms, we may have to alter our development and commercialization plans. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may seek one or more collaborators for the
development and commercialization of one or more of our product candidates. Likely collaborators may include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and
biotechnology companies. In addition, if we are able to obtain regulatory approval for product candidates from foreign regulatory authorities, we may enter into collaborations with international biotechnology or pharmaceutical companies for the
commercialization of such product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a
definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation
of a number of factors. Those factors may include the potential differentiation of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA, the EMA or comparable foreign
regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The
collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product candidate.
If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we
may not be able to further develop our product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Collaborations are
complex and time-consuming to negotiate and document. Further, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any
collaboration agreements that we enter into in the future may contain restrictions on our ability to enter into potential collaborations or to otherwise develop specified product candidates. We may not be able to negotiate collaborations on a timely
basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other
development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we enter into collaborations with third parties for the development and commercialization of our product candidates, our prospects with respect to
those product candidates will depend in significant part on the success of those collaborations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may enter into collaborations
for the development and commercialization of certain of our product candidates. If we enter into such collaborations, we will have limited control over the amount and timing of resources that our collaborators will dedicate to the development or
commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. In addition,
any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Collaborations involving our product candidates pose a number of risks, including the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the
collaborators&#146; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing priorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, including trade secrets and intellectual property rights, contract interpretation, or the preferred course of development might cause
delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be
time-consuming and expensive; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual
property or proprietary information or expose us to potential litigation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any
future collaborator of ours is involved in a business combination, it could decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may have to alter our development and commercialization plans if we are not able to establish collaborations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will require additional funds to complete the development and potential commercialization of RTB101 alone or in combination with everolimus
and other product candidates. For some of our product candidates, we may decide to collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking and obtaining appropriate collaborators. Whether
we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s
evaluation of a number of factors. Those factors may include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design or results of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of approval by the FDA or comparable foreign regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential market for the subject product candidate; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs and complexities of manufacturing and delivering such product candidate to patients; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for competing products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our patent position protecting the product candidate, including any uncertainty with respect to our ownership of our technology or our licensor&#146;s ownership of technology we license from them, which can exist if
there is a challenge to such ownership without regard to the merits of the challenge; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to seek licenses or <FONT STYLE="white-space:nowrap">sub-licenses</FONT> to third-party intellectual property;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">industry and market conditions generally. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The collaborator may also consider alternative
product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future
license agreements from entering into agreements on certain terms with potential collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced
number of potential future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are unable to reach agreements with suitable collaborators on a timely basis, on
acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any
sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain
additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and
commercialization activities, we may not be able to further develop our product candidates or bring them to market and our business may be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We only have a limited number of employees to manage and operate our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;16, 2018, we have seven full-time employees. Our focus on the development of RTB101, alone or in combination with
everolimus, requires us to optimize cash utilization and to manage and operate our business in a highly efficient manner. We cannot assure you that we will be able to hire and/or retain adequate staffing levels to develop RTB101, alone or in
combination with everolimus, or run our operations and/or to accomplish all of the objectives that we otherwise would seek to accomplish. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cyber-attacks or other failures in our telecommunications or information technology systems, or those
of our collaborators, contract research organizations, third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data corruption and significant disruption of our business operations.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, our collaborators, our CROs, third-party logistics providers, distributors and other contractors and consultants utilize
information technology, or IT, systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate attacks and
attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our, our collaborators&#146;, our CROs&#146;, third-party logistics providers&#146;,
distributors&#146; and other contractors&#146; and consultants&#146; systems and networks, and the confidentiality, availability and integrity of our data. There can be no assurance that we will be successful in preventing cyber-attacks or
successfully mitigating their effects. Similarly, there can be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants will be successful in protecting our clinical and other
data that is stored on their systems. Any cyber-attack or destruction or loss of data could have a material adverse effect on our business and prospects. For example, the loss of clinical trial data from completed or ongoing clinical trials for any
of our product candidates could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we may suffer reputational harm or face litigation or adverse
regulatory action as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend heavily on our executive officers, principal consultants and others and the loss of their services would materially harm our business.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our success depends, and will likely continue to depend, upon our ability to hire, retain the services of our current executive
officers, principal consultants and others, including Chen Schor, our president and chief executive officer, and Joan Mannick, our chief medical officer. We have entered into employment agreements with Mr.&nbsp;Schor and Dr.&nbsp;Mannick, but they
may terminate their employment with us at any time. Although we do not have any reason to believe that we will lose the services of Mr.&nbsp;Schor and Dr.&nbsp;Mannick in the foreseeable future, the loss of their services might impede the
achievement of our research, development and commercialization objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our ability to compete in the biotechnology and
pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. Our industry has experienced a high rate of turnover of management personnel in recent years. Replacing
executive officers or other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval
of and commercialize products successfully. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Competition to hire from this limited pool is intense, and we may be unable to hire, train,
retain or motivate these additional key employees on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical
personnel from universities and research institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We rely on consultants and advisors, including scientific and clinical advisors,
to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may
limit their availability to us. If we are unable to continue to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">One of our shareholders, PureTech Health, currently provides us with strategic medical, clinical and scientific advice pursuant to a business
services, personnel and information management agreement. In addition, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we currently share administrative resources and offices with PureTech Health, including legal, accounting and human resources support, computer and telecommunications systems and other office
infrastructure pursuant to the agreement. While we intend to occupy our own office space and hire additional qualified personnel to provide certain of these functions internally in the future, we are currently dependent on PureTech Health for these
services.&nbsp;If PureTech Health was unable or unwilling to continue to provide these shared resources, we may be unable to replace in a timely manner or on comparable terms the shared resources or other benefits that PureTech Health currently
provides.&nbsp;Also, upon the termination of the shared resources provided under the services agreement, such services will be provided internally or by unaffiliated third parties, and we expect that in some instances, we will incur higher costs to
obtain such services than we incurred under the terms of such agreement.&nbsp;If we are unable to transition the shared resources that PureTech Health provides to internal employees or unaffiliated third parties, or to do so in a cost effective and
timely manner, we may not be able to operate our business effectively and our business and financial condition could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
employees, independent contractors, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and
requirements, which could cause significant liability for us and harm our reputation. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our
employees, independent contractors, consultants, collaborators and contract research organizations may engage in fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless and/or negligent conduct
or disclosure of unauthorized activities to us that violates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA regulations or similar regulations of comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to
such authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing standards; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities; and
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">laws that require the reporting of financial information or data accurately. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Activities
subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product
materials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. Additionally, we are subject to the risk
that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare
programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the
areas of regulatory affairs and sales, marketing and distribution, as well as to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
support our public company operations. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and
continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Moreover, our expected growth could require us to relocate to a different
geographic area of the country. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion or relocation of our
operations, retain key employees, or identify, recruit and train additional qualified personnel. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to
operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other
projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to
implement our business strategy, including the successful commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our current operations are concentrated
primarily in a single location and any events affecting our headquarters may have material adverse consequences. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our current
operations are primarily located in our principal office in Boston, Massachusetts. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other
natural or manmade accidents or incidents that result in us being unable to fully utilize the office may have a material adverse effect on our ability to operate our business, and have significant negative consequences on our financial and operating
conditions. Loss of access to this office may result in increased costs, delays in the development of our product candidates or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels
that we believe are appropriate for our business. However, in the event of an accident or incident at our office, our insurance coverage may not be sufficient to satisfy all of our damages and losses. If our office is unable to operate because of an
accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prior to this offering, we operated as a private company and therefore, have no experience operating as a public company and complying with public
company obligations. Complying with these requirements will increase our costs, require additional management resources and qualified accounting and financial personnel, and we may fail to meet all of these obligations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will face increased legal, accounting, administrative and other costs and expenses as a public company. Compliance with the Sarbanes-Oxley
Act of 2002, the Dodd-Frank Act of 2010 and the rules promulgated thereunder, as well as rules of the SEC and Nasdaq, for example, will result in significant initial cost to us as well as ongoing increases in our legal, audit and financial
compliance costs, particularly after we are no longer an &#147;emerging growth company.&#148; The Securities Exchange Act of 1934, as amended, or the Exchange Act, requires, among other things, that we file certain periodic reports with respect to
our business and financial condition. Our executive officers and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations may make it more difficult and more expensive for us
to obtain director and officer liability insurance, and require us to incur substantial costs to maintain the same or similar coverage. We expect to incur significant expense and devote substantial management effort toward ensuring compliance with
Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 once we lose our status as an &#147;emerging growth company.&#148; We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with
appropriate public company experience and technical accounting knowledge, and it may be difficult to recruit and maintain such personnel. Implementing any appropriate changes to our internal controls may require specific compliance training for our
directors, officers and employees, entail substantial costs to modify our existing accounting systems, and take a significant period of time to complete. Such changes may not, however, be effective in maintaining the adequacy of our internal
controls, and any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
failure to maintain that adequacy, or consequent inability to produce accurate financial statements or other reports on a timely basis, could increase our operating costs and could materially
impair our ability to operate our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain an effective system of internal control over financial reporting, we may not be
able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate
disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition,
any testing by us conducted in connection with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial
reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause
investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required
to assess the effectiveness of these controls annually. However, for as long as we are an &#147;emerging growth company&#148; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness
of our internal controls over financial reporting pursuant to Section&nbsp;404. We could be an &#147;emerging growth company&#148; for up to five years. An independent assessment of the effectiveness of our internal controls over financial reporting
could detect problems that our management&#146;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to financial statement restatements and require us to incur the expense of
remediation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure controls and
procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the
time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be
circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures
due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have conducted and expect to continue to conduct our operations in jurisdictions outside of
the United States, and such foreign operations subject us to additional risks. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A portion of our operations, including our
clinical research and development efforts, have been undertaken outside of the United States, and we expect to continue to conduct a portion of our business in foreign countries. For example, we are conducting our ongoing Phase 2b clinical trial
across two hemispheres. In addition, we may utilize third party contract organizations, some of which may be located in foreign jurisdictions, for the conduct of our clinical trials, the manufacturing of our product candidates and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization of our product candidates, if approved. Such operations subject us to additional risks related to international business operations, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">price and currency exchange fluctuations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in tariffs, trade barriers and regulatory requirements; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in complying with tax, employment, immigration and labor laws for personnel living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting a product candidate and/or finished drug product supply or manufacturing capabilities abroad; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and terrorism, or natural disasters, including earthquakes, hurricanes, typhoons, floods and
fires;&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These and other risks may materially adversely affect our ability to conduct our business in international markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we
may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in
connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from
undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our
existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> responsibilities, increase our
expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.<B> </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and this Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not develop or be sustainable. If an active trading market does not develop, investors may not be able
to resell their shares at or above the initial public offering price and our ability to raise capital in the future may be impaired. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock will be
determined through negotiations with the underwriters. This price may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. Although our common stock has been approved for listing on The Nasdaq Global
Select Market, an active trading market for our shares may never develop or, if developed, be maintained following this offering. If an active market for our common stock does not develop or is not maintained, it may be difficult for you to sell
shares you purchase in this offering without depressing the market price for the shares or at all. An inactive trading market may also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to
acquire other companies or technologies by using our shares as consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock in this offering, you will
suffer immediate dilution in the net tangible book value of your investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common
stock is substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book
value per share after this offering. Based on the initial public offering price of $15.00 per share, you will experience immediate dilution of $10.05&nbsp;per share, representing the difference between our pro forma net tangible book value per share
after giving effect to this offering and the initial public offering price. Purchasers of common stock in this offering will have contributed approximately&nbsp;56.67% of the aggregate price paid by all purchasers of our capital stock and will own
approximately&nbsp;20.84% of our common stock outstanding after this offering, excluding any shares of our common stock that they may have acquired prior to this offering. Furthermore, if the underwriters exercise their over-allotment option or our
previously issued options and other rights to acquire common stock at prices below the initial public offering price are exercised, you will experience further dilution. For additional information on the dilution that you will experience immediately
after this offering, see the section titled &#147;Dilution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of our common stock is likely to be highly volatile, which
could result in substantial losses for purchasers of our common stock in this offering. Securities class action or other litigation involving our company or members of our management team could also substantially harm our business, financial
condition and results of operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be highly volatile. The stock market in general and the market
for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell
your common stock at or above the initial public offering price and you may lose some or all of your investment. The market price for our common stock may be influenced by many factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the success of existing or new competitive products or technologies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory actions with respect to our product candidates or our competitors&#146; products and product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and results of clinical trials of RTB101 alone or in combination with everolimus and any other product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commencement or termination of collaborations for our development programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or discontinuation of any of our development programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results of clinical trials of product candidates of our competitors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory or legal developments in the United States and other countries; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patent applications, issued patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recruitment or departure of key personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses related to any of our product candidates or clinical development programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our efforts to develop additional product candidates or products; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in estimates as to financial results or development timelines; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us, our insiders or other stockholders; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">variations in our financial results or those of companies that are perceived to be similar to us; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in estimates or recommendations by securities analysts, if any, that cover us; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of healthcare payment systems; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market conditions in the pharmaceutical and biotechnology sectors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic, industry and market conditions; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the other factors described in this &#147;Risk Factors&#148; section. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the past, securities
class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility
in recent years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways with which
you do not agree and in ways that may not yield a return on your investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we currently intend to use the net proceeds
from this offering in the manner described in the section titled &#147;Use of Proceeds&#148; in this prospectus, our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways
that do not improve our results of operations or enhance the value of our common stock. You will not have the opportunity to influence our decisions on how to use the net proceeds from this offering. The failure by our management to apply these
funds effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering
in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure
requirements applicable to emerging growth companies may make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are an emerging
growth company, and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to &#147;emerging growth
companies.&#148; We could remain an &#147;emerging growth company&#148; for up to five years, or until the earliest of (1)&nbsp;the last day of the first fiscal year in which our annual gross revenue exceeds $1.07&nbsp;billion, (2)&nbsp;the date
that we become a &#147;large accelerated filer&#148; as defined in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> under the Securities Exchange Act of 1934, which would occur if the market value of our common stock that is held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of the last business day of our most recently completed second fiscal quarter or (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt during the preceding three-year period. So long as we remain an &#147;emerging growth company,&#148; we expect to avail ourselves of the exemption from the requirement that our independent
registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404. When our independent registered public accounting firm is
required to undertake an assessment of our internal control over financial reporting, the cost of our compliance with Section&nbsp;404 will correspondingly increase. Moreover, if we are not able to comply with the requirements of Section&nbsp;404
applicable to us in a timely manner, or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock
could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an
&#147;emerging growth company,&#148; we will incur significant legal, accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. We also anticipate that we will
incur costs associated with relatively recently adopted corporate governance requirements, including requirements of the Securities and Exchange Commission, or SEC, and The Nasdaq Global Select Market. We expect these rules and regulations to
increase our legal and financial compliance costs and to make some activities more time-consuming and costly. We also expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer
liability insurance and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified
individuals to serve on our board of directors or as executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are currently evaluating and monitoring developments with
respect to these rules, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of
specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated
by ongoing revisions to disclosure and governance practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, or Section&nbsp;404,
we will be required to furnish a report by our management on our internal control over financial reporting beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the Securities and Exchange
Commission, or the SEC, after we become a public company. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered
public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this
regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve
control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk
that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&nbsp;404. If we identify one or more material weaknesses, it could result in an
adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares is restricted from immediate resale but may be
sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in
the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Following this offering, we will have 27,196,315 shares of common stock outstanding based on
5,659,089&nbsp;shares of our common stock outstanding as of December 31, 2017 and after giving effect to the conversion of all outstanding shares of our preferred stock into 15,870,559 shares of our common stock upon the closing of this offering. Of
these shares, the 5,666,667&nbsp;shares sold by us in this offering may be resold in the public market immediately, unless purchased by our affiliates. The remaining 21,529,648&nbsp;shares are currently restricted under securities laws or as a
result of <FONT STYLE="white-space:nowrap">lock-up</FONT> or other agreements, but will be able to be sold after this offering as described in the &#147;Shares Eligible for Future Sale&#148; section of this prospectus. The representatives of the
underwriters may release these stockholders from their <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters at any time and without notice, which would allow for earlier sales of shares in the public market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, after this offering, holders of an aggregate of&nbsp;15,870,559&nbsp;shares of our common stock will have rights, subject to
conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also plan to register all shares of common stock that we
may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Accordingly, stockholders must rely on capital
appreciation, if any, for any return on their investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have never declared nor paid cash dividends on our capital stock. We
currently plan to retain all of our future earnings, if any, to finance the operation, development and growth of our business. In addition, the terms of any future debt or credit agreements may preclude us from paying dividends. As a result, capital
appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of ownership of our common
stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based upon shares outstanding as of December 31, 2017, and after giving effect to the conversion of all outstanding shares of preferred stock
into shares of our common stock, upon the closing of this offering, our executive officers and directors, combined with our stockholders who owned more than 5% of our outstanding common stock before this offering and their affiliates, will, in the
aggregate, beneficially own shares representing approximately 72.3% of our common stock. Certain of our existing stockholders, including certain affiliates of our directors, have indicated an interest in purchasing an aggregate of up to
$35&nbsp;million of shares of our common stock in this offering at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less
or no shares in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, less or no shares in this offering. The foregoing discussion does not give effect to any purchases by these stockholders in this
offering. As a result, if these stockholders were to choose to act together, they would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to
act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, defer or prevent a change in control; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entrench our management or the board of directors; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of these persons or entities may have interests different than yours. For example, because many of these stockholders purchased their
shares at prices substantially below the price at which shares are being sold in this offering and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors or they may want us
to pursue strategies that deviate from the interests of other stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our corporate charter documents and under Delaware law
may prevent or frustrate attempts by our stockholders to change our management or hinder efforts to acquire a controlling interest in us. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Provisions in our corporate charter and our bylaws that will become effective upon the closing of this offering may discourage, delay or
prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that
investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team,
these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors such that all members of the board are not elected at one time; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allow the authorized number of our directors to be changed only by resolution of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit the manner in which stockholders can remove directors from the board; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit who may call a special meeting of stockholders; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#147;poison pill&#148; that would work to dilute the stock ownership of a potential hostile
acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the approval of the holders of at least 66.7% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the General Corporation Law of the
State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of
our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This could discourage, delay or prevent someone from acquiring us or merging with us, whether or not it is desired by, or beneficial to, our
stockholders. This could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the
price that investors are willing to pay for our stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our restated certificate of incorporation will provide that, unless we consent in writing to the
selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable
judicial forum for disputes with us or our directors, officers, employees or agents. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation,
which will become effective upon the closing of this offering, specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal
actions involving claims brought against us by stockholders. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our restated
certificate of incorporation described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe this provision benefits us by providing increased consistency in the application
of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However,
the provision may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#146;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes
with us or our directors, officers, employees or agents. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection
with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum
provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business,
financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable
research about our business, our share price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be
influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry
analysts commence coverage of us, or one or more of the analysts who cover us issues an adverse opinion about our company, our stock price would likely decline. If one or more of these analysts ceases research coverage of us or fails to regularly
publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY
DATA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than
statements of historical facts, contained in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected
market growth are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148;
&#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;would&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements
contain these identifying words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These forward-looking statements include, among other things, statements about: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize RTB101 alone or in combination with everolimus and other product candidates, including the therapeutic potential and clinical benefits thereof; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ongoing and future clinical trials for RTB101 alone or in combination with everolimus, whether conducted by us or by any future collaborators, including the timing of initiation of these trials and of the
anticipated results; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance and clinical utility of any products for which we receive regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intellectual property position and strategy; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify additional product candidates with significant commercial potential; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to enter into collaborations for the development and commercialization of product candidates; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential benefits of any future collaboration; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations related to the use of proceeds from this offering; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments relating to our competitors and our industry; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of government laws and regulations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed
in the forward-looking statements we make. We have included important factors in the cautionary statements included in this prospectus, particularly in the &#147;Risk Factors&#148; section, that could cause actual results or events to differ
materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or
enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we have filed as exhibits to the
registration statement of which this prospectus is a part completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus includes statistical and
other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information
has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this prospectus, and we believe these industry
publications and third-party research, surveys and studies are reliable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our issuance and sale of 5,666,667&nbsp;shares of our common stock in this offering will be
approximately $77.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise in full their option to purchase additional shares, we estimate that the net proceeds
from this offering will be approximately $89.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently estimate that we will use the net proceeds from this offering,
together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $85 million to fund the development of RTB101, alone and in combination with everolimus, for RTIs, through the completion of our ongoing Phase 2b clinical trial of RTB101 alone or in combination with
everolimus, the completion of a subsequent pivotal Phase 3 clinical program, assuming a successful outcome in our Phase 2b clinical trial of RTB101 alone or in combination with everolimus, and the filing of an NDA with the FDA, assuming a successful
outcome in our Phase 3 clinical program; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $16 million to fund the development of RTB101, alone and in combination with other rapalogs such as everolimus, for other indications, through the completion of at least one additional proof of concept
trial in an additional indication and to fund the development of our other TORC1 follow-on candidate and other pipeline candidates; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder, if any, for working capital and other general corporate purposes, which may include funding for the costs of operating as a public company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds from this offering and our existing cash represents our intentions based upon our current plans and
business conditions, which could change in the future as our plans and business conditions evolve. For example, we may use a portion of the net proceeds for the acquisition of businesses or technologies to continue to build our pipeline, our
research and development capabilities and our intellectual property position, although we currently have no agreements, commitments or understandings with respect to any such transaction. The amounts and timing of our actual expenditures may vary
significantly depending on numerous factors, including the progress of our development and commercialization efforts, the status of and results from clinical trials, any collaborations that we may enter into with third parties for our product
candidates and any unforeseen cash needs. Moreover, our estimates of the costs to fund our trials are based on the current designs of the trials. If we were to modify the design of any of these trials, for instance, to increase the number of
patients in the trials, our costs to fund the trials could increase. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on our current plans, we believe that our existing cash and cash equivalents, together with the net proceeds from this offering, will be
sufficient to enable us to fund our operating expenses and capital expenditure requirements at least through 2020, including the completion of our ongoing Phase 2b clinical trial of RTB101 alone or in combination with everolimus, the completion of a
subsequent pivotal Phase 3 clinical program, assuming a successful outcome in our Phase 2b clinical trial of RTB101 alone or in combination with everolimus, and the filing of an NDA with the FDA, assuming a successful outcome in our Phase 3 clinical
program. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We do not have any committed external source of funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments,
including short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to
finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and capitalization as of September&nbsp;30, 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma basis to give effect to (i)&nbsp;the sale and issuance of 7,763,975 shares of our Series A preferred stock in October 2017 for aggregate net proceeds of $15.0 million, (ii) the sale and issuance of
4,792,716 shares of our Series B preferred stock in November 2017 for aggregate net proceeds of $39.9&nbsp;million, (iii) the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 15,870,559 shares of common
stock upon the closing of this offering, and (iv)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this offering; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a pro forma as adjusted basis to give further effect to our issuance and sale of 5,666,667&nbsp;shares of our common stock in this offering at the initial public offering price of $15.00 per share, after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our capitalization following the
closing of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. You should read this table together with our financial statements and the related notes appearing at the end of
this prospectus and the sections of this prospectus titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands, except share and per<BR>share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series A), $0.0001 par value; 10,351,968 shares
authorized, 7,763,976 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock (Series B), $0.0001 par value; no shares authorized, issued
or outstanding, actual, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value; no shares authorized, issued or outstanding, actual;
10,000,000 shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 19,000,000 shares authorized, 5,659,089 shares issued and
outstanding, actual; 30,000,000 shares authorized, 21,529,648 shares issued and outstanding, pro forma;&nbsp;150,000,000&nbsp;shares authorized, 27,196,315 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The table above does not include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">111,320 shares of our common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30, 2017, at a weighted average exercise price of $0.81 per share; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">426,594 additional shares of our common stock available for future issuance as of September&nbsp;30, 2017 under our 2017 stock incentive plan, and the subsequent increase by 92,748 and 1,235,347 shares available for
future issuance in October and November 2017, respectively, which will no longer be available for future issuance following this offering; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,475,290&nbsp;additional shares of our common stock that will become available for future issuance under our 2018 stock incentive plan and our 2018 employee stock purchase plan, each effective upon the effectiveness of
the registration statement of which this prospectus forms a part, and from which we intend to grant options to purchase an aggregate of 331,310 shares of common stock to certain of our officers at the pricing of this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value (deficit) as of September&nbsp;30, 2017 was $(9.0) million, or $(1.60) per share of our common stock.
Our historical net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities and preferred stock, which is not included within stockholders&#146; equity (deficit). Historical net tangible book value
(deficit) per share represents our historical net tangible book value (deficit) divided by the 5,659,089 shares of our common stock outstanding as of September&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of September&nbsp;30, 2017 was $57.0 million, or $2.65 per share of our common stock. Pro forma net
tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to (i)&nbsp;the sale and issuance of 7,763,975 shares of our Series A preferred stock in October 2017 for aggregate gross proceeds
of $15.0&nbsp;million, (ii) the sale and issuance of 4,792,716 shares of our Series B preferred stock in November 2017 for aggregate net proceeds of $39.9&nbsp;million and (iii)&nbsp;the automatic conversion of all outstanding shares of our
preferred stock into an aggregate of 15,870,559 shares of our common stock upon the closing of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of shares outstanding
as of September&nbsp;30, 2017, after giving effect to the foregoing adjustments and the automatic conversion of all outstanding shares of our preferred stock into common stock upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After giving further effect to our issuance and sale of&nbsp;5,666,667&nbsp;shares of our common stock in this offering at the initial public
offering price of $15.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September&nbsp;30, 2017 would have been $134.6
million, or $4.95 per share. This represents an immediate increase in pro forma as adjusted net tangible book value per share of $2.30 to existing stockholders and immediate dilution of $10.05 in pro forma as adjusted net tangible book value per
share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per
share paid by new investors. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to the automatic conversion of preferred stock upon the closing of
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net
tangible book value per share after this offering would be $5.22 per share, representing an immediate increase in pro forma as adjusted net tangible book value per share of $2.57 to existing stockholders and immediate dilution in pro forma as
adjusted net tangible book value per share of $9.78 to new investors purchasing common stock in this offering, at the initial public offering price of $15.00 per share, and after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. If any shares are issued upon exercise of outstanding options, you will experience further dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes, as of September&nbsp;30, 2017, on the pro forma as adjusted
basis described above, the differences between the number of shares of common stock purchased from us, the total consideration paid to us and the average price per share paid by existing stockholders and by new investors purchasing shares of common
stock in this offering. The calculation below is based on the initial public offering price of $15.00 per share, before deducting underwriting discounts and commissions and estimated offering expenses payable by us: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Average&nbsp;Price<BR>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,529,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,000,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">20.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,000,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">56.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">27,196,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders, including certain affiliates of our directors, have indicated an
interest in purchasing an aggregate of up to $35&nbsp;million of shares of our common stock in this offering at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the
underwriters may determine to sell more, less or no shares in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, less or no shares in this offering. The table above does not reflect the potential
purchases by such stockholders in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The table above assumes no exercise of the underwriters&#146; option to purchase
additional shares in this offering. If the underwriters&#146; option to purchase 850,000 additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to&nbsp;39.94% of the total
number of shares of our common stock outstanding after this offering, and the number of shares of common stock held by new investors participating in the offering would be increased to&nbsp;60.06% of the total number of shares of our common stock
outstanding after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares purchased from us by existing stockholders is based on 5,659,089 shares of our
common stock outstanding as of September&nbsp;30, 2017, and gives effect to (i)&nbsp;the sale and issuance of 7,763,975 shares of our Series A preferred stock in October 2017, (ii) the sale and issuance of 4,792,716 shares of Series B preferred
stock in November 2017 and (iii)&nbsp;the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 15,870,559 shares of common stock upon the closing of this offering, and excludes: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">111,320 shares of our common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30, 2017, at a weighted average exercise price of $0.81 per share; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">426,594 additional shares of our common stock available for future issuance as of September&nbsp;30, 2017 under our 2017 stock incentive plan, and the subsequent increase by 92,748 and 1,235,347&nbsp;shares available
for future issuance in October and November 2017, respectively which will no longer be available for future issuance following this offering; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,475,290 additional shares of our common stock that will become available for future issuance under our 2018 stock incentive plan and our 2018 employee stock purchase plan, each effective upon the effectiveness of the
registration statement of which this prospectus forms a part, and from which we intend to grant options to purchase an aggregate of 331,310 shares of common stock to certain of our officers at the pricing of this offering. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_8"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following tables summarize our financial data as of the dates and for the periods indicated. The selected statements of operations data
for the period from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and the nine months ended September&nbsp;30, 2017 and the balance sheet data as of December&nbsp;31, 2016 and September&nbsp;30, 2017 have been derived from our audited
financial statements included elsewhere in this prospectus. The statement of operations data for the period from July 5, 2016 (inception) through September 30, 2016 have been derived from our unaudited financial statements included elsewhere in this
prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal, recurring adjustments, necessary for a fair statement of
the financial information in those statements. Our historical results from any prior period are not necessarily indicative of results to be expected in any future period, and our interim period results are not necessarily indicative of results to be
expected for a full year or any other interim period. The selected financial data below should be read in conjunction with the section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
and our financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:64.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)<BR>through<BR>December&nbsp;31,&nbsp;2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)<BR>through<BR>September&nbsp;30,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine
Months<BR>Ended<BR>September&nbsp;30,&nbsp;2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares used in computing net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,978,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,919,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,839,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares used in computing pro forma net loss per share, basic and diluted
(unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,230,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See Notes 2 and 12 in the notes to our financial statements included elsewhere in this prospectus for an explanation of the calculation of our basic and diluted net loss per share, the weighted-average common shares
used in computing basic and diluted net loss per share, basic and diluted pro forma net loss per share and the weighted-average common shares used in computing basic and diluted pro forma net loss per share. The information presented in this table
does not give effect to the sale and issuance of our Series A preferred stock in October 2017 and Series&nbsp;B preferred stock in November 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of
operations together with the section entitled &#147;Selected Financial Data&#148; and our financial statements and related notes included elsewhere in this prospectus. This discussion and other parts of this prospectus contain forward-looking
statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#147;Risk Factors&#148; included elsewhere in this prospectus. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Our lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled
trial, the potential to treat multiple diseases of aging for which there are no approved therapies. The decline in immune function that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases, including
respiratory tract infections, or RTIs, that significantly contribute to morbidity and mortality in the elderly. Our approach focuses on the mechanistic target of rapamycin, or mTOR, pathway, an evolutionarily conserved pathway that regulates aging,
and specifically on selective inhibition of the target of rapamycin complex 1, or TORC1. Our initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR
inhibitors such as everolimus&#151;as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunotherapy program designed to improve immune function and thereby reduce the incidence of RTIs in the elderly
regardless of the causative pathogen. We licensed the worldwide rights to our TORC1 program, including RTB101 alone or in combination with everolimus or other mTOR inhibitors, from Novartis International Pharmaceutical Ltd., or Novartis, in March
2017. We are evaluating RTB101 alone and in combination with everolimus in a Phase 2b clinical trial for the reduction of RTI incidence in the elderly and expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in the
second half of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since our inception in July 2016, we have devoted substantially all of our resources to: identifying, acquiring, and
developing our product candidate portfolio; organizing and staffing our company; raising capital; developing manufacturing capabilities; conducting clinical trials; and providing general and administrative support for these operations. To date, we
have primarily financed our operations through the issuance and sale of our redeemable convertible preferred stock. From our inception through September&nbsp;30, 2017, we received gross proceeds of $10.0&nbsp;million from the issuance and sale of
our redeemable convertible preferred stock. In October 2017, we received an additional $15.0&nbsp;million in gross proceeds from the issuance and sale of our redeemable convertible Series A preferred stock. In November 2017, we received an
additional $40.0 million in gross proceeds from the issuance and sale of our redeemable convertible Series B preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have
never generated revenue and have incurred significant net losses since inception. Our net losses were $1,000, $1,000 and $10.7&nbsp;million, for the period from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016, the period from
July&nbsp;5, 2016 (inception) to September&nbsp;30, 2016 and for the nine months ended September&nbsp;30, 2017, respectively. As of September&nbsp;30, 2017, we had an accumulated deficit of $10.7&nbsp;million. Our net losses may fluctuate
significantly from quarter to quarter and year to year. We expect to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially as we: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">invest significantly to further develop and seek regulatory approval for RTB101 alone or in combination with everolimus, including to continue our ongoing Phase 2b clinical trial; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expand our pipeline of potential product candidates, including the initiation of at least one additional proof of concept trial in an additional indication; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical, scientific, management and administrative personnel; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ultimately establish a sales, marketing and distribution infrastructure or collaborate with third parties to commercialize any drugs for which we may obtain regulatory approval; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other assets and technologies; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add additional operational, financial and management information systems and processes to support our ongoing development efforts, any future manufacturing or commercialization efforts and our transition to operating as
a public company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that our available funds subsequent to this offering will be sufficient to fund our operations
through 2020. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We do not expect to generate revenue from product sales unless and until we
successfully complete development and obtain regulatory approval for a product candidate or enter into collaborative agreements with third parties, which we expect will take a number of years and the outcome of which is subject to significant
uncertainty. Additionally, we currently use third parties such as contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, to carry out our preclinical and clinical development activities and we do not yet have a
sales organization. If we obtain regulatory approval for our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. To fund our current and future operating
plans, we will need additional capital, which we may obtain through one or more equity offerings, debt financings or other third-party funding, including potential strategic alliances and licensing or collaboration arrangements. We may, however, be
unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial
condition and our ability to develop our current product candidates, or any additional product candidates, if developed. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our
preclinical and clinical development efforts. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Novartis License Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;23, 2017, we entered into a license agreement with Novartis, pursuant to which we were granted an exclusive, field-restricted, worldwide license to certain intellectual property rights owned or controlled by Novartis, including patents,
patent applications, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property, to develop, commercialize and sell one or more therapeutic products comprising RTB101 or RTB101 and everolimus in a fixed
dose combination.&nbsp;Under the license agreement, we have been licensed a patent portfolio of ten patent families directed to composition of matter of RTB101 and its salts, formulations of everolimus and methods of using RTB101 and everolimus to
enhance the immune response among others.&nbsp;The exclusive field under the license agreement is for the treatment, prevention and diagnosis of diseases and other conditions in all indications in humans and animals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As initial consideration for the license, we issued Novartis Institutes for Biomedical Research, Inc., or NIBR, 2,587,992 shares of our Series
A Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement may be terminated by either party upon a material breach of obligation by the other party that is not
cured with 60 days after written notice. We may terminate the agreement in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis with or without cause with 60 days&#146; prior written notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Novartis may terminate the portion of the agreement related to everolimus if we fail to use commercially reasonable efforts to research, develop and commercialize a product utilizing everolimus
for a period of three years. Novartis may terminate the license agreement upon our bankruptcy, insolvency, dissolution or winding up. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As
additional consideration for the license, we are required to pay up to an aggregate of $4.3&nbsp;million upon the satisfaction of clinical milestones, up to an aggregate of $24&nbsp;million upon the satisfaction of regulatory milestones for the
first indication approved, and up to an aggregate of $18&nbsp;million upon the satisfaction of regulatory milestones for the second indication approved. In addition, we are required to pay up to an aggregate of $125&nbsp;million upon the
satisfaction of commercial milestones, based on the amount of annual net sales. We are also required to pay tiered royalties ranging from a <FONT STYLE="white-space:nowrap">mid-single</FONT> digit percentage to a
<FONT STYLE="white-space:nowrap">low-teen</FONT> digit percentage on annual net sales of products. These royalty obligations last on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the latest of (i)&nbsp;the expiration of the last valid claim of a Novartis patent covering a subject product, (ii)&nbsp;the expiration of any
regulatory exclusivity for the subject product in a country, or (iii)&nbsp;the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> anniversary of the first commercial sale in the country, and are subject to a reduction after the expiration of
the last valid claim of a Novartis patent or the introduction of a generic equivalent of a product in a country. In addition, if we sublicense the rights under the license agreement, we are required to pay a certain percentage of the sublicense
revenue to Novartis. Novartis will no longer be entitled to sublicense revenue following the last visit of the 400<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> subject in any human clinical trial conducted by us or a sublicensee of ours,
which we expect to occur by the end of our ongoing Phase&nbsp;2b clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Milestone payments to Novartis will be recorded as
research and development expenses in our statements of operations once achievement of each associated milestone has occurred or the achievement is considered probable. In May 2017, we initiated a Phase 2b clinical trial for a first indication,
triggering the first milestone payment under the agreement. Accordingly, we paid the related $0.3&nbsp;million payment in May 2017. As of September&nbsp;30, 2017, none of the remaining development milestones, regulatory milestones, sales milestones,
or royalties had been reached or were probable of achievement. We also enter into contracts in the normal course of business with various third parties for preclinical research studies, clinical trials, testing and other services. These contracts
generally provide for termination upon notice, and therefore we believe that our noncancelable obligations under these agreements are not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have not generated any revenue from the sale of our products, and we do not expect to generate any revenue unless and until we
obtain regulatory approval of and commercialize RTB101, alone or in combination with everolimus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for the development of our product candidates, which include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">personnel costs, which include salaries, benefits and stock-based compensation expense; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with consultants, third-party contract organizations and investigative clinical trial sites that conduct research and development activities on our behalf; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">laboratory and vendor expenses related to the execution of preclinical studies and clinical trials; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lab supplies and equipment used for internal research and development activities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have not provided program costs since inception because historically we have not tracked
or recorded our research and development expenses on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. We use our personnel and infrastructure resources across multiple research and
development programs directed toward developing our TORC1 program and for identifying and developing product candidates. We manage certain activities such as contract research and manufacturing of RTB101 alone or in combination with everolimus and
our discovery programs through our third-party vendors, and do not track the costs of these activities on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are
recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and
development activities related to developing our product candidates, including investments in manufacturing, as our programs advance into later stages of development and we continue to conduct clinical trials. The process of conducting the necessary
clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and
development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and
completion costs of the current or future preclinical studies and clinical trials or if, when, or to what extent we will generate revenues from the commercialization and sale of our product candidates. We may never succeed in achieving regulatory
approval for our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful completion of preclinical studies and Investigational New Drug-enabling studies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successful enrollment in, and completion of, clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receipt of regulatory approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining patent and trade secret protection and <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effectively competing with other therapies and treatment options; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile following approval; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enforcing and defending intellectual property and proprietary rights and claims; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">achieving desirable medicinal properties for the intended indications. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these factors could mean a significant change in the costs
and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA, or another regulatory authority were to require us to conduct clinical trials beyond those that we currently
anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional
financial resources and time on the completion of preclinical and clinical development. We expect our research and development expenses to increase for the foreseeable future as we continue the development of product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel costs, costs related to maintenance and filing of intellectual property,
depreciation expense and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation expense. We expect our general and
administrative expenses to increase for the foreseeable future due to anticipated increases in headcount to advance our product candidates and as a result of operating as a public company, including expenses related to compliance with the rules and
regulations of the Securities and Exchange Commission, The Nasdaq Global Select Market, additional insurance expenses, investor relations activities and other administration and professional services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income, Net </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income,
net, consists of <FONT STYLE="white-space:nowrap">non-cash</FONT> changes in fair value of the tranche rights liability associated with the redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Polices and Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and
liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other
factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ
from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas
involving management&#146;s judgments and estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We accrue for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of
preclinical studies and clinical trials, and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided, and include these costs in accrued liabilities
in our balance sheets and within research and development expense in our statements of operations. These costs are a significant component of our research and development expenses. We accrue for these costs based on factors such as estimates of the
work completed and in accordance with agreements established with our third-party service providers. We make judgments and estimates in determining the accrued liabilities balance in each reporting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred and consist of personnel costs, lab supplies and other costs, as well as fees paid to
third parties to conduct research and development activities on our behalf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Amounts incurred in connection with license agreements are also included in research and development expenses. We record payments made to outside vendors for services performed or goods being
delivered for use in research and development activities as either prepaid expenses or accrued expenses, depending on the timing of when services are performed or goods are delivered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Determination of Fair Value of Common and Preferred Shares and Tranche Rights Liabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As there has been no public market for our equity securities to date, the estimated fair value of our common and preferred shares has been
determined by the board of directors as of the grant date, with input from management, considering our most recently available third-party valuations of common shares and preferred shares and the board of directors&#146; assessment of additional
objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third party valuations were performed in accordance with the guidance outlined
in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>, or the Practice Aid. Our common and preferred share valuations were
prepared using either an option-pricing method, or OPM, or a probability-weighted expected return method, or PWERM, which uses a combination of market approaches and an income approach to estimate our enterprise value. The OPM treats common
securities and preferred securities as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#146;s securities changes. Under this
method, the common and preferred shares have value only if the funds available for distribution to stockholders are expected to exceed the value of the preferred security liquidation preference at the time of the liquidity event, such as a strategic
sale or a merger. The PWERM is a scenario-based methodology that estimates the fair value of common and preferred shares based upon an analysis of future values for the enterprise, assuming various outcomes. The common and preferred share values are
based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of common and preferred securities. The future value of the common and
preferred shares under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common and preferred shares. The estimated fair value of
the tranche liability was determined using the difference between the total purchase price of our Series A Preferred Stock and the total fair value of the Series A Preferred Stock using a risk-adjusted forward contract model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We recognize equity-based compensation expense for awards of equity instruments to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> based on the grant date fair value of those awards in accordance with the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 718, <I>Stock
Compensation</I>, or ASC 718. ASC 718 requires all equity-based compensation awards to employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, including grants of restricted shares and stock options, to be recognized as expense
in the Statements of Operations based on their grant date fair values. We estimate the fair value of stock options using the Black-Scholes option pricing model. We use the value of our common stock to determine the fair value of restricted shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We account for restricted stock and common stock options issued to nonemployees under FASB ASC Topic
<FONT STYLE="white-space:nowrap">505-50,</FONT> <I>Equity-Based Payments to <FONT STYLE="white-space:nowrap">Non-Employees,</FONT> </I>or ASC <FONT STYLE="white-space:nowrap">505-50.</FONT> As such, the value of such options is periodically
remeasured and income or expense is recognized over their vesting terms. Compensation cost related to awards with service-based vesting schedules is recognized using the straight-line method. We determine the fair value of the restricted stock and
common stock granted to nonemployees as either the fair value of the consideration received or the fair value of the equity instruments issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i)&nbsp;the expected volatility,
(ii)&nbsp;the expected term of the award, (iii)&nbsp;the risk-free interest rate and (iv)&nbsp;the expected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividend yield. Due to the lack of a public market for the trading of our common stock and a lack of company-specific historical and implied volatility data, we have based our estimate of
expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The group of representative
companies has characteristics similar to us, including stage of product development and focus on the life science industry. We use the simplified method, which is the average of the final vesting tranche date and the contractual term, to calculate
the expected term for options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to nonemployees, we utilize the contractual term of
the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. We use an assumed dividend yield of zero as we have
never paid dividends and have no current plans to pay any dividends on our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There were no stock options granted during the
period from July&nbsp;5, 2016 (inception) to December&nbsp;31, 2016. The following table presents the assumptions used to estimate the fair value of options granted during the nine months ended September&nbsp;30, 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine
Months<BR>Ended<BR>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Employees:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Nonemployees:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.79&nbsp;-&nbsp;$1.00</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">74.6%&nbsp;-&nbsp;76.9</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the period from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016, the nine months ended
September&nbsp;30, 2017, and the period from July&nbsp;5, 2016 (inception) through September&nbsp;30, 2016, stock-based compensation expense was $0, $0.3&nbsp;million, and $0, respectively. As of September&nbsp;30, 2017, we had $1.0&nbsp;million of
total unrecognized stock-based compensation expense, which we expect to recognize over a weighted-average period of 2.84 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
following table presents the grant dates of common shares, stock options, and awards that we granted from July&nbsp;5, 2016 (inception) through September&nbsp;30, 2017 along with the corresponding purchase or exercise price for each grant and our
estimate of the fair value per share of our common stock on each grant date, which we utilized to calculate stock-based compensation expense: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:38.85pt; font-size:8pt; font-family:Times New Roman"><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:51.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Type of Award</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:62.15pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Purchase&nbsp;or<BR>Exercise&nbsp;Price&nbsp;per<BR>Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:69.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Estimate&nbsp;of<BR>Common&nbsp;Stock&nbsp;Fair<BR>Value per Share on<BR>Grant
Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">7/11/2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted common shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,772,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">3/1/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,886,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.0001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">6/12/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">9/14/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">12/05/2017</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>1/12/2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Determination of the Fair Value of Common Stock on Grant Dates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Historically, for all periods prior to this offering, the fair values of the shares of common stock underlying our share-based awards were
estimated on each grant date by our board of directors. The restricted common shares were granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> and subsequently were marked to market at each reporting date. On April&nbsp;4, 2017, the <FONT
STYLE="white-space:nowrap">non-employees</FONT> became employees of our company and the fair value of the remaining unvested shares was fixed at $0.79 per share. In order to determine the fair value of our common stock our board of directors
considered, among other things, contemporaneous valuations of our common stock prepared by an independent third-party valuation specialist in accordance with the guidance provide by the Practice Aid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Given the absence of a public trading market for our common stock, our board of directors exercised their judgment and considered a number of
objective and subjective factors to determine the best estimate of the fair value of our common stock, including our stage of development; progress of our research and development efforts; the rights, preferences and privileges of our preferred
stock relative to those of our common stock; equity market conditions affecting comparable public companies; the lack of marketability of our common stock; and valuations obtained from issuance of our preferred stock to unrelated parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We performed common stock valuations, with the assistance of an independent third-party valuation specialist, as of March&nbsp;23, 2017,
September&nbsp;8, 2017, November 30, 2017 and December 31, 2017, which resulted in valuations of our common stock of $0.79, $1.00, $9.33 and $13.17, respectively. In conducting the valuations, the independent third-party valuation specialist
considered all objective and subjective factors that it believed to be relevant for each valuation conducted in accordance with the Practice Aid, including our best estimate of our business condition, prospects and operating performance at each
valuation date. Other significant factors included: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prices of our preferred stock sold to outside investors in arm&#146;s length transactions, and the rights, preferences and privileges of our preferred stock as compared to those of our common stock, including the
liquidation preferences of our preferred stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our stage of development and business strategy and the material risks related to our business and industry; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed mergers and acquisitions of guideline companies; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our results of operations and financial position; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the composition of, and changes to, our management team and board of directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the lack of liquidity of our common stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any external market conditions affecting the life sciences and biotechnology industry sectors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of achieving a liquidity event for the holders of our common stock and stock options, such as an initial public offering, or IPO, or a sale of our company, given prevailing market conditions; and
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the state of the IPO market for similarly situated privately held life sciences companies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The dates of our contemporaneous valuations have not always coincided with the dates of our stock option grants. In determining the exercise
prices of the stock options set forth in the table above, our board of directors considered, among other things, the most recent valuation of our common stock and their assessment of additional objective and subjective factors that were relevant as
of the grant dates. The additional factors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
considered when determining whether any changes in the fair value of our common stock had occurred between the most recent valuation and the grant dates included our stage of research and
development, our operating and financial performance and current business conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The estimates of fair value of our common stock are
highly complex and subjective. There are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates include assumptions regarding our future operating performance, the time
to completing an IPO or other liquidity event, the related valuations associated with these events, and the determinations of the appropriate valuation methods at each valuation date. The assumptions underlying these valuations represent
management&#146;s best estimates, which involve inherent uncertainties and the application of management judgment. If we had made different assumptions, our stock-based compensation expense, net loss and net loss per share applicable to common
stockholders could have been materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For valuations after the completion of this offering, our board of directors will
determine the fair value of each share of underlying common stock based on the closing price of our common stock as reported on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Determination of Estimated Offering Price </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We and our underwriters determined the price set forth on the cover of this prospectus, which is $15.00 per share. In comparison, our estimate
of the fair value of our common stock was $0.79 per share at June 12, 2017, which was determined by our board of directors with the assistance of a third-party valuation of our common stock as of March 23, 2017, $1.00 per share at September 14,
2017, which was determined by our board of directors with the assistance of a third-party valuation of our common stock as of September 8, 2017, $9.33 per share at December 5, 2017, which was determined by our board of directors with the assistance
of a third-party valuation of our common stock as of November 30, 2017 and $13.17 per share at January 12, 2018, which was determined by our board of directors with the assistance of a third-party valuation of our common stock as of December 31,
2017. With the exception of the December 31, 2017 valuation, all valuations were predicated on arm&#146;s length capital raises that transpired at each valuation date. The December 31, 2017 valuation was predicated on the estimated price range set
forth on the cover of the preliminary prospectus, adjusted for risk and lack of marketability. These valuations utilized the option pricing method, or OPM, to allocate value amongst the various ownership classes. The valuation for our June 2017
option grants attributed a 50% probability to an initial public offering, or IPO, and a 50% probability of a non-IPO liquidity event, and reflected a probability weighted average incremental discount for lack of marketability of 49.3% applied to the
non-IPO scenario. The valuation for our September 2017 option grants attributed a 60% probability to an initial public offering and a 40% probability of a non-IPO liquidity event and reflected a probability weighted average incremental discount for
lack of marketability of 49.4% applied to the non-IPO scenario. The valuation for our December 2017 option grants attributed a 75% probability to an initial public offering and a 25% probability of a non-IPO liquidity event, and reflected a
probability weighted average incremental discount for lack of marketability of 20% applied to the non-IPO scenario. The valuation for our January 2018 option grants attributed a 90% probability to an initial public offering and a 10% probability of
a non-IPO liquidity event, and reflected a probability weighted average discount for lack of marketability of 12%. In addition to quantitative analysis from third-party valuations of our common stock, we also considered macro-economic and market
conditions, including our subjective assessment of market conditions for initial public offerings of companies similarly situated to ours and our subjective assessment as to the likelihood of successfully executing an initial public offering in the
coming months, among other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We note that, as is typical in initial public offerings, the price for this offering was not derived
using a formal determination of fair value, but was determined based upon discussions between us and the underwriters. Among the factors considered in setting the price were prevailing market conditions, estimates of our business potential, progress
in our clinical trials and developments in our business, the general condition of the securities market and the market prices of, and demand for, publicly-traded common stock of generally comparable companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the periods from July&nbsp;5, 2016 (Inception) to December&nbsp;31, 2016, the Nine Months Ended September&nbsp;30, 2017,
and the period from July&nbsp;5, 2016 (Inception) to September&nbsp;30, 2016 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)&nbsp;through<BR>December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)&nbsp;through<BR>September&nbsp;30,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine
Months<BR>Ended<BR>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $0 for the periods from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and from
July&nbsp;5, 2016 (inception) through September&nbsp;30, 2016, as our primary operations did not commence until March&nbsp;23, 2017, when we acquired our license to develop, make, use, and sell products incorporating RTB101 alone or in combination
with everolimus. Research and development expenses increased to $10.0&nbsp;million for the nine months ended September&nbsp;30, 2017, and were primarily attributable to $3.9&nbsp;million of costs associated with our license agreement, including the
license of the intellectual property in exchange for Series A preferred stock, $1.0&nbsp;million of costs related to contract research and supplies, $4.0&nbsp;million of costs related to clinical trials, including the ongoing Phase 2b clinical
trial, $0.5&nbsp;million of costs related to external consulting incurred to supplement our research and development personnel, and $0.6&nbsp;million of personnel costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $1,000 for the periods from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and from
July&nbsp;5, 2016 (inception) through September&nbsp;30, 2016, and consisted entirely of registration and filing fees related to our incorporation. General and administrative expenses increased to $1.3&nbsp;million for the nine months ended
September&nbsp;30, 2017, and were primarily attributable to $0.5&nbsp;million of personnel, and $0.8&nbsp;million of professional services fees, including costs related to intellectual property, legal and filing costs, accounting costs, and external
consulting costs incurred to supplement our personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Other Income, Net </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income, net was $0 for the periods from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and from July&nbsp;5, 2016
(inception) through September&nbsp;30, 2016. Other income, net was $0.6&nbsp;million for the nine months ended September&nbsp;30, 2017, and entirely consisted of the change in fair value of our tranche liability related to our redeemable convertible
preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity, Capital Resources and Plan of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since inception through September&nbsp;30, 2017, our operations have been financed solely by net proceeds of $10.0&nbsp;million from the
issuance and sale of shares of our redeemable convertible preferred stock. As of September&nbsp;30, 2017, we had $4.0&nbsp;million in cash and an accumulated deficit of $10.7&nbsp;million. In October 2017, we received an additional
$15.0&nbsp;million in gross proceeds from the issuance and sale of our redeemable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convertible Series A preferred stock, or the Series A preferred stock, at the final closing of our Series A financing, as well as $40.0 million in gross proceeds from the issuance and sale of our
redeemable convertible Series B preferred stock, or the Series B preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our primary use of cash has been to fund operating
expenses, which consist of research and development and general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts
payable and accrued expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based upon our current operating plan, we believe that the net proceeds from this offering, together with
our existing cash will enable us to fund our operating expenses and capital expenditure requirements through our ongoing Phase&nbsp;2b clinical trial of RTB101 alone or in combination with everolimus, the completion of a subsequent pivotal
Phase&nbsp;3 clinical program, assuming a successful outcome in our Phase&nbsp;2b clinical trial of RTB101 alone or in combination with everolimus, and the filing of an NDA with the FDA, assuming a successful outcome in our Phase&nbsp;3 clinical
program. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product
candidate through clinical development, to develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity or
debt financings, collaborative or other arrangements, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms, or at all. Any failure to raise capital as and when needed could have a negative
impact on our financial condition and on our ability to pursue our business plans and strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Further, our operating plans may
change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the
numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and
anticipated product development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we need to raise additional capital to fund our operations, funding may not be available to
us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our clinical trials, research and development programs or commercialization efforts. We
may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, and collaborations or licensing arrangements. If we do raise additional capital through public or private equity
offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#146; rights. If we raise additional capital
through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If additional funding is required, there can
be no assurance that additional funds will be available to us on acceptable terms on a timely basis, if at all. If we are unable to raise capital, we will need to curtail planned activities to reduce costs. Doing so will likely have an unfavorable
effect on our ability to execute our business plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)&nbsp;through<BR>December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)&nbsp;through<BR>September&nbsp;30,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine
Months<BR>Ended<BR>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Operating Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No cash was used in operating activities for the periods from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and from
July&nbsp;5, 2016 (inception) through September&nbsp;30, 2016. Cash used in operating activities for the nine months ended September&nbsp;30, 2017 was $6.0&nbsp;million, consisting of a net loss of $10.7&nbsp;million adjusted for noncash items
primarily including stock-based compensation expense of $0.3&nbsp;million and expense related to the acquisition of intellectual property of $3.2&nbsp;million partially offset by gains resulting from the change in fair value of the tranche liability
of $0.6&nbsp;million. The change in our net operating assets and liabilities were due primarily to an increase in accounts payable of $1.1&nbsp;million as a result of payment timing and an increase in accrued liabilities of $1.0&nbsp;million
primarily due to increased clinical activities, which were partially offset by an increase in prepaid expenses and other current assets of $0.2&nbsp;million due to prepayments for our research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Investing Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No cash was used in investing activities for the periods from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and from
July&nbsp;5, 2016 (inception) through September&nbsp;30, 2016. Cash used in investing activities for the nine months ended September&nbsp;30, 2017 was $39,000 and consisted of the purchases of property and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows from Financing Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No cash was provided by financing activities for the periods from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and from
July&nbsp;5, 2016 (inception) through September&nbsp;30, 2016. Cash provided by financing activities for the nine months ended September&nbsp;30, 2017 was $10.0&nbsp;million from the issuance of redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Other Commitments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our outstanding contractual obligations as of payment due date by period at September&nbsp;30, 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:18.20pt; font-size:8pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:57.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Less&nbsp;than&nbsp;1&nbsp;Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:40.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1&nbsp;to&nbsp;3&nbsp;Years</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:40.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3&nbsp;to&nbsp;5&nbsp;Years</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:42.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>More&nbsp;than&nbsp;5<BR>Years</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$&#151;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$&#151;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we entered into a license Agreement with Novartis. See &#147;&#151;Overview&#151;Novartis
License Agreement.&#148; Amounts owed under this license agreement are not included in the table above as they were considered a contingent payment as of September&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2018, we entered into a multi-year agreement to lease office space in Boston, Massachusetts under an operating lease agreement. Our
minimum rent commitment under the lease totals approximately $0.7&nbsp;million. Payments under the contract are expected to commence in March 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Operating Loss Carryforwards. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2017, we had federal and state net operating loss carryforwards of $7.5&nbsp;million and $7.4&nbsp;million, respectively, which begin to expire in various amounts in 2036. As of September&nbsp;30, 2017, we also had federal
research and development tax credit carryforwards of $0.1&nbsp;million, which begin to expire in 2037. These net operating loss and tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities. In addition,
in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#147;ownership change&#148; is subject to limitations on its ability to utilize its pre-change net operating
losses or tax credits, or NOLs or credits, to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who own at least
5% of a corporation&#146;s stock increases its ownership by more than 50 percentage points over its lowest ownership percentage within a specified testing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period. Our existing NOLs or credits may be subject to limitations arising from previous ownership changes, and if we undergo an ownership change in connection with or after this offering, our
ability to utilize NOLs or credits could be further limited by Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and
383 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. If we determine that an ownership change has occurred and our ability to use our
historical NOLs or credits is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. We have not performed an ownership change analysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U. S. federal and state
taxable income. As described above under &#147;Risk Factors&#151;Risks Related to our Financial Position and Need for Additional Capital,&#148; we have incurred significant net losses since our inception and anticipate that we will continue to incur
significant losses for the foreseeable future; and therefore, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOL or credit carryforwards that are subject to limitation by Sections
382 and 383 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have not entered into any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements and do not have any holdings in variable
interest entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business. We had no cash equivalents, investments or outstanding debt as of
December&nbsp;31, 2016 and September&nbsp;30, 2017 and, as such, minimal exposure to market risk. At December&nbsp;31, 2016 and September&nbsp;30, 2017, we had cash in an operating account of $0 and $4.0&nbsp;million, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Accounting Election </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the
enactment of the JOBS Act until such time as those standards apply to private companies. We are considering whether to &#147;opt out&#148; of this provision and thereby comply with new or revised accounting standards as required when they are
adopted. If we do decide to &#147;opt out,&#148; this decision to &#147;opt out&#148; of the extended transition period under the JOBS Act is irrevocable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject
to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation, providing an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to
Section&nbsp;404(b) of the Sarbanes-Oxley Act. We would cease to be an emerging growth company upon the earliest of: (1)&nbsp;the last day of the fiscal year ending after the fifth anniversary of our initial public offering; (2)&nbsp;the last day of
the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; (3)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700.0&nbsp;million of equity securities held by
<FONT STYLE="white-space:nowrap">non-affiliates;</FONT> or (4)&nbsp;the issuance, in any three-year period, by our company of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities held by <FONT
STYLE="white-space:nowrap">non-affiliates.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued and Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU <FONT STYLE="white-space:nowrap">2014-15</FONT><I>,</I><I></I><I>&nbsp;Disclosure of Uncertainties about
an Entity&#146;s Ability to Continue as a Going Concern</I>, or ASU <FONT STYLE="white-space:nowrap">2014-15.</FONT> ASU <FONT STYLE="white-space:nowrap">2014-15</FONT> requires management to evaluate relevant conditions, events, and certain
management plans that are known or reasonably knowable that, when considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the aggregate, raise substantial doubt about the entity&#146;s ability to continue as a going concern within one year after the date that the financial statements are issued, for both annual
and interim periods. ASU <FONT STYLE="white-space:nowrap">2014-15</FONT> also requires certain disclosures around management&#146;s plans and evaluation, as well as the plans, if any, that are intended to mitigate those conditions or events that
will alleviate the substantial doubt. ASU <FONT STYLE="white-space:nowrap">2014-15</FONT> is effective for fiscal years ending after December&nbsp;15, 2016. We adopted this guidance on July&nbsp;5, 2016 (inception). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> Compensation&#151;<I>Stock Compensation (Topic
718)</I>, or ASU <FONT STYLE="white-space:nowrap">2016-09.</FONT> The guidance changes how companies account for certain aspects of equity-based payments to employees. Entities will be required to recognize income tax effects of awards in the income
statement when the awards vest or are settled. The guidance also allows an employer to repurchase more of an employee&#146;s shares than it can under current guidance for tax withholding purposes providing for withholding at the employee&#146;s
maximum rate as opposed to the minimum rate without triggering liability accounting and to make a policy election to account for forfeitures as they occur. The updated guidance is effective for annual periods beginning after December&nbsp;15, 2017.
Early adoption is permitted. We adopted this guidance on July&nbsp;5, 2016 (inception) and made the policy election to account for forfeitures as they occur. No awards have been forfeited as of September&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> <I>Statement of Cash Flows</I>, or ASU <FONT
STYLE="white-space:nowrap">2016-18,</FONT> which requires that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of cash flows. ASU
<FONT STYLE="white-space:nowrap">2016-18</FONT> is effective for fiscal years beginning after December&nbsp;15, 2018 and should be applied using a retrospective transition method to each period presented. Early adoption is permitted. We do not
expect the impact of ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> to be material to our financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May 2017, the
FASB issued ASU <FONT STYLE="white-space:nowrap">2017-09,</FONT> <I>Compensation&#151;Stock Compensation</I> (Topic 718): Scope of Modification Accounting, or ASU <FONT STYLE="white-space:nowrap">2017-09.</FONT> ASC
<FONT STYLE="white-space:nowrap">2017-09</FONT> provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The guidance is effective for annual
periods beginning after December&nbsp;15, 2017, with early adoption permitted, including adoption in any interim period for which financial statements have not yet been issued. We are currently evaluating the potential effects of adopting the
provisions of ASU <FONT STYLE="white-space:nowrap">2017-09.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Accounting for Certain Financial Instruments with Down Round Features</I>, or ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> which updates the guidance related to the classification analysis
of certain equity-linked financial instruments (or embedded features) with down round features. Under ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> a down round feature no longer precludes equity classification when assessing whether the
instrument is indexed to an entity&#146;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence
of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is
triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> is effective for public entities for all annual and interim periods
beginning after December&nbsp;15, 2019. Early adoption is permitted. We are currently evaluating the impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> will have on our financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Our lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled
trial, the potential to treat multiple diseases of aging for which there are no approved therapies. The decline in immune function that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases, including
respiratory tract infections, or RTIs, that significantly contribute to morbidity and mortality in the elderly. Our approach focuses on the mechanistic target of rapamycin, or mTOR, pathway, an evolutionarily conserved pathway that regulates aging,
and specifically on selective inhibition of the target of rapamycin complex 1, or TORC1. Our initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR
inhibitors such as everolimus&#151;as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunotherapy program designed to improve immune function and thereby reduce the incidence of RTIs in the elderly
regardless of the causative pathogen. We licensed the worldwide rights to our TORC1 program, including RTB101 alone or in combination with everolimus or other mTOR inhibitors, from Novartis International Pharmaceutical Ltd., or Novartis, in March
2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our TORC1 immunotherapy approach is supported by a randomized, placebo-controlled Phase 2a clinical trial in 264 elderly subjects
that provided statistically significant and clinically meaningful results. This trial demonstrated that treatment with RTB101 alone and in combination with everolimus can enhance the ability of the aging immune system to fight infectious pathogens
and consequently reduce the incidence of all infections, including RTIs in elderly subjects. Six weeks of treatment with RTB101 alone and in combination with everolimus met a prespecified endpoint of reducing the incidence of infections by 33%
(p=0.008) and 38% (p=0.001), respectively, during a period of one year following initiation of therapy. We are evaluating RTB101 alone and in combination with everolimus in a Phase 2b clinical trial for the reduction in the incidence of RTIs in the
elderly and expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in the second half of 2018. We expect market exclusivity for RTB101 alone and in combination with everolimus until at least 2031 in the United States
2032 in major European markets, and 2030 in Japan, and additional pending patent applications may prolong the exclusivity of these product candidates up to 2036. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Recent scientific findings, including those published in the scientific journals Cell, Nature and Science, suggest that aging and
aging-related conditions, such as immunosenescence, are attributable not only to random cellular wear and tear, but also to specific intra-cellular signaling pathways, including the mTOR pathway. mTOR is a protein kinase that signals via two
multiprotein complexes, known as TORC1 and TORC2. TORC1 inhibition has been observed to prolong lifespan, enhance immune function, ameliorate heart failure, enhance memory and mobility, decrease adiposity and delay the onset of aging-related
diseases in multiple animal studies. Specifically with respect to enhanced immune function, TORC1 inhibition was observed in preclinical studies to rejuvenate blood, or hematopoietic, stem cell function, increase infection-fighting white blood cell
production and enhance antibody-mediated, or adaptive, immunity. On the other hand, TORC2 inhibition has been observed to decrease lifespan in preclinical studies and cause unwanted side effects of hyperlipidemia and hyperglycemia in certain animals
and humans. Therefore, based on these observations and data from the Phase 2a clinical trial, we believe our TORC1 program is well-suited to improve immune function and counteract immunosenescence in the elderly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The reduced ability of elderly patients to effectively detect and fight infections is most commonly manifested in their susceptibility to RTIs
and the negative effects such infections have on their overall health. According to the U.S. Census Bureau, RTIs are the fifth leading cause of death in people age 85 and over and the seventh leading cause of death in people age 65 and over, and
result in high healthcare burdens and costs for the elderly population and the healthcare system. The majority of RTIs are caused by viruses for which there are no approved therapies. Despite this, antibiotics, which are ineffective against viruses,
are often prescribed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indiscriminately to treat RTIs, which may cause side effects related to antibiotic use and contribute to the growing global problem of antibiotic resistance. As the elderly represent the fastest
growing population in the world as a whole, we believe there is significant unmet medical need for innovative therapeutic options for reducing the incidence of RTIs by enhancing the function of the aging immune system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe our approach to addressing RTIs in the elderly possesses several clinical and commercial advantages. Our TORC1 program offers an
immunotherapy approach that has the potential to address a broad range of viral, and bacterial, pathogens. Statistically significant and clinically meaningful reductions in RTI incidence were observed in the Phase 2a clinical trial that evaluated
RTB101 alone and in combination with everolimus. We believe the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">risk-to-benefit</FONT></FONT> ratio of our program is well-suited to the elderly due to the following observations: our
oral product candidates were well-tolerated in elderly subjects and none of the participants in the active treatment arms experienced a serious adverse event that was related to the study drug, and the doses being investigated in our ongoing Phase
2b clinical trial are 60 to 240 times lower than maximum tolerated doses established in prior clinical trials for other indications. Based on communications including those during a high-level policy meeting with the U.S. Food and Drug
Administration, or FDA, to date, we believe a reduction in the incidence of RTIs has the potential to be a clinically relevant endpoint. Subject to receiving positive results from our ongoing Phase 2b clinical trial with respect to reduction in RTI
incidence, we plan to conduct a Phase 3 pivotal program and to seek regulatory approval for commercialization of RTB101 alone or in combination with everolimus in the United States, Europe and Japan. In some markets, we may collaborate with third
parties for the development and commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We were founded by Chen Schor, who serves as our President
and Chief Executive Officer, Joan Mannick, M.D., who serves as our Chief Medical Officer, and PureTech Health LLC, or PureTech Health, an affiliate of PureTech Health plc, an advanced clinical-stage biopharma company. Dr.&nbsp;Mannick led the TORC1
clinical program at Novartis Institutes for Biomedical Research, Inc., or NIBR, prior to our <FONT STYLE="white-space:nowrap">in-licensing</FONT> of the program. PureTech Health currently provides us with certain business services pursuant to a
business services, personnel and information management agreement. In addition, we currently share administrative resources with PureTech Health, including legal, accounting and human resources support, computer and telecommunications systems and
other office infrastructure pursuant to the agreement. PureTech Health has also assisted with our market research efforts, including conducting a market survey in the United States prior to our initiation of our ongoing Phase 2b clinical trial of
RTB101 alone and in combination with everolimus. We were a subsidiary of PureTech Health until the closing of our Series B financing. Based on the number of shares outstanding as of December&nbsp;31, 2017 and after giving effect to the sale of
5,666,667 shares in this offering (without giving effect to any potential purchases by PureTech Health of shares of our common stock in this offering), PureTech Health will beneficially own shares representing approximately 35.2% of our outstanding
common stock. In addition, PureTech Health has appointed two directors to our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our management team includes veterans
in drug development and discovery, with executive experience in leading global pharmaceutical companies. We are supported by investors that include both private equity venture capital funds and public healthcare investment funds. Our investors
include OrbiMed Advisors, Fidelity Management &amp; Research Company, Rock Springs Capital, Quan Capital and Nest Bio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our goal is to be a leading biopharmaceutical company focused on treating aging-related diseases. We strive to maintain a leadership position
in the TORC1 inhibitor class of pharmaceutical products. The key elements of our strategy to achieve this goal include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Rapidly advance our TORC1 program as immunotherapy for reducing the incidence of RTIs in elderly subjects.
</I>We initiated our Phase 2b clinical trial of RTB101 alone and in combination with everolimus in elderly subjects at increased risk of mortality and morbidity due to RTIs in the second quarter of 2017, and we expect to report <FONT
STYLE="white-space:nowrap">top-line</FONT> data from this trial in the second half of 2018. If </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the results of our Phase 2b clinical trial are positive, we plan to initiate a Phase 3 clinical trial in 2019 with a goal to submit a new drug application, or NDA, to the FDA for regulatory
approval of RTB101 alone or in combination with everolimus in the United States in 2020. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Develop our TORC1 program for additional indications. </I>We also intend to develop RTB101, alone or in combination with everolimus, for the treatment of additional aging-related diseases based on preclinical and
clinical evidence on the effects of TORC1 inhibition. We believe that there is strong rationale to support the investigation of RTB101, alone or in combination with everolimus, for the treatment of additional aging-related indications, such as
urinary tract infections, heart failure and neurodegenerative diseases. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialize our product candidates in the United States and potentially collaborate with others globally to maximize their commercial value.</I> We plan to directly commercialize our product candidates in the
United States with a sales force targeting <FONT STYLE="white-space:nowrap">top-prescribing</FONT> physicians with high flow of elderly patients and may consider collaborating with third parties to broaden the distribution of our product candidates
in the United States. In other markets for which commercialization may be less capital efficient for us, we may selectively pursue strategic collaborations with third parties in order to maximize the commercial potential of our product candidates.
We believe there are significant opportunities to market RTB101, if approved, in Europe and Japan, which we may choose to pursue in collaboration with others. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Maintain and grow a robust intellectual property portfolio in the field of TORC1 inhibition for aging-related diseases. </I>We have an exclusive license to ten patent families directed to compositions of matter,
methods and formulations covering RTB101 alone or in combination with everolimus. We intend to aggressively pursue and maintain broad intellectual property protection for RTB101 alone or in combination with everolimus or other compounds for the
prevention of RTIs and the prevention or&nbsp;treatment of other aging-related diseases through U.S. and international patents. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates that enhance our global leadership position. </I>We have additional TORC1 inhibitor compounds in discovery that we may
develop, and we may acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates targeting TORC1 and other pathways that regulate aging to support our goal to be the leading biopharmaceutical company focused on the
treatment of aging-related diseases with significant unmet medical need. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Pipeline </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes key information about our product candidates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g16r29.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Other infections include those that the elderly are at increased risk of contracting, such as urinary tract infections. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">For heart failure with preserved ejection fraction, autophagy-related neurodegenerative diseases and certain other infections, we may be required to file an investigational new drug application, or IND, prior to
initiating Phase 2 clinical trials. We expect to have the ability to initiate these Phase 2 clinical trials without the need to conduct prior Phase 1 clinical trials. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also have a follow-on TORC1 inhibitor program at discovery stage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Aging and its Regulation by the mTOR Pathway </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advances in the scientific understanding of aging have until recently been limited, despite high growth in the elderly population </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The elderly are the fastest growing population around the globe. According to the U.S. Census Bureau, the population age 65 and older in the
United States is expected to double by 2050 compared to 2012 estimates. According to global census data, there are nearly 150&nbsp;million people age 65 and older, and approximately 20&nbsp;million people age 85 years and older in the United States,
the major European countries and Japan. Despite age being the major risk factor for multiple chronic diseases, we believe few therapies are being developed to target the aging immune system, and none have been approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>mTOR is an evolutionarily conserved pathway that regulates aging </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">mTOR is a serine/threonine protein kinase that regulates the process of aging and aging-related diseases and conditions. Inhibition of the
mTOR pathway has been observed to prolong lifespan in multiple animals. These data support the potential for drugs that target the mTOR pathway to have therapeutic benefits for aging and aging-related conditions in humans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In preclinical studies, the mTOR pathway has been observed to be hyperactivated in some cell types, including hematopoietic stem cells, or
HSCs, at an advanced age. It was observed that suppressing mTOR activity in these cell types to levels found at younger ages may enhance cell function, including their ability to generate white blood cells. Furthermore, preclinical studies found
that mTOR activity stimulates protein synthesis and cell growth, but inhibits protective processes such as autophagy in which damaged proteins and organelles are broken down and recycled. Therefore, these studies suggest that increased mTOR activity
is beneficial during years of growth and reproduction but may be harmful during post-reproductive years when cells accumulate damage and require protective mechanisms such as autophagy to prevent and repair damage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">mTOR signals via two multiprotein complexes, known as TORC1 and TORC2. TORC1 inhibition has
been observed to prolong lifespan, enhance immune responses, ameliorate heart failure, enhance memory and mobility, decrease adiposity, and delay onset of aging-related diseases in multiple animal studies. On the other hand, TORC2 inhibition has
been observed to decrease lifespan and cause hyperlipidemia and hyperglycemia in certain animals and humans. Therefore, we believe the optimal approach for the treatment of aging-related conditions through mTOR inhibition is a regimen that inhibits
TORC1 without inhibiting TORC2. mTOR within the TORC1 complex introduces phosphates to, or phosphorylates, multiple proteins including S6K, 4EBP1 and Ulk1, as shown in the figure below. More complete inhibition of TORC1, as measured by decreased
phosphorylation of multiple proteins downstream of TORC1, may also be more beneficial compared to partial inhibition of TORC1 for the treatment of aging-related diseases. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g77j27.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe TORC1 inhibition may have
therapeutic benefit in multiple aging-related diseases. Preclinical studies suggest that key mechanisms involved in the anti-aging effects of TORC1 inhibition include improved stem cell function, increased autophagy, increased expression of
mitochondrial proteins that are important for energy production, decreased adiposity and increased expression of proteins that are responsible for cellular maintenance and repair. Based on preclinical data, these biological effects have the
potential to improve multiple aging-related pathologies: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><I>Decreased immune function and increased risk of infections.</I> The immune system has several important functions, including protection against harmful pathogens, cancer immunosurveillance and clearance of senescent
cells. Innate immunity is the body&#146;s first line of defense against a wide range of pathogens, while adaptive immunity is a more pathogen-specific immune response that develops over time. Immune cells are produced by HSCs in the bone marrow,
which can lose functionality with age. In preclinical studies, aged dendritic cells, a type of innate immune cell, demonstrated defective Type 1 interferon production, a central component of anti-viral immunity, in response to a virus. This response
is consistent with the observation that dendritic cells from older subjects produced less interferon upon stimulation with a virus than those from younger subjects. Adaptive immunity also declines with age. The number and functionality of certain
white blood cells known as lymphocytes, including antibody-producing B lymphocytes, have been observed to be decreased in elderly human subjects. We believe that this decline in immune function contributes to the higher incidence of common
infections such as respiratory and urinary tract infections in the elderly. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Decreased mitochondrial function and organ dysfunction.</I> During aging, mitochondrial function, which is
important for metabolism and energy production in cells, is diminished. This diminution is </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
linked to a switch from more efficient fatty acid oxidation to less efficient glucose oxidation in aging organs. The detrimental nature of this metabolic change has been extensively described in
animal and human studies of aging-related conditions, including heart failure. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><I>Decreased autophagy and accumulation of damaged proteins</I>. Autophagy is the process in which a cell breaks down and recycles damaged cellular components, including damaged and aggregated proteins. Preclinical data
suggests that an aging-associated decrease in autophagy leads to the accumulation of toxic proteins and may result in aging-associated pathologies such as neurodegeneration. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immunosenescence and Respiratory Tract Infections in the Elderly </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential for TORC1 inhibition to address decreased immune function associated with aging </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">TORC1 inhibition has been observed to enhance immune function in at least three independent preclinical studies to date, conducted by
laboratories at the University of Michigan, Emory University and St.&nbsp;Jude Children&#146;s Research Hospital, where administration of mTOR inhibitors improved immune response to influenza vaccination. Further, findings from these preclinical
studies suggest that short-term treatment of aged animals with a TORC1 inhibitor can rejuvenate HSC function, increase the number of infection-fighting white blood cells, and increase longevity. We believe these findings suggest that TORC1
inhibition has the potential to improve immune function in elderly humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Respiratory tract infections in the elderly </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The reduced ability of the aging immune system to effectively detect and fight infections results in increased susceptibility of the elderly
to RTIs, which, in turn negatively impacts such patients&#146; overall health and quality of life. We believe that decreasing the incidence of RTIs is a large unmet medical need in the elderly, particularly in subjects at an increased risk of <FONT
STYLE="white-space:nowrap">RTI-related</FONT> morbidity and mortality. We believe there is a significant unmet medical need for an innovative therapy to reduce the incidence of RTIs in the elderly for the following reasons: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>The large and growing elderly population is particularly susceptible to morbidity and mortality from RTIs</I>. The elderly represent the fastest growing population across the globe. In the United States, RTIs are the
fifth leading cause of death in people age 85 and over and the seventh leading cause of death in people age 65 and over. Mortality among people age 75 and over is highest each year during winter cold and flu season. Age is a risk factor for RTIs,
with men aged <FONT STYLE="white-space:nowrap">85-89</FONT> experiencing lower RTIs at twice the rate of men aged <FONT STYLE="white-space:nowrap">65-69.</FONT> As a result, RTIs, which are typically not serious in healthy adults, are exacerbated in
the elderly. Elderly patients with comorbidities may also be at a higher risk of morbidity and mortality due to RTIs as compared to healthy elderly subjects. Comorbidities among the elderly aged 65 and older are common, with approximately 14% having
chronic obstructive pulmonary disease, or COPD, 7% having asthma, 20% having type 2 diabetes mellitus, or T2DM, and 13% having congestive heart failure, or CHF. Prior to initiating the Phase&nbsp;2b clinical trial, PureTech Health conducted market
research with five payers and 55 physicians in the United States. The results of the research provided further support that the efficacy demonstrated in the Phase&nbsp;2a clinical trial is clinically meaningful and that there is unmet medical need
in the elderly, particularly in the elderly at high risk of mortality from RTls. Specifically, a reduction in the incidence of RTls of similar or lower magnitude to that observed in the Phase 2a trial was described as a clinically meaningful
improvement by the majority of respondents in a survey of 50 physicians. Further, 84% of the physicians who participated in the survey perceived that there is unmet need for either prophylactics or treatment options, or both, for viral respiratory
infections. Phone interviews with payers also illustrated that, subject to FDA approval, payers may be able to include a product with our efficacy and safety profile into a preferred tier on their formularies and may request a modest rebate. The
following figures highlight the number of elderly people in the United States, major European countries and Japan, along with their comorbidities, based on global census data and our market research performed in the U.S., and the historical rates of
lower RTIs in the elderly population in the U.K. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Estimated Size of Population Susceptible to
<FONT STYLE="white-space:nowrap">RTI-related</FONT> Morbidity and Mortality </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g16k55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lower Respiratory Tract Infection Rates Increase with Age </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g79t13.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>RTIs contribute to high healthcare burden and costs</I>. At least 11%, 56% and 80% of CHF exacerbations, COPD exacerbations requiring hospitalization and asthma exacerbations, respectively, are associated with RTIs,
and 7% of people aged 85 years and over go to the emergency room with RTIs each year. In addition, <FONT STYLE="white-space:nowrap">two-thirds</FONT> of people aged 85 and over who go to the emergency room for infection-related reasons are
hospitalized, and once hospitalized, <FONT STYLE="white-space:nowrap">one-third</FONT> of people aged 85 and over are admitted to a nursing home. These figures illustrate the large economic impact of RTIs on the healthcare system in the United
States. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>The majority of RTIs are caused by viruses for which no available therapy exists</I>. The majority of RTIs are
caused by viruses, most of which lack approved prophylactics or therapies, leaving physicians with few treatment options. Based on Center for Disease Control, or CDC, guidelines, vaccines are given to prevent influenza and pneumococcal infections.
However, even if vaccinated, the elderly are less likely to develop sufficient protective immunity against influenza and pneumococcal infections due to immunosenescence. In addition, vaccines against most of the viral
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
pathogens that cause RTIs are not currently available. The following figure illustrates the specific pathogens detected in patients 80 years or older hospitalized with community-acquired
pneumonia. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:9%">


<IMG SRC="g475892g99k81.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Antibiotics are often prescribed indiscriminately to treat RTIs, leading to potential side effects and contributing to growing antibiotic resistance</I>. Antibiotics, which are ineffective against viruses, are often
prescribed indiscriminately to treat RTIs, which may cause side effects related to antibiotic use and contribute to the growing global problem of antibiotic resistance. As antibiotic use is a primary driver of antibiotic resistance, we believe that
reducing the incidence of RTIs in the elderly could also indirectly limit the rise of antibiotic-resistant bacteria. Furthermore, the elderly are at increased risk of antibiotic-related adverse events due to increased organ sensitivity, increased
exposure due to changes in pharmacokinetics, and polypharmacy. According to a study conducted by McGill University, antibiotics have been linked to 17% of adverse drug-related events in the elderly who visit emergency departments. Antibiotic use can
also lead to lethal superinfections such as <I>C. difficile </I>infections. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Lack of immunotherapy drugs to address RTIs</I>. Immunotherapies ideally enhance both innate and adaptive immunity to provide broad, acute and long-lasting protection against pathogens. Currently, however, there are
no approved immunotherapies to enhance either innate or adaptive immunity in the elderly. We believe RTB101 alone or in combination with everolimus represent immunotherapies aimed at enhancing either innate or innate and adaptive immunity in the
elderly, and thereby decreasing the incidence of RTIs caused by a broad spectrum of pathogens, particularly viral pathogens. In addition, beyond an individual level, we believe immunotherapies may benefit the wider population through indirect
protection that occurs when a large percentage of the population has become immune to a disease, thereby preventing or limiting the spread of infection and providing a measure of protection for individuals who are not immune, a phenomenon known as
herd immunity. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our TORC1 Program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we
obtained a license from Novartis to the worldwide rights to RTB101 for all indications, and the rights to use everolimus in combination with RTB101 for all aging-related indications. RTB101 is an orally administered, small molecule, potent TORC1
inhibitor that binds to the active site of mTOR on the TORC1 complex, a mechanism known as catalytic inhibition. In contrast, everolimus, also an orally administered small molecule, inhibits mTOR activity by changing the shape of TORC1, a mechanism
known as allosteric inhibition, that is distinct from and synergistic with catalytic inhibition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The downstream signaling cascade of
TORC1 that we believe occurs in scenarios of baseline, RTB101 alone and RTB101 in combination with everolimus are pictured in the following figure. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g21d19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our TORC1 program includes evaluation of RTB101 alone because we believe RTB101 monotherapy can effectively
inhibit phosphorylation of multiple downstream signaling nodes of TORC1, specifically S6K and 4EBP1, that are key drivers of TORC1 downstream activity. Decreased phosphorylation of S6K leads to decreased activity, while decreased phosphorylation of
4EBP1 and Ulk1 leads to increased activity. We believe RTB101 alone consistently inhibits more downstream signaling nodes of TORC1 than a rapalog, such as everolimus, alone. Furthermore, we believe RTB101 at the low doses that we are evaluating in
our clinical studies can achieve these effects without inhibiting TORC2. RTB101 at higher doses, while able to more completely inhibit TORC1, may also inhibit TORC2, which may lead to undesirable side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our TORC1 program also includes evaluation of RTB101 in combination with everolimus, as the combination of catalytic and allosteric inhibitors
may yield complete inhibition of all nodes downstream of TORC1, including 4EBP1 and Ulk1, without affecting TORC2. It was observed in preclinical in vitro studies that RTB101 and everolimus at the comparable doses that we are evaluating in our
clinical trials synergistically inhibit 4EBP1. The synergy of RTB101 and everolimus, as measured by Loewe additivity, was up to 43% in those studies. Loewe additivity in excess of 30% is considered to be high. We believe everolimus may induce a
conformation change in TORC1 that allows lower concentrations of RTB101 to inhibit TORC1 without inhibiting TORC2. Preclinical and clinical data suggest that for some indications, RTB101 monotherapy may be adequate to yield clinically meaningful
benefit to patients, while for other indications, the combination of RTB101 and everolimus may be more beneficial. Accordingly, our TORC1 program includes evaluation of both RTB101 alone and in combination with everolimus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Development of RTB101 Alone and in Combination with Everolimus </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We consider data from a Phase 2a clinical trial conducted by our licensor, Novartis, which became available in 2016 to be the most directly
relevant dataset for our near-term development of RTB101 alone and in combination with everolimus, including the design of our ongoing Phase 2b trial evaluating the safety, tolerability and efficacy of our product candidates to reduce the incidence
of RTIs in the elderly. If results from our ongoing Phase 2b clinical trial are positive, we intend to initiate a Phase 3 program for RTB101 alone or in combination with everolimus in 2019. We believe that safety data of high-dose RTB101 alone and
in combination with everolimus, at similar or higher doses than those tested in our Phase 2b clinical trial, that was generated by our licensor, Novartis, in clinical trials conducted from 2006 to 2016, provide additional support for the clinical
development of our program. The potential for TORC1 inhibition to ameliorate immunosenescence was also demonstrated in a previous Phase 2a clinical trial of everolimus monotherapy conducted by Novartis and published in Science Translational Medicine
in December 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2a Clinical Development </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The primary objectives of the RTB101 and RTB101+ everolimus Phase 2a clinical trial were to assess the safety, tolerability and efficacy of
RTB101 alone and in combination with everolimus compared to placebo in enhancing the immune response to vaccination in elderly subjects, as determined by the subjects&#146; immune response to the seasonal influenza vaccine. A <FONT
STYLE="white-space:nowrap">pre-specified</FONT> exploratory endpoint assessed the effect of a <FONT STYLE="white-space:nowrap">six-week</FONT> course of RTB101 alone or in combination with everolimus on infection rates during the year following
initiation of study drug treatment. The trial was a double-blinded, placebo-controlled, randomized clinical trial that enrolled a total of 264 male and female subjects at least 65 years of age without underlying unstable medical conditions, and was
conducted across 12 trial centers in the southern hemisphere. Subjects were randomized to one of five treatment arms, in which they were administered daily oral doses of everolimus 0.1 mg, everolimus 0.5 mg, RTB101 10 mg, RTB101 10 mg+everolimus 0.1
mg, or placebo. The trial met its primary endpoint and the <FONT STYLE="white-space:nowrap">pre-specified</FONT> exploratory infection rate endpoint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subjects were treated for six weeks with the study drug and, after a two week drug-free interval, were given the seasonal influenza vaccine.
The subjects were followed for one year following initiation of study drug treatment. The overall infection rate in each treatment group was assessed by having subjects record any infections they experienced during the year following the initiation
of study drug treatment in a diary. The sites reviewed the infection diary at each study visit. In addition, sites administered infection questionnaires during phone calls with subjects that occurred weekly during the
<FONT STYLE="white-space:nowrap">six-week</FONT> study drug dosing period and then monthly for the remainder of the trial. Investigators reviewed and approved the information contained in the telephone questionnaire reports within 24 hours. The
infection data in the diaries and telephone reports were reconciled by sites prior to entering infections in the clinical trial database. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the RTB101 monotherapy and RTB101+everolimus combination treatment arms in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> population, statistically significant and clinically meaningful reductions in the annual rate of infections of 33% (p=0.008) and 38% (p=0.001), respectively,
compared to placebo, were observed. The FDA utilizes the reported statistical measures when evaluating the results of a clinical trial, including statistical significance as measured by p-value as an evidentiary standard of efficacy, to evaluate the
reported evidence of a product candidate&#146;s safety and efficacy. If not otherwise specified, we used a conventional 5% or lower p-value (p &lt; 0.05) to define statistical significance for the clinical trials and data presented in this
prospectus. A lesser, <FONT STYLE="white-space:nowrap">non-statistically</FONT> significant effect was observed with everolimus monotherapy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g07q36.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since the most common infections that occurred during the trial were RTIs, a <FONT
STYLE="white-space:nowrap">post-hoc</FONT> analysis was performed to determine whether a reduction in RTIs contributed to the significant reduction in infections at one year following initiation of study drug treatment in the RTB101 monotherapy and
RTB101+everolimus combination treatment arms. As shown in the figure below, both RTB101 monotherapy and the RTB101+everolimus combination therapy were observed to reduce the incidence of RTIs at one year by 42% (p=0.006) and 36% (p=0.01),
respectively, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat</FONT></FONT> population. Greater reductions in the incidence of RTIs were observed during the <FONT STYLE="white-space:nowrap">six-week</FONT>
dosing period in the RTB101 monotherapy and RTB101+everolimus combination arms. Given that the magnitude of the reduction in RTI incidence was greater at six&nbsp;weeks than at one year, these findings suggest that the reduction in RTI rates was
greatest during the period when subjects were receiving the study drug. The typical duration of the peak cold and flu season is approximately 16 weeks. As shown in the figure below, analysis of the Phase 2a clinical data also revealed reductions of
45% (p=0.039) and 50% (p=0.013) in RTIs from treatment with RTB101 alone and in combination with everolimus, respectively, during the 16 weeks following initiation of therapy despite only six weeks of treatment. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g80i74.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To assess possible molecular mechanisms underlying the decrease in infection rates in the
RTB101 monotherapy and RTB101+everolimus combination treatment groups, mRNA sequencing analysis of whole blood from subjects at baseline and after six weeks of study drug treatment was conducted. Analysis of whole-blood gene expression data revealed
a highly statistically significant <FONT STYLE="white-space:nowrap">up-regulation</FONT> of pathways related to interferon signaling in the RTB101 monotherapy and RTB101+everolimus combination treatment arms but not in the placebo arm, as shown in
the figures below. Genes that were <FONT STYLE="white-space:nowrap">up-regulated</FONT> the most, including MX1, OAS3, ISG15 and IFIT1, encode a subset of Type 1 interferon-induced proteins that play a critical role in the acute, innate immune
response to viruses, suggesting that RTB101 alone and in combination with everolimus may enhance innate immunity. Pathways, or groups of genes, related to cytokine signaling and interferon signaling were significantly upregulated, with p-values
ranging between 10<SUP STYLE="font-size:85%; vertical-align:top">-45</SUP> to 10<SUP STYLE="font-size:85%; vertical-align:top">-10</SUP>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g14y95.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">While the effects of RTB101 monotherapy and RTB101+everolimus combination therapy on
reducing RTIs incidence in the elderly and <FONT STYLE="white-space:nowrap">up-regulating</FONT> innate immunity genes were comparable, only the combination therapy met the primary endpoint of the Phase 2a clinical trial of enhancing influenza
vaccination response, defined as a greater than 20% increase in antibody concentrations, or titers, to at least two of the three tested influenza vaccine strains as compared to placebo, measured at 12 weeks following initial dosing of the study
drug. We believe these results suggest that the RTB101+everolimus combination therapy may also enhance the adaptive immune system, in addition to enhancing the innate immune system, given that the RTB101+everolimus combination resulted in broader
TORC1 inhibition. The adaptive immune response to influenza vaccination across all treatment arms is shown in the figure below, where asterisks indicate a 100% probability that titers are greater than those observed in the placebo group. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g16s95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Overall, all treatment regimens were well tolerated. None of the participants in the active treatment arms
experienced a serious adverse event, or SAE, that was related to the study drug. The following table summarizes the SAEs experienced by trial subjects during the year they were followed in the trial. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Everolimus<BR>0.1mg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Everolimus<BR>0.5mg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RTB101&nbsp;10mg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RTB101&nbsp;10mg&nbsp;+<BR>Everolimus&nbsp;0.1mg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Placebo</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total SAEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subjects with SAEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">% of subjects with SAEs*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Percentages are based on the total number of subjects in each arm that received at least part of one dose of study drug </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The ten most prevalent adverse events, or AEs, during the 12&nbsp;months that patients were
followed in the trial is summarized in the figure below. Diarrhea was the most frequently reported AE that occurred more often in the study drug treatment groups than the placebo groups and was generally mild or moderate in severity, transient and
resolved with no treatment. Of note, the rate of upper RTI, nasopharyngitis and cough was lower for RTB101 monotherapy and RTB101+everolimus combination than for placebo, suggesting greater freedom from respiratory symptoms in the treatment groups
as compared to the placebo groups. Furthermore, rates of hyperglycemia and hypercholesterolemia, which are AEs associated with TORC2 inhibition, were less than 5% in all treatment groups and were the same or lower in the mTOR inhibitor treatment
groups than the placebo groups, suggesting that these low dose mTOR inhibitor treatment regimens did not inhibit TORC2. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g74c97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the Phase 2a clinical trial results provide proof of concept for the potential therapeutic
benefit of RTB101 alone or in combination with everolimus as immunotherapy to reduce the incidence of RTIs in elderly patients, given the statistically significant and clinically meaningful reduction in RTI rates, the increased expression of innate
anti-viral genes and the enhanced immune response to vaccination observed across the treatment groups. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ongoing Phase 2b Clinical Development </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are conducting a randomized, double-blinded, placebo-controlled Phase 2b clinical trial to assess the safety, tolerability and efficacy of
16 weeks of treatment with RTB101 alone or in combination with everolimus as compared to placebo in elderly patients without unstable medical conditions but who are at increased risk of <FONT STYLE="white-space:nowrap">RTI-related</FONT> morbidity
or mortality. Elderly patients at increased risk of <FONT STYLE="white-space:nowrap">RTI-associated</FONT> morbidity and mortality are defined as subjects who are 85 years of age or older or subjects 65 years of age or older with asthma, chronic
obstructive pulmonary disease, chronic bronchitis, Type 2 diabetes mellitus, congestive heart failure, an emergency room visit or hospitalization for an RTI within the past 12&nbsp;months, or who are current smokers. We are conducting the trial in
two parts across two hemispheres. The first part was conducted during the winter cold and flu season in the southern hemisphere. Following an interim analysis that we conducted in October 2017, we commenced the second part during the winter cold and
flu season in the United States in the fourth quarter of 2017. We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in the second half of 2018. The primary endpoint of the trial is to determine if RTB101 alone or
in combination with everolimus decreases the percentage of subjects with RTIs compared to placebo during the <FONT STYLE="white-space:nowrap">16-week</FONT> administration period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the first part of the trial, 179 patients were randomized to receive RTB101 10 mg daily, RTB101 5 mg daily or placebo daily. We selected
RTB101 10 mg daily as a dose because in the Phase 2a clinical trial, the same dose was well-tolerated and was observed to significantly decrease the rate of all infections as well as the rate of RTIs, and was associated with upregulation of
antiviral gene expression in whole blood. To determine the minimal efficacious dose of RTB101, we also evaluated RTB101 5 mg daily in the Phase 2b trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">An interim analysis on data from the first part of the trial was completed in October 2017
by an independent data monitoring committee, or DMC. The DMC reviewed the safety and efficacy data from the first part of the trial and selected the doses of RTB101 and RTB101 in combination with everolimus to be tested in the second part of the
trial in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We commenced the second part of the Phase 2b clinical trial in the fourth quarter of 2017. Based on the DMC
recommendation, we expect to randomize at least 424 patients to receive placebo or one or more of the following TORC1 inhibitor treatment regimens: RTB101 10 mg once daily, RTB101 10 mg twice daily and RTB101 10 mg in combination with everolimus 0.1
mg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are studying the combination of RTB101 and everolimus 0.1mg because in the Phase 2a clinical trial, this combination not only
reduced the incidence of infections similar to RTB101 monotherapy, but also led to a greater improvement in influenza vaccination response than either RTB101 or everolimus monotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Phase 2b clinical trial has a greater than 80% power to detect a statistically significant reduction in the percentage of subjects with
RTIs, assuming an effect size of 40% reduction. The effect size of 40% was conservatively estimated based on the reduction observed in the Phase 2a RTI rates at 16 weeks, which is the duration specified for the Phase 2b primary endpoint, of 45%
(p=0.039) and 50% (p=0.013) in the RTB101 monotherapy and RTB101+everolimus combination arms respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on communications with
the FDA, including those during a high-level policy meeting, to date, we believe a reduction in the incidence of RTIs has the potential to be a clinically relevant endpoint. We completed a <FONT STYLE="white-space:nowrap">pre-investigational</FONT>
new drug, or <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting, with the FDA in July 2017 and subsequently submitted an investigational new drug application, or IND, for RTB101 alone and in combination with everolimus as immunotherapy designed
to reduce the incidence of RTIs in elderly patients at increased risk of <FONT STYLE="white-space:nowrap">RTI-related</FONT> morbidity or mortality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 3 Clinical Development Plan </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If
the results from the ongoing Phase 2b clinical trial are positive, we intend to conduct two Phase 3 pivotal clinical trials across two hemispheres. The Phase 3 clinical program is expected to start in the southern hemisphere in the first half of
2019 at the beginning of the winter cold and flu season and run through the second quarter of 2020. If our Phase 3 clinical trials are successful, we anticipate filing an NDA with the FDA in 2020, and an MAA with the EMA in 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the results from the ongoing Phase 2b clinical trial are favorable for RTB101 monotherapy, we expect to randomize approximately 600 elderly
subjects at increased risk of <FONT STYLE="white-space:nowrap">RTI-associated</FONT> morbidity and mortality to receive daily oral administration of RTB101 monotherapy or placebo for 16 weeks in each of the proposed Phase 3 clinical trials. The
primary endpoint would be the reduction in RTI incidence over the dosing period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the results from the ongoing Phase 2b are not
positive for RTB101 monotherapy but are positive for the RTB101+everolimus combination therapy, we expect to initiate a Phase 3 program with the combination of RTB101+everolimus and may include enhanced immune response to vaccination as an
additional <FONT STYLE="white-space:nowrap">co-primary</FONT> endpoint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Safety Data from Clinical and Preclinical Development at High Doses of RTB101
Alone and in Combination with Everolimus </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Originally, RTB101 was developed for oncology indications. In preclinical studies, at doses
higher than those we are developing, RTB101 was found to prevent cellular proliferation and tumor progression. Clinical trials in humans were conducted under two open INDs for RTB101 filed with the FDA Division of Oncology Products. More than 440
oncology patients have been treated with RTB101 alone in doses up to 1,600 mg per </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
day, or in combination with other drugs including 200 mg of RTB101 in combination with 2.5 mg of everolimus per day. RTB101 has also been administered to more than 60 healthy volunteers in
pharmacokinetic, or PK, studies at doses of up to 1,000 mg per day. To date, the majority of the reported adverse events, or AEs, were mild or moderate and include gastrointestinal disturbances, fatigue, decreased appetite, rash and
thrombocytopenia, which are consistent with those that have been reported for marketed mTOR inhibitors such as rapamycin and everolimus. No dose-limiting toxicities occurred at doses less than 800&nbsp;mg per day, and the maximum tolerated dose for
RTB101 as a monotherapy was established at 1,200&nbsp;mg per day. We are developing RTB101 at daily doses of 5 mg to 20 mg, 60 to 240 times lower than the established maximum tolerated dose, and therefore expect the RTB101 to have an acceptable
tolerability profile for the indications that we plan to pursue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Standard preclinical safety and good laboratory practice, or GLP,
toxicology studies, up to six months in rats and dogs, have been completed for RTB101, which we believe support the clinical development of the program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Potential Indications for Our TORC1 Program </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may evaluate RTB101 alone or in combination with everolimus or other drugs for the treatment of additional indications, such as heart
failure with preserved ejection fraction, urinary tract infections, Huntington&#146;s disease and Parkinson&#146;s disease. We plan to initiate at least one Phase 2 proof of concept study in 2018. We expect to select indications based on strong
scientific rationale, preclinical or clinical data, unmet medical need and other relevant considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Prevention of recurrent urinary tract
infections </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Urinary tract infections, or UTIs, are the most common bacterial infection in the elderly, with the incidence higher
in women than men. According to studies of 959 and 395 women published in 2000 and 2010, respectively, nearly 10% of women older than 65 years of age and nearly 30% of women over the age of 85 reported having a UTI within the 12&#151;month period
preceding the study. The incidence of UTIs also increases substantially in men over the age of 85 years. Elderly subjects who have had a prior UTI are at increased risk of a recurrent UTI. Urinary tract infections are most commonly bacterial, and E.
coli&nbsp;is the organism most frequently responsible for UTIs. Hence, empiric treatment of UTIs with antibiotics is common, and UTIs are the most common reason for antibiotic prescriptions in older adults. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the Phase 2a clinical trial, a decrease in the rate of UTIs was observed in the RTB101 10 mg monotherapy and RTB101 10 mg+everolimus 0.1 mg
combination arms as compared to placebo. We believe these data suggest that RTB101 alone or in combination with everolimus may have therapeutic benefit for reducing the rate of UTIs in the elderly, particularly elderly at risk for recurrent UTIs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Treatment of viral respiratory tract infections </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the Phase 2a clinical trial, an increase of antiviral gene expression was observed in the RTB101 10&nbsp;mg monotherapy and RTB101 10
mg+everolimus 0.1 mg combination arms. We plan to conduct a biomarker study to assess the speed at which antiviral genes are upregulated after elderly subjects are treated with RTB101 alone or in combination with everolimus. If we observe a rapid
increase of antiviral gene expression, we believe RTB101 alone or in combination with everolimus may have therapeutic benefit for the treatment of viral RTIs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Heart failure with preserved ejection fraction </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Heart failure is one of the most common causes of hospitalizations in people age 65 and older, and heart failure with preserved ejection
fraction, or HFpEF, affects about 2.25&nbsp;million people in the United States, and a combined 6.24&nbsp;million in the United States, Europe and Japan. HFpEF predominantly affects elderly subjects,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
particularly older women, in whom 90% of new heart failure cases are HFpEF. Patients with HFpEF experience the clinical symptoms of heart failure, despite having the percentage of total blood in
the left ventricle of the heart that is pushed out with each heartbeat, known as ejection fractions, in the normal range. These symptoms are attributable in part to stiffened heart muscle that limits blood flow into the heart, known as diastolic
dysfunction. Outcomes following hospitalization for decompensated HFpEF are poor. Approximately one third of patients are rehospitalized or die within 90 days of discharge. To date, there are no FDA approved therapies to reduce hospitalization or
mortality for HFpEF. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">According to scientific literature published by research groups at the Harvard Stem Cell Institute and the
University of Washington, aging mice develop stiffened heart muscle and diastolic dysfunction similar to elderly humans with HFpEF. Preclinical studies have shown that a 10 week course of mTOR inhibitor therapy reverses diastolic dysfunction in
aging mice. This beneficial effect is likely partly due to an increase in proteins involved in mitochondrial function and fatty acid oxidation. Fatty acids are the predominant substrate used in mitochondrial energy production in healthy adults, but
are replaced by glucose as the preferred substrate in heart failure. The shift to glucose as a substrate results in less ATP production by mitochondria. Since ATP is the main cellular fuel, a decrease in ATP production may contribute to heart
failure. mTOR inhibitors shift mitochondria back to using fatty acids as a substrate and as a result may increase ATP production in the heart and improve heart function. These findings suggest that RTB101 alone or in combination with everolimus may
have therapeutic benefit for the treatment of HFpEF in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Huntington&#146;s disease </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Huntington&#146;s disease, or HD, is a disease that affects neurons in the brain and causes movement, psychiatric and cognitive impairment. HD
is caused by mutations in a gene encoding protein called huntingtin. Mutant huntingtin forms aggregate in neurons and cause the neurons to degenerate. The mutant huntingtin aggregates can be cleared from neurons by a process called autophagy in
which cells remove and recycle intracellular debris including protein aggregates. Preclinical data from brain slices in a HD mouse model has shown that RTB101 in combination with everolimus synergize to prevent neurodegeneration, likely by inducing
autophagy and clearing mutant huntingtin aggregates. We believe these findings support the potential that RTB101 in combination with everolimus to have therapeutic benefit for the treatment of HD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Parkinson&#146;s disease </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Parkinson&#146;s disease, or PD, is a progressive neurodegenerative disease that affects approximately 7.5&nbsp;million people worldwide. The
incidence of PD increases rapidly in people 60 years of age and older, with a mean age at diagnosis of 70.5 years. Patients with PD develop shaking, rigidity, slowness of movement and difficulty walking. Similar to HD, PD may be attributed in part
to neuronal damage caused by the accumulation within neurons of abnormal aggregates containing the protein <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-synuclein. Preclinical studies in mouse models of PD have shown that mTOR inhibition can induce
autophagy, reduce <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-synuclein accumulation and decrease neuronal cell death. Therefore, induction of autophagy with RTB101 in combination with everolimus may have therapeutic benefit for patients with PD.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We strive to
protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patent protection intended to cover the composition of matter of our product candidates, including RTB101, their methods of use,
related technology, and other inventions that are important to our business. We licensed a patent portfolio of ten patent families from Novartis. See &#147;&#151;License Agreement with Novartis.&#148; As of October 31, 2017, one family within this
patent portfolio covering compositions of matter was issued in 42 countries and is pending in five. This patent family is expected to expire in 2026 before patent term extensions. We expect market exclusivity for RTB101, alone and in combination
with everolimus, until at least 2031 in the United States, 2032 in major European markets, and 2030 in Japan, and additional pending patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications covering methods of enhancing immunity, reducing incidence of RTIs and other infections, and other indications, may prolong the exclusivity of these product candidates up to 2036. In
October 2017, we filed an additional patent application directed to compositions of matter for novel mTOR inhibitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition to
patent protection, we rely on trade secrets and confidentiality agreements to protect our technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other aspects of our business that are not amenable to, or that we do not consider appropriate
for, patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary
protection for commercially important technology, inventions, and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business, defend and enforce the patents we own or control, maintain our licenses to use intellectual property owned by
third parties, preserve the confidentiality of our trade secrets, and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual
questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will
be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide
sufficient proprietary protection from competitors. Any patents that we hold or control may be challenged, circumvented or invalidated by third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement with Novartis </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we entered into a license agreement with Novartis, pursuant to which we were granted an exclusive, field-restricted, worldwide
license to certain intellectual property rights owned or controlled by Novartis, including patents, patent applications, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property, to develop,
commercialize and sell one or more therapeutic products comprising RTB101 alone or RTB101 and everolimus in a fixed dose combination.&nbsp;Under the license agreement, we have been licensed a patent portfolio of ten patent families directed to
composition of matter of RTB101 and its salts, formulations of everolimus and methods of using RTB101 and everolimus to enhance the immune response among others.&nbsp;These families include certain granted patents and pending patent applications in
the United States and foreign jurisdictions, including Canada, the United Kingdom, Germany, France, Italy, Spain, Russia, Japan, Korea and China. Patents in these families will begin expiring in 2026, subject to possible patent term extensions. We
believe that patent term extension and the potential grant of certain pending patent application may provide exclusivity for RTB101 and RTB101+everolimus combination until 2036 in the United States and the major European markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The exclusive field for RTB101 is for the treatment, prevention and diagnosis of diseases and other conditions in all indications in humans
and animals.&nbsp;With respect to the fixed dose combination of RTB101 and everolimus, the exclusive field of use is for any indication in humans related to the improvement in immune function or immunosenescence in the elderly, the reduction of
infection frequency, severity, duration, health care resource utilization, hospitalization, morbidity or mortality, or the treatment of infections, the reduction of pulmonary disease exacerbation frequency, severity, or related hospitalization, the
enhancement of therapeutic or prophylactic benefits of vaccines, or any aging-related disease, excluding in each case the application of everolimus in connection with organ transplantation, oncology, immune-oncology or in the cardiac stent field.
Novartis has agreed not to enforce any rights to improvements related to RTB101 developed after the effective date in connection with the exercise of our rights under this agreement.&nbsp;In addition, we have agreed to grant back to Novartis for use
outside of the exclusive fields any improvements related to everolimus that we develop after the effective date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are required to use commercially reasonable efforts to develop and commercialize at least
one product in the field in at least one major market, which includes the United States, Japan and certain identified countries in Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As initial consideration for the license, we issued NIBR 2,587,992 shares of our Series&nbsp;A preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As additional consideration for the license, we are required to pay up to an aggregate of $4.3&nbsp;million upon the satisfaction of clinical
milestones, up to an aggregate of $24&nbsp;million upon the satisfaction of regulatory milestones for the first indication approved, and up to an aggregate of $18&nbsp;million upon the satisfaction of regulatory milestones for the second indication
approved.&nbsp;In addition, we are required to pay up to an aggregate of $125&nbsp;million upon the satisfaction of commercial milestones, based on the amount of annual net sales.&nbsp;We are also required to pay tiered royalties ranging from a <FONT
STYLE="white-space:nowrap">mid-single</FONT> digit percentage to a <FONT STYLE="white-space:nowrap">low-teen</FONT> digit percentage on annual net sales of products.&nbsp;These royalty obligations last on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the latest of (i)&nbsp;the expiration of the last valid claim of a
Novartis patent covering a subject product, (ii)&nbsp;the expiration of any regulatory exclusivity for the subject product in a country, or (iii)&nbsp;the 10th anniversary of the first commercial sale of the product in the country, and are subject
to a reduction after the expiration of the last valid claim of a Novartis patent or the introduction of a generic equivalent of a product in a country.&nbsp;In addition, if we sublicense the rights under the license agreement, we are required to pay
a certain percentage of the sublicense revenue to Novartis. Novartis will no longer be entitled to sublicense revenue following the last visit of the 400th subject in any human clinical trial conducted by us or a sublicensee of ours, which we expect
to occur by the end of our ongoing Phase 2b clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Either we or Novartis may terminate the license agreement if the other party
commits a material breach and fails to cure such breach within 60 days after written notice.&nbsp;Novartis may terminate the license agreement upon our bankruptcy, insolvency, dissolution or winding up.&nbsp;In addition, Novartis may partially
terminate the license agreement with respect to everolimus if we fail or cease to use commercially reasonable efforts to research, develop and commercialize a product utilizing everolimus for a period of three years, provided that our license
related to RTB101 and Novartis&#146;s license to our improvements related to everolimus will continue. In addition, we may terminate the license agreement, with or without cause, in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, upon 60 days&#146; prior written notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the license agreement, NIBR entered into certain stockholder agreements related to this investment.&nbsp;See &#147;Certain
Relationship and Related Party Transactions&#151;Series A Preferred Stock Financing.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We hold worldwide commercialization rights to our product candidates. We do not have our own marketing, sales or distribution capabilities. In
order to commercialize our product candidate if approved for commercial sale, we must either develop a sales and marketing infrastructure or collaborate with third parties that have sales and marketing experience. We plan to directly commercialize
our product candidates in the United States with a focused sales force targeting <FONT STYLE="white-space:nowrap">top-prescribing</FONT> physicians with high flow of elderly patients. For some indications, we may also directly commercialize our
product candidates in the European Union. In other markets or for certain indications outside the United States for which commercialization may be less capital efficient for us, we may selectively pursue strategic collaborations with third parties
in order to maximize the commercial potential of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">RTB101 and everolimus are small molecules that can be manufactured using commercially available technologies. We acquired data from Novartis
related to the chemical synthesis and manufacturing of RTB101, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which is currently being manufactured by a single contract manufacturing organization, and are outsourcing the manufacturing of everolimus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe there are multiple sources for all of the materials required for the manufacture of our product candidates. Our manufacturing
strategy enables us to more efficiently direct financial resources to the research, development, and commercialization of product candidates rather than diverting resources to internally develop manufacturing facilities. As our product candidates
advance through development, we expect to enter into longer-term commercial supply agreements with key suppliers and manufacturers to fulfill and secure the ongoing and planned preclinical, clinical, and, if our product candidates are approved for
marketing, our commercial supply needs for ourselves and our collaborators. Our long-term strategy is to secure at least two sources for the manufacturing of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Manufacturing of any product candidate is subject to extensive regulations that impose various procedural and documentation requirements,
which govern recordkeeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. We expect that all of our contract manufacturing organizations will manufacture RTB101 under current Good Manufacturing
Practice, or cGMP, conditions. cGMP is a regulatory standard for the production of pharmaceuticals to be used in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We consider Navitor Pharma to be our most direct competitor in developing novel therapeutics targeting TORC1 for aging-related diseases.
However, Navitor has not publicly announced testing of any pipeline candidate in human subjects to date. We are aware of multiple other allosteric and catalytic mTOR inhibitors in development by other companies. We are not aware of any product with
comparable TORC1 selectivity being commercially developed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are also aware of other companies seeking to develop treatments to prevent
or treat aging-related diseases through biological pathways unrelated to mTOR inhibition, including Calico and Unity. Calico has not yet disclosed any pipeline candidates, and Unity&#146;s most advanced candidate, based on publicly disclosed
information, is in preclinical development. Hence, we believe that we currently have the most clinically advanced program based on the stage of development of our competitors&#146; programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are aware of other companies that are potential competitors for prevention or treatment of respiratory tract infections. Companies pursuing
broad-spectrum prophylactic and therapeutic treatments in respiratory tract infections include PrEP BioPharm and Innavac. Based on publicly disclosed information, we believe that we have the most clinically advanced program, and the only program
based on TORC1 selectivity. Narrow-spectrum prophylactic treatments are also being developed by potential competitors. Several of these treatments target the respiratory syncytial virus, or RSV, one of the top known causes of RTIs in older adults.
However, as RTIs in the elderly are largely caused by many different viruses, we believe that our approach may be more broadly applicable in addressing RTIs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Drug development is highly competitive and subject to rapid and significant technological advancements. Our ability to compete will
significantly depend upon our ability to complete necessary clinical trials and regulatory approval processes, and effectively market any drug that we may successfully develop. Our current and potential future competitors may include pharmaceutical
and biotechnology companies, academic institutions and government agencies. The primary competitive factors that will affect the commercial success of any product candidate for which we may receive regulatory approval include efficacy, safety and
tolerability profile, dosing convenience, price, formulary coverage and reimbursement. Our existing or potential future competitors may have substantially greater financial, technical and human resources than we do and significantly greater
experience in the discovery and development of product candidates, as well as in obtaining regulatory approvals of those product candidates in the United States and in foreign countries. Our current and potential future competitors may also have
significantly more experience commercializing drugs that have been approved </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a small number of our competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Accordingly, our competitors may be more successful than us in obtaining regulatory approval for therapies and in achieving widespread market
acceptance of their drugs. It is also possible that the development of a more effective treatment method for prevention of respiratory tract infections by a competitor could render our product candidate
<FONT STYLE="white-space:nowrap">non-competitive</FONT> or obsolete or reduce the demand for our product candidate before we can recover our development and commercialization expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Government
authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality
control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory
approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial
resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review and Approval of Drugs in the United States </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The
failure to comply with applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including
refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities. In addition, an applicant
may need to recall a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">An applicant seeking approval to market and distribute a new drug product in the United States must
typically undertake the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of nonclinical, or preclinical, laboratory tests, animal studies and formulation studies in compliance with the FDA&#146;s good laboratory practice, or GLP, regulations; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an IND, which must take effect before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval by an independent Institutional Review Board, or IRB, representing each clinical site before each clinical trial may be initiated at that site; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug product for each indication;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparation and submission to the FDA of a new drug application, or NDA, and payment of user fees; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review of the product by an FDA advisory committee, where appropriate or if applicable; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing
Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#146;s identity, strength, quality and purity; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA review and approval of the NDA; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval studies required by the FDA. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preclinical Studies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before an applicant
begins testing a compound in humans, the drug candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient and
the formulated drug or drug product, as well as in vitro and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject
to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other
things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The IND and IRB Processes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">An IND is an
exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational drug to humans. Such authorization must
be secured prior to interstate shipment and administration of the investigational drug. In an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments. In addition, the results of the preclinical tests,
manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. The FDA requires a <FONT STYLE="white-space:nowrap">30-day</FONT>
waiting period after the filing of each IND before clinical trials may begin. At any time during this <FONT STYLE="white-space:nowrap">30-day</FONT> period, the FDA may raise concerns or questions about the conduct of the trials as outlined in the
IND and impose a clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A
clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND.
No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may
only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the
investigation can proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign
clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study is conducted in accordance with good clinical
practice, or GCP, including review and approval by an independent ethics </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committee, or IEC, and informed consent from subjects. The GCP requirements are intended to help ensure the protection of human subjects enrolled in
<FONT STYLE="white-space:nowrap">non-IND</FONT> foreign clinical studies, as well as the quality and integrity of the resulting data. FDA must also be able to validate the data from the study through an
<FONT STYLE="white-space:nowrap">on-site</FONT> inspection if necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing IND requirements, an IRB
representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review of the study at least annually. The IRB
must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial
at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety
monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Suspension or termination of
development during any phase of clinical trials can occur if it is determined that the subjects or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving business
objectives and/or competitive climate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Information about certain clinical trials must be submitted within specific timeframes to the
National Institutes of Health, or NIH, for public dissemination on its ClinicalTrials.gov website. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Human Clinical Trials in Support of an NDA
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified
investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are
conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Phase</I><I></I><I>&nbsp;1.</I> The drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage
tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Phase</I><I></I><I>&nbsp;2.</I> The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific
targeted diseases and to determine dosage tolerance and optimal dosage. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Phase</I><I></I><I>&nbsp;3.</I> The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to
evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Phase</I><I></I><I>&nbsp;4.</I> Post-approval studies may be conducted after initial regulatory approval. These studies are used to gain additional experience from the treatment of patients in the intended
therapeutic indication. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials must be submitted at least
annually to the FDA. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or in vitro testing that suggest a significant risk
in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not
be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an
unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if
the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the
chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
batches of the drug candidate and, among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and
stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review of
an NDA by the FDA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical
studies and clinical trials, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the
drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently exceeding $2.4&nbsp;million for applications requiring clinical data, and an annual prescription
drug program fee exceeding $304,000. These fees are typically increased annually. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for drugs with orphan designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA conducts a preliminary review of an NDA within 60&nbsp;days of its receipt, before accepting the NDA for filing, to determine whether
the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The
resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> substantive review. The FDA has agreed to
specified performance goals in the review process of NDAs. Applications for drugs containing novel active moieties are meant to be reviewed within ten months from the date of filing, and applications for &#147;priority review&#148; products
containing novel active moieties are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an
outstanding deficiency identified by the FDA following the original submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA typically will inspect
the facility or facilities where the product is or will be manufactured. These <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections may cover all facilities associated with an NDA submission, including drug component manufacturing (such
as active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP
requirements and adequate to assure consistent production of the product within required specifications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, as a condition of approval, the FDA may require an applicant to develop a REMS.
REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the
product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication guides, physician
communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the
potential market and profitability of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA is required to refer an application for a novel drug to an advisory committee or
explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fast Track, Breakthrough Therapy, and Priority Review </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA has a number of programs intended to facilitate and expedite development and review of new drugs if they are intended to address an
unmet medical need in the treatment of a serious or <FONT STYLE="white-space:nowrap">life-threatening</FONT> disease or condition. Three of these programs are referred to as fast track designation, breakthrough therapy designation, and priority
review designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in
combination with one or more other products, for the treatment of a serious or <FONT STYLE="white-space:nowrap">life-threatening</FONT> disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or
condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#146;s application before the application is complete. This rolling review may be available
if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining
information and the sponsor must pay applicable user fees. However, the FDA&#146;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation
may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other
products, to treat a serious or <FONT STYLE="white-space:nowrap">life-threatening</FONT> disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more
clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the
development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a <FONT STYLE="white-space:nowrap">cross-disciplinary</FONT> project lead for the
review team; and taking other steps to design the clinical trials in an efficient manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Third, the FDA may designate a product for
priority review if it is a product that treats a serious or life-threatening disease or condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased
effectiveness in the treatment of a condition, elimination or substantial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reduction of a <FONT STYLE="white-space:nowrap">treatment-limiting</FONT> product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and
evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#146;s goal for taking action on a marketing
application from ten months to six months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accelerated Approval Pathway </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage
to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on an intermediate clinical endpoint that can be measured earlier than an
effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of
alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical
sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is
a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints,
but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the
therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway is most
often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accelerated approval pathway is usually contingent on a sponsor&#146;s agreement to conduct, in a diligent manner, additional
post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of
Phase&nbsp;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, could result in the FDA&#146;s withdrawal
of the approval and require the withdrawal of the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The FDA&#146;s Decision on an NDA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
the basis of the FDA&#146;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities and select clinical trial sites, the FDA may issue an approval letter or a complete response
letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial
additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has
committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the FDA approves a product, it may limit the approved indications for use for the
product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess the drug&#146;s safety or effectiveness
after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially
affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Approval Requirements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Drugs
manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution,
advertising and promotion and reporting of adverse experiences with the product. After approval, many changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also
are annual program fee requirements for certain marketed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may impose a number of post-approval requirements as a
condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the NDA holder and any third-party
manufacturers that the NDA holder may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or
if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a
REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or voluntary product recalls; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning or untitled letters or holds on post-approval clinical trials; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is
found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the
registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hatch-Waxman Amendments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing
authorization for a new drug. A Section&nbsp;505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy
but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the
investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application.
Section&nbsp;505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application, or ANDA. An ANDA provides for marketing of a generic drug product that has
the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product, known as a reference listed drug, or RLD. ANDAs are termed
&#147;abbreviated&#148; because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is
bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject&#146;s bloodstream in the same amount of time
as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Non-Patent</FONT> Exclusivity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Hatch-Waxman Amendments, the FDA may not approve (or in some cases
accept) an ANDA or 505(b)(2) application until any applicable period of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity for the RLD has expired. The FDCA provides a period of five years of
<FONT STYLE="white-space:nowrap">non-patent</FONT> data exclusivity for a new drug containing a new chemical entity, or NCE. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the
FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the
expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification, which states the proposed generic drug will not infringe one or more of the already approved product&#146;s listed patents or that such patents are
invalid or unenforceable, in which case the applicant may submit its application four years following the original product approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
FDCA also provides for a period of three years of exclusivity for <FONT STYLE="white-space:nowrap">non-NCE</FONT> drugs if the NDA or a supplement to the NDA includes reports of one or more new clinical investigations, other than bioavailability or
bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application or supplement. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new
dosage form, route of administration, combination or indication, but it generally would not protect the original, unmodified product from generic competition. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the
FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product; it only prevents FDA from approving such ANDAs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hatch-Waxman Patent Certification and the <FONT STYLE="white-space:nowrap">30-Month</FONT> Stay </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In seeking approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the
applicant&#146;s product or an approved method of using the product. Upon approval, each of the patents listed by the NDA sponsor is published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the
Orange Book. Upon submission of an ANDA or 505(b)(2) NDA, an applicant is required to certify to the FDA concerning any patents listed for the RLD in the Orange Book that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no patent information on the drug product that is the subject of the application has been submitted to the FDA; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such patent has expired; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which such patent expires; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such patent is invalid, unenforceable or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA
applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use,
the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV certification the applicant must send notice
of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV
certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application until the earlier of 30 months from the
receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#146;s favor or settled, or such shorter or longer period as may be
ordered by a court. This prohibition is generally referred to as the <FONT STYLE="white-space:nowrap">30-month</FONT> stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s)
regularly take action to trigger the <FONT STYLE="white-space:nowrap">30-month</FONT> stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a
significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s decision to initiate patent litigation. If the drug has NCE exclusivity and the ANDA is submitted four years after approval,
the <FONT STYLE="white-space:nowrap">30-month</FONT> stay is extended so that it expires 7 <SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">2</SUB> years after approval of the innovator drug, unless the patent
expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pediatric Studies and Exclusivity
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto for a drug with certain innovative features
(<I>e.g.</I>, new active ingredient, new indication, new dosage form) must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support
dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation Act, or FDASIA, in 2012, sponsors must also submit pediatric study plans
prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by
regulation. The applicant, the FDA, and the FDA&#146;s internal review committee must then review the information submitted, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until
after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity in the United States and, if granted,
provides for the attachment of an additional six months of marketing protection to the term of certain existing <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity periods, including orphan exclusivity. This
<FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data within certain time periods. The data do not need to show the
product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#146;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and
accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the
regulatory period during which the FDA cannot approve another application after expiration of a patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation and Exclusivity
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a drug product as an &#147;orphan drug&#148; if it is intended to treat a rare
disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United
States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the
therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If a product with orphan status receives the first FDA approval for the drug for the disease or condition for which it has such designation or
for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for
the same product for the same indication for seven years, except in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the
same product but for a different indication. If a drug or drug product designated as an orphan product ultimately receives regulatory approval for an indication broader than what was designated in its orphan product application, it may not be
entitled to exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patent Term Restoration and Extension </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a
patent term restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective
date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&nbsp;years from
the product&#146;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question and within 60 days of
drug approval. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or
restoration in consultation with the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review and&nbsp;Approval of Medicinal Products in the European Union </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of
other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a
product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process
governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the
safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities
before the product can be marketed and sold in the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trial Approval </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on Good Clinical Practice, or GCP, and the related national implementing
provisions of the individual EU Member States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the competent national authority of the EU Member States in
which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. The clinical trial application must be accompanied
by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC, Directive 2005/28/EC, where relevant the implementing national provisions of the
individual EU Member States and further detailed in applicable guidance documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical Trials Regulation,
(EU) No 536/2014 (Clinical Trials Regulation) was adopted. The Regulation is anticipated to apply in 2019. The Clinical Trials Regulation will be directly applicable in all the EU Member States, repealing the current Clinical Trials Directive
2001/20/EC. Conduct of all clinical trials performed in the European Union will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be
governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical trial continues for more than three years from the day on which the
Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, the &#147;EU
portal&#148;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which
is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned). Part II is assessed separately by each
Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the
concerned EU Member State. However, overall related timelines will be defined by the Clinical Trials Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketing Authorization
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To obtain a marketing authorization for a product under European Union regulatory systems, an applicant must submit an MAA either
under a centralized procedure administered by the European Medicines Agency, or EMA, or one of the procedures administered by competent authorities in the EU Member States </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(decentralized procedure or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the European Union. Regulation (EC) No 1901/2006 provides
that prior to obtaining a marketing authorization in the European Union, applicants have to demonstrate compliance with all measures included in an <FONT STYLE="white-space:nowrap">EMA-approved</FONT> Paediatric Investigation Plan, or PIP, covering
all subsets of the pediatric population, unless the EMA has granted (1)&nbsp;a product-specific waiver, (2)&nbsp;a class waiver or (3)&nbsp;a deferral for one or more of the measures included in the PIP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU
Member States and three of the four European Free Trade Association, or EFTA, States,&nbsp;Iceland, Liechtenstein and Norway. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for
medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for
the treatment of HIV or AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are a
significant therapeutic, scientific or technical innovation and whose authorization would be in the interest of public health at EU level, the centralized procedure is optional. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the EMA is responsible for
conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the
centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210&nbsp;days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to
questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If
the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an
accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 67 days from the date of the CHMP Opinion, the
European Commission will adopt its final decision on the marketing authorization application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unlike the centralized authorization
procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is
identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a
valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot
approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The mutual recognition procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing
authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority
recognize the marketing authorization delivered by the competent authority of another EU Member State. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory Data Protection in the European Union </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the European Union, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of
data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance the centralized
authorization procedure. Data exclusivity prevents applicants for authorization of generics of these innovative products from referencing the innovator&#146;s data to assess a generic (abbreviated) application for a period of eight years. During an
additional <FONT STYLE="white-space:nowrap">two-year</FONT> period of market exclusivity, a generic marketing authorization application can be submitted and authorized, and the innovator&#146;s data may be referenced, but no generic medicinal
product can be placed on the European Union market until the expiration of the market exclusivity. The overall <FONT STYLE="white-space:nowrap">ten-year</FONT> period will be extended to a maximum of 11 years if, during the first eight years of
those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in
comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if
such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Periods of Authorization and Renewals </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on
the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent
authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be
valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five year period of marketing authorization. Once subsequently
definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the European Union market (in case of centralized procedure) or on
the market of the authorizing EU Member State within three years after authorization ceases to be valid (the <FONT STYLE="white-space:nowrap">so-called</FONT> sunset clause). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory Requirements after a Marketing Authorization has been Obtained </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In case an authorization for a medicinal product in the European Union is obtained, the holder of the marketing authorization is required to
comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Compliance with the European Union&#146;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The manufacturing of authorized medicinal products, for which a separate manufacturer&#146;s license is mandatory, must also be conducted in strict compliance with the applicable European Union laws, regulations and
guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with European Union cGMP standards when
manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European
Union. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in
the European Union notably under Directive 2001/83/EC, as amended, and EU Member State laws. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Brexit and the Regulatory Framework in
the United Kingdom </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union
(commonly referred to as &#147;Brexit&#148;). Thereafter, on March&nbsp;29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The withdrawal of the United Kingdom from
the European Union will take effect either on the effective date of the withdrawal agreement or, in the absence of agreement, two years after the United Kingdom provides a notice of withdrawal pursuant to the EU Treaty. Since the regulatory
framework for pharmaceutical products in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from
European Union directives and regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom. It remains to be seen how, if at all, Brexit will impact
regulatory requirements for product candidates and products in the United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare Law and Regulation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted
regulatory approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to physicians and teaching hospitals and
patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, include the following:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in
cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare
and Medicaid; a person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation; in addition, the government may assert that a claim that includes items or
services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or
causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent; knowingly making a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property
to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional
federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering up a material fact
or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose
obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the
Affordable Care Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, within the United States Department of Health and Human
Services, information related to payments and other transfers of value made by that entity to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that are reimbursed by
<FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some state laws
require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report
information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which
differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pharmaceutical Insurance
Coverage and Healthcare Reform </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their
conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part,
on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement
levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved.
Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage
to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide
discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce
physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#146;s decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be approved. Further, one payor&#146;s determination to provide </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from
payor to payor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of
products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption
of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved products. Coverage
policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable
coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There have been a number of federal and state proposals
during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.
For example, in March 2010, the United States Congress enacted the Affordable Care Act, which, among other things, includes changes to the coverage and payment for products under government health care programs. Among the provisions of the
Affordable Care Act of importance to our potential product candidates are: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government
healthcare programs; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby
potentially increasing a manufacturer&#146;s Medicaid rebate liability; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expanded manufacturers&#146; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#147;average manufacturer
price,&#148; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expanded the types of entities eligible for the 340B drug discount program; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">established the Medicare Part&nbsp;D coverage gap discount program by requiring manufacturers to provide a 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale-discount</FONT></FONT> off
the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#146; outpatient drugs to be covered under Medicare Part&nbsp;D; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the
Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013
through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went
into effect in April </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2013 and will remain in effect through 2025 unless additional Congressional action is taken. In January 2013, then-President Obama signed into law the American Taxpayer Relief Act of 2012, which,
among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed bills
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Individual
states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on
certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On January&nbsp;20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the
Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or
manufacturers of pharmaceuticals or medical devices. Further legislative changes to or regulatory changes under the Affordable Care Act remain possible in the 115th U.S. Congress and under the Trump Administration. The nature and extent of any
legislative or regulatory changes to the Affordable Care Act are uncertain at this time, however. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Outside the United States, ensuring
coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of
regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be
marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or <FONT
STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their
national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect
controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit
prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the
severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being
erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various
European Union member states, and parallel trade, i.e., arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls
or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;16, 2018, we had seven full-time employees, including a total of three employees with M.D. or Ph.D. degrees. Of our
workforce, four employees are directly engaged in research and development activities, and three employees provide administrative, business and operations support. None of our employees are represented by labor unions or covered by collective
bargaining agreements. We consider the relationship with our employees to be good. We also use outside consultants and contractors for limited engagements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We occupy office space
within the offices of PureTech Health pursuant to the terms of our Business Services, Personnel and Information Management Agreement with PureTech Health. In January 2018, we entered into a multi-year agreement to lease office space in Boston,
Massachusetts under an operating lease agreement. We believe that this office is sufficient to meet our current needs and that suitable additional space will be available as and when needed. See &#147;Transactions with Related Persons.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are not currently
subject to any material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age as of the date of this prospectus, and position of each of our executive officers and directors.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="64%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:13.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chen Schor(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Mannick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John J. McCabe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Finance</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Fonteyne(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Silverstein(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Steinberg(1)(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lynne Sullivan(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daphne Zohar(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Member of audit committee </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Member of compensation committee </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Member of nominating and corporate governance committee </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Chen Schor</I></B> has served as our President and Chief Executive Officer and as a member of our board of directors since our
incorporation in July 2016. Mr.&nbsp;Schor previously served as President, Chief Executive Officer and director of Synta Pharmaceuticals Corp. from May 2015 until its merger with Madrigal Pharmaceuticals in July 2016, and prior to that, from 2014
until 2016, Mr.&nbsp;Schor served as its Executive Vice President and Chief Operation Officer. From 2012 to 2014, Mr.&nbsp;Schor served as President and Chief Executive Officer of Novalere FP,&nbsp;Inc., a
<FONT STYLE="white-space:nowrap">pre-commercial</FONT> stage allergy therapeutics company. From 2011 to 2012, Mr.&nbsp;Schor served as Chief Business Officer of Eleven Biotherapeutics, an emerging therapeutics company. From 2009 until 2011,
Mr.&nbsp;Schor served as Vice President of Business Development, global branded products at Teva Pharmaceuticals. Prior to joining Teva, Mr.&nbsp;Schor was Chief Business Officer at Epix Pharmaceuticals,&nbsp;Inc. (formerly known as Predix
Pharmaceuticals&nbsp;Inc.) from 2003 until 2009. Prior to joining Epix, Mr.&nbsp;Schor was a Partner at Yozma Venture Capital from 1998 until 2003, managing the fund&#146;s investments in biotechnology and medical device companies. Mr.&nbsp;Schor
currently sits on the board of Brainstorm Cell Therapeutics&nbsp;Inc., a public biotechnology company. Mr.&nbsp;Schor received his MBA from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and a B.A. in Biology from Tel
Aviv University. We believe that Mr.&nbsp;Schor is qualified to serve on our board of directors due to his service as our President and Chief Executive Officer and his extensive knowledge of our company and industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Joan Mannick, M.D., </I></B>has served as our Chief Medical Officer since March 2017 and served as a member of our board of directors
from March 2017 to November 2017. From November 2010 until March 2017, Dr.&nbsp;Mannick was Senior Director and subsequently Executive Director in the Translated Medical Division of NIBR, where Dr.&nbsp;Mannick led the clinical program at NIBR that
targets pathways regulating aging to treat aging-related conditions. Prior to joining NIBR in 2010, Dr.&nbsp;Mannick was a Medical Director at Genzyme from 2007 to 2010 working in multiple therapeutic areas and a faculty member at Harvard Medical
School from 1991 to 1999 and University of Massachusetts Medical School from 2000 to 2011. Her <FONT STYLE="white-space:nowrap">NIH-sponsored</FONT> laboratory focused on the role of protein <FONT STYLE="white-space:nowrap">S-nitrosylation</FONT> in
physiology and pathophysiology. Dr.&nbsp;Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women&#146;s Hospital and an Infectious Disease
fellowship as part of the Harvard Combined Infectious Disease Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>John J. McCabe, C.P.A.,</I></B> has served as our Vice
President, Finance since October 2017. Mr.&nbsp;McCabe served as Chief Financial Officer for Eleven Biotherapeutics, Inc. from January 2016 until October 2017 and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to that served as Senior Vice President from June 2013 to December 2015 and Director of Financial Reporting from April 2012 to June 2013. Mr.&nbsp;McCabe also provided independent financial
and accounting consulting services from June 2011 to April 2012. Prior to that, Mr.&nbsp;McCabe served as Vice President of Finance at Clinical Data, Inc., from December 2010 to June 2011 and as the Senior Director of Financial Reporting of Clinical
Data from August 2007 to December 2010. Prior to that, Mr.&nbsp;McCabe served in several financial roles at Interleukin Genetics, Inc. He began his career working for the accounting firm of Coopers&nbsp;&amp; Lybrand LLP, now known as
PricewaterhouseCoopers LLP. Mr.&nbsp;McCabe received a B.S. in Business Administration from the University of Vermont and is also a Certified Public Accountant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Paul Fonteyne</I></B> has served as a member of our board of directors since December 2017. Mr. Fonteyne has served as the United States
Country Managing Director and President and Chief Executive Officer of Boehringer Ingelheim USA Corporation since 2011. Previously, Mr. Fonteyne served as Senior Corporate Vice President in Boehringer Ingelheim GmbH from 2009 to 2011. From 2003 to
2008 he served as Executive Vice President, Head of Marketing and Sales for Prescription Medicines at Boehringer-Ingelheim Pharmaceuticals, Inc. Prior to 2003, Mr. Fonteyne served in numerous leadership positions at Merck and Co. Inc, including Vice
President of Sales in North Central US, Vice President of Marketing and Senior Director of Marketing. Mr. Fonteyne currently serves on the advisory board of the Brigham and Women&#146;s Hospital Lung Center and the board of PhRMA (the leading
pharmaceutical industry association). Mr. Fonteyne received his MBA from Carnegie-Mellon University and his MS in Chemical Engineering from the Polytechnic School at the University of Brussels. We believe Mr. Fonteyne is qualified to serve on our
board of directors as a result of his past experience in the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Jonathan Silverstein</I></B><I></I> has
served as a member of our board of directors since November 2017. Mr. Silverstein is currently a general partner at OrbiMed, a healthcare investment firm, where he has worked since December 1998. Previously, Mr. Silverstein was a director of life
sciences in the investment banking department at Sumitomo Bank. Mr. Silverstein serves on the board of directors of Glaukos Corporation and Ascendis Pharma A/S. Mr. Silverstein also serves on the boards of directors of several private companies. Mr.
Silverstein holds a B.A. from Denison University and a J.D. and M.B.A. from the University of San Diego. We believe that Mr. Silverstein&#146;s strategic development and capital markets experience qualifies him to serve on our board of directors.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>David Steinberg</I></B> has served as a member of our board of directors since March 2017. Mr. Steinberg is a Co-founder of
PureTech Health plc and has been the Chief Innovation Officer for over five years. PureTech Health (PRTC.L) is an advanced clinical stage biopharma company developing new categories of medicines targeting the brain-immune-gut &#147;BIG&#148;
axis.&nbsp;As a senior executive officer of PureTech Health, Mr. Steinberg is a member of the executive committee. He has been involved in initiating and leading multiple PureTech programs, including PureTech&#146;s microbiome initiative, lymphatic
biology platform and immune-oncology pipeline. Prior to joining PureTech Health, he was a strategy consultant with Vertex Partners and the Boston Consulting Group, where he focused on research and development and product strategy and strategic
alliances for Fortune 500 pharmaceutical and biotechnology clients. Mr. Steinberg is also a member of the UChicago Tech Innovation Fund Advisory Committee. He received his B.A. in Biology with distinction from Cornell University and graduated with
high honors from the University of Chicago Booth School of Business with an M.B.A. in Strategy and Finance.&nbsp;We believe that Mr. Steinberg is qualified to serve on our board of directors due to his finance background and industry experience.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Lynne Sullivan</I></B> has served as a member of our board of directors since December 2017. Ms. Sullivan is currently the Senior
Vice President of Finance for Biogen Inc., where she has worked since 2008. Ms. Sullivan has global responsibility for Biogen&#146;s Financial Planning &amp; Analysis, Corporate Tax, and Corporate Finance groups, which includes ownership of
long-range planning, capital allocation projects and the financial aspects of Mergers &amp; Acquisitions/Business Development. Previously, Ms. Sullivan was the Vice President of Tax for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Biogen, Vice President Tax for EMD Serono and the Vice President of Tax for North America at Merck KgaA. She was also a Tax Partner at Arthur Andersen, where she led the North East Region&#146;s
Tax Consulting Practice for the firm. Ms. Sullivan is on the Board of Solid Biosciences LLC, where she chairs the Audit Committee since 2015. Ms. Sullivan holds a B.S. in Accounting from Suffolk University and a M.S. in Taxation from Bentley
College. We believe that Ms. Sullivan is qualified to serve on our board of directors due to her finance background and experience in the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B><I>Daphne Zohar</I></B> has served as a member of our board of directors since December 2017. Ms. Zohar is the founder and Chief Executive
Officer of PureTech Health plc (PRTC.L), an advanced clinical stage biopharma company developing new categories of medicines targeting the brain-immune-gut &#147;BIG&#148; axis. Ms. Zohar has also co-founded and currently sits on the board of
directors of a number of private life science companies, as well as on the board of PureTech Health plc, which is FTSE indexed and listed on the main market of the London Stock Exchange. Ms. Zohar also serves on the advisory board of the Technology
Development Fund Advisory Board at Children&#146;s Hospital Boston, is an Editorial Advisor to Xconomy, a national news company, and is on the board of advisors of Life Science Cares. Ms. Zohar has been recognized as a leader and innovator in
biotechnology by a number of sources, including Ernst &amp; Young, BioWorld, MIT&#146;s Technology Review, the Boston Globe, and Scientific American. Ms. Zohar has been an entrepreneur since an early age and received her B.A. in entrepreneurship and
new venture creation from Northeastern University. We believe Ms. Zohar is qualified to serve on our board of directors given her experience and knowledge of the life sciences industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board
Composition </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of five members. Our directors hold office until their successors have been
elected and qualified or until the earlier of their resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws that will become
effective as of the closing date of this offering provide that the authorized number of directors may be changed only by resolution of our board of directors. Our certificate of incorporation and bylaws will also provide that our directors may be
removed only for cause by the affirmative vote of the holders of at least 66.7% of our shares of capital stock present in person or by proxy and entitled to vote, and that any vacancy on our board of directors, including a vacancy resulting from an
enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In accordance with the
terms of our certificate of incorporation and bylaws that will become effective as of the closing date of this offering, our board of directors will be divided into three classes, class I, class II and class III, with members of each class serving
staggered three-year terms. Upon the closing of this offering, the members of the classes will be divided as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the class I directors will be Jonathan Silverstein and David Steinberg, and their term will expire at the annual meeting of stockholders to be held in 2019; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the class II directors will be Lynne Sullivan and Daphne Zohar, and their term will expire at the annual meeting of stockholders to be held in 2020; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the class III directors will be Chen Schor and Paul Fonteyne, and their term will expire at the annual meeting of stockholders to be held in 2021. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at
the annual meeting of stockholders in the year in which their term expires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have no formal policy regarding board diversity. Our priority in selection of board
members is identification of members who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members,
knowledge of our business and understanding of the competitive landscape. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Applicable Nasdaq Stock Market, or Nasdaq, rules require a majority of a listed company&#146;s board of directors to be comprised of
independent directors within one year of listing. In addition, the Nasdaq rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and corporate governance committees be
independent. Audit committee members must also satisfy the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and compensation
committee members must also satisfy the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> under the Exchange Act. Under applicable Nasdaq rules, a director will only qualify as an &#147;independent
director&#148; if, in the opinion of the listed company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order
to be considered independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of
directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its
subsidiaries. In order to be considered independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1,</FONT> the board must consider, for each member of a compensation committee of a listed company, all factors specifically relevant
to determining whether a director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to:
the source of compensation of the director, including any consulting, advisory or other compensatory fee paid by such company to the director; and whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In December 2017, our board of directors undertook a review of the composition of our board of directors and its committees and the
independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that Jonathan
Silverstein, Paul Fonteyne and Lynne Sullivan are each an &#147;independent director&#148; as defined under applicable Nasdaq rules. In making such determination, our board of directors considered the relationships that each such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances that our board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital
stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. Mr.&nbsp;Schor is not an independent director under these rules because he is our President and Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors
has established an audit committee, a compensation committee and a nominating and corporate governance committee. Each of these committees will operate under a charter that has been approved by our board of directors. The composition of each
committee will be effective as of the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are Chen Schor, David Steinberg and Lynne Sullivan, and Lynne Sullivan is the chair of the audit committee.
Effective as of the date of this prospectus, our audit committee&#146;s responsibilities will include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from that firm; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing our internal audit function, if any; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discussing our risk assessment and risk management policies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt and retention of accounting related complaints and concerns; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">meeting independently with our internal auditing staff, if any, our independent registered public accounting firm and management; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving or ratifying any related person transactions; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing the audit committee report required by the SEC rules. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All audit and <FONT
STYLE="white-space:nowrap">non-audit</FONT> services, other than <I>de minimis</I> <FONT STYLE="white-space:nowrap">non-audit</FONT> services, to be provided to us by our independent registered public accounting firm must be approved in advance by
our audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that Lynne Sullivan is an &#147;audit committee financial expert&#148; as
defined in applicable SEC rules and that each of the members of our audit committee possesses the financial sophistication required for audit committee members under Nasdaq rules. Under the applicable Nasdaq rules, a company listed in connection
with its initial public offering is permitted to phase in its compliance with the independent audit committee requirements set forth in Marketplace Rule 5615(b)(1) on the same schedule as it is permitted to phase in its compliance with the
independence audit committee requirement pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3(b)(1</FONT> )(iv)(A) under the Exchange Act, that is, (1) one independent member at the time of listing; (2)&nbsp;a majority of independent members
within 90 days of listing; and (3) all independent members within one year of listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are Paul Fonteyne, Jonathan Silverstein and David Steinberg, and Paul Fonteyne is the chair of the
compensation committee. Effective as of the date of this prospectus, our compensation committee&#146;s responsibilities will include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving, or making recommendations to our board of directors with respect to, the compensation of our chief executive officer and our other executive officers; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing an evaluation of our senior executives; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and making recommendations to our board of directors with respect to our incentive-compensation and equity-based compensation plans; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing and administering our equity-based plans; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and making recommendations to our board of directors with respect to director compensation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and discussing annually with management our &#147;Compensation Discussion and Analysis&#148; disclosure if and to the extent then required by SEC rules; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing the compensation committee report if and to the extent then required by SEC rules. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the applicable Nasdaq rules, a company listing in conjunction with its initial public offering is permitted to phase in its compliance
with the independent committee requirements set forth in Nasdaq Rules &#167;5605(d) and (e) as follows: (1) one independent member at the time of listing; (2) a majority of independent members within 90 days of listing; and (3) all independent
members within one year of listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The members of our nominating and corporate governance committee are Paul Fonteyne, Jonathan Silverstein and Daphne Zohar, and Jonathan
Silverstein is the chair of the nominating and corporate governance committee. Effective as of the date of this prospectus, our nominating and corporate governance committee&#146;s responsibilities will include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying individuals qualified to become members of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending to our board of directors the persons to be nominated for election as directors and to each of our board&#146;s committees; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing and recommending to our board of directors corporate governance principles; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing an annual evaluation of our board of directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the applicable Nasdaq rules,
a company listing in conjunction with its initial public offering is permitted to phase in its compliance with the independent committee requirements set forth in Nasdaq Rules &#167;5605(d) and (e) as follows: (1) one independent member at the time
of listing; (2) a majority of independent members within 90 days of listing; and (3) all independent members within one year of listing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation
Committee Interlocks and Insider Participation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">None of our executive officers serves, or in the past year has served, as a member of
the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None
of the members of our compensation committee is, or has ever been, an officer or employee of ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have adopted, effective upon the effectiveness of the registration statement of which this prospectus forms a part, a written code of
business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Following
this offering, we will post a copy of the code on the Corporate Governance section of our website. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will
disclose the nature of such amendment or waiver on our website or in a current report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This section describes the material elements of compensation awarded to, earned by or paid to our named executive officers in 2017, who were
Chen Schor, our President and Chief Executive Officer, Joan Mannick, our Chief Medical Officer, and John McCabe, our Vice President, Finance. These individuals represent our principal executive officer and our next two most highly compensated
executive officers in the year ended December&nbsp;31, 2017. We are an &#147;emerging growth company,&#148; within the meaning of the JOBS Act, and have elected to comply with the reduced compensation disclosure requirements available to emerging
growth companies under the JOBS Act. This section also provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our named executive officers and is intended to place in perspective the data
presented in the tables and narrative that follow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding compensation awarded to, earned by or paid to our named executive officers during 2017
and 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:97.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.90pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Salary</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:22.20pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Option<BR>Awards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:26.70pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:55.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Non-Equity<BR>Incentive<BR>Compensation<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>All Other<BR>Compensation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:49.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:18.20pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>($)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chen Schor<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">268,826</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">36,000<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7,400</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">312,226</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Mannick<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">236,035</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">30,000<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6,484</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">272,519</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John McCabe<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Vice President, Finance</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">47,526</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">485,474</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">314</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">533,314</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in the &#147;Option Awards&#148; column reflects the aggregate grant date fair value of share- based compensation awarded during the year computed in accordance with the provisions of Financial
Accounting Standards Board Accounting Standards Codification, or ASC, Topic 718. See Note 2 to our financial statements appearing at the end of this prospectus regarding assumptions underlying the valuation of equity awards. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Each of our named executive officers is eligible to earn cash incentive compensation for 2017 based upon achievement of clinical and developmental objectives. Such amounts have not yet been determined, but are expected
to be determined and paid in the first quarter of 2018 and will be reported at such time as required by SEC rules. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Amounts reflecting Company matching contributions to our 401(k) plan. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Schor has served as a director and as our President and Chief Executive Officer since July 2016, but did not become an employee of our company until April 4, 2017. Mr.&nbsp;Schor did not earn any compensation
for his services until he commenced his employment relationship with us in 2017. In 2016, he purchased 1,886,363 shares of restricted common stock as founder shares at the then-current fair market value. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Amounts represent bonuses paid upon achievement of certain milestones in 2017 as further described below. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Mannick commenced her employment with us in April 2017. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;McCabe commenced his employment with us in October 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our sole executive officer during 2016 was our President and Chief Executive Officer, Chen Schor. Mr.&nbsp;Schor did not receive any
compensation for his services in 2016, but purchased restricted stock at the then-current fair market value at incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we appointed Dr.&nbsp;Joan Mannick as our Chief Medical Officer. In April
2017, Mr.&nbsp;Schor and Dr.&nbsp;Mannick commenced an employment relationship with us, and at that time, began receiving base salary and eligibility for performance-based bonuses, as described in greater detail below under &#147;&#151;Employment
Arrangements with Our Named Executive Officers.&#148; John McCabe, our Vice President, Finance, has provided consulting services to us since September 2017, and was appointed to his current position in October 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2016, the board of directors issued and sold at the then-current fair market value 1,886,363 shares of restricted common stock to each
of Mr.&nbsp;Schor and Dr.&nbsp;Mannick as founder shares. These equity awards are subject to a repurchase option in favor of us, pursuant to which we may repurchase any unvested shares at the purchase price paid for such shares in the event that
either Mr.&nbsp;Schor or Dr.&nbsp;Mannick ceases providing services to us. In the case of a qualified funding (as defined in the applicable award agreement), which was satisfied upon the closing of our Series A preferred stock financing, a portion
of the unvested shares accelerated and vested in full. In the case of a liquidity event (as defined in the applicable award agreement), which includes this initial public offering, the remaining unvested shares will accelerate and vest in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We use base salaries and performance-based bonuses to recognize the experience, skills, knowledge and responsibilities required of all our
employees, including our named executive officers. Although we do not have a formal policy with respect to the grant of equity incentive awards to our current and future named executive officers, we believe that equity grants provide these officers
with a strong link to our long-term performance, create an ownership culture and help to align the interests of these officers and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive
retention because this feature incents our current and future named executive officers to remain in our employment during the vesting period. Accordingly, our board of directors intends to periodically review the equity incentive compensation of our
current and future named executive officers and from time to time may grant equity incentive awards to them in the form of stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding
Equity Awards at 2017 Year End </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding outstanding equity awards held by our named
executive officers as of December 31, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:52.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Option Awards</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:47.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stock Awards</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:41.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:47.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number
of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:28.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Option<BR>Exercise<BR>Price<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:36.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Option<BR>Expiration<BR>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:31.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number<BR>of Shares<BR>of
Stock<BR>that have<BR>not<BR>Vested<BR>(#)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:34.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Market<BR>Value&nbsp;of<BR>Shares&nbsp;of<BR>Stock&nbsp;that<BR>have not<BR>Vested
($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chen Schor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">548,224<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,220,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Mannick</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">548,224<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,220,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John McCabe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,100<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12/5/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">These shares of restricted stock were issued on July 11, 2016 to Mr.&nbsp;Schor and Dr.&nbsp;Mannick, and vest in 48 equal monthly installments through July 11, 2020. Upon the closing of a liquidity event (as defined in
the award agreement), which includes this initial public offering, the unvested shares of restricted stock will accelerate and vest in full. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">On December&nbsp;5, 2017, Mr.&nbsp;McCabe was awarded an option to purchase 78,100 shares of our common stock under our 2017 Plan. The shares underlying this option vest as follows: 25% of the shares vest on
October&nbsp;23, 2018, and the remaining shares vest in six equal semi-annual installments following October&nbsp;23, 2018, subject to Mr.&nbsp;McCabe&#146;s continued service. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements with Our Named Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with their commencement of employment with us, we have entered into employment offer letters with each of our named executive
officers. Mr. Schor&#146;s and Dr. Mannick&#146;s offer letters have been amended effective upon the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Chen
Schor Offer Letter </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we entered into an offer letter with Mr.&nbsp;Schor. The offer letter established
Mr.&nbsp;Schor&#146;s title, his base salary of $361,000 per year, his eligibility for an annual bonus and certain milestone-based bonuses, and his eligibility for benefits made available to employees generally and also provides for certain benefits
upon termination of his employment under specified conditions. Our board of directors determined that Mr.&nbsp;Schor was eligible to receive an annual bonus of up to 40% of his base salary, including a bonus at the same rate for the period from
January 1, 2017 through March 31, 2017, when his offer letter was signed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Schor&#146;s offer letter also provided for the
following milestone-based bonuses: (i) $18,000 after the first subject is dosed in a Phase 2 study following the <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting or call with the FDA (or written feedback to a
<FONT STYLE="white-space:nowrap">pre-IND</FONT> briefing book from the FDA) provided such dosing occurs by April 4, 2018; (ii) $18,000 after we enroll the first subject following interim analysis review by a committee defined by the Phase 2 study
protocol, provided such enrollment occurs by April 4, 2019; and (iii) $36,000 after we achieve the primary end point with a <FONT STYLE="white-space:nowrap">p-value</FONT> equal to or less than 0.05 in a Phase 2 study, provided such achievement
occurs by April 4, 2020. The Company achieved the milestones described in clauses (i) and (ii) above and paid such amounts to Mr. Schor in 2017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Schor&#146;s employment is at will. Under the terms of his offer letter, if Mr.&nbsp;Schor&#146;s employment is terminated by us
without cause or by Mr.&nbsp;Schor for good reason, each as defined in his offer letter, and subject to Mr.&nbsp;Schor&#146;s execution of a general release of potential claims against us, we have agreed to pay Mr.&nbsp;Schor an amount equal to 6
months of his then-current base salary and provide continued coverage under our health and dental plans for 6 months if such termination occurs within the first 12 months of his employment or an amount equal to 12 months of his then-current base
salary and continued coverage under our health and dental plans for 12 months if such termination occurs thereafter. In addition, if such termination occurs following a change of control (as defined in his offer letter), Mr.&nbsp;Schor will also be
eligible to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of his annual performance bonus for the calendar year in which his employment was terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Schor&#146;s offer letter also provides that he will (1)&nbsp;not compete with us during his employment and for a period of six
months after the termination of his employment, (2)&nbsp;not solicit our employees, independent contractors or customers during his employment and for a period of six months after the termination of his employment, (3)&nbsp;protect our confidential
and proprietary information and (4)&nbsp;assign to us related intellectual property developed during the course of his employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
amended Mr. Schor&#146;s offer letter, effective upon the closing of this offering. Pursuant to this amendment, Mr.&nbsp;Schor will be entitled to receive an annual base salary of $450,000 and an annual target bonus equal to 50% of his annual base
salary. Mr. Schor&#146;s amended offer letter provides that, in the event that his employment is terminated by us without cause or by him for good reason, and such termination occurs within the 12-month period following a change of control, then in
lieu of the payments and benefits described above, Mr.&nbsp;Schor shall be entitled to receive (i) a lump sum cash payment equal to 1.5 times the sum of his base salary and target annual incentive compensation, (ii) continued coverage under our
health and dental plans for up to 18 months following termination and (iii) full acceleration of all time-based stock options and other time-based stock-based awards held by Mr. Schor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we granted to Mr.&nbsp;Schor a stock option to purchase
238,311 shares of our common stock, at an exercise price equal to the per share price of our common stock in this offering. Such option will vest 25% on the first anniversary of the grant date, and the remainder ratably each month over the remaining
three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Joan Mannick Offer Letter </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we entered into an offer letter with Dr.&nbsp;Mannick. The offer letter established Dr.&nbsp;Mannick&#146;s title, her base
salary of $318,250 per year, her eligibility for an annual bonus and certain milestone-based bonuses, and her eligibility for benefits made available to employees generally and also provides for certain benefits upon termination of her employment
under specified conditions. Dr. Mannick&#146;s annual base salary shall be subject to increase in the discretion of our board of directors; provided that her base salary shall be increased by no less than 5% upon the earlier of April&nbsp;4, 2019 or
her eligibility to receive the bonus described in clause (iii)&nbsp;of the following paragraph. Our board of directors determined that Dr.&nbsp;Mannick was eligible to receive an annual bonus of up to 35% of her base salary, and a bonus at the rate
of 23.33% for the period from January 1, 2017 through March 31, 2017, when her offer letter was signed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mannick&#146;s offer
letter also provided for the following milestone-based bonuses: (i) $15,000 after the first subject is dosed in a Phase 2 study following the <FONT STYLE="white-space:nowrap">pre-IND</FONT> meeting or call with the FDA (or written feedback to a <FONT
STYLE="white-space:nowrap">pre-IND</FONT> briefing book from the FDA) provided such dosing occurs by April 4, 2018; (ii)&nbsp;$15,000 after we enroll the first subject following interim analysis review by a committee defined by the Phase 2 study
protocol, provided such enrollment occurs by April 4, 2019; and (iii)&nbsp;$30,000 after we achieve the primary end point with a <FONT STYLE="white-space:nowrap">p-value</FONT> equal to or less than 0.05 in a Phase 2 study, provided such achievement
occurs by April 4, 2020. The Company achieved the milestones described in clauses (i) and (ii) above and paid such amounts to Dr. Mannick in 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mannick&#146;s employment is at will. Under the terms of her offer letter, if Dr.&nbsp;Mannick&#146;s employment is terminated by us
without cause or by Dr.&nbsp;Mannick for good reason, each as defined in her offer letter, and subject to Dr.&nbsp;Mannick&#146;s execution of a general release of potential claims against us, we have agreed to pay Dr.&nbsp;Mannick an amount equal
to 6 months of her then-current base salary and provide continued coverage under our health and dental plans for 6 months if such termination occurs within the first 12 months of her employment or an amount equal to 9 months of her then-current base
salary and continued coverage under our health and dental plans for 9 months if such termination occurs thereafter. In addition, if such termination occurs following a change of control (as defined in her offer letter), Dr.&nbsp;Mannick will also be
eligible to receive a <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of her annual performance bonus for the calendar year in which her employment was terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mannick&#146;s offer letter also provides that she will (1)&nbsp;not compete with us during her employment and for a period of six
months after the termination of her employment, (2)&nbsp;not solicit our employees, independent contractors or customers during her employment and for a period of six months after the termination of her employment, (3)&nbsp;protect our confidential
and proprietary information and (4)&nbsp;assign to us related intellectual property developed during the course of her employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
amended Dr. Mannick&#146;s offer letter, effective upon the closing of this offering. Pursuant to this amendment, Dr. Mannick&#146;s base salary will be increased to $360,000 per year. Dr. Mannick&#146;s amended offer letter provides that, in the
event that her employment is terminated by us without cause or by her for good reason, and such termination occurs within the 12-month period following a change of control, then in lieu of the payments and benefits described above, Dr. Mannick shall
be entitled to receive (i) a lump sum cash payment equal to the sum of her base salary and target annual incentive compensation, (ii) continued coverage under our health and dental plans for up to 12 months following termination and (iii) full
acceleration of all time-based stock options and other time-based stock-based awards held by Dr. Mannick. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we granted to Dr.&nbsp;Mannick a stock option to purchase
92,999 shares of our common stock, at an exercise price equal to the per share price of our common stock in this offering. Such option will vest 25% on the first anniversary of the grant date, and the remainder ratably each month over the remaining
three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we have entered into a letter agreement with Dr.&nbsp;Mannick, effective from and after the closing of this
offering, to provide her with certain rights to participate in meetings of our board of directors as a <FONT STYLE="white-space:nowrap">non-voting</FONT> observer and to receive copies of materials provided to our board of directors. We may exclude
Dr.&nbsp;Mannick from such participation for any reason, including if we believe that such exclusion is reasonably necessary to preserve the attorney-client privilege, to protect confidential proprietary information or for other similar reasons. The
observer rights will terminate in the event that Dr.&nbsp;Mannick is no longer serving as an officer of our company for any reason, or if she materially breaches any employment agreement or confidentiality agreement with us, or if we undergo a
merger or consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>John McCabe </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In October 2017, we entered into an offer letter with Mr.&nbsp;McCabe. The offer letter established Mr.&nbsp;McCabe&#146;s title, his base
salary of $250,000 per year, his eligibility for an annual bonus, and his eligibility for benefits made available to employees generally and also provides for certain benefits upon termination of his employment under specified conditions. Our board
of directors determined that Mr.&nbsp;McCabe was eligible to receive an annual bonus of up to 30% of his base salary, <FONT STYLE="white-space:nowrap">pro-rated</FONT> for 2017 to reflect his partial year of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;McCabe&#146;s employment is at will. Under the terms of his offer letter, if Mr.&nbsp;McCabe&#146;s employment is terminated by us
without cause or by Mr.&nbsp;McCabe for good reason, each as defined in his offer letter, and such termination occurs following the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of his start and not in connection with a change in
control, then subject to Mr.&nbsp;McCabe&#146;s execution of a general release of potential claims against us and continued compliance with the restrictive covenants described below, we have agreed to pay Mr.&nbsp;McCabe an amount equal to three
months of his then-current base salary and provide continued coverage under our health and dental plans on the same terms and conditions in effect prior to his termination until the earlier of the expiration of the three- month period for which he
is entitled to receive severance and the date Mr.&nbsp;McCabe commences new employment which offers health coverage. If Mr.&nbsp;McCabe&#146;s employment is terminated by us without cause or by Mr.&nbsp;McCabe for good reason within 12 months after
a change in control, and subject to Mr.&nbsp;McCabe&#146;s execution of a general release of potential claims against us and continued compliance with the restrictive covenants described below, we have agreed to pay Mr.&nbsp;McCabe (1)&nbsp;an
amount equal to six months of his then-current base salary, (2)&nbsp;up to 50% of a <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of his annual performance bonus for any partial year of service and (3)&nbsp;continued coverage under the
Company&#146;s health and dental plans until the earlier of the expiration of 6 months and the date Mr.&nbsp;McCabe commences new employment which offers health coverage. In addition, all equity-based awards held by Mr.&nbsp;McCabe shall accelerate
in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;McCabe&#146;s offer letter also provides that he will (1)&nbsp;not compete with us during his employment and for a
period of one year after the termination of his employment, (2)&nbsp;not solicit our employees, independent contractors or customers during his employment and for a period of one year after the termination of his employment, (3)&nbsp;protect our
confidential and proprietary information and (4)&nbsp;assign to us related intellectual property developed during the course of his employment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option and Other Compensation Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The three equity incentive plans described in this section are our 2017 stock incentive plan, or the 2017 Plan, our 2018 stock option and
incentive plan, or the 2018 Plan, and our 2018 employee stock purchase plan, or the ESPP. Prior to this offering, we granted awards to eligible participants under the 2017 Plan. Following the closing of this offering, we expect to grant awards to
eligible participants only under the 2018 Plan and the ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The 2017 Plan was adopted by our board of directors in June 2017 and approved by our stockholders in August 2017. The 2017 Plan provides for
the grant of incentive stock options, nonqualified stock options, restricted stock awards, restricted stock units, stock appreciation rights and other stock-based awards. Our employees, officers, directors, consultants and advisors are eligible to
receive awards under the 2017 Plan; however, incentive stock options may only be granted to our employees. Our board of directors, or a committee appointed by our board, administers the 2017 Plan and, subject to any limitations set forth in the 2017
Plan, will select the recipients of awards and determine: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of common stock covered by options and the dates upon which those options become exercisable; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the type of options to be granted; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise prices of options; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the duration of options; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of common stock subject to any restricted stock or other stock-based awards and the terms and conditions of those awards, including the issue price, conditions for repurchase or forfeiture and
repurchase price. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If our board of directors delegates authority to an executive officer to grant awards under the 2017
Plan, the executive officer has the power to make awards to employees and officers, except executive officers. Our board of directors will fix the terms of the awards to be granted by such executive officer, including the exercise price of such
awards, and the maximum number of shares subject to awards that such executive officer may make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The 2017 Plan provides that a maximum of
1,866,009&nbsp;shares of our common stock are authorized for issuance under the plan. Our board of directors may amend, suspend, or terminate the 2017 Plan at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of
shares, spinoff, or other similar change in capitalization or event, or any dividend or distribution to holders of our common stock other than an ordinary cash dividend, under the terms of the 2017 Plan, we are required to equitably adjust (or make
substitute awards, if applicable), in the manner determined by our board of directors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and class of securities available under the 2017 Plan; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and class of securities and exercise price per share of each outstanding option; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the share and <FONT STYLE="white-space:nowrap">per-share</FONT> provisions and the measurement price of each outstanding stock appreciation right; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares subject to and the repurchase price per share subject to each outstanding restricted stock award; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the share and <FONT STYLE="white-space:nowrap">per-share-related</FONT> provisions and the purchase price, if any, of each outstanding other stock-based award. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of a merger or consolidation of our company with or into another entity
as a result of which all of our common stock is converted into or exchanged for the right to receive cash, securities, or other property or is cancelled; any transfer or disposition of all of our common stock for cash, securities, or other property
pursuant to a share exchange or other transaction; or a liquidation or dissolution of our company, our board of directors may, on such terms as our board of directors determines (except to the extent specifically provided otherwise in an applicable
award agreement or other agreement between us and the plan participant), take any one or more of the following actions pursuant to the 2017 Plan, as to some or all outstanding awards, other than restricted stock awards: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that awards shall be assumed, or substantially equivalent awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof); </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon written notice to a plan participant, provide that the participant&#146;s unexercised awards will terminate immediately prior to the consummation of such transaction unless exercised by the participant (to the
extent then exercisable) within a specified period; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that outstanding awards shall become exercisable, realizable or deliverable, or restrictions applicable to an award shall lapse, in whole or in part, prior to or upon such transaction; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the event of a transaction under the terms of which holders of common stock will receive upon consummation thereof a cash payment for each share surrendered in the transaction, make or provide for a cash payment to a
plan participant; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that, in connection with a liquidation of dissolution of the company, awards shall convert into the right to receive liquidation proceeds; or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any combination of the foregoing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors is not obligated under the 2017 Plan
to treat all awards, all awards held by a participant, or all awards of the same type, identically. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the occurrence of any corporate
transaction described above, other than our liquidation or dissolution, our repurchase and other rights under each outstanding restricted stock award will continue for the benefit of our successor and will, unless our board of directors determines
otherwise, apply to the cash, securities, or other property which our common stock was converted into or exchanged for in the transaction in the same manner and to the same extent as they applied to the common stock subject to the restricted stock
award; provided, however, that the board may provide termination or deemed satisfaction of such repurchase or other rights under the restricted stock award agreement, either initially or by amendment, or provide for forfeiture of such restricted
stock if issued at no cost. Upon our liquidation or dissolution, except to the extent specifically provided to the contrary in the restricted stock award agreement or any other agreement between the plan participant and us, all restrictions and
conditions on all restricted stock awards then outstanding will automatically be deemed terminated or satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors,
in its sole discretion, may accelerate the exercisability of any option or time at which any restrictions shall lapse or be removed from any restricted stock award, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December 31, 2017, there were 195,668 shares of common stock outstanding under the 2017 Plan at a weighted average exercise price of
$4.49 per share, and 1,670,341 shares of common stock were available for future issuance under the 2017 Plan. On and after the effective date of the 2018 Stock Incentive Plan, or 2018 Plan, described below, we will grant no further stock options or
other awards under the 2017 Plan. However, any shares of common stock subject to awards under our 2017 Plan that expire, terminate, or otherwise are surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in
any common stock being issued will become available for issuance under our 2018 Plan up to a specified number of shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Stock Option and Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted, and our stockholders have approved, the 2018 Plan, which became effective upon the effectiveness of the
registration statement of which this prospectus forms a part. The 2018 Plan replaced our 2017 Plan. The 2018 Plan allows the board of directors and the compensation committee to make equity-based incentive awards to our officers, employees,
directors and other key persons (including consultants). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock that is reserved for issuance under the
2018 Plan is 2,200,260&nbsp;shares, or the Initial Limit. The 2018 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by 4% of the
outstanding number of shares of our common stock on the immediately preceding December 31 or such lesser number of shares as determined by our compensation committee, or the Annual Increase. The Initial Limits and other share limits in the 2018 Plan
are subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares we issue under
the 2018 Plan will be authorized but unissued shares or shares that we acquire. The shares of common stock underlying any awards that are forfeited, cancelled, held back upon exercise of an option or settlement of an award to cover the exercise
price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock or are otherwise terminated (other than by exercise) under the 2018 Plan or the 2017 Plan will be added back to the shares of common stock available
for issuance under the 2018 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The maximum number of shares that may be issued as incentive stock options may not exceed the Initial
Limit cumulatively increased on January 1, 2019 and on each January 1 thereafter by the lesser of the Annual Increase or 1,359,815 shares. The value of all awards made under the 2018 Plan and all other cash compensation paid by us to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year shall not exceed $1.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The 2018 Plan will be
administered by our compensation committee. Our compensation committee has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and
to determine the specific terms and conditions of each award, subject to the provisions of the 2018 Plan. Persons eligible to participate in the 2018 Plan will be those full- or part-time officers, employees,
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The 2018 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under
Section&nbsp;422 of the Code and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on the date of
grant. The term of each option will be fixed by our compensation committee and may not exceed ten years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our compensation committee may award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock
appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price may not be less than 100% of the fair market value of our common
stock on the date of grant. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed ten years from the date of grant. Our compensation committee will determine at what time or times each stock
appreciation right may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our compensation committee may award restricted shares of common stock and restricted stock units to
participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. Our
compensation committee may also grant shares of common stock that are free from any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrictions under the 2018 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation
due to such participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our compensation committee may grant performance share awards to participants that entitle the recipient to
receive awards of common stock upon the achievement of certain performance goals and such other conditions as our compensation committee may determine. Our compensation committee may grant dividend equivalent rights to participants that entitle the
recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our
compensation committee may grant cash bonuses under the 2018 Plan to participants, subject to the achievement of certain performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our compensation committee may grant awards that vest or become payable upon the attainment of performance goals that are established by our
compensation committee and related to one or more performance criteria. The performance criteria that could be used with respect to any such awards are limited to: total stockholder return, earnings before interest, taxes, depreciation and
amortization, net income (loss) (either before or after interest, taxes, depreciation and/or amortization), changes in the market price of our common stock, economic value-added, sales or revenue, coverage decisions, research and development,
publication clinical, regulatory or commercial milestones, acquisitions or strategic transactions, including licenses, collaborations, joint ventures or promotional arrangements, operating income (loss), cash flow (including, but not limited to,
operating cash flow and free cash flow), return on capital, assets, equity, or investment, return on sales, gross or net profit levels, productivity, expense, margins, operating efficiency, customer satisfaction, working capital, earnings (loss) per
share of our common stock, sales or market shares and number of customers, any of which may be measured either in absolute terms or as compared to any incremental increase or as compared to results of a peer group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The 2018 Plan provides that upon the effectiveness of a &#147;sale event,&#148; as defined in the 2018 Plan, an acquirer or successor entity
may assume, continue or substitute outstanding awards under the 2018 Plan. To the extent that awards granted under the 2018 Plan are not assumed or continued or substituted by the successor entity, upon the effective time of the sale event, the 2018
Plan and all awards thereunder shall terminate. In the event of such termination, except as may otherwise be provided in the relevant award certificate, all options and stock appreciation rights that are not exercisable immediately prior to the
effective time of the sale event shall become fully exercisable as of the effective time of the sale event, all other awards with time based vesting, conditions or restrictions, shall become fully vested and nonforfeitable as of the effective time
of the sale event and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in the discretion of the administrator or to the extent specified in the relevant award
certificate. In addition, in connection with the termination of the 2018 Plan and awards thereunder upon a sale event, we may make or provide for a cash payment to participants holding vested and exercisable options and stock appreciation rights
equal to the difference between the per share cash consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation rights or each grantee, shall be permitted within a specified period of time prior
to the sale event, to exercise all outstanding stock options and stock appreciation rights held by such grantee to the extent exercisable. We shall also have the option to make or provide for payment, in cash or in kind, to the grantees of other
awards equal to the per share cash consideration payable to stockholders in the sale event multiplied by the number of vested shares of common stock subject to such awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors may amend or discontinue the 2018 Plan and our compensation committee may amend or cancel outstanding awards for
purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2018 Plan require the approval of our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No awards may be granted under the 2018 Plan after the date that is ten years from the date of stockholder approval of the 2018 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted, and our stockholders have approved, the ESPP, which became effective upon the effectiveness of the
registration statement of which this prospectus is a part. The ESPP is intended to qualify as an &#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423(b) of the Code. The ESPP initially reserves and authorizes the issuance
of up to a total of 275,030 shares of common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2019 and each January
1 thereafter through January 1, 2028, by the least of (i) 1% of the outstanding number of shares of our common stock on the immediately preceding December 31; (ii)&nbsp;543,926&nbsp;shares or (iii)&nbsp;such number of shares as determined by the
ESPP administrator. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All employees who have completed at least three months of employment and whose customary employment is for more than 20 hours per week are
eligible to participate in the ESPP. However, any employee who owns 5% or more of the total combined voting power or value of all classes of stock is not eligible to purchase shares under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will make one or more offerings each year to our employees to purchase shares under the ESPP. Unless otherwise determined by the
compensation committee, offerings will usually begin on each January 1 and July 1 and will continue for <FONT STYLE="white-space:nowrap">six-month</FONT> periods, referred to as offering periods. Each eligible employee may elect to participate in
any offering by submitting an enrollment form at least 15 business days before the relevant offering date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each employee who is a
participant in the ESPP may purchase shares by authorizing payroll deductions of up to 15% of his or her base compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her
accumulated payroll deductions will be used to purchase shares on the last business day of the offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period,
whichever is lower. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of common stock, valued at the start of the purchase period, under the ESPP in any calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An
employee&#146;s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of common stock
authorized under the ESPP and certain other amendments require the approval of our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Retirement Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We participate in a 401(k) retirement plan sponsored by PureTech Health, our shareholder, that is intended to be a <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> defined contribution plan under Section&nbsp;401(k) of the Internal Revenue Code. In general, all of our employees are eligible to participate, beginning two months after the commencement of their
employment. The 401(k) plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit and have the amount of the reduction contributed to the 401(k)
plan. We currently contribute to each employee&#146;s 401(k) account, in the first quarter of each year, 3% of his or her eligible earnings from the prior year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As permitted by Delaware law, we expect our board of directors and stockholders to adopt provisions in our certificate of incorporation, which
will become effective as of the closing date of this offering, that limit or eliminate the personal liability of our directors. Our certificate of incorporation, which will become effective as of the closing date of this offering, limits the
personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the General Corporation Law of the State of Delaware and provides that no director will have personal liability to us or to our stockholders for monetary
damages for breach of fiduciary duty. However, these provisions do not eliminate or limit the liability of any of our directors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for any breach of the director&#146;s duty of loyalty to us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for voting for or assenting to unlawful payments of dividends, stock repurchases or other distributions; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for any transaction from which the director derived an improper personal benefit. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any
amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to such amendment or repeal. If the General Corporation Law of the State of
Delaware is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our directors will be further limited to the greatest extent permitted by the General Corporation Law of
the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, our certificate of incorporation, which will become effective as of the closing date of this
offering, provides that we must indemnify our directors and officers and we must advance expenses, including attorneys&#146; fees, to our directors and officers in connection with legal proceedings, subject to very limited exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers specified liabilities of our directors and officers arising out of claims based
on acts or omissions in their capacities as directors or officers. In addition, we expect to enter into indemnification agreements with each of our officers and directors prior to the completion of this offering. These indemnification agreements
will require us, among other things, to indemnify each such director or officer for some expenses, including attorneys&#146; fees, judgments, fines and settlement amounts, incurred by him or her in any action or proceeding arising out of his or her
service as one of our directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through
their relationships with their employers, be insured or indemnified against specified liabilities incurred in their capacities as members of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, executive officers or persons
controlling us, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which
they will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades pursuant to parameters established by the director or officer
when entering into the plan, without further direction from the director or officer. The director or officer may amend or terminate the plan in some circumstances. Our directors and executive officers may also buy or sell additional shares outside
of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material, nonpublic information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have historically not compensated our directors for their services to us. We reimburse our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for reasonable travel and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with attending board of directors
and committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has approved a compensation policy for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors that became effective upon the effectiveness of the registration statement of which this prospectus forms a part. This policy is intended to provide a total compensation package that
enables us to attract and retain qualified and experienced individuals to serve as directors and to align our directors&#146; interests with those of our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the policy, each director who is not an employee will be paid cash compensation from and after the completion of this offering, as set
forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Member<BR>Annual<BR>Fee</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chairperson<BR>Additional<BR>Annual</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:43.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each annual cash retainer will be payable in arrears in four quarterly installments on the last day of each
quarter, provided that the amount of each payment will be prorated for any portion of a quarter that a director is not serving on our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, each new <FONT STYLE="white-space:nowrap">non-employee</FONT> director elected to our board of directors following this offering
will be granted an option to purchase 28,828&nbsp;shares of our common stock on the date of such director&#146;s election or appointment to the board of directors, which will vest in the following manner, subject to continued service through such
vesting date: 33% on first anniversary of grant, then the remainder should vest ratably monthly over two years. On the date of each annual meeting of stockholders of our company, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director
will be granted an option to purchase 14,414&nbsp;shares of our common stock, which will vest in the following manner, subject to continued service as a director through such vesting date: in full upon the earlier to occur of the first anniversary
of the date of grant or the date of the next annual meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_13"></A>TRANSACTIONS WITH RELATED PERSONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since our incorporation in July 2016, we have engaged in the following transactions in which the amount involved exceeded $120,000 and any of
our directors, executive officers or beneficial holders of more than 5% of any class of our voting securities, or any of their affiliates, had a material interest. We believe that all of these transactions were on terms comparable to terms that
could have been obtained from unrelated third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Founders Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2016, Chen Schor and Joan Mannick purchased 1,886,363 shares of common stock at $0.0001 per share. See the &#147;Executive
Compensation&#148; section of this prospectus for a further discussion of these purchases. In addition, on March 1, 2017, we issued 1,886,363 shares of our common stock to PureTech Health as founder shares at par value, the fair market value of the
shares at the time of their issuance for an aggregate price of $242. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series&nbsp;A Preferred Stock Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2017, we entered into a Series&nbsp;A preferred stock purchase agreement for the sale of up to 10,351,968 shares of Series&nbsp;A
preferred stock in one or more closings at a price per share of $1.932. In March 2017, we issued and sold an aggregate of 5,434,783 shares of our Series&nbsp;A preferred stock in the first closing of our Series&nbsp;A preferred stock financing.
PureTech Health paid $5,017,989 for such Series&nbsp;A shares, and the remaining $482,011 of the purchase price was net settled against invoices paid by PureTech Health on our behalf prior to the closing of our Series A financing and as
reimbursement for certain due diligence costs incurred in connection with the financing. The shares of Series&nbsp;A preferred stock issued to NIBR were issued in consideration for a license from Novartis, as discussed further below. The Series A
preferred stock purchase agreement provided that, after the initial closing, PureTech Health would purchase up to an additional 4,917,185 shares of Series A preferred stock at $1.932 per share at future dates based on the occurrence of certain
events as specified under the agreement. In addition, we entered into a side letter with PureTech Health under which PureTech Health agreed to purchase up to 5,175,984 additional shares of Series A preferred stock at $1.932 per share at a future
date based on the occurrence of certain events as specified under the letter. We refer to these agreements to purchase such additional shares as the tranche rights. Such tranche rights were exercised to the extent described below and, as of the date
of this prospectus, have been terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of shares of our Series&nbsp;A preferred stock
purchased by our directors, executive officers and 5% stockholders and their affiliates and the aggregate purchase price paid for such shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:61.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares&nbsp;of&nbsp;Series&nbsp;A<BR>Preferred Stock<BR>Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate<BR>Cash<BR>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,846,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novartis Institutes for Biomedical Research, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,587,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,434,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2017, we issued and sold an additional 2,329,193 shares of our Series&nbsp;A preferred stock at a
price per share of $1.932 in the second closing of our Series&nbsp;A preferred stock financing, for a purchase price of approximately $4.5&nbsp;million. The following table sets forth the number of shares of our Series&nbsp;A preferred stock
purchased by our directors, executive officers and 5% stockholders and their affiliates and the aggregate purchase price paid for such shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:61.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares&nbsp;of&nbsp;Series&nbsp;A<BR>Preferred&nbsp;Stock<BR>Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate<BR>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,329,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,329,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,500,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In October 2017, we issued and sold an additional 7,763,975 shares of our Series A preferred
stock at a price per share of $1.932 in the third and final closing of our Series A preferred stock financing, for a purchase price of approximately $15.0&nbsp;million. The following table sets forth the number of shares of our Series A preferred
stock purchased by our directors, executive officers and 5% stockholders and their affiliates and the aggregate purchase price paid for such shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:61.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares&nbsp;of&nbsp;Series&nbsp;A<BR>Preferred Stock<BR>Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate<BR>Cash<BR>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,658,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments VI, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,105,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,763,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series&nbsp;B Preferred Stock Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In October 2017, we entered into a Series B preferred stock purchase agreement for the sale of up to 4,792,716 shares of Series B preferred
stock in one or more closings at a price per share of $8.346. In November 2017, we issued and sold an aggregate of 4,792,716 shares of our Series B preferred stock for gross proceeds of approximately $40.0 million. The following table sets forth the
number of shares of our Series&nbsp;B preferred stock purchased by our directors, executive officers and 5% stockholders and their affiliates and the aggregate purchase price paid for such shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:61.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>Preferred Stock<BR>Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:51.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate<BR>Cash<BR>Purchase&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments VI, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,396,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,396,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in this Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders, including certain affiliates of our directors, have indicated an interest in purchasing an aggregate of
up to $35&nbsp;million of shares of our common stock in this offering at the initial public offering price. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more,
less or no shares in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, less or no shares in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreement with Novartis </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
March 2017, we entered into a license agreement with Novartis pursuant to which we were granted an exclusive worldwide license to certain intellectual property rights owned or controlled by Novartis, including patents, patent applications,
proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property, to develop, commercialize and sell one or more therapeutic products comprising RTB101 or RTB101 and everolimus in a fixed dose
combination.&nbsp;See &#147;Business&#151;Intellectual Property&#151;License Agreement with Novartis.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PureTech Health Shared Resources </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">PureTech Health is a founder of our company and in that capacity has provided us with strategic medical, clinical and scientific advice
pursuant to a business services, personnel and information management agreement. PureTech Health also played a significant role in securing our foundational intellectual property from Novartis, leveraging its connections to establish the
relationship, assisting in the negotiation of the license agreement and providing strategic advice throughout the process. In addition, we currently share administrative resources and offices with PureTech Health, including legal, accounting and
human resources support, computer and telecommunications systems and other office infrastructure pursuant to the agreement. Beginning in April 2017, PureTech has invoiced us at cost for such services, with such amounts totaling $109,063 as of
September 30, 2017. In addition, PureTech Health periodically invoices us for reimbursement of out of pocket expenses reasonably incurred on our behalf in connection with providing such business services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a party to an investors&#146; rights agreement, dated as of November 29, 2017, with holders of our preferred stock, including some of
our 5% stockholders and entities affiliated with our directors. Such holders consisted of entities affiliated with OrbiMed, PureTech Health and Novartis, each a 5% stockholder. Each of PureTech Health and OrbiMed have appointed representatives to
our board of directors. The investor rights agreement provides these holders the right, following the completion of this offering, to demand that we file&nbsp;a registration statement or request that their shares be covered by a registration
statement that we are otherwise filing. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a party to a
voting agreement, dated as of November 29, 2017, with holders of our preferred stock, including some of our 5% stockholders and entities affiliated with our directors. Such holders consisted of entities affiliated with OrbiMed, PureTech Health and
Novartis, each a 5% stockholder. Each of PureTech Health and OrbiMed have appointed representatives to our board of directors. The voting agreement provides the holders the right to elect certain directors to the Board. Pursuant to the voting
agreement, we agreed to appoint to our board of directors two representatives designated by PureTech Health, who are David Steinberg and Daphne Zohar, and one representative designated by an entity affiliated with OrbiMed who is Jonathan
Silverstein. The voting agreement will terminate upon completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Right of First Refusal and
<FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a party to a right of first refusal and <FONT
STYLE="white-space:nowrap">co-sale</FONT> agreement, dated as of November 29, 2017, with holders of our preferred stock, including some of our 5% stockholders and entities affiliated with our directors. Such holders consisted of entities affiliated
with OrbiMed, PureTech Health and Novartis, each a 5% stockholder. Each of PureTech Health and OrbiMed have appointed representatives to our board of directors. The right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement
provides the key holders the right to purchase all or any portion of transfer stock, as well as the right of <FONT STYLE="white-space:nowrap">co-sale</FONT> and participate in any proposed transfers. The agreement shall terminate upon completion of
this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">See the &#147;Executive Compensation&#151;Employment Arrangements with Our Named Executive Officer and Other Executive Officers&#148; section
of this prospectus for a further discussion of these arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation that will become effective as of the closing date of this offering provides that we will indemnify our
directors and officers to the fullest extent permitted by Delaware law. In addition, we plan to enter into indemnification agreements with each of our officers and directors that may be broader in scope than the specific indemnification provisions
contained in the Delaware General Corporation Law. See &#147;Executive Compensation&#151;Limitations on Liability and Indemnification&#148; for additional information regarding these agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors reviews and approves transactions with directors, officers and holders of 5% or more of our voting securities and their
affiliates, each a related party. Prior to this offering, the material facts as to the related party&#146;s relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such transaction, and the
transaction is not considered approved by our board of directors unless </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a majority of the directors who are not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related party, the material
facts of the related party&#146;s relationship or interest in the transaction are disclosed to the stockholders, who must approve the transaction in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we have adopted a written related party transactions policy that such transactions must be approved by our
audit committee. This policy became effective on the date on which the registration statement of which this prospectus is part was declared effective by the SEC. Pursuant to this policy, the audit committee has the primary responsibility for
reviewing and approving or disapproving &#147;related party transactions,&#148; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person
has or will have a direct or indirect material interest. For purposes of this policy, a related person is defined as a director, executive officer, nominee for director, or greater than 5% beneficial owner of our common stock, in each case since the
beginning of the most recently completed year, and their immediate family members. Our audit committee charter provides that the audit committee shall review and approve or disapprove any related party transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock as of December 31, 2017 by: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our named executive officer; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our directors and executive officers as a group; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The column entitled &#147;Percentage of Shares Beneficially Owned&#151;Before Offering&#148; is based on a total of 5,659,089&nbsp;shares of
our common stock outstanding as of December 31, 2017, and assumes the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 15,870,559 shares of our common stock upon the closing of this offering. The column
entitled &#147;Percentage of Shares Beneficially Owned&#151;After Offering&#148; is based on 27,196,315 shares of our common stock to be outstanding after this offering, including the 5,666,667 shares of our common stock that we are selling in this
offering, but not including any additional shares issuable upon exercise of outstanding options or any exercise by the underwriters of their option to purchase additional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with
respect to our common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within 60&nbsp;days after December 31, 2017 are considered outstanding and beneficially owned by the person holding the options
for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, the persons and entities in this table have sole voting and
investment power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise set forth below, the address of the beneficial owner is c/o resTORbio, Inc.,
500 Boylston Street, 12th floor, Boston, Massachusetts 02116. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain of our existing stockholders, including certain affiliates of our
directors, have indicated an interest in purchasing an aggregate of up to $35 million of shares of our common stock in this offering at the initial public offering price. However, because indications of interest are not binding agreements or
commitments to purchase, the underwriters may determine to sell more, less or no shares in this offering to any of these stockholders, or any of these stockholders may determine to purchase more, less or no shares in this offering. The table below
does not give effect to the potential purchases by such stockholders in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Percentage
of<BR>Shares<BR>Beneficially Owned</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:89.90pt; font-size:8pt; font-family:Times New Roman"><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares<BR>Beneficially&nbsp;Owned</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Before<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:29.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>After<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Stockholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,567,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Novartis Institutes for BioMedical Research,
Inc.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,021,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments VI,
LP<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,297,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chen Schor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,886,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul Fonteyne</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan Mannick, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,886,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John McCabe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jonathan Silverstein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Steinberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lynne Sullivan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daphne Zohar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Current Executive Officers and Directors as a Group (8&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,772,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Consists of (a)&nbsp;1,886,363 shares of common stock and (b)&nbsp;7,680,700 shares of common stock issuable upon conversion of preferred stock. Voting and investment power over the shares held by PureTech Health LLC is
exercised by its parent entity, PureTech Health plc. The board of directors of PureTech Health plc consists of Mr.&nbsp;Joi Ito, Dr.&nbsp;Raju Kucherlapati, Dr.&nbsp;John LaMattina, Dr.&nbsp;Robert Langer, Dame Marjorie Scardino, Dr.&nbsp;Ben
Shapiro, Mr.&nbsp;Christopher Viehbacher, Ms.&nbsp;Daphne Zohar and Mr.&nbsp;Stephen Muniz. None of the members of the board of directors of PureTech Health plc or PureTech Health LLC has individual voting or investment power with respect to such
shares. The address for PureTech Health LLC and the individuals listed above is c/o&nbsp;PureTech Health LLC, 501&nbsp;Boylston Street, Suite&nbsp;6102, Boston, MA 02116. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,021,237 shares of common stock issuable upon conversion of preferred stock. All shares are held by NIBR. NIBR is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG. The address for NIBR
is 250 Massachusetts Avenue, Cambridge, MA 02139. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 4,297,054 shares of common stock issuable upon conversion of preferred stock held by OrbiMed Private Investments VI, LP (&#147;OPI VI&#148;). OrbiMed Capital GP VI LLC (&#147;GP VI&#148;) is the sole general
partner of OPI VI. OrbiMed Advisors LLC (&#147;OrbiMed Advisors&#148;) is the managing member of GP VI. Samuel D. Isaly is the managing member of and owner of a controlling interest in OrbiMed Advisors. By virtue of such relationships, GP VI,
OrbiMed Advisors, and Mr.&nbsp;Isaly may be deemed to have voting and investment power with respect to the shares held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. Jonathan T. Silverstein, a member of OrbiMed
Advisors, is a member of our board of directors. Each of GP VI, OrbiMed Advisors, Mr. Isaly and Mr. Silverstein disclaims beneficial ownership of the shares held by OPI VI, except to the extent of its or his pecuniary interest therein if any. The
address of these entities is 601 Lexington Avenue, 54th floor, New York, New York 10022. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_15"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>The following descriptions are summaries of the material terms of our amended and restated certificate of incorporation, which will be
effective upon the closing of this offering and amended and restated bylaws, which became effective upon the effectiveness of the registration statement of which this prospectus is a part. The descriptions of the common stock and preferred stock
give effect to changes to our capital structure that will occur immediately prior to the completion of this offering. We refer in this section to our amended and restated certificate of incorporation as our certificate of incorporation, and we refer
to our amended and restated bylaws as our bylaws. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, our authorized capital stock will consist of&nbsp;150,000,000&nbsp;shares of common stock, par value $0.0001
per share, and&nbsp;10,000,000&nbsp;shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock will be undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December 31, 2017, 5,659,089 shares of our common stock, 15,527,951 shares of Series&nbsp;A preferred stock and 4,792,716 shares of
Series B preferred stock were outstanding and held by 11 stockholders of record. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The
holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any
preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets
remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our common stock. Upon
the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to&nbsp;10,000,000&nbsp;shares of preferred stock in one or more series and to fix the rights, preferences,
privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or
the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will
receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Immediately after
consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the completion
of this offering, the holders of 15,870,559 shares of our common stock, including those issuable upon the conversion of preferred stock, will be entitled to rights with respect to the registration of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these securities under the Securities Act. These rights are provided under the terms of an investors&#146; rights agreement between us and holders of our preferred stock. The investors&#146;
rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses,
including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Beginning 180&nbsp;days after the effective date of this registration statement, the holders of&nbsp;15,870,559 shares of our
common stock, including those issuable upon the conversion of preferred stock, are entitled to demand registration rights. Under the terms of the investors&#146; rights agreement, we will be required, upon the written request of the holders of at
least 40% of our outstanding registrable securities, as defined in the investors&#146; rights agreement, to file&nbsp;a registration statement and use commercially reasonable efforts to effect the registration of all or a portion of their
registrable securities for public resale so long as the total amount of registrable shares requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, of least $15.0&nbsp;million. We are required to
effect only two registrations pursuant to this provision of the investors&#146; rights agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Short-Form Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the investor rights agreement, if we are eligible to file&nbsp;a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3,</FONT> upon the written request of the holders of at least 30% of our outstanding registrable securities, as defined in the investors&#146; rights agreement so long as the total amount of registrable
securities requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, of least $10.0&nbsp;million. We are required to effect only two registrations in any twelve month period pursuant to the
investors&#146; rights agreement. The right to have such shares registered on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is further subject to other specified conditions and limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other
security holders, the holders of these shares are entitled to include their shares in the registration. Subject to certain exceptions contained in the investors&#146; rights agreement, we and the underwriters may limit the number of shares included
in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our investor
rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us,
and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The demand registration rights and short form registration rights granted under the investor rights agreement will terminate on the fifth
anniversary of the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or preventing
another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue
<FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition and Filling Vacancies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for the division of our board of directors into three classes serving staggered three-year terms,
with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of 66.7% or more of the shares then entitled to vote at an
election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in
office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board
of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Written Consent of Stockholders </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or
special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our bylaws or removal of
directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of Stockholders </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call
special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of
stockholders to those matters properly brought before the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Requirements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as
directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be
taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify
the requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or
our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the
amendment of the provisions relating to stockholder action, board composition and limitation of liability must be approved by not less than 66.7% of the outstanding shares entitled to vote on the amendment, and not less than 66.7% of the outstanding
shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote of a majority of the directors then in office or by the affirmative vote of at least a majority of the outstanding shares entitled to vote on
the amendment, subject to any limitations set forth in the bylaws; except that certain enumerated provisions in our bylaws may be amended by the affirmative vote of at least 66.7% of the outstanding shares entitled to vote on the amendment, or, if
our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares
of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of
directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other
transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and
preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also
adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our certificate of
incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on our
behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant to
any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or
(5)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Our certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to
have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is
challenged in a proceeding or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In
general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an
interested stockholder, unless the business combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following
conditions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the
interested stockholder; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested
stockholder; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select
Market Listing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our common stock has been approved for listing on The Nasdaq Global Select Market under the trading symbol
&#147;TORC.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent and registrar&#146;s
address is 250 Royall Street, Canton, Massachusetts 02021, and its telephone number is <FONT STYLE="white-space:nowrap">(800)&nbsp;962-4284.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_16"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the
availability of such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to
contractual and legal restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time
and our ability to raise equity capital in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on the number of shares outstanding as of December 31, 2017, upon the
completion of this offering, 27,196,315&nbsp;shares of our common stock will be outstanding, assuming the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 15,870,559 shares of our common stock upon the
closing of this offering, no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable, except that any
shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in compliance with the limitations described below. All remaining shares of common stock held by existing stockholders immediately
prior to the completion of this offering will be &#147;restricted securities&#148; as such term is defined in Rule 144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are
eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In general, under
Rule&nbsp;144, beginning 90&nbsp;days after the date of this prospectus, any person who is not our affiliate and has not been our affiliate at any time during the preceding three months and has held their shares for at least six months, including
the holding period of any prior owner other than one of our affiliates, may sell shares without restriction, subject to the availability of current public information about us. In addition, under Rule&nbsp;144, any person who is not our affiliate
and has not been our affiliate at any time during the preceding three months and has held their shares for at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited
number of shares immediately upon the closing of this offering without regard to whether current public information about us is available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Beginning 90&nbsp;days after the date of this prospectus, a person who is our affiliate or who was our affiliate at any time during the
preceding three months may sell any unrestricted securities, as well as restricted securities that the person has beneficially owned for at least six months, including the holding period of any prior owner other than one of our affiliates, under
Rule&nbsp;144. Affiliates selling restricted or unrestricted securities may sell a number of shares within any&nbsp;three-month&nbsp;period that does not exceed the greater of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of shares then outstanding, which will equal approximately 271,963&nbsp;shares immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares; or
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our common stock on The Nasdaq Global Select Market during the four calendar weeks preceding the filing of a notice on Form&nbsp;144 with respect to the sale. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sales under Rule&nbsp;144 by our affiliates are also subject to manner of sale provisions and notice requirements and to the availability of
current public information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In general, under Rule&nbsp;701 of the Securities Act, any of our employees, consultants or advisors, other than our affiliates, who purchased
shares from us in connection with a qualified compensatory stock plan or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
written agreement is eligible to resell these shares 90&nbsp;days after the date of this prospectus in reliance on Rule&nbsp;144, but without compliance with the holding period requirements of
Rule&nbsp;144 and without regard to the volume of such sales or the availability of public information about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">However, substantially
all Rule&nbsp;701 shares are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as described below and under &#147;Underwriting&#148; included elsewhere in this prospectus and will become eligible for sale upon the expiration of
the restrictions set forth in those agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All of our directors, executive officers and stockholders have signed a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement which
prevents them from selling any of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180&nbsp;days from the date of this prospectus without the prior written consent of
the representatives, subject to certain exceptions. See the section entitled &#147;Underwriting&#148; appearing elsewhere in this prospectus for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon completion of
this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities Act.&nbsp;Registration of these shares under the Securities Act would result in these shares
becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration.&nbsp;See the section entitled &#147;Description of Capital Stock&#151;Registration Rights&#148; appearing elsewhere in this
prospectus for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to
register our shares issued or reserved for issuance under our equity incentive plans. The first such registration statement is expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the
SEC. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such shares are subject to vesting restrictions with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions
described above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_17"></A>MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following is a general discussion of the material U.S. federal
income tax considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this
discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign corporation or any other foreign organization taxable as a corporation for U.S. federal income tax purposes; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a foreign estate or trust, the income of which is not subject to U.S. federal income tax on a net income basis. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This discussion does not address the tax treatment of partnerships or other entities that are past-through entities for U.S. federal income
tax purposes or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax advisor regarding
the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing
and proposed U.S. Treasury Regulations promulgated hereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus, all of which are subject to change or to differing interpretation, possibly with
retroactive effect. Any such change could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. In addition, the U.S. government has recently enacted comprehensive tax legislation that
includes significant changes to the taxation of business entities. This prospectus does not discuss such tax legislation and we cannot assure you that such a change in law does not impact that tax considerations that we describe in this summary.
There can be no assurance that the Internal Revenue Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder holds shares of our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code, generally property held for investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to a particular <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it address any aspects of any U.S. federal tax other than the income tax, U.S. state,
local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, the alternative minimum tax, or the Medicare tax on net investment income. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insurance companies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers or dealers in securities; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulated investment companies; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pension plans; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">passive foreign investment companies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that have a functional currency other than the U.S. dollar; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons for whom our stock constitutes &#147;qualified small business stock&#148; within the meaning of Section&nbsp;1202 of the Code; and </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain U.S. expatriates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This discussion is for general information only and is not tax
advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
tax consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Distributions, if any, on our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current
or accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT>
return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in
&#147;Gain on sale, exchange or other disposition of our common stock.&#148; Any such distributions will also be subject to the discussions below under the sections titled &#147;Backup Withholding and Information Reporting&#148; and
&#147;Withholding and Information Reporting Requirements&#151;FATCA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dividends paid to a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such
holder&#146;s country of residence. Dividends that are treated as effectively connected with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty
so provides, that are attributable to a permanent establishment or a fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United&nbsp;States, are generally exempt from the 30% withholding tax if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal
income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances,
be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who claims the benefit of an applicable income tax treaty
between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or successor form) and satisfy applicable certification and other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult their tax advisors regarding their
entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess
amounts withheld by timely filing a U.S. tax return with the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale, Exchange or Other Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below under &#147;Backup Withholding and Information Reporting&#148; and &#147;Withholding and Information
Reporting Requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income tax on any gain realized upon such holder&#146;s sale, exchange or other disposition of
shares of our common stock unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a
permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net
income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described
above in &#147;Distributions on Our Common Stock&#148; also may apply; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United States for 183 days or more in the taxable year of the disposition and certain other conditions
are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of
residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the
United States, provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses); or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we are, or have been, at any time during the five-year period preceding such disposition (or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property
holding corporation,&#148; unless our common stock is regularly traded on an established securities market and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly,
actually or constructively, during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT> period ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock.
If we are determined to be a U.S. real property holding corporation and the foregoing exception does not apply, then a purchaser may withhold 15% of the proceeds payable to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder from a sale of our
common stock and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the
Code). Generally, a corporation is a U.S. real property holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its
other assets used or held for use in a trade or business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can
be provided that our common stock will be regularly traded on an established securities market for purposes of the rules described above. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions
on our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder
is not a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to
withholding of U.S. federal income tax, as described above in &#147;Distributions on Our Common Stock,&#148; generally will be exempt from U.S. backup withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding will generally apply to the proceeds of a
disposition of our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes,
dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a
broker. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them. Copies of information returns may be made available to
the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or agreement. Backup withholding is not an additional tax. Any amounts
withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax
liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withholding and Information Reporting
Requirements&#151;FATCA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Foreign Account Tax Compliance Act, or FATCA, generally imposes a U.S. federal withholding tax at a rate
of 30% on payments of dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity
undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any, or
(iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Under applicable U.S. Treasury regulations, withholding under FATCA currently applies to payments of dividends on our common stock, but will only apply to payments of gross proceeds from
a sale or other disposition of our common stock made after December&nbsp;31, 2018. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of the tax. An intergovernmental
agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the possible
implications of this legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the
imposition of the 30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_18"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated and Leerink Partners LLC are acting as representatives of each of the underwriters
named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from
us, the number of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Underwriter</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.10pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; text-indent:-5.15em; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith<BR>Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,153,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,813,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,133,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">566,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,666,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting
underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $0.63 per share. After the initial offering, the public offering price, concession or any other term of the offering may be changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds before expenses to us. The information assumes either
no exercise or full exercise by the underwriters of their option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:34.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:54.35pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Without&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:43.25pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>With&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$15.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$85,000,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$97,750,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$5,950,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$6,842,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$13.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$79,050,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$90,907,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at $1.5&nbsp;million and
are payable by us. We have also agreed to reimburse the underwriters for up to $50,000 of their expenses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incurred in connection with the review and clearance by the Financial Industry Regulatory Authority, Inc., or FINRA, of the terms of this offering, as set forth in the underwriting agreement.
Under the rules of FINRA, certain affiliates of Leerink Partners LLC are each deemed to be a &#147;related person&#148; of Leerink Partners LLC and, therefore, the 119,818 shares of Series B preferred stock purchased by such affiliates in our Series
B financing in November 2017 are regarded by FINRA as additional compensation to the underwriters and will be subject to FINRA&#146;s lock-up requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to&nbsp;850,000 additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this
option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, our
executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the
date of this prospectus without first obtaining the written consent of the representatives. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offer, pledge, sell or contract to sell any common stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell any option or contract to purchase any common stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase any option or contract to sell any common stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">grant any option, right or warrant for the sale of any common stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lend or otherwise dispose of or transfer any common stock; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">request or demand that we file or make a confidential submission of a registration statement related to the common stock; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such swap or transaction is to be settled by delivery of shares or other
securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock
and to securities convertible into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement
later acquires the power of disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol &#147;TORC.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our common stock. The initial public offering price was determined through
negotiations between us and the representatives. In addition to prevailing market conditions, the factors considered in determining the initial public offering price were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial information; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the history of, and the prospects for, our company and the industry in which we compete; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the present state of our development; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the likelihood of approval for our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the offering the shares will not trade in the public
market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to sell more than 5% of the shares in the aggregate
to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing
our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing
shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect
investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open
market.&nbsp;The underwriters may conduct these transactions on The Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the
direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these
transactions or that these transactions, once commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
addition, affiliates of Leerink Partners LLC were also investors in our Series&nbsp;B financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, no offer of shares which are the subject of the offering has been, or will be
made to the public in that Member State, other than under the following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the representatives for any such offer; or </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no
such offer of shares referred to in (a)&nbsp;to (c) above shall result in a requirement for us or the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant to Article 16 of the
Prospectus Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each person located in a Member State to whom any offer of shares is made or who receives any communication in
respect of an offer of shares, or who initially acquires any shares will be deemed to have represented, warranted, acknowledged and agreed to and with the representatives and us that (1)&nbsp;it is a &#147;qualified investor&#148; within the meaning
of the law in that Member State implementing Article 2(1)(e) of the Prospectus Directive; and (2)&nbsp;in the case of any shares acquired by it as a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, the shares
acquired by it in the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than qualified investors, as that term is defined in the Prospectus Directive, or
in circumstances in which the prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consent of the representatives has been given to the offer or resale; or where shares have been acquired by it on behalf of persons in any Member State other than qualified investors, the offer
of those shares to it is not treated under the Prospectus Directive as having been made to such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, the representatives and
their respective affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgments and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This
prospectus has been prepared on the basis that any offer of shares in any Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person
making or intending to make an offer in that Member State of shares which are the subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for us or the representatives to publish a
prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither we nor the representatives have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for
us or the representatives to publish a prospectus for such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer of
shares to the public&#148; in relation to any shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to
purchase or subscribe the shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended) and
includes any relevant implementing measure in each Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling
restrictions set out below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the
Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment
activity to which this document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;)
or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the
disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing
material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither
this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the
offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes
(&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority
(&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this
prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations
Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance and any rules made under that Ordinance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or
to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or
purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person
pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any
other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant
person which is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals,
each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that
trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<I>Requirements, Exemptions and Ongoing Registrant Obligations</I>.<I> </I>Any resale of the<B> </B>shares<B> </B>must be made in accordance with an exemption from, or in a transaction not
subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of
Canada may provide a purchaser with remedies for rescission or damages if this prospectus<B> </B>(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser
within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for
particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed
by the government of a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI
<FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_19"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The validity of the shares of our common stock offered hereby is being passed upon for us by Goodwin Procter LLP, Boston, Massachusetts.
Certain legal matters relating to this offering will be passed upon for the underwriters by Latham&nbsp;
&amp; Watkins LLP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_20"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The financial statements of resTORbio, Inc. as of December&nbsp;31, 2016 and September&nbsp;30, 2017 and for the period July 5, 2016
(inception) through December 31, 2016 and the nine months ended September 30, 2017, have been included herein in reliance upon the reports of KPMG LLP, an independent registered public accounting firm, appearing elsewhere herein, and upon the
authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_21"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect
to the common stock we are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our common stock, you should refer to the
registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should refer to the exhibits attached to the
registration statement for copies of the actual contract, agreement or other document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the completion of the offering, we will be
subject to the informational requirements of the Exchange Act and will file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the
SEC&#146;s website at www.sec.gov. You may also read and copy any document we file with the SEC at its public reference facility at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. We also maintain a website at www.restorbio.com. Upon
completion of the offering, you may access, free of charge, our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and amendment to those reported filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished to,
the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F
Street, N.E., Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the operation of the
public reference facilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc475892_22"></A>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:16.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin475892_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Statements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin475892_2">Balance Sheets as of December&nbsp;31, 2016, September&nbsp;
30, 2017, and September&nbsp;30, 2017 pro forma (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin475892_3">Statements of Operations for the period from July&nbsp;
5, 2016 (inception) to December&nbsp;31, 2016, the period from July&nbsp;5, 2016 (inception) to September&nbsp;30, 2016 (unaudited) and the nine months ended September&nbsp;30, 2017 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin475892_4">Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; (Deficit)
Equity for the period from July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016, the nine months ended September&nbsp;30, 2017 and September&nbsp;30, 2017 pro forma (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin475892_5">Statements of Cash Flows for the period from July&nbsp;
5, 2016 (inception) to December&nbsp;31, 2016, the period from July&nbsp;5, 2016 (inception) to September&nbsp;30, 2016 (unaudited), and the nine months ended September&nbsp;30, 2017</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin475892_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin475892_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resTORbio, Inc.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>of resTORbio, Inc. as of
December&nbsp;31, 2016 and September&nbsp;30, 2017, and the related statements of operations, statements of redeemable convertible preferred stock and stockholders&#146; (deficit) equity, and cash flows for the period July&nbsp;5, 2016 (inception)
through December&nbsp;31, 2016 and the nine months ended September&nbsp;30, 2017. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on
our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits
provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to above present fairly, in all material
respects, the financial position of resTORbio, Inc. as of December&nbsp;31, 2016 and September&nbsp;30, 2017, and the results of its operations and its cash flows for the period July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and the
nine months ended September&nbsp;30, 2017 in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October 26, 2017, except for note 14,
as to which the date is January 16, 2018 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin475892_2"></A>Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2016</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,
2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:22.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Actual</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro Forma</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">58,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets (including related party amounts of $0 and $4 as of December&nbsp;31, 2016
and September&nbsp;30, 2017, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred stock and stockholders&#146; (deficit)
equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable (including related party amounts of $0 and $45 as of December&nbsp;31, 2016 and
September&nbsp;30, 2017, respectively)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche rights liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (see Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, Series A, $0.0001 par value, None and 10,351,968 shares
authorized as of December&nbsp;31, 2016 and September&nbsp;30, 2017, respectively; 0 and 7,763,976 shares issued and outstanding as of December&nbsp;31, 2016 and September&nbsp;30, 2017, respectively; no shares issued and outstanding pro forma
(unaudited); aggregate liquidation preference of $0 and $15,000 as of December&nbsp;31, 2016 and September&nbsp;30, 2017, respectively, and none pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 7,000,000, 19,000,000 and 30,000,000 shares authorized as of
December&nbsp;31, 2016, September&nbsp;30, 2017 actual and September 30, 2017 pro forma (unaudited), respectively; 3,772,726, 5,659,089 and 21,529,648 shares issued and outstanding as of December 31, 2016, September&nbsp;30, 2017 actual and
September&nbsp;30, 2017 pro forma (unaudited), respectively; 2,082,860, 4,456,533 and 21,529,648 shares vested as of December&nbsp;31, 2016, September&nbsp;30, 2017 actual and September&nbsp;30, 2017 pro forma (unaudited), respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; (deficit)
equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin475892_3"></A>Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)<BR>through<BR>December&nbsp;31,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)<BR>through<BR>September&nbsp;30,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine
Months<BR>Ended<BR>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares used in computing net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,978,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,919,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,839,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.30</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares used in computing pro forma net loss per share, basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,230,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin475892_4"></A>Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; (Deficit) Equity </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:96.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series A
Redeemable<BR>Convertible&nbsp;Preferred&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:96.05pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series B
Redeemable<BR>Convertible&nbsp;Preferred&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:52.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:36.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Additional<BR>Paid
In<BR>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:45.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:47.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shareholders&#146;<BR>(Deficit)<BR>Equity</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Shares</U>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Amount</U>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Shares</U>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;<U>Amount</U>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><U>Shares</U></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><U>Amount</U></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at July&nbsp;5, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,082,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,082,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of common shares to PureTech (see Note 13)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,886,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock, net of tranche liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,763,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at September&nbsp;30, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,763,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,456,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,725</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock and corresponding extinguishment of
tranche liability (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,763,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $54
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,792,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of redeemable convertible preferred shares into common shares (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,527,951</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,792,716</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,870,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accelerated vesting of restricted shares (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,202,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro Forma Balance at September&nbsp;30, 2017 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,529,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,346</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin475892_5"></A>Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)<BR>through<BR>December&nbsp;31,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)<BR>through<BR>September&nbsp;30,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine
Months<BR>Ended<BR>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of tranche liability (see Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expense related to acquisition of intellectual property (see Note&nbsp;6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin475892_6"></A>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">resTORbio, Inc.
(&#147;the Company&#148;) was incorporated in the State of Delaware on July&nbsp;5, 2016. The Company is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of
aging-related diseases and conditions. The Company&#146;s principal operations are located in Boston, Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since inception, the
Company has been primarily involved in research and development activities.&nbsp;The Company devotes substantially all of its efforts to product research and development, initial market development and raising capital. The Company has not generated
any product revenue related to its primary business purpose to date and is subject to a number of risks similar to those of other early stage companies, including dependence on key individuals, competition from other companies, the need for
development of commercially viable products and the need to obtain adequate additional financing to fund the development of its product candidates. The Company is also subject to a number of risks similar to other companies in the life sciences
industry, including regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection
of proprietary technology, dependence on third parties, product liability and dependence on key individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the course of its development activities, the Company has sustained operating losses and expects such losses to continue over the next
several years. The Company&#146;s ultimate success depends on the outcome of its research and development activities. The Company has incurred net losses from operations since inception and has an accumulated deficit of $10.7&nbsp;million as of
September&nbsp;30, 2017. The Company intends to raise additional capital through the issuance of additional equity, and potentially through strategic alliances with third parties. If financing is not available at adequate levels, the Company may
need to reevaluate its operating plans. Management believes currently available resources, which includes the $15.0&nbsp;million in gross proceeds the Company received in connection with the October 2017 issuance of 7,763,975 shares of the
Company&#146;s Series A Preferred Stock, will provide sufficient funds to enable the Company to meet its operating plans for at least the next twelve months from the date these financial statements are issued. However, if the Company&#146;s
anticipated operating results are not achieved in future periods, planned expenditures may need to be reduced in order to extend the time period over which the then-available resources would be able to fund the Company&#146;s operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Use of Estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#147;U.S.
GAAP&#148;). The Company&#146;s fiscal year end is December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted
accounting principles as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Updates (&#147;ASUs&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). The preparation of financial statements in
conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities, as of the date of the financial statements, and the
reported amounts of any expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to accrued liabilities, fair value of tranche liabilities, fair value of common stock, income taxes, and
stock-based compensation expense. Management bases its estimates on historical experience, and on various other market-specific relevant assumptions that management </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
believes to be reasonable, under the circumstances. Actual results may differ from those estimates or assumptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Financial Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying interim statements of operations and statements of cash flows for the period from July&nbsp;5, 2016 (inception) to
September&nbsp;30, 2016 and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared in accordance with U.S. GAAP. In management&#146;s opinion, the unaudited interim financial statements have
been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) necessary for the fair presentation of the Company&#146;s results of operations and its cash flows for the
period from July&nbsp;5, 2016 (inception) to September&nbsp;30, 2016. The results for the period from July&nbsp;5, 2016 (inception) to September&nbsp;30, 2016 are not necessarily indicative of the results expected for the full fiscal year or any
other interim period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Financial Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October 26, 2017, the Company&#146;s board of directors authorized the Company to file&nbsp;a registration statement with the Securities
and Exchange Commission (&#147;SEC&#148;) permitting the Company to sell shares of its common stock to the public. Upon the closing of a qualified (as defined in the Company&#146;s Certificate of Incorporation) initial public offering
(&#147;IPO&#148;), all of the Company&#146;s redeemable convertible preferred stock will automatically convert into common stock and all unvested restricted shares will become vested. The unaudited pro forma balance sheet and statement of redeemable
convertible preferred stock and stockholders&#146; equity as of September&nbsp;30, 2017 reflect the assumed conversion of all of the outstanding shares of Series&nbsp;A Redeemable Convertible Preferred Stock (&#147;Series&nbsp;A Preferred
Stock&#148;) into shares of common stock as well as the accelerated vesting of all restricted stock. In addition, the pro forma financials give effect to (i)&nbsp;the sale and issuance of $15.0&nbsp;million (7,763,976 shares) of the Company&#146;s
Series&nbsp;A Preferred Stock; (ii)&nbsp;the sale and issuance of $40.0&nbsp;million (4,792,716 shares) of the Company&#146;s Series&nbsp;B Preferred Stock; and (iii)&nbsp;the automatic conversion of all of the shares of preferred stock into an
aggregate of 15,870,559 shares of common stock. See Note&nbsp;14 &#147;Subsequent Events.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unaudited pro forma net loss per share is
computed using the weighted-average number of common shares outstanding after giving effect to the conversion of all Series A Preferred Stock into shares of the common stock, as well as the vesting of the unvested restricted shares, as if such
conversion had occurred at the beginning of the period presented, or the date of original issuance, if later. The conversion of Series A Preferred Stock has been reflected assuming shares of Series A Preferred Stock convert into shares of fully paid
common stock at the applicable conversion ratio. The pro forma basic and diluted net loss per share attributable to common stockholders does not include the effects of extinguishment of Series&nbsp;A Preferred Stock or the vesting of the unvested
restricted shares. As the period of July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016 and the nine months ended September&nbsp;30, 2017 resulted in net losses, there is no income allocation required under the <FONT
STYLE="white-space:nowrap">two-class</FONT> method or dilution attributed to pro forma weighted average shares outstanding in the calculation of pro forma diluted loss per share attributable to common stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">See Note&nbsp;7 for further discussion of the Series A Preferred Stock conversion features, as well as a discussion of the rights and
preferences of the redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price at which an asset could be exchanged in a current transaction between knowledgeable, willing parties. A
liability&#146;s fair value is defined as the amount that would be paid to transfer the liability to a new obligor, not the amount that would be paid to settle the liability with the creditor. Where available, fair value is based on observable
market prices, or parameters derived from such prices. Where observable prices or inputs are not available, valuation models are applied. These valuation techniques involve some level of management estimation and judgment. The degree of management
estimation and judgment is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dependent on the price transparency for the instruments, or market, and the instruments&#146; complexity. The authoritative accounting guidance describes a fair value hierarchy based on three
levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable. These levels of inputs are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs (other than quoted prices included in Level&nbsp;1) are either directly or indirectly observable for the asset
or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Unobservable inputs that reflect management&#146;s best estimate of what market participants would use in pricing the asset or
liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair
value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is
based on the lowest level of any input that is significant to the fair value measurement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Financial instruments measured at fair value on
a recurring basis include the tranche liability associated with the redeemable convertible preferred stock (Note&nbsp;7). The fair value of the financial liability was determined based on Level&nbsp;3 inputs as described in Note&nbsp;3. An entity
may elect to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized gains and losses on items for which the fair value option has been elected will be reported in net loss. The
Company did not elect to measure any additional financial instruments or other items at fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There have been no changes to the
valuation methods utilized by the Company during the period from July&nbsp;5, 2016 (inception) to December&nbsp;31, 2016, the period from July&nbsp;5, 2016 (inception) through September&nbsp;30, 2016, or the nine months ended September&nbsp;30,
2017. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the period from July&nbsp;5, 2016 (inception) to December&nbsp;31, 2016, the period from
July&nbsp;5, 2016 (inception) to September&nbsp;30, 2016, or the nine months ended September&nbsp;30, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#146;s
cash is held by financial institutions in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with
respect to the financial institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Manufacturing Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017, the Company had manufacturing arrangements with vendors for the supply of materials for use in preclinical and
clinical studies. If the Company were to experience any disruptions in either party&#146;s ability or willingness to continue to provide manufacturing services, the Company may experience significant delays in its product development timelines and
may incur substantial costs to secure alternative sources of manufacturing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is recorded using the straight-line method over the
estimated useful lives of the respective assets. Depreciation begins at the time the asset is placed in service. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon
sale or retirement of assets, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The estimated useful lives of property and equipment are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:37.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Useful&nbsp;Life<BR>(in years)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and manufacturing equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2-8&nbsp;years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1-5</FONT> years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in circumstances
indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its
remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. The Company has recorded no impairment of any long-lived
assets during any of the periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the
conduct of preclinical studies and clinical trials, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided, and includes these costs
in accrued liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of the Company&#146;s research and development expenses. The Company accrues for these
costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each
reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred and consist of personnel costs, lab supplies and other costs, as well as fees paid to
third parties to conduct research and development activities on the Company&#146;s behalf. Amounts incurred in connection with license agreements are also included in research and development expenses. The Company records payments made to outside
vendors for services performed or goods being delivered for use in research and development activities as either prepaid expenses or accrued expenses, depending on the timing of when services are performed or goods are delivered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recognizes equity-based compensation expense for awards of equity instruments to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> based on the grant date fair value of those awards in accordance with FASB ASC Topic 718, <I>Stock Compensation </I>(&#147;ASC 718&#148;). ASC 718 requires all equity-based compensation awards to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees and nonemployee directors, including grants of restricted shares and stock options, to be recognized as expense in the Statements of Operations based on their grant date fair values.
The Company estimates the fair value of stock options using the Black-Scholes option pricing model. The Company uses the value of its common stock to determine the fair value of restricted shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounts for restricted stock and common stock options issued to nonemployees under FASB ASC Topic
<FONT STYLE="white-space:nowrap">505-50,</FONT> <I>Equity- Based Payments to <FONT STYLE="white-space:nowrap">Non-Employees</FONT> </I>(&#147;ASC <FONT STYLE="white-space:nowrap">505-50&#148;).</FONT> As such, the value of such options is
periodically remeasured and income or expense is recognized over their vesting terms. Compensation cost related to awards with service-based vesting schedules is recognized using the straight-line method. The Company determines the fair value of the
restricted stock and common stock granted to nonemployees as either the fair value of the consideration received or the fair value of the equity instruments issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i)&nbsp;the expected share price
volatility, (ii)&nbsp;the expected term of the award, (iii)&nbsp;the risk-free interest rate and (iv)&nbsp;the expected dividend yield. Due to the lack of a public market for the trading of the Company&#146;s common stock and a lack of
company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based
on a period of time commensurate with the expected term assumption. The group of representative companies have characteristics similar to the Company, including stage of product development and focus on the life science industry. The Company uses
the simplified method, which is the average of the final vesting tranche date and the contractual term, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable
basis upon which to estimate the expected term. For options granted to <FONT STYLE="white-space:nowrap">non-employees,</FONT> the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free
interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The Company uses an assumed dividend yield of zero as the Company has never paid dividends and has no current plans to pay any
dividends on its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company expenses the fair value of its equity-based compensation awards granted to employees on a
straight-line basis over the associated service period, which is generally the period in which the related services are received. The Company measures equity-based compensation awards granted to nonemployees at fair value as the awards vest and
recognizes the resulting value as compensation expense at each financial reporting period. The Company accounts for award forfeitures as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Determination of Fair Value of Common and Preferred Shares and Tranche Rights Liability </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As there has been no public market for our equity instruments to date, the estimated fair value of the Company&#146;s common and preferred
shares has been determined by the board of directors as of the grant date, with input from management, considering the Company&#146;s most recently available third-party valuations of common shares and the board of directors&#146; assessment of
additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the
guidance outlined in the American Institute of Certified Public Accountants&#146; Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. Our common and preferred share valuations were
prepared using either an option-pricing method, or OPM, or a probability-weighted expected return method, or PWERM, which uses a combination of market approaches and an income approach to estimate the Company&#146;s enterprise value. The OPM treats
common securities and preferred securities as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#146;s securities changes. Under
this method, the common and preferred shares have value only if the funds available for distribution to members are expected to exceed the value of the preferred security liquidation preference at the time of the liquidity event, such as a strategic
sale or a merger. The PWERM is a scenario-based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
methodology that estimates the fair value of common and preferred shares based upon an analysis of future values for the enterprise, assuming various outcomes. The common and preferred share
values are based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of common and preferred securities. The future value of the
common and preferred shares under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common and preferred shares. The estimated
fair value of the tranche liability was determined using the difference between the total purchase price of the Company&#146;s Series A Preferred Stock and the total fair value of the Series A Preferred Stock using a risk-adjusted forward contract
model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company uses the asset and liability method of accounting for income taxes in accordance with FASB ASC Topic 740, <I>Income Taxes</I>. Under this method, deferred tax assets and liabilities are determined based on the differences between the
financial reporting and the tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the
resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion, or all of a deferred tax asset will not be realized. Due to the Company&#146;s lack of earnings history, the net
deferred tax assets have been fully offset by a valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recognizes benefits of uncertain tax positions if it is
more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#146;s policy
is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, the Company has no uncertain tax positions and there have been no interest charges or penalties related to
unrecognized tax benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during
the period without consideration of common stock equivalents. Diluted net loss per common share is the same as basic net loss per common share for all periods presented, since the effects of potentially dilutive securities are antidilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU <FONT STYLE="white-space:nowrap">2014-15,</FONT><I>&nbsp;Disclosure of Uncertainties about an
Entity</I><I>&#146;</I><I>s Ability to Continue as a Going Concern</I> (&#147;ASU 2014-15&#148;). ASU <FONT STYLE="white-space:nowrap">2014-15</FONT> requires management to evaluate relevant conditions, events, and certain management plans that are
known or reasonably knowable that, when considered in the aggregate, raise substantial doubt about the entity&#146;s ability to continue as a going concern within one year after the date that the financial statements are issued, for both annual and
interim periods. ASU <FONT STYLE="white-space:nowrap">2014-15</FONT> also requires certain disclosures around management&#146;s plans and evaluation, as well as the plans, if any, that are intended to mitigate those conditions or events that will
alleviate the substantial doubt. ASU <FONT STYLE="white-space:nowrap">2014-15</FONT> is effective for fiscal years ending after December&nbsp;15, 2016. The Company adopted this guidance on July&nbsp;5, 2016 (inception). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> <I>Compensation&#151;Stock Compensation (Topic
718) </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2016-09&#148;).</FONT> The guidance changes how companies account for certain aspects of equity-based payments to employees. Entities will be required to recognize income tax effects of awards in
the income statement when the awards vest or are settled. The guidance also allows an employer to repurchase more of an employee&#146;s shares than it can under current guidance for tax withholding purposes providing for withholding at the
employee&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
maximum rate as opposed to the minimum rate without triggering liability accounting and to make a policy election to account for forfeitures as they occur. The updated guidance is effective for
annual periods beginning after December&nbsp;15, 2017. Early adoption is permitted. The Company adopted this guidance on July&nbsp;5, 2016 (inception) and made the policy election to account for forfeitures as they occur. No awards have been
forfeited as of September&nbsp;30, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> <I>Statement of Cash Flows</I> (&#147;ASU
2016-18&#148;), which requires that amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of cash flows.
ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> is effective for fiscal years beginning after December&nbsp;15, 2018 and should be applied using a retrospective transition method to each period presented. Early adoption is permitted. The Company
does not expect the impact of ASU <FONT STYLE="white-space:nowrap">2016-18</FONT> to be material to its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May
2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-09,</FONT> <I>Compensation&#151;Stock Compensation</I> (Topic 718): Scope of Modification Accounting (&#147;ASU <FONT STYLE="white-space:nowrap">2017-09&#148;).</FONT> ASC <FONT
STYLE="white-space:nowrap">2017-09</FONT> provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The guidance is effective for annual periods
beginning after December&nbsp;15, 2017, with early adoption permitted, including adoption in any interim period for which financial statements have not yet been issued. The Company is currently evaluating the potential effects of adopting the
provisions of ASU <FONT STYLE="white-space:nowrap">2017-09.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2017-11,</FONT> <I>Accounting for Certain Financial Instruments with Down Round Features</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2017-11&#148;),</FONT> which updates the guidance related to the classification
analysis of certain equity-linked financial instruments (or embedded features) with down round features. Under ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT> a down round feature no longer precludes equity classification when assessing whether
the instrument is indexed to an entity&#146;s own stock. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the
existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it
is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> is effective for public entities for all annual and interim periods
beginning after December&nbsp;15, 2019. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> will have on its financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Financial Instruments </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There were no
assets or liabilities measured at fair value as of December&nbsp;31, 2016. Below is a summary of liabilities measured at fair value as of September&nbsp;30, 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:86.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of September&nbsp;30,
2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:30.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Quoted<BR>Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level&nbsp;1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:39.05pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Significant<BR>Observable<BR>Inputs<BR>(Level&nbsp;2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:47.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Significant<BR>Unobservable<BR>Inputs<BR>(Level&nbsp;3)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:18.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tranche rights liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The tranche rights liability is considered a Level&nbsp;3 liability because its fair value measurement is
based, in part, on significant inputs not observed in the market. The Company determined the fair value of the liability as described in Note 7. Any reasonable changes in the assumptions used in the valuation could materially affect the financial
results of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Property and equipment, net </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:17.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and manufacturing equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $0, $0 and $2,738, for the period from July&nbsp;5, 2016 (inception) to
December&nbsp;31, 2016, the period from July&nbsp;5, 2016 (inception) through September&nbsp;30, 2016, and the nine months ended September&nbsp;30, 2017, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Accrued Liabilities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Accrued
liabilities consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:17.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. License Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Novartis License Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;23, 2017, the Company entered into an exclusive license agreement with Novartis International Pharmaceutical Ltd. (&#147;Novartis&#148;). Under the agreement, Novartis granted the Company an exclusive, field-restricted, worldwide license,
to certain intellectual property rights owned or controlled by Novartis, to develop, commercialize and sell one or more therapeutic products comprising RTB101 or RTB101 in combination with everolimus in a fixed dose combination. The exclusive field
under the license agreement is for the treatment, prevention and diagnosis of disease and other conditions in all indications in humans and animals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As initial consideration for the licensed rights, the Company issued Novartis Institutes for Biomedical Research (&#147;NIBR&#148;) 2,587,992
shares of the Company&#146;s Series&nbsp;A Preferred Stock. The fair value of the Novartis license was $3.2&nbsp;million based on the fair value of the Series&nbsp;A Preferred Stock which was determined to be $1.22 per share based on an independent
third-party valuation, and is recorded as research and development expenses in the statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The agreement may be
terminated by either party upon a material breach by the other party that is not cured within 60 days after written notice. The Company may terminate the agreement in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis with or without cause with 60 days&#146; prior written notice.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Novartis may terminate the portion of the agreement related to everolimus if the Company fails to use commercially reasonable efforts to research, develop and commercialize a product utilizing
everolimus for a period of three years. Novartis may terminate the license agreement upon the Company&#146;s bankruptcy, insolvency, dissolution or winding up. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As additional consideration for the license, the Company is required to pay up to an aggregate of $4.3&nbsp;million upon the satisfaction of
clinical milestones, up to an aggregate of $24&nbsp;million upon the satisfaction of regulatory milestones for the first indication approved, and up to an aggregate of $18&nbsp;million upon the satisfaction of regulatory milestones for the second
indication approved. In addition, the Company is required to pay up to an aggregate of $125&nbsp;million upon the satisfaction of commercial milestones, based on the amount of annual net sales. The Company is also required to pay tiered royalties
ranging from a mid single-digit percentage to a low teen-digit percentage on annual net sales of products. These royalty obligations last on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the latest of (i)&nbsp;the expiration of the last valid claim of a Novartis patent covering a subject product, (ii)&nbsp;the expiration of any
regulatory exclusivity for the subject product in a country, or (iii)&nbsp;the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> anniversary of the first commercial sale in the country, and are subject to a reduction after the expiration of
the last valid claim of a Novartis patent or the introduction of a generic equivalent of a product in a country. In addition, if the Company sublicenses the rights under the license agreement, the Company is required to pay a certain percentage of
sublicense revenue to Novartis. Novartis will no longer be entitled to sublicense revenue following the last visit of the 400<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> subject in any human clinical trial conducted by the Company or a
sublicensee of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Milestone payments to Novartis will be recorded as research and development expenses in the statements of
operations once achievement of each associated milestone has occurred or the achievement is considered probable. In May 2017, the Company initiated a Phase 2b clinical trial for a first indication, triggering the first milestone payment under the
agreement. Accordingly, the Company paid the related $0.3&nbsp;million payment in May 2017. As of September&nbsp;30, 2017, none of the remaining development milestones, regulatory milestones, sales milestones, or royalties had been reached or were
probable of achievement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017, the Company had 10,351,968 shares of preferred stock authorized, of which 7,763,976 shares were issued and
outstanding and were designated as $0.0001 par value Series A Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s redeemable convertible preferred shares
have been classified as temporary or mezzanine equity on the accompanying balance sheets in accordance with U.S. GAAP for the classification and measurement of redeemable securities as the Series A Preferred Stock are contingently redeemable at the
option of the holder for reasons outside of the Company&#146;s control. As of September&nbsp;30, 2017, there has been no accretion of the redeemable convertible preferred shares to redemption value as at that date the shares are not redeemable or
probable of being redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On March&nbsp;23, 2017, the Company entered into a Series A Preferred Stock Purchase Agreement with PureTech
Health LLC (&#147;PureTech&#148;) and NIBR. Under the agreement, in the initial March 2017 closing, PureTech purchased 2,846,791 shares of Series A Preferred Stock at a purchase price of $1.932 per share, resulting in aggregate gross proceeds of
$5.5&nbsp;million, and NIBR was issued 2,587,992 shares of Series&nbsp;A Preferred Stock as consideration for an exclusive, field-restricted, worldwide license, to certain intellectual property rights owned or controlled by Novartis, to develop,
commercialize and sell one or more therapeutic products comprising RTB101, alone or in combination with everolimus in a fixed dose combination. PureTech also agreed to purchase up to 4,917,185 additional shares (the &#147;Tranche Rights&#148;), at
$1.932 per share at future dates based on the occurrence of certain events as specified under the agreement. The fair value of the Series&nbsp;A Preferred Stock on the date of issuance was determined to be $1.22 per share based on an independent
third-party valuation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On March&nbsp;23, 2017, the Company also entered into a side letter with PureTech under
which PureTech agreed to purchase up to 5,175,984 additional shares at $1.932 per share at a future date based on the occurrence of certain events as specified under the letter. The Tranche Rights were evaluated under ASC 480 <I>&#150;
Distinguishing Liabilities from Equity</I> and it was determined that they met the requirements for separate accounting from the initial issuance of Series A Preferred Stock as freestanding financial instruments and are accounted for as liabilities.
The Company adjusts the carrying value of the Tranche Rights to its estimated fair value at each reporting date up to the closing of each tranche financing. Increases or decreases in fair value of the Tranche Rights are recorded as other income
(expense) in the statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At the date of issuance, the Tranche Rights liability was recorded at fair value of
$2.0&nbsp;million as a liability on the balance sheet. From the date of issuance to September&nbsp;30, 2017, the change in fair value of the Tranche Rights was $0.6&nbsp;million and was recorded as other income in the statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In September 2017, the Company received gross proceeds of $4.5 million in exchange for the issuance of 2,329,193 shares of Series A Preferred
Stock at $1.932 per share pursuant to the second closing on August 29, 2017. The fair value of the Series A Preferred Stock on the date of issuance was determined to be $1.34 per share based on an independent third-party valuation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The rights, privileges, and preferences of convertible preferred stock are summarized as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the
event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, or Deemed Liquidation Event (as defined below), the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the
assets of the Company available for distribution to its stockholders before any payment shall be made to the holders of common stock, an amount per share equal to the Series A Original Issue Price of $1.932, plus any dividends declared and unpaid
thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If upon any liquidation, dissolution, winding up of the Company or Deemed Liquidation Event, the assets of the Company available
for distribution to shareholders is insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they shall be entitled, the holders of Series A Preferred Stock will share ratably in any distribution of the assets
available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After payment of all preferential amounts required to be paid to the holders of preferred stock, the remaining funds and assets available for
distribution to the shareholders of the Company will be distributed among the holders of Series A Preferred Stock and common stock, pro rata based on the number of shares held by each such holder, provided, however, that if the aggregate amount
which the holders of Series A Preferred Stock are entitled to receive exceeds $3.864 per share, each holder of Series A Preferred Stock shall be entitled to receive the greater of (i) $3.864 or (ii)&nbsp;the amount such holder would have received if
all shares of Series A Preferred Stock had been converted into common stock immediately prior. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following events are defined as Deemed
Liquidation Events unless the holders of a majority of the then outstanding shares of Series A Preferred Stock elect otherwise by written notice to the Company: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">a merger or consolidation; or </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company of all or substantially all the assets or intellectual property of the
Company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each holder of shares of Series A Preferred Stock is entitled to the number of votes equal to the number of whole shares of common stock into
which such shares of Series A Preferred Stock could be converted and has voting rights and powers equal to the voting rights and powers of the common stock, and except as provided by law or by other provisions of the Certificate of Incorporation,
shall vote together with the common stock as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis on all matters as to which holders of common stock have the right to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The holders of Series A Preferred Stock, voting together as a single class, are entitled to elect three members of the Company&#146;s board of
directors. The holders of common stock, exclusively and as a separate class, are entitled to elect two members of the Company&#146;s board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Series A
Preferred Stock may be redeemed upon a Deemed Liquidation Event. The Series A Preferred Stock may be redeemed at $1.932 per share, or the holders of Series A Preferred Stock may receive an amount equal to the amount entitled if the Series A
Preferred Stock converted into shares of common stock on a 1.2804:1 basis on the redemption date. At September&nbsp;30, 2017, the shares of Series A Preferred Stock were not redeemable and the likelihood of an occurrence of a Deemed Liquidation
Event was not deemed to be probable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The holders of Series A Preferred Stock are subject to certain optional and mandatory conversion rights. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"><I>Optional Conversion Rights:</I>&nbsp;Each share of convertible preferred stock is convertible, at the option of the holder, into such number of fully paid shares of common stock as is determined by dividing the
original issuance price by the conversion price in effect at the time of conversion. As of September&nbsp;30, 2017, the conversion ratio was 1.2804:1 for the Series A Preferred Stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"><I>Mandatory Conversion Rights:</I>&nbsp;Upon either (a)&nbsp;the closing of the sale of shares of common stock to the public at a price of at least $7.421 per share (subject to appropriate adjustment in the event of
any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock), in a firm-commitment underwritten public offering pursuant to an effective registration statement resulting in at least
$25&nbsp;million of gross proceeds to the Company or (b)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of a majority of the then outstanding shares of Series A Preferred Stock, then all
outstanding shares of Series A Preferred Stock shall automatically be converted into shares of common stock, at the then effective conversion rate. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The conversion price for Series A Preferred Stock is subject to adjustment upon certain events including certain dilutive issuances of shares,
share subdivisions such as stock splits and stock dividends, combinations or other similar recapitalizations with respect to the common stock, or other similar events. At September&nbsp;30, 2017 the Series A Preferred Stock had an original issuance
price of $1.932 per share and a conversion price of $2.474. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the Company declares or makes any dividends to holders of common stock of the Company, each holder of Series A Preferred Stock shall be
entitled to receive such dividend on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. Such dividends shall not accrue and shall not accumulate. No dividends had been declared as of September&nbsp;30, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The voting, dividend and
liquidation rights of the holders of common stock are subject to and qualified by the rights, powers, and preferences of the holders of the shares of Series A Preferred Stock. The common stock has the following characteristics: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The holders of the common
stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings, provided, however, that except as otherwise required by law, holders of common stock as such shall not be
entitled to vote on any amendment to the Company&#146;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or
together with the holders of one or more other such series, to vote thereon pursuant to the Company&#146;s Certificate of Incorporation or pursuant to Delaware General Corporation Law. There shall be no cumulative voting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The holders of shares
of common stock are entitled to receive dividends, if and when declared by the Board of Directors. Cash dividends may not be declared or paid to the holders of common stock until paid on the Series A Preferred Stock. As of September&nbsp;30, 2017,
no dividends have been declared or paid since the Company&#146;s inception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After payment to the holders of shares of Series A Preferred Stock of their liquidation preference, the holders of the common stock are
entitled to share ratably in the Company&#146;s assets available for distribution to stockholders, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or upon the occurrence of a Deemed Liquidation
Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reserve for future issuance </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the Company had not reserved any shares of common stock for future issuance. As of September&nbsp;30, 2017, the
Company has reserved the following number of shares of common stock for future issuance upon the conversion or exercise of preferred stock or options or grant of equity awards: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:68.40pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As&nbsp;of&nbsp;September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT>
basis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,063,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options available for future grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,601,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Stock-based Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In 2017, the Company adopted the 2017 Stock Incentive Plan (the &#147;Plan&#148;). Under the Plan, shares of the Company&#146;s common stock
have been reserved for the issuance of stock options to employees, directors, and consultants under terms and provisions established by the Board of Directors. A total of 537,914 shares were reserved for issuance under the Plan. Under the terms of
the Plan, options may be granted at an exercise price not less than fair market value. The terms of options granted under the Plan may not exceed ten years. The Board shall determine the terms and conditions of a Restricted Stock Award, including
the conditions for vesting and repurchase (or forfeiture) and the issue price, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation Expense </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense is recognized for stock options granted to employees and
<FONT STYLE="white-space:nowrap">non-employees</FONT> and has been reported in the Company&#146;s statements of operations as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)<BR>through<BR>December&nbsp;31,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:57.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)<BR>through<BR>September&nbsp;30,<BR>2016&nbsp;(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine
Months<BR>Ended<BR>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A following table summarizes stock option activity under the Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:44.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shares<BR>Available&nbsp;for<BR>Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:42.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number
of<BR>Options<BR>Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price<BR>per Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:51.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Weighted-<BR>Average<BR>Remaining<BR>Contract&nbsp;Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:51.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares reserved for issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">537,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options granted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable, September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest, September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Company granted 46,860 stock options to non-employees during the nine months ended September&nbsp;30, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the
exercise price of the options and the estimated fair value of the Company&#146;s common stock, as determined by the board of directors, as of September&nbsp;30, 2017. No options were exercised during the nine months ended September&nbsp;30, 2017.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There were no stock options granted to employees or non-employees during the period from July&nbsp;5, 2016 (inception) to
December&nbsp;31, 2016 or the period from July&nbsp;5, 2016 (inception) to September&nbsp;30, 2016. During the nine months ended September&nbsp;30, 2017, the Company granted options to employees to purchase an aggregate of 64,460 common shares with
a grant date fair value of $0.53. During the nine months ended September&nbsp;30, 2017, the Company granted options to non-employees to purchase an aggregate of 46,860 common shares with a weighted-average grant date fair value of $0.67. The expense
related to options granted to employees and non-employees was $2,606 and $2,352, respectively, for the nine months ended September&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2017, the total unrecognized compensation expense related to unvested employee options was $31,339 which the Company
expects to recognize over an estimated weighted-average period of 3.62 years. As of September&nbsp;30, 2017, the total unrecognized compensation expense related to unvested nonemployee options was $35,774 which the Company expects to recognize over
an estimated weighted-average period of 3.76 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of stock options for employees and non-employees was estimated using a
Black-Scholes option pricing model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine
Months<BR>Ended<BR>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Employees:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-employees:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.79&nbsp;-&nbsp;1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">74.6%&nbsp;-&nbsp;76.9</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Fair Value of Common Stock:</I>&nbsp;Given the absence of a public trading market, the Board of Directors
considered numerous objective and subjective factors to determine the fair value of common stock at each grant date. These factors included, but were not limited to, (i)&nbsp;contemporaneous valuations of common stock<I></I>&nbsp;performed by
independent third-party specialists; (ii)&nbsp;the prices for preferred stock sold to outside investors; (iii)&nbsp;the rights, preferences and privileges of preferred stock relative to common stock; (iv)&nbsp;the lack of marketability of common
stock; (v)&nbsp;developments in the business; and (vi)&nbsp;the likelihood of achieving a liquidity event, such as an initial public offering or a merger or acquisition of the Company, given prevailing market conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
July&nbsp;11, 2016, certain founding non-employee directors purchased 3,772,726 common shares that are subject to a repurchase right upon termination or cessation of services at the original purchase price of $0.0001 per share, or $483. On
April&nbsp;4, 2017, the non-employee directors became employees of the Company. Compensation expense of such unvested shares was remeasured at fair value until vested at each reporting date. On April&nbsp;4, 2017, compensation expense of such
unvested shares was remeasured at fair value and fixed and is being recognized over the remaining period. The repurchase right lapses as vesting occurs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A summary of restricted stock activity and related information follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:42.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number
of<BR>Restricted<BR>Shares<BR>Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested shares &#151; July&nbsp;5, 2016 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,772,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,082,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested shares &#151; December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,689,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested shares &#151; September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,202,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recognized $0, $0, and $0.3&nbsp;million of stock based compensation expense related to restricted
shares during the period from July&nbsp;5, 2016 (inception) to December&nbsp;31, 2016, the period from July&nbsp;5, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2016 (inception) to September&nbsp;30, 2016, and the nine months ended September&nbsp;30, 2017, respectively. As of September&nbsp;30, 2017, there was $1.0&nbsp;million of unrecognized stock
based compensation expense related to unvested restricted stock. This amount is expected to be recognized over a remaining weighted-average period of 2.78 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income Taxes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provision (Benefit) for Income
Taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the period from July&nbsp;5, 2016 (inception) to December&nbsp;31, 2016, the period from July&nbsp;5, 2016 (inception)
to September&nbsp;30, 2016, and the nine months ended September&nbsp;30, 2017, the Company did not record a current or deferred income tax expense or benefit. The Company&#146;s loss before income taxes consists solely of a domestic loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the financial
statements is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:66.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)&nbsp;through<BR>December&nbsp;31,&nbsp;2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:57.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;5,
2016<BR>(inception)<BR>through<BR>September&nbsp;30,<BR>2016&nbsp;(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nine
Months<BR>Ended<BR>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Tax Assets and Liabilities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of
assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of deferred income taxes were as follows as of December&nbsp;31, 2016 and September&nbsp;30, 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:17.55pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As of</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:46.65pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,<BR>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; width:48.85pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>September&nbsp;30,<BR>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating tax losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,482</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which
are uncertain. Due to the lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Operating Loss
and Tax Credit Carryforwards </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and September&nbsp;30, 2017, the Company had net operating loss
carryforwards for federal income tax purposes of approximately $1,000 and $7.5&nbsp;million, respectively which will begin to expire in 2036. As of December&nbsp;31, 2016 and September&nbsp;30, 2017, the Company had total state net operating loss
carryforwards of approximately $1,000 and $7.4&nbsp;million, respectively which will begin to expire in 2036. Utilization of some of the federal and state net operating loss and credit carryforwards are subject to annual limitations due to the
&#147;change of ownership&#148; provisions under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before
utilization. The Company has not performed an ownership change analysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and September&nbsp;30, 2017, the
Company had federal research credits of $0 and $0.1&nbsp;million, respectively which will begin to expire in 2037 and state research credits of $0 and approximately $45,000, respectively which will begin to expire in 2032. These tax credits are
subject to the same limitations discussed above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unrecognized Tax Benefits </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has incurred net operating losses since inception and has no significant unrecognized tax benefits. The Company&#146;s policy is
to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the statements of operations. If in the future the Company recognizes uncertain tax positions, the Company&#146;s effective tax rate
will be reduced. Currently, the Company has a full valuation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allowance against its net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Any
adjustments to uncertain tax positions would result in an adjustment of net operating loss or tax credit carry forwards rather than resulting in a cash outlay. As of September&nbsp;30, 2017, the Company had no unrecognized tax benefits and no
accrued interest or penalties related to uncertain tax positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Income tax returns are filed in the U.S. and Massachusetts. The Company
is not currently under examination. Due to net operating losses and research credit carryovers, all of the tax years remain open to examination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.
Commitments and Contingences </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities as of
September&nbsp;30, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Net Loss per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As described in Note 2, the Company computes basic and diluted earnings (losses) per share using a methodology that gives effect to the impact
of outstanding participating securities (the <FONT STYLE="white-space:nowrap">&#147;two-class&#148;</FONT> method). Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the
period and excludes any dilutive effects of share-based awards. Diluted net loss per share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, convertible preferred
stock, and unvested restricted common stock. As the Company had net losses for the period from July&nbsp;5, 2016 (inception) to December&nbsp;31, 2016, the nine months ended September&nbsp;30, 2017, and the period from July&nbsp;5, 2016 (inception)
to September&nbsp;30, 2016, there is no income allocation required under the <FONT STYLE="white-space:nowrap">two-class</FONT> method or dilution attributed to weighted average shares outstanding in the calculation of diluted loss per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Related Party Transactions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since
the Company&#146;s incorporation in July 2016, the Company has engaged in transactions with related parties. The transactions were on terms comparable to terms that could have been obtained from unrelated third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2017, the Company issued 1,886,363 shares of common stock and made payments to PureTech for
certain founding services and cost reimbursements. PureTech is a founder of the Company and holds shares of common stock and preferred stock of the Company. See Note 7. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is a party to an intellectual property license agreement with Novartis. In addition, NIBR is a preferred stock shareholder of the
Company. See Note 6. During the nine months ended September&nbsp;30, 2017, the Company made payments to Novartis for milestones achieved pursuant to the license agreement and for the purchases of materials for use in the Company&#146;s clinical
trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Aggregate payments for the above related party transactions totaled $0.9&nbsp;million for the nine months ended
September&nbsp;30, 2017. No payments were made to related parties during the periods from July&nbsp;5, 2016 (inception) to December&nbsp;31, 2016 or from July&nbsp;5, 2016 (inception) to September&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the purposes
of the financial statements as of December&nbsp;31, 2016 and September&nbsp;30, 2017, and the period from July&nbsp;5, 2016 (inception) to December&nbsp;31, 2016, the period from July&nbsp;5, 2016 (inception) to September&nbsp;30, 2016, and the nine
months ended September&nbsp;30, 2017, the Company has evaluated subsequent events through October&nbsp;26, 2017, the date the financial statements were originally issued, and has evaluated for disclosures and additional subsequent events occurring
after such date through January&nbsp;16, 2018, which is the date these financial statements were available for reissuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;11, 2017, the Company increased the number of authorized shares of common
stock from 19,000,000 shares to 24,000,000 shares, and increased the number of authorized shares of Series&nbsp;A Preferred Stock from 10,351,968 shares to 15,527,951 shares. In addition, the Company increased the number of shares of common stock
available for issuance under the Plan from 537,914 shares to 630,662 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2017, the Company amended the Series A
Preferred Stock Purchase Agreement to accelerate the third and fourth closings under the original agreement (as discussed in Note 7). The Company issued 7,763,975 shares of Series A Preferred Stock at $1.932 per share for aggregate gross proceeds of
$15.0&nbsp;million, of which $9.0&nbsp;million was from PureTech and $6.0&nbsp;million from a new investor. These amounts have been included in the pro forma balance sheet. Following these additional closings of the Series A Preferred Stock
financing, the Tranche Rights have been terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October 27, 2017, the Company entered into the Series B Preferred Stock Purchase
Agreement for the issuance and sale of up to 4,792,716 shares of Series B Preferred Stock at $8.346 per share. On November 29, 2017, the Company issued and sold 4,792,716 shares of Series B Preferred Stock at $8.346 per share for aggregate gross
proceeds of $40.0 million (the &#147;Series B Financing&#148;), of which $20.0 million was from a Series A investor. These amounts have been included in the pro forma balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Series B Financing, the Company filed an amended and restated certificate of incorporation, pursuant to
which it (i) increased the number of shares of Common Stock that the Company is authorized to issue to an aggregate of 30,000,000 shares, (ii)&nbsp;increased the number of shares of Preferred Stock that the Company is authorized to issue to an
aggregate of 20,320,667 shares, (iii) authorized and created a new series of Preferred Stock designated as Series B Preferred Stock, consisting of an aggregate of 4,792,716 shares for issuance, (iv) established the rights, preferences, privileges,
restrictions and other matters relating to the Series B Preferred Stock, and (v) made certain other changes in connection with the Series B Financing. The Company also increased the number of shares of Common Stock available for issuance under the
Company&#146;s 2017 Stock Incentive Plan from 630,662 to 1,866,009. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On January&nbsp;12, 2018, the Company effected a one-for-1.2804 reverse stock split of its issued and outstanding shares of common stock and a
proportional adjustment to the existing conversion ratios for each series of the Company&#146;s Preferred Stock. Accordingly, all common stock share and per share amounts and preferred stock conversion prices and ratios for all periods presented in
the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Through and including&nbsp;February
19, 2018 (the 25th day after the date of this prospectus), all dealers effecting transactions in the common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a
dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </P>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>5,666,667 Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g475892g92q50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BofA Merrill Lynch </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Leerink Partners </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Evercore ISI </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>Wedbush
PacGrow </B></P> <P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>January 25, 2018 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P><center> <P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g475892g07q36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g07q36.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Z$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "L< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  /2&%R:7!R87-A9"!2
M86IU #A"24T$)0      $("8&0C<-9#7>&5]"QZ%1 8X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ /      0 ! \     !  $X0DE-!"8       X             /X   #A"
M24T#\@      "@  ________   X0DE-! T       0   !X.$))3009
M   $    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M       !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             ##@   Y0          0
M   !              .4   ##@                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   ##@    !29VAT;&]N9P   Y0    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   PX     4F=H=&QO;F<   .4     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    ".$))300,     !0/     0   *    ")
M   !X  ! .   !/S !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" ") * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
M/P#U5)5L^^^BD/H;O?N:-FUSI!^DW]'_ #?_ !C_ -&K!)["4E(,YESZ VG=
MN]2J=AVG:+*S;[M/\%O62^OKSV4N<76VL#;PTAC&>KZ67^KV>F6[L=E[</\
M.W[W_P [_HMR3X)2?!)3C5W=9AAL-YJ+G;7LJK]0N_1[&9#+ QK*=WK_ *1M
M='_&L_1VY,'MZQ07[77[7.?^E8VNVS^=RG45M99MJ]':ZG\S?_-?F?I,?<D^
M"4GP24XMK_K RMUA+BYV[]%6QA#=KJO392]P<[]/^G9Z]S;=G^BK4KLGJ[NH
M9+,7<\4O#:JW,8*"/09:?5O_ )[U?7L]O_JRZG8D^">3X)*<KISNL/N8<E[_
M $&L>?=6QKG/_1!K;?HN]CO7V;&4_P!>S^<MK"[KMF,:',M<^VMT6%K6<-O:
M\RST_0?:[[/Z#/IL_P!)_/6K=D^"4GP24X#LKJ@>UC38Z_:XU>LQK;0!Z+<M
M[*:#Z+VT[OU?U/IV_P"F_1^M9Q[.KFVIN0;@UP&QS*ZX<"ZS>[+W^ZI[*?1=
M[/1_XK_M+5K2?!*3^ZDIQGGK=&'A,K]5]K<=N[1CW/R &?HLQ[OYNCZ?J6T_
M]N_0]>62_KS6/B6M;;Z8?6UKWNK#;'LR&LVO_G;'X^/;7Z?L]&VS^;M]6K7D
M^"4GP24YCJ^J6]*RQ>7'*?O]%E<5[=O\UZ3JW;_<YN_])<BYUV<S,QZ<4AS;
MP=P('L](BUUA/^CN;^J_\'9;38KTGP2D^"2G"9=U\T VFUI)]SJZJS8+-@_1
M-99MK=B^M_A/_9GTOUEFITW[<:"_.<?6>X_HX: QH]K6M]/Z6[Z?N>K,GP2D
M^"2F22C)\$\GP24__]#U5)9S^L,8VPE@_1W>D8>TZ#^<LT]WZ+_"5UML_P#/
MGIZ!("2ETE'<//[BH-NW6V,+2 S;#N9W#P24E23;AY_<4VX>?W%)3))-N'G]
MQ3;AY_<4E,DE'<//[BEN'G]Q24R24=P\_N*6X>?W%)3))1W#S^XI;AY_<4E,
MDDVX>?W%-N'G]Q24R24=P\_N*?<//[BDI=)1W#S^XI]P\_N*2G__T?4O0I!)
M]-LD[B8',[MW];<IH61DUXU?J6[MLP2UI='\IVT':QO[R(2!R824TNK=9Z?T
M?'9D=0L-=5CQ4TM8Y_N+761MJ:]WT:WK';]>_JPVVQYR7P\-C]!=VG_@U7_Q
MED'HN+!G]<;_ .>LA>='A21@"+*V4B"^W8N33EXU650=U-[&VUN(():\;V':
MZ'-]I15G?5X@= Z9)_[24?\ GMBT-S?$*,KETERW7>H?7"O(L;TS$/I"F\,-
M8KN!>US?LEVZRS'?ZC_\+B>G[*;?6KLR;*_3J&<#ZR]7MNP>H9>3AXY<S(Q\
MS%%=&PUV'?A.VV776[]_Z*S^9]/&JR/TGJI*>M23;F^(2W-\0DI=)5']6Z56
MYS;,RACJW.K>'6L!:]C?6LK=+O;8RG]*]G^B_2*LWZS=#?U#%Z=5ELNR,YMC
ML;TOTC'>D-UK?7JW4M<UK7?2>DIU$.^^K'HLR+CMJJ:Y[W03#6C<X[6[G.]H
M_-4]S?$(&7B8>;6*\EC; T[JW3#V/AU?K46LVVX][66/V7TOKNK_ #$E.=9]
M;_J_74VUV0\L<6!NVB]Q)L;996-C:2__ +3WL=_H[ZK,>W]/^C6PTR 8(D3!
MY62SZO\ 0O2=A"AWI-JJH>TV6$.JK;:S&K<]UGZ3T&WV^G_H[/2M_G:*/3TL
M>FC&QZL:@!E-+&UUMDF&L&QC=SB7?1"2DJS>J5]9LLK&"YC*668[W$.BQP%[
M/MM5F]CZ_L[L'U/H?IO56CN;XA*6G24E/(](POKO4_ OZE?9D/:_;G8YMI95
ML+[@V]OH4^H]]-;O4?1OK];]4_X:G'Z]!QGEV/4Y[MSG,:23$DD3VA%W-\0D
MI__2]0OQJ<AK6V@D,<+&PXM]S=6'V%OT410-] :7&QH:';"2X0'3MV?UT1)3
MR/\ C+_Y%Q?_  XS_P ]9"\Z/!7HO^,O_D7%_P##C/\ SUD+SH\%38_E8Y[O
ML7U>C]@=,_\ "E'_ )[8C]3Q\C(Z=D48C_2R+*W-K>"6$$C_ $K/?5N_TU?Z
M2K^<8@?5W_Q/],_\*4?^>V+141W+(\S9T'ZT96$YF1UIU5[R[]'4W:P!SF/:
M#D8_V7+W5['[?2LH^GZ7Z2G^<AU#ZL?6+*NR+:NMOH]?=L8SUFAFYNV6;<C8
MQW^!_FO3KK_6JZ_MWZ9=.YS-6N(UY!0L-S!BTM!'\VW0? )MCNG5K]'Q,W%Q
M'59UWVBSU;"QY)<=A=[/?9[_ '_SOI_]I_4^S,_1TI^J9^!AT!N=8ZFO(WUA
M["X.$,?8]PLI_2U>QGLL9_AO2]/]*^M7E4ZATO ZG6RK.J%S&.W-:2X:D%AW
M;"W<QS'^^MWZ-%#QMO3?J;F=9KL;U2W*RG6EX:/3NJ:!56UGVM_H'<S9Z%7K
MY5S\C+_H^1?>M+H75_JYA5NHP[,J\%[C4RVIQ=4YU?J6XE'Z*MS/YFNVVK_3
MYE'_ '(6_?@=-)QA9AU6>B=F--;#Z0+=KO2W_P TSTZ]GZ-1'0^CMJ?57A4T
MM>T,/HL%3@ +&LV64^F^MS/7N]-];M]?JOV)*;5%U.117?2X/JM:'UO'!:X;
MF._M-53K'5J>DXS,BVMUK7V"L-9$R0Y\^\M_T:N555TU,IJ:&55M#&,;H UH
MVM:W^JU8'UW_ .2Z/_#+?^HN3\41*<0=B6/-(QQRD-P$+?KK@"U[_LM_N#1'
MZ/M/_"+H<+)9F8E.4QI:V]C;&M=$@.&Z'0O,1RO1N@_\B8'_ (7J_P"I:IN8
MQ0A$&(JRP<KGGDE(2-@"]F] 6'U3ZU4=.SGX;\:RUU8:2]I:![AN_.(6ZN ^
MM?\ R_D?U*O^I3.7A&<R)"Q5LG-9)8\8,31NG;Z;];<>^[%P1BV-=86U![BP
M@:<Z'^2NC@+S?HG_ "Q@?\<W\CEZ2CS&.,#$1%6+1RN6>2,C(W4J?__3](NZ
M:RT.'J.:'6>L8#9#O:-S'%NZMS6M]CV*X0"G224\A_C+ '1<7_PXS_SUD+SL
M\%>B_P",O_D7%_\ #C/_ #UD+SD\%38_E8Y[OL?U> /0.F<_T2CO_P &Q:&T
M>?WE9_U=_P#$_P!,_P#"E'_GMBT5$=RR-+(TM=I.@_UU0\-I I:X;7!K01X$
M-_DHF1_/.^2:G^=9\?X+//\ /?X?_=-@?)_@MW://[RF+0!.OWE23.^B?@K[
M7:-N3+J3M_P@_./[KU9IL]7=(B([D\JD6!VTDD;2'"/&(U_SE:P_S_E_%5,.
M6<IQ!E8-WH&:<(B)("?://[RN?\ KN(Z71_X9;_U%RZ)<[]=_P#DNC_PRW_J
M+E?P?SL?-I\S_,S\GC%Z+T( ]$P/_"]??^2%YTO1N@_\B8'_ (7J_P"I:K/-
M_+'S:G(_/+^ZWMH\_O*X'ZU?\O9']2K_ *E=^N ^M?\ R_D?U*O^I47*?SA_
MNL_/?S0_O#\I-7HO_+.#_P <W\CEZ1M'G]Y7F_1?^6<'_CF_D<O24><^:/DM
MY#Y)_P![_N8O_]3T_)I=<Q@:=I;8Q\Z\-<U[AI^\T;44@]C"=))3R/\ C*G]
MB8LF?UQO_GK(7G1X*]%_QE_\BXO_ (<9_P">LA><G@J;'\K'/=]C^KP/[ Z9
MK'ZI1_Y[8K\._>5#ZN_^)_IG_A2C_P ]L6BHCN61I9'\\[X!-3_.M^/\$^1_
M/.^ 34_SK/C_  6>?Y[_  _^Z; ^3_!;D']Y(@P=>RDF=]$_!7RUW/'"L8@/
MO@QQ_%5QP%8Q/S_E_%4.7_G(_7_HMC)\I3P?%<_]=P?V71)G]9;_ -1<NB7.
M_7?_ )+H_P##+?\ J+EIX/YV/FT>9_F9^3QB]%Z$#^Q,#6/U>O\ ZEJ\Z7HW
M0?\ D3 _\+U?]2U6>;^6/FU>1^>7]UNP?%<%]:O^7LC^I5_U*[]<!]:_^7\C
M^I5_U*BY3^</]UFY[^:']X?E)J]%_P"6<'_CV_D<O2(/BO-^B_\ +.#_ ,<W
M\CEZ2CSGS1\EO(?)/^]_W,7_U?0G'K$/ #MWJ@M/Z*"T$[JYW-<S'>W9[]EN
M3_.+2,]DZ22GD/\ &7/[%Q9_[F,_\]9"\[/"]%_QE_\ (N+_ .'&?^>LA><G
M@J;'\K'/=]C^KV[]@=,@#^B4=_\ @V+0]W@/O_V+/^KO_B?Z9_X4H_\ /;%H
MJ([ED:61_/&? )J?YUOQ3Y'\\?@$U/\ .L^/\%GG^>_P_P#NFP/D_P %N^[P
M'W_[$QW0=!QX_P"Q23.^B?@KY:[GC@*QB3[XUX_BJXX5C$Y?\OXJAR_\Y'Z_
M]%L9/E+8]W@/O_V+GOKO/[+HG_N2W_J+ET2YWZ[_ /)='_AEO_47+3P?SL?-
MH\S_ #,_)XQ>B]"W?L3 @#^CU=_Y+5YTO1N@_P#(F!_X7J_ZEJL\W\L?-J<C
M\\O[K>]W@/O_ -BX'ZU?\O9']2K_ *E=^N ^M?\ R_D?U*O^I47*?SA_NL_/
M?S0_O#\I-7HO_+.#_P >W\CEZ1[O ??_ +%YOT7_ )9P?^.;^1R])1YSYH^2
MWD/DG_>_[F+_ /_6]*ZCE7XU;'TU^H7/@B">Q(9[/HNM=^B;8[]'6K1,=I3I
M)*>=^N_2.H=7Z91CX%0LMKR6VN#G!@VBNZN=SOY5C%QA^HOUIC^BU_\ ;S%Z
M+D8?4#;;=CY):7D;*R?:&AFW3<RUK7^K[_YO_P!*5PLQNMNB,I@ F0  2=S7
M-VN]-WI-VC;L<V_9_A/M/^#<)D"D&(*;H]%V+TC!Q;V;;J,>JNP @@.8QK'C
M=^=[FJY)_=/X?WJOB5YK-_VNUMLQLVB(_>[>W^K^D_XS])Z5-E-2U;JK7V%S
M6Z&.X35TVML:XMT!UU"I64$7E@S'B[UG/EWJ!K6RS(-1U]':VOZ.[^=1*/1.
M0U[,YEC'%HK8+"XDM$[/YQS7>QW_ ()^D_P2B]B'%Q:W?$O]PU6FU.G)_=/X
M?WIB201!_#^])[V,:7O<&M'+B8 6/3CY3;&L=G[WXSF_:I<\#:0]T;7';]"V
MO\[_ -)J58W1CW1]'\0C8[+*]VYO,1J%3I+JK=]V8U[6D.+0\N);L-9]G]>V
MC_,];^=O4&5Y1<7LZ@T5,:!8X.#SIM'N]5MC*]C?6_2?X9]OZ7^844,$(D2%
MZ+SD)%&G5D_NG\/[UC_6CIV9U'!JIQ&!UC+FO<'.#1M#;&\_UGJUCLZJ['R6
MY#VBYP+<=PB =L>H-K/97O\ <QC_ %K&?OH+W]2K+*OM5%>QA?8'^ZP5AH'J
MN_J6^I_F5_\ ",4\9&,A(;ABG 3B8G8]GEO^:?7O]!7_ -N#^Y=ETJBW%Z9B
M8US8MII8QX!!&YK0UVJ#LZH72[)JKT/GIJYIVPWZ6W_MG_A/TJ/0.H^JPW.K
M=2 02V9=P:[/H^W]W9_YPGY,TL@ E6G9CQ<O#$28DZZ:MJ3^Z?P_O7)=?^K_
M %;-ZM;E8U375/:P-+GAIEK8=[5TF97FOLJ?C/#0S>7M<8#B1^BWP/<S=]-5
M&W]1L=[,O'>+'.%#6<N#=N__ $G\W'O_ /56QN/(8&Q6U:K\N*.2/#*ZN]'G
M^F?5GK./U+%R+JF-JIM#WD6 F #V7:2? _@L]C>IMU&359K+:C^</:_;ZD;F
M[F.?^;^C_0JWBC*%9&46N?N,%G&WLEDRRR$&5:::(Q88X@1&]3>K_]?U5)))
M)2DDDDE*22224A?B8UEGJ/8"_63KKN;Z;I_L#:H.Z?C.OKO@M=7) :2&N,N>
M/4;^?L?98]G]=64DE,+::KZW57,;96[1S'@.:?BURH9F/B'*97;0+&Y))L<X
MNYV^C[-LL;^C_G/=5_I/YQ:222G%=7C5-J'[/L<WTPZSTR=K9WS['.8^RQK/
M7_,]3_!?X9'P\;IV?C"X4!C3NKAKY:0#M^G2[9:S3<S^7_+6FH4_S3?@DID
M  !P- @V8E-EIM=NDC:0'$-/(G;^]M=MW(Z22FG=TO#MW.V!MK@ +0 7 @-#
M#[MWT?3;])6,>AF/170R2VMH:">3'P1$DE*51O3,5NT>XANX %Q/TF^EW_X+
M]&K:22FB.CX;;ZKJF^EZ1W;& !KC+G-W>WV[-_\ @U>2224__]D .$))300A
M      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      4I-30 J    "  ( 1(  P    $  0   1H !0    $
M  !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @
M !0   "< 3L  @   !    "PAVD !     $   #     [  C&&   "<0 ",8
M8   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C$P.C(T
M(#$P.C4U.C$Y $AA<FEP<F%S860@4F%J=0   Z !  ,    !__\  * "  0
M   !   #E* #  0    !   ##@         & 0,  P    $ !@   1H !0
M  $   $Z 1L !0    $   %" 2@  P    $  @   @$ !     $   %* @(
M!     $              $@    !    2     $X0DE- _T       @
M     /_A 4Q-30 J    "  ( 1(  P    $      1H !0    $   !N 1L
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M 1L !0    $   %" 2@  P    $  @   @$ !     $   %* @( !     $
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %& 7X# 1$
M A$! Q$!_\0 'P !  $$ P$! 0            @&!PD* P0% @L!_\0 8!
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M1JS5E9M9(YGVGYI^_P!N\ESLKB8@>G7L/A1-IL79^QY)'L#C&%ZL@1*<3=V
M:63:.YD;# $4A\9!N'W703?E7(I@[(V<#Q-G*S59!(X>>CQCZ+5TM,][+G3
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M^PT8W_U@@\LT;*Y(,T.:SA2UDDL<E,L<;A1LEW?KN,P2%;&6+J&(SL<OKT'
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MXK(S%M&ZWTON\-)S&R-5R.9RG9^I)CK6/Z4"P.>QR<F)#>52P4/!226X) %
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M.Y:*3;L]2I$ 44FP'!]E$3XR3X@<5L 3,ZD\6%O+KMA[>WM\RN@VJ)5I6/\
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MV YCHYP@H3Q(2>(-G9=7V-AW3\PW>(MPJ'B+W>CHF' 3^*4-5)RB; H4'_=
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MBB^1S3=MFZR0>Y*^#_A5GD+U+KF<\.NF9K!-#N0#S3$4EVNXO)0FL7<68H#
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ML\L@2K>S>[%H\OVO>TQXO)VZT']X]#!!=^:@A<.F.[#>6VLY3M6:[WW.3UC
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MD,.4!-2[^WSLWI2+[TMQ&;XPT3LGI3MP<&0#;*?$JDPGPN#RG7TFA<&X?VW
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MI)L?9NLP,-V[($5-FQB-X" L;V5K5@[&XQ^3%9W"CPQ)H0<'73B*ETP3R.2
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M4\H%!NB\!'M..'G^SH9\X=U333OPPTAYQN]&EZ&;F'R?Z*<TV>G<2[K4F^%
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MUV-M>Z8LFMA>_>'?^RJBSS2SM_\ NPSRQO\ RU333SPPTAYQN]&AZ%[F$_\
MR_T4[_%-GYI_SW/(EQXJU]R)?(QC]!K4F^:X\OW3V'BK7W(E\C&/T&AKCR_=
M/8>*M?<B7R,8_0:&N/+]T]AXJU]R)?(QC]!H:X\OW3V-3CI9%L%^-&:J865Q
MQO%-?VM99!=LIY(NRM?FDX325M;^2]\+6RMY;7O;RU;#<H\"\#RK,-JN*,;N
MGRB9CR'*MBML;%20A\H*^U3>V.T=;97Y\L9]#KWZN-\K\K2$=?R8XVOEE?\
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M8A8T<K9H[YV''GA]TQ:O-@R!<P,B0&+G9,)BL-P7E/%_LC3@@FN['08N?'N
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M609@T:BV$)?.R409#VS=!-!FUC)!\\>!&[=--(<X<K*-L$\L\N8=\?"XD*\
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MO(W"N%]2*R#;<;A.N$(V:%FRDFD[:)M&*UF 8JJ8D[8LV6&H%1+D9(@BSF3
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MC5D8EA-V[MDK)41C]N=N'$+UCL)7AVW_  EF*D,6?3T/L9IJ:$2&?7E4D@[
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JF9-M!(;W@>SV(UQ1#+!@FU0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g475892g14y95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g14y95.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19N4&AO=&]S:&]P(#,N,  X0DE-! 0
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q >/            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ /      0 ! \     !  $X0DE-!"8       X
M/X   #A"24T#\@      "@  ________   X0DE-! T       0   !X.$))
M3009       $    'CA"24T#\P      "0           0 X0DE-! H
M  $  #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              /0   )D
M   !                          $             "9    /0
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   /0     %)G
M:'1L;VYG   )D     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   #T     !29VAT;&]N9P  "9     #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MUNDM'\H/<W5WM_P+U"YSV49;ZS#VAQ:8F"*V[="J^)DV9%6"^QKBY[*[#:0
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:  4
M   !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R
M  (    4    G $[  (    )    L(=I  0    !    O    .@ /.'P   G
M$  \X?   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ
M,#HR-B Q,#HR-SHP, !R<C$P-S R,0       Z !  ,    !__\  * "  0
M   !   )D* #  0    !   #T          & 0,  P    $ !@   1H !0
M  $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @(
M!     $              $@    !    2     $X0DE- _T       @
M 0   /_A 4A-30 J    "  ( 1(  P    $      1H !0    $   !N 1L
M!0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "<
M 3L  @    D   "PAVD !     $   "\    Z    \     !   #P     %!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C$P.C(V(#$P.C(W
M.C P ')R,3 W,#(Q       #H $  P    '__P  H ( !     $   F0H ,
M!     $   /0          8! P #     0 &   !&@ %     0   38!&P %
M     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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M   ! A$#!"$%,4%1\!)A<9&AT08'@;'!$T)RX10B\0@5(S())%+_V@ , P$
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MF85&[NPGY@7=CO$']+X9Q)W_ '[L6+#87[&W-H1M,=&]-I3I7M*UM6RK&8#
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M#&Q<B--CNPS=>+%@LSVG&H\]Q^-):9*SS @3C/XY^3/V\Q?W#\.P)[P& P&
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MC9NX<G4:4[MASV0C/@7]7LWV^]*_\@=A(W?6?O*?\*8# 8# 8# 8# 8# 8#
M8# 8# 8# BGD7]C6[[5NK?MX<PS3^[^4I6PTU-?28\XIT\YX[].*\RKU[*!;
M5<JP3^M/%KOV2GN S'/+0F B["N80"5]AQ199S<JL2XL$@%:-S7HQ*/$?GP2
MXT;O+[?A?OQNKL6H^/O$ZM!*.FX5>Y;10T0L\"*5=PA&'UP=%9E;K9OU,@$N
MMMI4@,6WLD-1[,.<I4IEW>PS:L=#IUR(&1=;--DYP!>DDV4Q"$;2$*GDQ:9,
M5Z;$C,$X*B08K!3/&.S(2I4"2SJ1M;>]8$<<9_'/R9^WF+^X?AV!/> P& P&
M P& P& P& P& P& P& P&!$M#_O![A_G"I_NPI>$C?/C^(2UA44=X$PSW#NR
M@R#(>1 ,\JZ$*FQ[ 24& OQ"%1+Q)#)LPF:-4)$.,O+02))(P%08:GI29D7;
M6GD!KW^BYOE?Z,%Z>=:MY&[W(2(Y)3;"9E=FY7V(?""5@/9XU:KX>?R80)$"
MXHR:_9GW5FT/V0U(GK(3W$-:CLMBW.+3X3&E]-_KWMCICJ=& W<)SLH8>CVV
MPQV90V @,=E0M-2U$VX&B)V(-? !GRKH8LR'BF2D"28?'3&!C4MYA:-$O%[<
M>O9@EE_YG^-?89Y'?MUXOY)WQX_B53[E# 8# 8# 8# 8# 8# 8# 8# 8# 8$
M3<U_&/MGVJQ_W5<OPS3^[^4M4OTR<"E-A^"V#H=F+B:Y$+V\3 $MOD)]<FV^
M40H!ZN3+!2ZA=:YT^X19.JR0I1.+SVMWLQ$J-WM:F10XA(%S\-?\\_&+=^MM
MW.T3MDXJ(V!XSR8#\:HGL-S.BB?F+@R8%7/T.JXN'J<L,22V0$JE:9^(V,GH
M;FP=K^%E)2^TXG00%XI\2MG+(/8-V*.4KDB_74B7&K58!MA()C[=*-,GW-^I
M<="-S=2FI4B+'2U7M(8'IBU<0X@DQ,)$?CE^(X==^?\ C?#>'C>N0I!*<8?C
M]YZ6APF3U!3/F*W+@*]Y)T-A#H.EZTK3>OAH4='L(3[25+]I:A'YG[RL;A3
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M6];3[Q2$[TCVD^UO7KKU*@BR_P#,_P :^PSR._;KQ?R3P\?Q(GW*& P& P&
MP& P& P& P& P& P& P(FYK^,?;/M5C_ +JN7X9I_=_*6O'Z6*IW6T<_Y9KG
M%I;I5W8M1:$!.L$:I1C,V27BCHNJF)[19;B"D<G595-H9DF %5Z 4FZBLZT"
M:;A;>66;:;]9TMP[^'#A>/*[9ESA@I&YW1(QKV]&8]-K#!;WMA5;G/F3(6"W
M.][:E18:K,Y\2EWV[ J'%V95ZD51F-R-MI*J_P"*?$NN<M3V:/TPA56-VZS^
M^I1"B39DM^!7F=FMP5RT&Q##2BD-LG'<^.+1SQB>13-2:+EQT40VP2/Z\N.^
MR1_&V&^.&=;@R2<XR_&[STMMPH3U 3/F[W,@+T[*2,@C8&G-:5I'_M8,9&TI
M3O:-K]I:A'OZ2L=A3 8# 8# 8# 8# 8# 8# 8# 8# 8$4\B_L:W?:MU;]O#F
M&:?W?RE*V&FKSZ5JL6NS<.IK-$L[-*N4?H4=NN69.JL%*,$R@,L*C!0_2;3=
M:FWRV797I;0=RV"1UU,(CR'(D:J3&W7GXY)GW\O:+S;N[E[>$PSH_BG)(%HV
M\JR0^;TN*>5(NF^COJ+L5X>V04]T!4,?N[.JE)=4Y:O@8?SY6]D]1F=2?825
M 7C3Q/K?-.B>19WH4NG) = M6YO-W:=-(R2<*O+L%V+I^L+18:PVLXSNQ1W=
MRY2S3VT>X&*G2(0MGWA.O7^_^W2+P$?(%V+R2@RS!(\^SWACVRI=(U)"5[7"
M^(+UM](@<*'Z]VE6FD>X@,>K:$[<]MSVW%E6.P& P& P& P& P& P& P& P&
M P& P(EH?]X/</\ .%3_ '84O"1OGQ_$):PK NJ&!E>YAT8^:,-5X.$HEN+E
M3SY6:"9"CAH A,G%GC8R-,)!VAT9EV6X4'Q)4X>AE4N)'>D,MMJ#5]]$O2Z;
M4 G?)56O#EGD7&[#+$1#'JA=(M_KNQI&Z4>0JW=3Z,-#W?K;1"RU"T,!IYP9
M#75DBB 9ME"W7T))$S;6+3'"-W/2VGT6MZ?X_7^W^6W%.XAIU/11:%7Y0JS#
MB3A!NUOS_P#ZJW E"5M"I+/P,9NPNMN0XQ@&J=+>8>,?-AHML5+''A^>/XEG
MID;+C>67+9[QTI/CS^&>0WPP>4T(0-$>XNWB\AS8]<,5%*+W)5_O'OF1(AK2
MU;TQIE'LHTY=_P#U5E,!@,!@,!@,#!.C79WGM.,VYBGW.^N"'!:$U3GP;1^V
ME/F9>"*4H4*7)AIE)@)G;)D5*DM)C"X<V4I6],;TIU^/NG/KO_+.]??UK?IZ
M>O\ TW^'7_QO"F P& P& P& P& P(FYK^,?;/M5C_NJY?AFG]W\I:7?II.G\
M5&3N05TQ?)E>ZY6):9@9L D$4)!]6&VT:Q4]=GK]TK)VJQ>?F;ESD2[:^@1E
M2+#1QX3W35?L(6Q&H&&K7Y=1/OU=NPXP,@!>/\I#BGXLD6)YO2!HV3!F22,*
M1 @UH9&AR(9"9%@RYT5Z.TV['F2H4.3):4AY^+'=6II CKJ=4EX$ <"_J]F^
MWWI7_D#L)&[ZS]Y3_A3 8# 8# 8# 8# 8# 8# 8# 8# 8$4\B_L:W?:MU;]O
M#F&:?W?RE*V&FBWZ:GI_% 52Y;6[9>"5>Z=7SR[77(]68!F;2.@&F9 P21>J
MER"$:@3JQ:W!A BPV!^7&-4:#IVS0XI07'-#)@ZZ\.'.=&V#QD'0A'CIPL8.
MG#B<&#R6@1XQ(00>*BB#;=8&:U-&DY P*]/@RM^K\66L.)V^PXAS0V#I6HS0
MA.6! G&?QS\F?MYB_N'X=@3W@,!@,!@,!@,!@,!@,!@,!@,!@,!@1+0_[P>X
M?YPJ?[L*7A(WSX_B$M85!ODG99E5XAT<C!I%EZ"[)K),*NN54)6;(37'/1'A
M$DF\!N)RN5HL("QY;A4X/+EXD.6)B2V'E*0YM.PUC_0T#XT"L^1B)/.'.2V?
M[H594=H6C\:WQ!$6>"FG A&+:IG2>C6N;JY1S$F_N""SE="5OZUH$UL5,]T6
M/%B7UG6^D:Q%HW?U;?.YNJPJ K+_ ,S_ !K[#/([]NO%[).^/'\2)]RA@,!@
M,!@,!Z:_P_#^' 8# 8# 8# 8# 8# 8$3<U_&/MGVJQ_W5<OPS3^[^4JI^8O"
MYOD;:Z!3ZMW\+SZ8#'V9GH',9,V5\1T&FEIU)*3VG6@5@"'A;JX A=+DFM)F
M?+JETFROC&XQEP7*T:Y\_MR73YU7)].Y]1:B5-/64I5J?6JX1L4C3FI!Z<$#
M0ALLT_IYZ0[IXH_&<FN:<D/K]M_?MO.J]5J$::,K8DQI/O?AY#+_ +AY<=_W
M+J'?<OM^GO&'?84KW;R/77MM+]E:?77M)UZZP('X%_5[-]OO2O\ R!V$C=]9
M^\I_PI@,!@,!@,!@,!@,!@,!@,!@,!@,"*>1?V-;OM6ZM^WAS#-/[OY2E;#2
MB?F-QF9Y!3^<46K=Z$\L."2961;:>]+=W.OU"LX2<*.C4Q11P,9BSG $:R#@
MQ?UEQ1+!8Z9C1-F!8V9"'W_[Y>*TG'J80YSRCG%!+'/K*3IE)K59G'];E;27
MDA1,4>[.;W.E39NVGU,;4UN9,E2MM>QN1(=>VM:@D)J1'?4\AA]EY<9SW,A#
M3J'%,/>RE?NGDH5O;3GL*2OV%Z2KV5)5Z>F];P(*XS^.?DS]O,7]P_#L">\!
M@,!@,!@,"-JSTF+9N@])YZU6;6+D\U^J7Q5B+#6HU:LOUM$O%F?JM/1*=>G[
M$H9W$+_$18GN):T(8^(;VIQ(23@,!@,!@,!@,!@,!@1+0_[P>X?YPJ?[L*7A
M(WSX_B$M85 GD_:>75/@O4)?;&CCO)RU./5:_P#U>%&BY%%7M(J8",;0Q7V)
M!2,AR%.>C[GQT)W#<>;>VXUI/O-#^O71"/A'S3QUHH2UDN WJTWYDY& LV4M
M;9LF:5T^LQ=;LT[-<DA KJR)$YT"TSY:W&W]QF7H0:+J$*$#8+!(^OU7@7-A
MM268;DJ.W+D(=<CQ5O-IDOML:3MY;+"E:<=2UI2=NJ;2K2-*3M7IZZPJ"[+_
M ,S_ !K[#/([]NO%[).^/'\2)]RA@,!@,!@,!@,!@,!@,!@,!@,!@,")N:_C
M'VS[58_[JN7X9I_=_*6O_P"D,XI(M-VY1T81Q S?F8=:Z36;5;>4\OYOT?M$
M$Q+@!)G+POP'1F'@_P!SF48AFW;+,]R_*ADH]>AJ?'!"9M]19B_IZ7M]_'O;
M'>6Q[)%YCSN+<H \7;X]%J3%J&"FH[ L=9&0 ]LW!',15+BLP(A-,EB(U&4I
MAN.VVAE6VTIWA5;_ !G\>[AR"+V1@Q(K5;D]"/.$ Q2AO*G3!^]?/&VBRV;
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MSAW$W6_BHM2!5H W\.VM$5KX$-$]IEEM<CW\E3TATJS6 P& P& P& P& P&
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M#+>XKS6T--I]$)*SS @#@7]7LWV^]*_\@=A(W?6?O*?\*8# 8# 8# 8# 8#
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MZ;_PWZ?@W_\ &_OX$!<"_J]F^WWI7_D#L)&[ZS]Y3_A3 8# 8# 8# 8# 8#
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M*3-E-;'MN,0F4K>U&<6-"1WW6X[,2)I#.Y,EZ0IZ3(>?7\FS]EX&SLOB49/
MQ9P?U;XN+,55?[UVIC]3$JTB(BGLT47O:+Q$U35?S_Y<?+'X%^4N3S>Q/A/!
MG)XFV<S.?S7^?M"<WM'._P"/15AX44U8DT53E\EA8E=.'1A844X<XF)7755B
M8M==5F;,2K0<$1*6^8&'UN$TA\K-L#L-@/&92^UIMV<]/VF(VVF1MGV%O;TG
M3ON]IW[?LYS'I[F.%Q+16*!=(P&S4X>0+0A*Y4=)&6+%21L,H0C0E.:DO0AT
MLR(C3I3;2F(KY0>T\M#DMA*PX,JU5F#8@]0F'1,:T6 <7+A*\]/BMF"HH X-
M9-DH Y3FI4J"*>,"69\IEI;,5TE";>6A4EK2@[_U3_CK_OK CV_7/E_-84>]
M=*L--ID&(YL/$MELFB0[<=PBE;RAD8P26RIO<QN&Y(=B,OZ]ZS#=D.HVS&<<
M;#,AI469B_&B9\,C#V\_'^*A/M28ZGHKJF)#:7FE*;6IEY"VU^RK>M*3O7K@
M=):2M*"H$D;C+KH]#1/:0<T^L<U[DRD?.E[T*>G;TILEH7#)2-?![U*W"CS%
M:]6FW?0,K]K7KZ>NO7\'IZZ]<#S@1-S7\8^V?:K'_=5R_#-/[OY2IK]('7II
M5[D<JO<QC]-MS[EIK(@;/@DJ\,1\Y+4(D,CR^VP;U1F.1D)%VK]-?JLU]T]/
M*VZ$$DU\#,. H6M%GAU'UZMX[E\N?AM5V@4FO( 1:KH'4:X'35X)-9F%7-#0
M\.%\BAF'6F72T41IGX".3=9:<G-1T2G&D*=VC157/%W@O2>20^^1[:3K >?>
MNA%9U&*TMA,SX>MJ#M*$V0VP4B-1RUPV9*%5%)I^ 2-$TC8$>P'[+$C#9#1/
M/KKC]K,\\81Y04"ZJ.-'I-H*Q.[=+;FV"9!&C)11W<V"O4AZ 'C0QD526U(9
MTW#BLM[2UI>T[<4M6Q'OYWU]5F,*8# 8# 8# 8# 8# 8# 8# 8# 8# BGD7]
MC6[[5NK?MX<PS3^[^4I6PTUZ_2"@W"5:Y;.&<]C]$L<:UG0HD5/!SVQ2&K56
M98EY!7IL2]4"-R-A\E\E6*M1$K.;<M<6N,C1$H^R'=CB=W7O'W7$X^"D5?E/
M.*[+JL>C3 M)K0V938EB?M\:K3(@B(S* LVJ4TS)LB!<A+D/1V0TV\5]U\<Z
MG2W]X%>/''@_0>6WWR9L5IFU>+#Z?>GBM%F5=I3TY(5TA:##!:S;F1F/FEC:
M?LS<>0^;8*$$*'[&_/"E?BAFXX9EXX"S08OY&#K!9Y=Q+1^\-_%V*<,$!Y,_
M;G#N)NM[<'@HL(7'^':6B,CX:,W[Q#*7'?;>6XM06;P& P& P& P,-Z'?JOR
MRBV[I%V(Z$U*CUXK9["0]TX^N,*#Q'9DM3,9G2GI4E;;6VXL5E*GI4A;4=E*
MG'$ZW\>-C8>7PL3'Q:NQA85%6)B53^VBB)JJGOTC=QW.IV]MO9OPUL7:GQ!M
MC,1E-E;&R&9VEG\Q--5?Z65RF%5C8M5.'1$UXE<TTS&'A41->)7--%$355$*
MV>+'G)PSRVH-FZ#0B)*LCZ:?8KUG'7] ROD!$D@G3@24^ZT4GBUP3C?M)&O-
M$5K<DLR8;C;<EA3>^!LS:V4VMA5XN5FN/TZXHQ*,2F*:Z9F+TS,155'9JB)[
M,WUM,;XE]$^5?S=^%/F_LC/[7^%__D,&-F9[_ S^1VIE\++YW+XE='ZN7Q:J
M,#'S.#7@9K"BJK!Q*,:K_;#Q<.NFC$PZJ8R0SY*)"V[I;3]'F.<GXN>14>K]
M10;9U*J%A5R^N=;=(?4?0Q<XQ0Q]9N53@%K2,,/%!]@,.H74UUH*<M _LWJ-
M^NNO1$A[Z1CA8-'8O:B7&0KE)>Q HTOZK6% &WSZ\(J*MR8=A;$2!H4$8N5X
MK=! 'C"VAYPP5@$1*IP64W-T.NO)E4;SW\=W"XH;)LI!F*?BB2 0O'JMUFBW
MPI6SBJ;'M4\JW6&P<"E3K!8:RR MR#$P*?%GQY^+(;"O-3727]M_&UYZ]G?2
M_+_G9GA9KNG+6)G0 86RUNK3HLJ+8*ND'*L9*JLI-7':ZT:/UNJAZ[< UY.F
M6JL8>'4]_P";J'.-H>2T)FW77T[[0PJ/](+P<:(FD+L4?"R \ .2LC50A'NJ
MA:S$+\ZI'0HLLO<*+7R%6<'%(MUBQ*J6$%"HNTZC[^7RT&&RX *5\[?](=X]
MUE "'&)')=FLQH>%$UHQ6[-59BY7W45<OL[#[A4$IQLA3YD&P&BPUF+)DK%A
M4[:]%&@BIPOUU^';1/I ?&V0/D356&T*<@^JYS$'G70YWI BE;=7S5C'_P#T
MM'E$:< L5$M00M:40F1T*:.83*VQHH,^+%^NO%=? 8# B6A_W@]P_P X5/\
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MAON;OXO(W\N0S"9E(]]OU6]\3+E>TO>]H]A/HG4Y=\_B?:RK)Y0P& P& P&
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MJ]MF&N(CU=E2G7M,S%SV(DN3\).EC6H4DB.'SW9$5ND7MJE#"F P& P& P&
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M-JJHB9B)F(FT3>UVHOO7#YWDG>1/<23S=-/UOEAZU<IYU9R*@%G(VWAUC61
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M&&2Z ?!];.7/G=PY7$9)U6HCZF>>NY .3.4_=I&W*\PR5ZL)L@BV6(RXD=?
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M7W@@:NL375+EJD1W%I/%3C32H+&F6T)=E:?(WK<3\.O&#QWJH6G<BXM0JN*
MU]%6A2G L8W870*)<*?\K(V@]HG8B<)4\= G;BSB;\9,N%%?;:0N,QML+)LL
ML,)]AAIIE.U..;0RA#:?;=<4ZZOV4:UKVG75J<<5Z>JW%*6K>U;WO8>_HC6_
M7T3[7X/7[WKZ??WZ>OX?^N_^^_\ ' \^NO\ '7_?6 ]=?XZ_[ZP'KK_'7_?
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MG+C#V8T"-)GJC[E/L0H[$1EUU3<9EIE*$)-,AP*4].\.(/27>@>U?)%;:O\
M=05TG2 U<8098) 0EA!BR3I519*9UGKJ+,X2I5E>AH>JI:G\SF,PIFJ9MHL2
MV_7?;\^_=/>G3@G(HO"N6U[F,(RL[% 2#TAJ=\O;$1D:.V F>5"'"6I,UL8-
M@+)*B0H:9<C3;+2=^\]5>RD1IUI]$Q856;LGCDWUJ_TJ_)NQ*LS*=6+W5F8L
M4:B;MR'?:X5K!1^!,W/A.BGE0C"Y<E*&Y39 F$JDE]*6@>X\TDQ?C;PW^?6_
MGJ^7CKXTBO'MZW.BC<0FFW1ZPW+8A % H[#M;BSH45##*S1AN,(&#Y<6O54$
M.2.'5RJAA O;9.<U+,3!$6]/3KJ=9L]A4+]]X[&[OS8GSJ8=?KT<E-&3%$68
M#9/W2QLI,EESX%V3$0N9">2V4"2]OIV(L4 .;2U)6-3%>)/7Y].K(^1XO#D]
MO%=MW;YSQ*%;[%<9(.2-U)A[)6'E/+N6/N");Q);P60F!S".^]*;:E:E#[+8
M@VV&4S-SMBWAY>'7ERUM3A7PE,?$QI$;WKK/Q##K'OF%>P\U[UM3?O65^F_9
M=;]KVFU>F_97K6_3?I@4<,^$  [R@'RZ;:HJ8M= VD",=BUB7!"I;M'3.?\
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MWK6OO[P/5IYI]M+K#C;S2_7V'&EI<;5Z;VG>TK3O:5:UO6];WK>]>NMZ_#K
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M"7.2] KB8BFY:R\A+<)N*\Q)6\EA]EQ8ZZ\W/!]EYG;:)7^FTFYUR\4&TE!
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M[;QP@PB5!ZKSN9&<B#YZ'XUSKSS2H)6P3JF,F:6V04G<4A:!A*NPG_7W4DY
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M(I'2+TY7*ZS,=F1![6[(5+'!#D=#KKKP36VL7].$\.<3:TQX\60D^.?2(\S
MRH/!KYVYMTM6><36:_;Y(DY5:W;NO=!\@.0W?ZOQW![;H4/QBIV'DG<M F)4
MB-[ZF-R)/Q;QN:VZZZZU6.&^(^NZ-WUGTO,S?LPZJS6_Z18FO@-K(@/*2M6Q
MN^UL^>J]=:05IRZS7>N4SF70 MT"AQ$"-N.:YQ4K3U. ]8S3\50[H&M 0,DX
MTJ:/)KW;IX5<M.<[_/A>-6RCP/.]6NC/:K)T7H%GN(>E=(,^/-&^<2Q,P:?%
M\.,&@A7JZ)0J+':GV+H)4H[!L,U/L1EKJ,3X:+&4I]O"QUUU+8)A3 8# 8#
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M;DW%NV0.W\ON?9KPS?+1SOAO70UNN86N;K-4L-I[CU*J6B+6JJ/VZZ]' \U
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MU&C1V&T-,L1V4);999:;TE#;33:4H;0A.DI2G2=:UK6!]\!@,!@,!@,!@,#
MXW+>:PK_ #^K0^?TR+TXJ':KY/H<>LAV;J1!,[8VR'FV=N&DS*&M[BQ?8A/3
M%QTZC1]:;UIEO20RN8(%$)8J?/&P)LT'+>GA9DJ(Q(DB9LF#*%R)@U]U"G84
ME\;.FCWGXRFW7(4R3%6K;+[J%!V.!PHPT?"D3Y<.#$BRBLAN63D1X[3+Y&4U
M%8A-29KK:$KE/MPXT:(AUY2UHC1V64JTVTA*0YN!@-;Y5S*FVBVW>I<]I58N
M5]?9E7>U@*P&$6*WR8^W%,/V4S AL$#;S*G75MN$9$A25N.+UO2EJWL,^P&
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M2%3VX\E^#+;;D,*5I$J!/BRAQ*$]IN8-)1)8Z>Q'FQ9##8?:[7BG<VJAR]=
MLX.F4VM0E$3]GLA**(""(25H:T_.(3768["7'W68["5+]Y(DO,QF$./O--K
M6O%/!!@UB,V0,,!6(M4P0(M-G,1X!8S>S RO4P9 DN+TW)FV<X9$B@L=O:G)
M\XA$CL:6X\C6PYD6SUZ;8S-0AFATFT5T4 .G0#,II942'M,D]#KA.?#2K;T:
M&;E5:QL#7W$Z1*="$D-;5N*[[(>"MHK@(I6 I@T-&%[H5F ZD.FRFF)EB,#@
M!BTSAHAA:M+FS(E<KYLV^PSI2VQHJ=*5K34=Q6@[[ 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MC1B]V.:3PZW];Y\6^+"& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P&!%_3^(\<[7%!P>P<MY_U"'62>S->BWZI [7'#%%M>X=F#F3<*:B*[(8
M](\OW24HEL:TS)2ZUK2-"]MR4,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g475892g16k55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g16k55.jpg
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M 0$! 0'_P  1" #X ?0# 1$  A$! Q$!_\0 '@ !  $$ P$!
M  @%!@<* P0) @'_Q !.$  !! ("   '# @% @,&!P % P0&!P$"  @)$1(3
M%!C6%18A4U97>)*6F-'7%SA46).7M](*(C$UMB,D&25!)B<S0E%A*#)'4G&1
ML?_$ !L! 0$! 0$! 0$            ! @,$!08'_\0 01$  @$! P@'!P(%
M @<!      $1 @,A,00205%A<9'1$U.!DI.A\!0B4E2QP=(%,B-"<N'Q-'0&
M%3-B@K*SHO_:  P# 0 "$0,1 #\ W^. . . . . . . . . . . . . . .
M. . . . . 1%[D1:,3:%51%)G' ,NBQSLG1#(W&I.('GP!AGF<,U<M"@8JW=
MCB#;*J::F4';99+.Z>F_D>5KKG %>]2?IG^Z1UC_ )"57[*<%EZWQ8]2?IG^
MZ1UC_D)5?LIP)>M\6/4GZ9_ND=8_Y"57[*<"7K?%CU)^F?[I'6/^0E5^RG E
MZWQ91)!U*Z+Q4:J8D/5GJX*&([:Z*.W%"5=E/7??7;;1/&$HBIOLHIY&=4D]
M--MU5/)23UV4WTTV8W(CJ:QJ?%G4"=6N@LD3U4 =;>HQ?&V,9\AA3%/N%M/'
MCQ^2JW3C65T=\?\ JFJGIOK_ /-KCE::Q0SY_F\RYO4GZ9_ND=8_Y"U7[*<A
M9>M\6/4GZ9_ND=8_Y"57[*<"7K?%CU)^F?[I'6/^0E5^RG EZWQ9QI=+>ESC
M3"J'4WJ^LGG;?7"B5$50IIG9/?9-37RM(KG7RDU--T]]?'X]-]=M-L8VUSC
M9SUOB<GJ3],_W2.L?\A*K]E.!+UOBQZD_3/]TCK'_(2J_93@2];XL>I/TS_=
M(ZQ_R$JOV4X$O6^+'J3],_W2.L?\A*K]E.!+UOBQZD_3/]TCK'_(2J_93@2]
M;XL>I/TS_=(ZQ_R$JOV4X$O6^+'J3],_W2.L?\A*K]E.!+UOBQZD_3/]TCK'
M_(2J_93@2];XL^<]*>F.-L:9ZE=8<;[:[;:Z9H:JO*VUTSKC?;&OO4\>==<[
MZ8VSC'BUSMKC/B\K'C"7K?%G[ZD_3/\ U]4CK'_Z_P"M"57C_3/BS_K%,?!\
M'P9_TSCX<>/&?'P)>M\649YU)Z+#QCPRZZN]5M!8_"V7KU.BZH<(MO1\[:N,
M*9;Q57.-D,Z;^?UQC.R6$U,J8UPGOG%A\<-!,_3G/BV8UQ5'@TMLXQCK[U8\
M><XQC_\ #E!\?#GX,?#F >+_ /OES*M7FN9.D7Q/S,R>I/TS_=(ZQ_R$JOV4
MYDU+UOBQZD_3/]TCK'_(2J_93@2];XL>I/TS_=(ZQ_R$JOV4X$O6^+'J3],_
MW2.L?\A*K]E.!+UOBQZD_3/]TCK'_(2J_93@2];XL>I/TS_=(ZQ_R$JOV4X$
MO6^+'J3],_W2.L?\A*K]E.!+UOBQZD_3/]TCK'_(2J_93@2];XL>I/TS_=(Z
MQ_R$JOV4X$O6^+'J3],_W2.L?\A*K]E.!+UOBQZD_3/]TCK'_(2J_93@2];X
ML>I/TS_=(ZQ_R$JOV4X$O6^+'J3],_W2.L?\A*K]E.!+UOBSHL.G72,HDLL.
MZI]7'B;=TZ8N-D*(JG?S#QDKL@Z:K:XBGE)+H*Z9U42WQKOCX-O%Y.VN<AG-
MZ7Q9R-.F?2I\GLLTZF=8UD=55$<*XH&K]4U-TMO(WRCOO$==5TL;8SKA=#*B
M&^VNV-%-LZ[8P&<WI?%G:]2?IG^Z1UC_ )"57[*<"7K?%CU)^F?[I'6/^0E5
M^RG EZWQ8]2?IG^Z1UC_ )"57[*<"7K?%CU)^F?[I'6/^0E5^RG EZWQ9J=>
M';HFCZ][<UT%@--U5!P[KKC$2CD3$*\B,:&N"2UFV\T6(KL H=DU5?*M63-L
MJ[42V<*-VC9'93*:"6NDA/%(Z4.5?KY&[#RG(< < < < < < < < < < < <
M < < < < < < < C'VA_VFE/I.4/_P T;< DYP!P!P!P"%/<&2.T6D2B:.5$
MV;Y5\<?[8QXM'&['S;1@CY>-_'MJCLZ=K+I;)^3YS+)37;.VGBUZ4+%]ASM-
M"("N2@IH_&C'A$>V*%LN\B![EXV1?D_<]'5P^R-:*J:N'F63?;5=WZ*FIZ,C
MMJHMY&F<;9Z',[P^P-4Q3LR*G&4P@[)/1\5'2;*8EAL%7<-3.CM\U>ZLVVPE
MRT=-B>JRNF6"S5PDZPDHBKKJ!FBH>RYY['UR<9L$1,HP@*(/A1-$ZSD[,PZ;
MO6#%,<Q-[O"C39)EOZ1G9H-\E7=%)^VQXG7H[AIETIW_ $PT^M\;34U4W8;&
ML.)).Q^S&-& ,37.4'$F,-Q+EXXWT;$FHC8DAG;(;39-?9HX-).%6R:NR>7;
M-KGSR"V?2]-DD<TT:_\ )IUZN/KUVD@*FB;B&P0*'?\ I>"BB>Y(RFZ?>GX1
M,$MO2B>C3;3_ +=NTV=[JJIMFNNJ.NZBJN^5G*R[A;%3EMFJ5"1D?D-#@#@#
M@#@#@#@#@%KR -'G#@9)3><(+13+I\Q?JDW8UHRPLGIASN]V1<(ME6NVJ*>5
M=7J:Z&NNN=LZ>+RL9J;P6DC2<-Z+R-_:>\@E;Q9,$]/BXCB4HL4G4SD)AB C
MX$63)8':;N2KY=))%<FIHLT1SMLGY*&RJJ&RCC":?-4K2\%]3-3T*^5Y;" :
MDTB3-P?"1F5Q$TT*,W+M$@)EX,X]<1D,8<"WIC14"3V1P!(%1ZJ:KEXU4:XV
M0T0;N<[:+JN.B:?KUNXG.&M?K7]8+ 0LRN-RP(/I8$)W+R-N.?QX5K*P6Q$\
MQ*8SN,>AF.K_ "Z*-".FNV[%RQ271=ZZ[;-]U,8SGEG1I"6QQINPUGOEC_3'
M_P#&/_\ .><[G[P!P!P!P!P!P!P!P!P!P!P##5@7A64,C)4HZM&L@[[523A0
M_O@G49%MW<JBV?1C8!+9Z31U<&01!1!H7#Z9R\8/%4F;])LHKKCE6*G .8<*
M^),?U=4A#<LYL A83\R*EFS63ZC0>VPT,8=E=%W;_0V-55)-G#9LJNDBPPW<
M>>U33SA15+.F$^:JJNB%=*W:H9A4Z9<7/?IO[=Y*/77737737'BUTUQKKC_Z
M:ZX\6,?#\/P8QXOAY@V?7 ' ' ' -//_ !!7ZYE9_1CAG]5+HX.M&';]D;AG
M!R' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' (Q]H?]II3Z3E#_\ -&W
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M"RN6A-D"($,_;.FNZP0\8]+'@8_'>%1Z"$XW.9@CV("M8K78F(220R Q#+,
M"7D/GECC*BB<]ACTY"AR-DUR6L@R+B6MC5UM*H,S)/F^Q"0-&F_I.!<VJ8B_
M"-JT;'L98;GPJW7(A9--C8?* 92EIK#>Y4DMFVY5M+*V>T:5Z=C*=,2V.S.
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MINT/^TTI])RA_P#FC;@R2<X X X X X X X X X X X X X X X X X X X
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M4EMJ;WN%ALC6\28_:'_::4^DY0__ #1MP9).< < < < < < < < < < < <
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M-H+R5NTU5RHM&V[@^GC8.@J]T%AZGP*=VA_VFE/I.4/_ ,T;<$).< < < <
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M3";H[<,7Q4>>XP&OX.O!J5#+(DKL([L<SWQ<]G[$--IK9'N.^K6"S\I)J-C
MN*>6WBA*8 @,%Z_B#^2X!LP9.@,D<"CQ+(D J3"=^$+MQ[);:["W=NE\B@/6
M&*=>FFDLE-H=FIM'AG9^7CY_:LNJ2."I1/BUW]H92  3(SM%H..F*"\]A$-6
MCT1BA623*=Q-V<$;(:&MAXK<O8E=<D]2P[)[8)K=H?\ ::4^DY0__-&W!DDY
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P#3S_P 05^N96?T8X9_52Z.#K1AV_9&SMTO_ %.^
MI_T::)_I=%N#F\7O?U,I'+>J:,)R162VA7<>2AHLH;EZAR:QH2G%0P1OL\-%
MY)N_)M]08L0TUV=%'Y/+5HP;Z[+NU4DL9VX(5\E,X>&<11H8E<:$NIV4]PX.
MV)'1;%Q,C60Q*1X#Q1%TZ24D)3WO!RYWW/$:O'?N,*)%/,^@L72Z0%R\ MV/
M2^)RW)W$4E$=DV8O(B40DV(\:&FLQV6!]6^Q>+G<#7+GW(D0K5VUV)!2'HY)
MCJY;Y<MDL+)^4!<7 ' ' +=?RZ)BY)'H:3D\='2^6LCQ**15^:&M)))AT5P+
MS)W\>!N'*9,TRCF#@7)YT-:N4 ^"XO)!1O@@T\Z!<&VVNFNV^^VNNFNN=MMM
MLXUUUUUQX]MMML^+&-<8QG.<YSXL8^'/ ,7@;QI65,8V3C-O5A(1TR8BRD1?
M!)]%2C24C#?D^XI".N&15=(TQ+^7I[F.ANSE!_Y>OHNZOE8\8%V!II#I&_("
MX]+(R>)B=MM2HX,=%E'XS;1;9OOJ09L72[AEMHXTW0VPY33SJMKLEGQ;ZYUP
M!SXE<7VD>\/UD@#:6IC\%MXM@P.S(]!>=\)X);A,.?=/4?G?;73#S+7#?.^<
M:X4\><8X!VQQL*75)("2XLHN&?;BS"(Y^T>JBB:6FBBHXDFV55W8ODTU$U-V
MCK"3C3133;9/&NVN<@53@#@#@#@%H,K"@)(?+BXZ<1!^*K\H;"3PFRDH5T/A
M)J-,T2,C$2YZ@]4;1LH 'N6[XVP,J,G8IFNBY?)((*Z;[ =>'V97%A*ET(#/
MX5-UP"4<<'$HC*0<D4#MYC'!TQB+@GH'?/-F*$IB1@3*(ZLYPFD;CQ-@9&[N
M1SM!PH!AKM#_ +32GTG*'_YHVX!)S@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&GG_B"OUS*
MS^C'#/ZJ71P=:,.W[(V=NE_ZG?4_Z--$_P!+HMP<WB][^IK;S+KG8BC;PVP5
M7KW8Y.TKHV[[N:0RUZ$2U^=FHF;0T&G$B,)[E( U]30^6Z,C0./T^*7WP9?O
M,NF.[ATYU:+/6#^N!N;Z'-RS9OPAWW8EVR>-]^99VRK!\^AW;4_/J/[:VH<J
MJ+'ZRV;=*XC2S'HG9L7ZYR\=/-(FT&9EYNPY O&IVMF=KJLS9XT(GXP2Z3@>
MR@+-2BZ^E2],YZE<-D=LE3I1SX4>P:N@@216[W&CI:?7YTGB-T>F4?:$0M&H
MV$G&VV.[92:-3>VZ)B\*5A+K&(@JZ=5R-GE258:%!C,2DR+,^W;.'KU_D>[+
MN6#B'*=RB<=N-[F,5);5HNN]?2\7:I^F'%FCW/97PB_;CJ9&0DU9HM71Z6]I
M876@KJSVZ%)E10Y*09A%A0$SN2D(C38.7$20PXU8JLQCC1,%#:PNI3>Y3-/;
MME\2;_A2[.NFH[ Z14U [7[?-1$YI7N(WF2G5B()6!>%CS.J:]IAS59E^''P
MR8'-O%-R>SD^4C(AGENB>)8-OAD0<GWC89IOG]N*QN5\[M_9K@CS7,O\+V2[
M)4^RMTU:$'-L('U#(-@K:HK+E5!V)J_ZY@'/:",V'(:RK W3,*F3J^7\V:$I
M'95E0<K#=@T3_1VT?1I;;!<5YNC"_2I5]UVFZ/\ ]=D;I3V!\)-676FQ++,3
MGO-%2P^B^IB?8$[<=4B(J3AO=J;][:%@\UB/4L?+J]#1B6P8I4TDLT$FVB#>
M9U"]%K0'7<FL9)$D]QI*EU1%+_=&-Z5+:F'KC4V708&>$O,DQ-NU3#NT,YD]
M61?PNXCJ!.^Q-8N@]QCH%*X!TWS2OZ2@\DB<9U'3"26$!N?%.![+CPDO+AD9
M#-UPSP6AYC9Z]>MY%FWIX>[-^F7,8W:VI^Q/^F77; WX./PA*THFURR^8/JI
MN[3KV/N"K[JKNV(<84ZUZ)XCN[^[ZRJ6<SMJK9^7IH%($8HN)'ORI&, #Y<2
M$'X:#.%2E+%3#F;]:G1<8O$]4JC[.S7P/[:!]9H3FLZYH&CNV5F=ITJ?CZ94
MM'*7K2( >L'7P/=68_N_?N"\V*L9U*8,@?\ 2&T$KAJ@Z::B#_D*BRTJKW+N
MB=;OV?YNV4KHQ5G8"F+^[!1CJA1<2S!2U?R"7NKX[:=,I5U&G6]URGL.YDA"
MHB=GB #:P.QL,0@AZ6'!LM:")#'09(!#A[25J,".&V@-II.KR<W1JOB_CJ(N
ME:+[F#O"96!=%:==S3ZVTKTO>6PL/+Z@F FH!4G,=%4*NA_8]3ODO#$1LHI.
M2SH:G$A_3]P>?%XRJ7]W=V38D/\ 11XU=FWNZ%AC^[!4[K\[F3D\%-U@[%5!
MOX2:J++K>7]?W%CS.MG\:N9.=JST]-;+DW5N!@+0N2,RUU"(D*EIXC8Z1&S#
MTI%-O<AI9DDDL,P.04B+AP]&:FGFZ84-1'\SA<"#L3[">%2NFDDK3=E;?91N
M']E:^Z;7B/IP)+)=+4VO5ZG[#CM^WM$QE+0"Q;.4 7!VU)C!$D*UI$I!)Q\;
M@ D:@T$1]U)%<#44IZ'=G*</>:A-N,*;[];>B_.FUF>$K97?T>CF4>VDJ< R
MW2UA<UFZ5E9D=IZW*UGLO+@[\D,FJ['7@=%:V.P^*KB%[,4N&S(O:(<\[0D<
M-KF,18&8=<&8IAS$^]%^&$0T[^$%/"J^$=@E1='[0E4][PVK:4_M&;/[UZWJ
M0.;1UPLQTM2)06")Z6/!*1.1BD@< KQF\FSZ*=AU0D!NAB8EA@A.&)T<&3R$
M4N<$E@YV:F[[]5^&*DDKX4"6=Y!-S&!E!N.VHR/I=4TBW5K;K)7/OTATI[N;
MV>:;.([V4,)PV4BXW6[:$(0)9OO9I")UFJ%)3YVJ86D#)DDW"F+IC&^7'NQH
MFZ<=LQK(#VY ^\D?V[)PC>%=P8A5=W=DO"228MIU;JE_)S-AVW*:AZ]!>N*,
MIP4ALG62ZY35[M;C'65+HCX&3*C4&\MDPY)FR<)BW7/W6TJ;F]%^=VX?93!(
M?KD.GL$L>9@@FG8. /X=X,_P+\.NMA1M?,I5<<?O(?9%ACMX\[@TH F6R.[2
MK%DPUP[O@NQ6(U8N8,J^@.A(QR@(XC;G5[HA??#:>VO:'_::4^DY0_\ S1MP
M8).< < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M < < < < < < < < < < < < T\_\05^N96?T8X9_52Z.#K1AV_9&SMTO_4[
MZG_1IHG^ET6X.;Q>]_4DMP0< < MJ0PR'2UU&7LKB<:DSR%2)&7PUW(00LTZ
MB4L;#B0=O*(RX)-7*H&1-Q)DP+1-BMVA)(<5),M'.K9\Z25 ^R$/B1:1QR8E
M8O'2<NA[8ZSB4I(!!CV1Q9I*$F"$F:QPXY;*$PC:1("QB)U 8Z:I%TAS!,AJ
MXT9M\)@7%P"W97#XE.PBT:G$6CLRCCAZ&).(_*P@R1!%R,=,CY''R"PHNU>,
M%7H*0B11X,ZW0V7&&1@\HR40?,VRZ8%Q< 9QC.,XSCQXS\&<9^'&<9_UQG'
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M& .T/^TTI])RA_\ FC;@$G. . . . . . . . . . . . . . . . . . .
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MS^C'#/ZJ71P=:,.W[(V=NE_ZG?4_Z--$_P!+HMP<WB][^I);@@X X X X X
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M\+0+FM'(73&$8W:L;\;[SUA[0_[32GTG*'_YHVX,DG. . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M. . :>?^(*_7,K/Z,<,_JI='!UHP[?LC9VZ7_J=]3_HTT3_2Z+<'-XO>_J26
MX(. 4>0@ \KCYR+2%BD4 24.3 '!B^=\($0YEDN.)L5LI;IJ82=LG*[=3*>^
MF^-%,^1OKMXLX IH>%1<&&B()F':K,H(+'"(HH4QL8(AV@L<@):[-RI3+LEE
MYZ V20<$%'6[YWXMMW3A93??;8"KH!0S8B^,-A(QN7)I((DBB#!JD1(HM=?(
M;)/GR:6KEVDWT_R()N%5-$M?\J>-<?!P#]<AA#P=H(=BAKH2FF@EH+<L6JX[
M1)KY'HR6C)5+9MJFW\VGYC3"6-4?(T\WC7R=?$!;_P"CZ&>_09868^RWF(.)
MO8."-*9744 10H1'EC <"S46V'A$#C\.#6/+"FC1T=TCT;;EW#UM'0B+ "OY
M"!MGJY+80,V(NL(ZNG^6#7+USANV=,V^%W64O/K80:/7K5'"BFV$FSMTAIY*
M3A77<#K)1B-(M!P]&/ TF ?*VPADD)8)M!>SA%PW7R.;:M\(L<KMW;I!;+;1
M+*J+EPEOY6BRFNP'>P,&X4T6P/8X63]&\VKAHAYQ/T/1=)IY&_F_*T]%3<N4
MVWDYQYC1POHEY.JJF-@./<,'50W;*"AJC91H\'J-]V+7=!1@1VUW(,MTMDLI
M[-'V^NN[QMMKE%UMKKLOIOG&,\ MI&MH*A,AU@HQ@8G+PT8?PP*8U34QN$C1
M=^,)FA81GYSW.#Z'7@,!N?<C&C5X=2CD::EG+QK'0B+ "ZUQ[!SZ7Z2Q9N/3
MVFH]]Y]LBKZ:PT])\AD[\YIMZ2TT]->>2V6\M'7TMSXM,>?5\H"D:PZ(Z-,C
M]8K'-6&76C[++4&,PTR]33V13>9;8:X1RZT1WV2T<>1YW5/;;37?&N<XR!65
MF#%SGQN&;5?.6KAAG*S=%7/H+SS/I;/Q[Z;?]JZ]'0](;_\ P5_,(^=TV\WI
MY(%JR&NH1*R\1.R*.#RQ2"'4I/%%W6JN4A,A;"#()@8U9Z*Z,7C\4+D1QN&<
M$&SO<*H4=NQ.6;Q7+C@%R/A(HFHQ6)#!Y!48[U?C57S)L[4'OM-=M-'K'==-
M39H[TTVVUU<-\IK:Z[;:XWQC.<< Y-1[#3".-&+/7#9VX?M\:MD=<(/G>767
M3U'&-,82=N<O7N7#C3R5ELNW65-]LN%?+ L^25E"):0KPB?")O=ZJDN)A!66
MKIZT#AI(G&S<29%=PC)PW$DU1(21%T0B)9F^:AGKA P,0:F!XU^T P_VA_VF
ME/I.4/\ \T;< DYP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#3S_ ,05^N96?T8X9_52Z.#K
M1AV_9&SMTO\ U.^I_P!&FB?Z71;@YO%[W]22W!",LI[C]:X7>8KK5([08,[Q
M-:1)1E7[8#+2Q'1*=O7P^(+$B >/OP85 \[&$$F*Y@HP1SADY55W312W4P+#
MB8NUG51[G]<E^L0GN,G/5_5X-L0)(;.LQ*9X779R:9,8 &5VBGN!F8)9=RLD
MS&;)J@=%&^JN7SG5(>FHZT"',:24G!#%@2Z:XD5P3^AA!Y1U:580ROK FL<R
M),H)"8I:+^:#(21T-.&"0(CN6>5]*DE&(TD[?#L#TU"39HF^8[. BZ=#E<(G
MZHRGP!P!P#%EJW17%*-H(\L@\H ;V7:<#I>&;IB3)?):Q[,+X!PP#OJ&8$-Q
MZ98GGT?<L2U:!A^/^L2?M$?^IP(GLO,I\ @W)_"1]+H.%=R*;78)B@5M8-Q5
ML@^* Y2KJ3-=?SB49N<V,0%A"+IS *WD2V DLLC9!*"AB&N4GQ]'7='=47->
MK5YWKCH1D*/=T^KTMO5UUIB]O I!=C'1%1W"PXZ1D,(:N(.PLIOG>2M@JD1\
M;F"%1DF;ZZG\[+CG[39'&ZSA)+8(<3%WI?4DVW=-G>FZC1R@Z337<M=U&ZR:
MVFCEFNHU=M]]T]MM=5VKI%5LY2SG"B"Z2B*NNJFFVN!#GX X X X!@@!V6IF
M3Q6])J%EBKJ-];9A8<#N,AM'Y(WS%)150%A)IT.2:.!*3T_H&"DF;O1['&Y9
MB2RKEN+</7*:B.@1';>=2E.T-,=A24E$U7)G1Q]%HA3]@$4'P ['U5H-?4'T
ML"JY6P1.CQ[AV'DX'4BCHKJCJN/. CX$F@S*B'C9,5IKUJ<%%[0_[32GTG*'
M_P":-N"$G. . . . . 6#9-HP.H8U[[;#D"0 *H3& V.=61,P6-GS3G5F&CL
M:C@%D4D<HD9=SMYD9'HZ**&7^VJGHC%7"2F= 2DM.-]B:8EEC":@"SECFU#=
M2CKU'UV5''(],]JH*R%U$V<P=QV0BQ90:U]\C)T%=CR39H9'$$-T"(UKMC'C
M".17ZVN.L+A]_N:QF@:::UA8TBJ*?;A555DXQ9,2;BW4DB!!11%+3)4.@:%[
MO,-MEV^GIB>FJ^V^JFN@&2^ . . . . . . . . . . 8/>=DJ1'VRVHYW/Q
MR5FNB30%J"]SS:C!"4$(LM.AL+?RM(7O#QD\*0ANK,Q4#(GVLQ*1/&LC8 W
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ML':/LYV@[Q="[/L"1V77<3ALTL3I18]2HR(X"@]A=AJ>Z67S8G:*<2.(-G:
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M]PJR;)0KRPH$$J.R7%D5'K5'5Z-BD)S[UJKHNZ;D1@MQ=K"EIG-BT?K,F-+
MHC4X\J6"P^0%</@BF8NNOQ33EX2VE=3&FYSIPST6D/A%!D>[*V58<R[D35:
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M;G,@6,#?>^><.W^_K8)40TISJ].$TTPYF+VM<7-8,SQX:7J+>W96^G12JJ7
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M^$DDHE;!8SD?[L"6H(H-6#ZO]I&UWC>A?.HJF;G#US'F>1#"BYU-:$Z'3.L
MESQ3L#$^L]75Z_"RJIC-?DJN7Z_UC(A4J.^F6U"11R S'<U8I^&184FP<CKC
ME#^NBC\<>I^#SA_D5O\ =JF<<?5TZHC%GI7T7,RLEU^CXJ3UIO6#>'.M(E%1
M2D,L&NU#,:8@ #_!I>&6NX>6.+?MSY,]%S!27/GI.:FHT1L!-SNPE;/701XX
MSK)A\$' ' ' ' -//_$%?KF5G]&.&?U4NC@ZT8=OV1L[=+_U.^I_T::)_I=%
MN#F\7O?U)+<$' ' ' ' ,.6'UVZ_6Y)XM-;7HNG;.F4&V3WA,ML*LH5-)-#]
MDGFI%+:+GI&$)% &4R&FC]/(ITT\A[IH[U\3C353 J;6#:W,S'P0< < < <
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M]IYO[2\ >I+U?^:MI]IYO[2\ >I+U?\ FK:?:>;^TO 'J2]7_FK:?:>;^TO
M'J2]7_FK:?:>;^TO 'J2]7_FK:?:>;^TO 'J2]7_ )JVGVGF_M+P!ZDO5_YJ
MVGVGF_M+P!ZDO5_YJVGVGF_M+P!ZDO5_YJVGVGF_M+P!ZDO5_P":MI]IYO[2
M\ >I+U?^:MI]IYO[2\ >I+U?^:MI]IYO[2\ >I+U?^:MI]IYO[2\ >I+U?\
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M3!XD239M"(P<T619L'[5N[:HI.$$E-0/@?6%:B'QTF*KR##"4H,C9%)B(^)
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MAI4I!YS-H86D#="3I^GCHD47CF#3],>)* M.U1YI_8A.ZZ)=E(G!)'K2Z)&
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M=^N/%$R\H5?"-SV1'"'ZU+L/3_@@X X X X X X X X X X X X X X X X
=X X X X X X X X X X X X X X X X X X!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g475892g16r29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g16r29.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[17H4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %L< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  AR<C$P
M-S R,1P"!0 J36EC<F]S;V9T(%!O=V5R4&]I;G0@+2!3,2!&:6=U<F5S7W8Q
M-RYP<'1X #A"24T$)0      $.@# 3?/I3C$A,T6V<4WMY$X0DE-!#H
M 0T    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
M    26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I
M=&)O;VP     "W!R:6YT97).86UE5$585    !4 80!Z #  ,0 U #$ +0!X
M &4 <@!O '@ +0 Q #@ ( !' $\ 3P!$       /<')I;G10<F]O9E-E='5P
M3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U
M<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU9
M2P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N
M<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M    0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T
M=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,
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M;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT
M;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #
MP     $  @/      0 ".$))300F       .             #^    X0DE-
M! T       0   !X.$))3009       $    'CA"24T#\P      "0
M     0 X0DE-! H       $  #A"24TG$       "@ !          $X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      .T   )T          !                          $
M    "=    .T                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   .T     %)G:'1L;VYG   )T     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #M     !2
M9VAT;&]N9P  "=     #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     ,X0DE-! P     "R<    !    H    #P   '@  !P@
M"PL &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #P
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M)/\ I+./$PU;[?JOT$\Y5P[Z6U_^DD8?5'ZOQ)R[P#.OJUQISKZ*7WG'W/\
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H #SA\
M)Q  /.'P   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z
M,3$Z,CD@,3$Z,#4Z,C$ <G(Q,#<P,C$       .@ 0 #     ?__  "@ @ $
M     0  "="@ P $     0   [0         !@$#  ,    !  8   $:  4
M   !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("
M  0    !              !(     0   $@    !.$))30/]       (
M      #_X0%(34T *@    @ " $2  ,    !      $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@   /      0   \     !
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ,3HR.2 Q,3HP
M-3HR,0!R<C$P-S R,0       Z !  ,    !__\  * "  0    !   )T* #
M  0    !   #M          & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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MA7[I/GK7_EA_=@]EMM:?"MVG_P 8;.+]=,.\W"7FS0/F>G?RT/"OW2?/6O\
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M;G*],5VKM3D]1I:HT]8ILHXTY)M3*1394SAE70F78#R7P@.?J==#B*_M,)S
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M@E+$M"7NY0RMP*N2VJQ5HG(Y2TD='75=%L9VCY$TX5RHZ=*."R8N@6.Y<'4
MQEE!-B[3Y!\2Z7Y&3>3*%)E0[+,N"6*0D),N%H(9*0E(3IY;!*0.0CD,56J2
MJIM4M4ZA+JJ&83ZF)V995/9U+4OC"VZDS6=3CBE:^IF4XLFY6J]A9';5SJ?Y
M0H9-I*5>(A4Z13<MW%CA8AY'VU]1Z!86=JJ<$JZ)+'@62D;/1[&15L$+7HJU
M2B[?>F)Y^+AWTCY]O!M&;JRJN>*>>,Y-U!,L^ZAR41.SS"Y::?"2T'UAQAQ;
M88>?=EFDJLTRWE3E^L=[HN(W* C#R52;$LFG4^D*G):7<9J#E.I<RW.2,LIQ
M+YE6U,S#3;JIN6E&)Y]2;S$T[F5FX#&YG9E0P398C,.\Q1;+)A-6,(VVS[ +
M!,@N=R$O-@UD$NMI,'*JK@'[_I#L%U%%05XAS&'OG*937M'6I\B[PS>C+ZDH
MPO09L$Z3.9LZ3>4!.FC*FP M81\LS6:Q+\1P]6J;'&/\3-Z,_-M<5,YBOB)G
M3>3KOYR5ZKN=S,2K-<DQ$*6ZV+-562UHL2K)>&C*XNS5FY-1JM7H5VB_AX%5
MN=T*2D+$OFS=[&11R"Q8.VZ#EJ@DLDF<NPE)1*@M,K+A:7G)A*PRV%)F'DE#
MSX4$W#SJ%*0XZ#G6DE*E$$B..J?GE-J:5.S:FE2[,FIM4R\IM4I++2[+RBD%
M929:7=2EQA@C2:<2E;:$J (CI66E9Z1>3$Y)R$S+R"QG+^5EGKF1DGS@X !E
MWCYXJLZ=+&   RJZIU#:!J8=,:---,-H98:;9:;&5MII"6VT)_50A "4CT
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MINU]U$*CYP_XK%^_[&=_]I:KL!_:5>GT0\'F!?-'#WS5*?PH9@^IZ[%&@?\
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MPA%2+E]ML]]\5OR"X0A=3DHY-ZE&*2#(DBLF59&/.Z0*]52#?$54VAE 7.F
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MR[Q]!/7A%3XR?A]D/T9X"^@?IQD?'^$?5%H=XSPI_*#UCC0<SZ_J$(9P[@]
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MVJZ"1/S&PND+L;@Y4WMO;3W*2D;'&3.'-PH#NW>W%[+P0TF'NNI!*!-  P
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M=A)OV[)-=L\43%1P2(=M6X%,8RT@9LQ3*9PX2(*%CY.7.&N,M=7FGSR+A[)
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MQ@I"=)75(M+IYSHY<>>:\QOZ'+[)]QO<$'.8@=(/R#D\(')UH("4.0;F]V1
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MAY.LGE!:4E2CE.[[NXF2+]9 38E6RK[ DCM0X1??&!0'[D/#(AR=B'<<HFT
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M&$(,(080BB&UYDD3-.P4N1-93P8QD1*,01+$]9 MQ'B"_%W^M&'#\>X8@D4
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M,;*6Q@BJ)SCF*H *B Z>2@FT H$T ?W4!J'8U]_4>8B :8CPY. ) PPCJ_\
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M%$[I*23>M;D[7/D&5.4<N>-]C=%40_[0E U%'_\ "PB.J*8I@/VR]_/4H^8
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MS0-^^U?-1N**L&ZD%%Q^.[ @<MK<S;,;Q\?L=3?<$GUW5>:1T_M$$ [1@'D
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M?&3\/LA\BXJ, J0A', %(#\(09MP%/?U VX/#[&\'(V[IJ'(=<9'Q[=A(O\
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MOBH.$ $=(:)#AD$B>D:RT3(<H%.1,.!H0AB]DQ2Z%,7D("&*J[/VA$P]QL!
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M")LGA#Y_6.$(^L(080@PA!A"*_9SO&B$A7TEW3=%06CY4"*K)IF%,7D<V X
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M8@CB34B]G;+9Y=^WB$UTHEBK,VR9G98D9%ING)8V*1>IQK#I"XM&B(K*":
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MO73I[7GSV-3/(RD18&K2E^:XQP=QNI5J4TE,Y;4FY1H)"9T95K4^RA"6TIG
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M5*>SA-@_TQ6^*SE)29GB^DN)XU4QGJBI_5XQ5=>F<0E\UR:F*@ZYM<K: H)
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M80BLUSS!E*;8(%@QB$YQ.8C@23C^E$CUE)>2OV7M,C%E)%4BZ;:.9!<'3Z1
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M#<.&N),WQ/#Z'!B1_&IG-3A11?QT7>B?PR)'Z[^7F^*77JW205!L+'J*Q=9
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M8E$5BBV2%*Z-?RW"BL)Z1E57;R^[9..13%>X LFJ)HC94<4NX'E)ZM^^0!1
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M$J%,8ID?*#K0;4G7%"E4;A:?+LE-03:#GXODQ 3>8"-, *1DR$ 7E=(M<+,
MV.;@^',@9U)(69'HI516ISO33B2;E:J6Z'KZ:];61[R>UQ,<9*K!(*.D#-&K
M(IZPE38JG3R:,TAKO^=P93I[7WD1;:='9]%X1BZ 9AT &75<T33>!0($8[R?
M5M9-XJ_DX-44OJO2/K0M]H"8K^EE9]EN9PI)-];5U->6/++Q6N)M,@H@MB<Z
M032DY#B%>$I:;A*DZ2;-,:0.6UF='1X6;3E%EF0X84]RJIS!SH[HA5>67>])
MK'TY3MHYUP7()T%N-QA, GZVZ1TD9.!.?0JJ19('W7R-2,L!4AG0M267Z3Q
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MWSL-J3X2FU!+=%.JUM,2%(0@D@XPNZ1)G)QR9"Z-0T*FPFIAB0H<BM)62;
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M/->\GH)ZL(D<OA/M,-C3O#T?0&,?>?XOJB8FF7B-Z0_*'&A\9/P^R$,S3O\
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M4ED7XPJB42HWBWU_$3\'9;?R_2N-MO)?GO9-@3S MO?;?;F;QF99<YN%(+U
M]J0*W3LB31E/6U@%F0A9"2RH<3$%%3+&WV]:OO;=%UNXQ\$^:7&13KL@Z:3Q
MGU=<.2LV4P!';;LY"W8JU]NPD7V\H%^9WHS+&XR-QBISJ6ZUJ&@<Q4K!6FES
MS)4M;N#:%R9OE:<R*C-A>+*VZ"K>9*!#J!.8E2N&;ARZ.DV8/I=BT0)V(_\
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MRA?(E(2[S9^(F(0P;H,3!VT9E4=3E?"F %&+2*53>X+E)S*R#-1Q$Y>YL2%
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M@&0X1Q:I;,)0S?'EW(G5X$2G2?%'O?X'OK;=H+<RWVBJ:W;<4\38A,9B+P"
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MQCQ]2BM7D4X:/G;@P+I1C\R$P];*M8R5AF+U03R^^]P/K'T[>4 +'GV6N/\
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M1S.6N.0V5U"&PGDG+9(V2T$Y<B$VW?$ME+ ;%N.X;02TGC^A$TW%==Y"2[G
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M8$% WB\#AE+H/571^C=!53TW.O>H>B=6"LGPRVY2K=5F5;?7 ^M::8V@:S8
M9D_K9KC\_GU-5)O?A>+U-?(;FG)GN("5]$&NB6PC.T"CHNBY*-)(M>5#9:#"
M@1EXW@-(RV=)0*N:5PP6V,0#"QG.Z!3-@QG7%(;B+\?> V\*DAT@''3DU -O
M#"DG@<]:%;J@IY'A8NM@;NB4E3-8E>V>+E4!L@ILC+ND62R$%.D0=A,F4*-#
M,+=(\'P^=!JB:#QF,*;NM3V?<N9PI.^>8SYP^"#?@!/ZO%::LW0XJ/%AMU-%
M7BM-/[GE9U]3E(H4#APNX  8\$>C]"<$$NX674BNCC&&>)&33LBU>ZK,\;'N
M:65RMUS_ ,K;;9@;;\]P]FSZJ"#<RXF,VN&U F23-A\-+33374TS"-=XY4HI
M<WZN9(/6E\FGI. ["97)Z9E2\DI345TXRI>:-:;PLNMX_P +; F<@*0\5;BB
MH B/$=BJ"W26YP'>&+ZTXW3R,% -Y/#,=8IQZR=97OZ&7V3><M+()4,J<N4]
MB+9<B@=M<L9=(NBW&</I*>29U%(55\28;Y%W<K=BYGSI/CO9BLK2H;\)Q96)
MA+!"NCQ-\1P[B:<YB%&'L&XRQZF #@)B\+0P#O#%BCP19N@ IB*SK:)X/0%'
MZ?#5L:$*$>I(H$M2M 7S(SDR0M8&Q[=B"-?-FU4*-BF47,9M9+)S)DES.L&5
MF135TT;#F)Z740Y<C+[IMFE2DHT' "0N>;D\AES,@)546Y#AU3#::HN@.8DQ
MC@C[,=R "?B*\?CZB;?>\;C],;J@.^:)+,\?K(K50IS5<DZ$H5FY)4E,STJC
MD%F14!N]K)R9?(WER:;B>0F#+!&@7 0F>,J&-1!J":&JH8LHVCA=L.LYFUD^
M_>SY^(:(-U2@G=03 95F-+3/<4&G44E>*$TG 6),)A.!@*"A03X1 TU8\/A=
M#=$$NZ$H:+!'JTS],2%GE(;JL\@W/9TLM5[[GKD]<6-[BZKGGJWS:B#?=C7)
MUTLD'A!,ZX:6))5:32L+8BXZU+*^?5*4VZS&0(T7DFPX@RN3AR^D@5 RAEB^
MTJIIPRY7\<X.R[[G_>*<45C\Q.[X@J=*9&Y",:$GQ>FIQJF^,'UKT].-6\G@
MN[;++*?/>MD>1%L@]ZU8)R.CEKEFVD7Q;BN'#1?29LTM5;K^%-!JV!NYF#Q]
M^[FS:DNKFJ5XG,)@2Q!X$3>NF7<Z/Z<:PSA3'?AA. D #]CAEY +3< G1W9
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ME(4+%*B"#'ZL;<2ZVVZC,$N(2XD+;6TL)6D*&=IU*'6U6(S-N(2M!NE:4J!
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MCF*G:7-;KLI!*SI;U8[Y8THX[4EN<QZ</"2=T3>L^,U=6(J\?*))61%I;9M
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HP/C_ +/T80@W ^/^S]&$(-P/C_L_1A")1D0.$;O]T'WOY)/BPA'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g475892g16s95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g16s95.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1L$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     ",< 5H  QLE1QP"   "   < E  #TAA<FEP<F%S860@4F%J=0 X0DE-
M!"4      !!D)F=E^E@@"@<!A9!47#4;.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0&D            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $
M 0/      0 !.$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             ";@  !-8          0
M                       !              36   ";@
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   ";@    !29VAT;&]N
M9P  !-8    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   FX     4F=H=&QO;F<   36     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    ".$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M=^KN^D9[/5KEL0(E/J+C]H:/.9*E#'^\1*_[LGU>C[/DM-F-EFY@.TNKL:X
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %*34T *@    @ " $2  ,    !  $   $:  4
M   !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R
M  (    4    G $[  (    0    L(=I  0    !    P    .P 'H2    G
M$  >A(   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ
M,#HR-" Q,#HU,3HQ,P!(87)I<')A<V%D(%)A:G4   .@ 0 #     ?__  "@
M @ $     0  !-:@ P $     0   FX         !@$#  ,    !  8   $:
M  4    !   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !
M2@("  0    !              !(     0   $@    !.$))30/]       (
M          #_X0%,34T *@    @ " $2  ,    !      $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    0    L(=I  0    !    P    .P   /      0   \
M   !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ,#HR-" Q
M,#HU,3HQ,P!(87)I<')A<V%D(%)A:G4   .@ 0 #     ?__  "@ @ $
M 0  !-:@ P $     0   FX         !@$#  ,    !  8   $:  4    !
M   !.@$;  4    !   !0@$H  ,    !  (   (!  0    !   !2@("  0
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MD96UT=7P%R1358.3E):AP<+#Q=+3UAA"4I+4X24F16+Q)\1D9>+_V@ , P$
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MH91$$E#%34%0I0(<0*;H80#";MZZ_",S#N$%W3>6C5VS4 %TX1?-54&P" B
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M[4+GQ?!!3UA[P3][UAZO7A-V[N_5ZZ+34.V0;N7$M&MVSLHF:N%G[5)!R4
M1,W5.J5-8H 8HB*9C  & 1^$,)NWKK]JRD8W<HLEY%@B\< F+=HJ[;IN5P5.
M)$A10.H554%#E,1,2$-WSE$I>H@(83=O77DLG&G>&CB2#$\@0!$[$KM SP@
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M(S4.X07=(2T:NU:]!=.47[51!L ^L!76(J9-'J'P>(8O7^3";MZZ#-0Y6A9
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MU+,Q8IRAC1OAJ"D]<)1JI'[ADV44>M6AO,.&Z20"8.J#+8RS*$$%VO++(/$
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M>^<I"@8W4>H]XP!U-U'UCU$>H^L<(O!4$"E,0J*12'_?E*F0"F_\10#H;_S
M<(G@(=P$_!2\,![P)^&3N /\X%Z=WKZQ]?3KZ\(AD$3 0#(I&!,.B8&3(($#
MU>H@"'0H>H/@Z? '\P81>122$X*"DF*@=.B@D*)PZ?!T,(=X.G\G0<(@))%.
M*A4DRJ&Z]XX$*!QZ_#U, =X>O0.O4?7A%X*@B0#%*BD4IPZ'*5,@ </6'0P
M  8/6/P]?A'^?")X"'<\/P4O#Z]?#\,G<Z_S]WIW>O\ QZ=<(AD$#%*0R*1B
MD]1"F3()2?\ A 0Z%_\ ( PB\F12,<IS))F.7IW3F(43EZ#U#NF$.H=!$1#H
M/J$>H81 22 XJ@FF"@_"H!"@<?5T]9^G>'U  ?#\&$7@J*)>_P!U)(OB (*=
MU,@=\!Z]0/T#WP#U'KUZ_"/\^$0$$ (*8(I F(]13!,G<$?5ZQ+T[HCZ@]8A
MU]0?S81!00,4I#(I"0G7ND%,@E+U^'NE$.@=?Y>@!A%Y,BD82F,DF8Q.G<,8
MA1$G0>H=T1#J7H/K#ITZ#A$\)+O^+X:?B_!XG<+W_@Z?O^G>^#U?#\'J^#"(
M5%$HF$J291/U[XE(4!/U]8]X0#J;J(^OKUZX1> 00 ADP12!,P]3$!,@$,(=
M.@F* =!'U!\(?R!_-A$%! 2 F**0IE'J5,4R"0HCUZB!>G= ?6/K /Y1_G'"
M+R9%$W<[R29O#Z 3O)E'N '3H!.H>]Z= Z=.G3H&$3PDA."HIIBH'P*=PO?#
MU=/4?IWO@]7P_!ZL(A44BF,<J293GZ]\Q2% QN\/4W>, =3=1]8]1'J/K'"+
MP5! I3$*BD4A_P!^4J9 *;_Q% .AO_,!PB> @) 3%%+PP'J"?AD[@#Z_6!>G
M= ?6/KZ=?6.$0R")@(!D4C F'1,#)D$" '3U$ 0]Z'J#U%Z? '\P81>122$X
M*"DF*@=.B@D*)PZ?!T,(=X.G\G0<(@))%.*A4DRJ&Z]XX$*!QZ_#U, =X>O0
M.O4?7A%X*@@4#%*BD4I_4<I4R !P]?J, !T-\(_#U^$?Y\(G@(=SP_!2\/KW
MO#\,G<Z_S]WIW>O_ !Z=<(AD$#E*4R*1BD]1"F3()2!_,4! 0+\ ?!T^#"+R
M**1CE4,DF8Y>G=.)"B<O0>H=TPAU#H(B(=!]0X1 22 XJ@FF"@_"H!"@<?5T
M]9^G>'U  ?#\&$0B228F%-)-,3?OA(0I1-_XA* =?A'X?Y\(O9A$PB81,(F$
M48>1E9L-BLG&!S!0LE+MZQR2KECL2T>T6=)PL WU_LB/7F)(R13 TCD7TDP:
M*.ENZB1=XW3,8#*D 8?+12RR8AXXSD:++5Y9' 7)HXQBL,4A[,_"#.[,Y/LS
M.[-ON[*PM:X^[>R/1[+3JS68\=KJO?OG"#F-2D.G-252LSNWD(6L6J\+F_4Q
MS S^255[2W#,T2$V:M6]3;,OMBHM1C;!!1L%67;B*ODQ.+.V4;6ZU+-/.+/'
M\>[;I+V@"1XC!Q;A-\(.>H)9VW<A)6CN<JC=LRUH EB&. RCLR2NXA%"8<3D
M0%L\^P;QQOQ>.[BD]0:DM8BEGI:.G<YF;V(QD5VG5ITS*',6K1315\?1L!S'
M.:*6,2O[0OVI7E"9VD\BHAZ)M"C-_?MJ;5U?R,N^];-19-6Q/I?15P@*?%5B
M)3-(M-*ZFBI--PFVB5WJA44R.A4E[K,]^<L#@A2(MHZ#QT["]F[=IY:SDI:I
MO*YXNS%",0>/''TAD#9@<W9FXGXYS;F2.W<'&>C[YQV,QJ'4.G]<935N0Q,Y
MW9[>E+]/%U<?5%[$6E--59CD&*L4Q<(M(Y6\O<=[=Z5F:.*M\_"S4NP=#7Z;
MCM@:Z<(([DJC:XU&?A22\]#Z/BF$C(/_ -K!*2KIP^2AX:G(32<A5'[<L9"3
MT@K8&22!7#"-368"E9QMHPM5"'M^!IX)8VDE"@($1OBI)'XFB")C8XB=P"0^
M8#<3B"ZNBG3.;T=F+L&:PI"&I\='E<9<J//;JZ0JPV)I6Z.III996KU,0-L9
M\7/ %>G=E._&T8%7KB<FMOUFPR^_>)L]%PLE(0M4M&V75EE6C19=A!-Y75,U
M%1BTHY3**3)-_)+HL6IUS$!9TH1%/J<0#)>]%*>4PL@1F4<,E]Y3$2<(V.KP
M@\A,VP<1>-'B=MWZFZU?^I:%VSJ_HYN5ZLTU7&Y/4,M^Q'&115([.F<C5@.<
MVZHQEL21P@Y;,4AB+=;J#<W6KFTXX[:XFKZ;V/-;NN>S=BNX2Y-Z-*KZ_GU;
MIM>1N59W,ZVR1J-2BBUB"DXMT[;RDRSML7)0)(5C$'$& 'MV2&P.*N84L?:E
MR$]RP06&KN]:5YKKSQ7RMMO$#11$'%QFTH$#1L#=3-B.Y0RH:%U-T;%IC.V=
M6Y;/9^2IDX\1;/!VBS&I+&5QVJY-4-"^*K>)U6S6GEALW(LO7LT>U(*9.-9S
M4S7^Q=67ND;>N6OKY8:91>3/,1W8(V$J$Q8;-'L]JOFB-&VW$4^,;.YZPPZR
M<>_CE'D!'2+YE&V,\BV059@^.G\UJMJG9@O6*UJ6"ME\T\@C7D.9FMM&$%T(
M6'F2Q$XDSG&Q<(EQBSMN[=N.P^:T]F,1J;)X7,7,5B=>=*LMRO2QMK(7ZT6I
MKK/AM2UL54CFO7ZSQ0SU7*C7LV(J^4><(WA&<AN[IW66TKK^V$FJ5.;(XFM+
MER/DKY!E=:YJ2DU;*S(ZQH$<,HX@;K$RC>+2FYUG)3CDA$&TRRDU749-)M)-
MM(,D:^A4NV?%*2O):PK390YP:2G'QS1%7A9B>.=O&L1LYOP]8DY1FS&),-QZ
M9P&H,FVM[6*MYSHWCRVO9LS2=\+B#MY+'2Z:P-5[,E+,4[L=8+]Z"Q=D%XH;
MT-CF5[8PV L0#Z1:3ND=K\EE]F:OV-OEONNG:M9TNQUK73FX-M@%JFLR4JQ:
MXMQ:U%NH37_I&SMI&Q&/8D(6EJ-+>]>IO@%D^22<,N/N99[E.SDNWZU0()8J
MO.&WR*G(FKSM$#A6>25B/A-FB<3(V?QKBNKEV]):DU[+G\!G=7QZLQNG(\3>
MQ^!ERHY@<;@&Q%W3^2;'5Y*>%YV1CLY%SR,>/PKAF9I&L-R9Q"M=1:PEVNV]
MZ62?U*UI+>?X\\?Z;#1#5NG+U^+-%5:[(V37E9GBQS%I-1]:=.HZ)=E8-&S=
MP1-@=1HF0[<A>VE3D[=RDDM%J[2XO'011L'%$&U:49JL$C (&,3\$9,#,W4&
MX[<*F],8"Q#J;5.0NZ<AQ(W=%Z)Q4%:(0M4J_:=+,M?PE&XT$(6ZV/DGAKGR
MX8HY!:$WA!B$6BQ1H[<E%A= UR:J^VM5-HGB7KBKJ7/5.@6NS-L6BW-73LLY
MJ&>L<W5K?'ZOCZ^DVCY%HC8X:)BWCJ2>O5K(Q+&'1")@"_7#'@<-VF(8:")Y
MJ6,:U>GE8S<Z1RR12M4:)F$Q&0 %W(B<V8=ECG$0ZIPU/0^-MT-2:<CI]&.F
M\<^6TWHR/46HKV7AW&_IB[?LXW+U=/5Z30P2@V1J5JL\MJ:9\E U5V:L."^F
MK[4[EJ65V'K:SUQS5.-6TJ>X=6R&3(K"6*7Y06>>+"GD$$ B324C6%&DFDI$
MF\G(0RY7<<8\8Y()NW3E"Q#8HE9J3Q<C#W8'>>)V:.8\S,;!QN/!QE"[&+@^
MQQ%Q#N!;J4Z)-+9C&Y'35O-X*]0FQ^A=08N23)01/-3NV]?W[SU"FA;M9YK%
M%X;''5?D3UW&2!W@)F7Q:@IMUTQ==+[!M>K[I.5J CN5U-"LUVN+3=OUZXN&
M]W%HJUS84-  GW5;L]7;$@S2]>CGHQS9U%>;*WBI RV?-&&?'S8^W-2LRQ0A
MEZ_:\,!26*I2Y!Y(K 5>J4H98FY?,B$F$7#=V V=_G36)RVF,OI;,Y# Y.SC
MJ<727BNTZ5,K60P9Y;6TF3QF3BQ$>]R2AD<9"%/MBA!,5>,ZK2@%68C&U<'3
MKC>M7R%RIU2V'38:A]HYM;8=KIVOH.GV+8]9KYX.2@TIB)J$G&6^LST[5I^9
M82\I6F,7/O&YRR(0:*\M&M%B4D4$]BF=B"O:ACKZJMV9:]:*$[<,7*Y;&$!#
M-&<D$ABYQ",G"_%P,[@SM:U;%97,:?ERF+Q^<P];"].NI<[DL9A:6(R&=HT2
MKW*8VZ^*L5LMCKURA=N5[MFA!5O6 =K#TADNUXG4X^)53D$]A[UV:LIO>58W
MI+7$2A<=XU^IZ_?W=Q48Z?(K*0^M(/7&N9V"1B49EO"+V&U1H/+.DV9D8HEC
MX9!PXN/"0EVWD[?#D7&QVH#6,@$,!62A"1G..K'6KG&,;&(/+(V\O5PLS [O
MEOHWQLXYK5^H))M97(\R. JQY/5^/QN!FRA8JO>8K%73U/ :?NTA@&X%.2[E
M*K3Y 8(6@'M:K%)+6&_JE9Y[=W%Z;A8"5E8BL.][GL4DQ9+N64(6=TW-0\,:
M3<)$,FT"4E5D8]B*QB^9>*$02[RA@+G=E(9I,CB#CBD,(ARG,, (ACYE$@CX
MR9G8>,_&AQ.W$74V[J8U9C;]O5O1[<JU)YZN.LZJ*]/%&1Q5!MZ9N5JSSDW5
M&T]@QABW\G(3"W6[*/%*T_;('079O0+;7TQ&3FN-CZVF;Y&I02[>2IZ*NM+X
MVMDA84BH%7BTU)R400F5W?A@H]>)$="910H#%0TIPQNE@&K*,E:]5DL"T1"<
M E%.\Q3-PL48N1,TCGLW$[,76[*QL/I;)4M&= ]$,+8KV]/Y?3]K-5QK.$V+
MWTKFX<I-<%FXH>+(6@CM$7DIYF8]W)21Y?QLZXH^MI^#K-EMI:!R#TEL*>AJ
M?"/K+9#5BJW5D]G7<7 1:2\I+K,61C.C,HULY>*))J&20.!#"67SH2O!2FBA
MFG[5RE&U+'7C>67DQ&3&01CXXW%B9]A9WVW?N,[M>_2;!;DPV%MU*-_(MA]:
M:/S=RMC*D^0OOCL9G*MB]+6HU@DLVS@@8I7@KQR3&(%RXR=ME$27JM]A'=IV
M*IK39,C"QO:)UK<HQL-2+!*6I]K8^IFM>6LT34VC(\_+-F<I(D;O$(]@X=H*
M-GI#H +1QX<$\-J,Y;?:=PXPU4%YP"O(\Q5"H%#S@AX>88B<C,_"+NSL7_26
MV.;F-R],LEFSP>;FJ0]-V-U5R:F*NV\C-@?H<I4CR%;&5X9+]@(K!N$D4-<Y
MP**5GBWC/AM=8M2;"9Q_(S4UK6Y7RLIMC<NP+7 5/6NN]>.-<;#KM\L*4M6)
MQ;<MAU!:R:_>UN+681TX>UV^,E:HXKZ9Z^P\'T6B:EEI6!#*4IPS4IW+]F:*
M&K6K]JVH[$K20R%=EJ3=K. \+2O+*)0.+< ]3,K:O:8ST4.NM,Y&UTD33ZDU
M7G<C2QV T_@9<%FJ&;O#:Q]M]67M*91L)+CZIP5;993+UK>/DQ_%CX7C[4$I
M)06F'K73/-N,L^IK5;7]_P!TWV50A8UTWK=XOM:]S="91\M5+(\9)H.'28QT
M@]@%B(%CI"69+-4TDQ=K%R2BH&V.U$$U&>P=C)62&-OI-BS#RZK#)#*4?CMG
M$SB=A<#D$A9O'.RR!6TL<6E^E>"_IS(Y&7.ZGS-KM2I+'1R^9I/CL/7AL8Z]
M*,8/.+5I9*)/P0RV87!F'F$JBXK$V4;;5J7?N=B7[6H:YC&#+:&]-*I:BV_%
M6!C8%1::W4DUZ_4)78D SCEY"7>3*M;)'QLL*:#66>J/%2$[\+VWV_,Y]M6*
MG:@B-S(T&I70E:9^&IQN$9VHQ#B,S<. #868NO9ZOH\\7GU%D2FGSF<P/B)6
MAAU!K#23:7U16O07#X,$4TF.P]C.T8X9)[9W"QHP062X([EDY9&#(1ETK,R8
M1,(F$3")A$PB81,(F$3")A$PB814)2_NAL'V[<_5FKX15WA$PB\"(  B(@
M B(B/0  /6(B(^H  /A'"*DJY?Z3;Y"QQ57M,'/250FSUNS,8N1;NW4+.)P%
M7M1XQ\BD<3I.25R[5&:,  8H1UDAG(F[C]N)R*KL(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81<4G.P:TX\K"4S%*V2.BHV=D*\G(LS
MSC&#F7DK'Q$R\B2K"_;14J_@IQC&R*S<C-\\AI5LU656CG9$2+E<(F$3")A$
MPB81,(F$3")A%Q4[.0]9A96Q6&29PT%!Q[N5F):07(V81L:P0.Y>OGCA0030
M;-FZ:BRRIQ I$R&,(] SXEDCAC.64QCCC$CD,GV$ %MR(G]1F9MW=4]JU6HU
MK%VY/%5J5(9;-JS.8QPUZ\(/)--+(3L,<<<8D9F3L(BSN[LS+[&;QK(,VL@Q
M<).F3YL@\9ND#@HBY:N4BK-W")R^HZ2R1R*)G#U&(8!#U#G(D)B)@[$)BQ"3
M=;$)-NSL_JL[.SLNV.0)8PEC,3CD 9(S%V<3 V8@,7;J<2%V=G;J=GW7"3UQ
MJE68STE8K'"PK&KPA[+8W$A(M6Q8.O$!V8TW*%.H"C*+Z,'W=?+D(W.+-T4B
MAA;J@3KEL00C*4LL<8PQ\Z5R)FY<7COIAMONP/PDS$[;.XNS;NSJDN9/'8^&
MY8O7JM2''U"OWI)YXXQJ40:0BMV>(FY-86AF=YCX8_I4GCO&%MSS=PBZ00=-
ME2+MW**;ANLF8#)K(K$*HDJF8/48BA#%.4P>H2B AG:),3,0NSB3,0NW<=G;
M=G;[3MUJL$A,1,'8A,6(2;K8A)MV=G]5G9V=E[LY7TF$7QH2#!TZ>L6SYFX>
MQAD"2+1!RBJZCSND2N6Q'K=,YE6AG#<Q7"!5R)BLB8JJ8&3$#9\L8$1")"Y!
MLQBQ,Y Y-Q"Q,S[CN+L[;[;L^[=2ZPFADDEB"6,Y8'!IX@D$I(7D'CC:4&=R
MC<P=C!C9N(7XAW;K7V9]+L3"+@7MHKL=/P=5?S4<TLEE;2SR A%W*:<E,-8$
MC529<,&IA!1PE&)O69WATP$$"N41/T[Y>O44\(2Q0%( S3-(44;NS'(T3,\C
MBW=?@8F<O69U2R7J<-NK0EM01W;H6):E4Y!&>S'4:-[1PQ._'(,#31/*0L[!
MS XMN)ESV=JJE:/9ND-?[:=5Z4M32<:V"J>DB5RTU&UV6D6F(;32;=*8CVU@
MJDI$29HR5(T:^?C5W"S)PHU;+&0\=NDH2@NXVK>>(YFE&6'C:*:":6O,#2;<
M8C+"8%PGPMQ"[NS[*W<[I7#:BEHV,C%:"YC>V&H9#'9'(8G(50MB 6X8[N-L
MU;#U[(Q1<^N<A0R%%#(4?,BC(:BU_KRD:BI[.G4:&;URKQ(OWH-RN';M95V_
M<KR4M+2DG(N'<E*RDD]7</Y.5DG;I\]<JJ+N5U#CUSNK5:]&!H*\8Q0AQ%MN
M[]9.Y&9F3N1$3N[D1$[OZKJLPV$Q.F\;%B\/4"CCZSS2M&)RRD4L\AV+-FQ8
MG.6Q:LV)CDGLVK,LMB>4RDED,W=USU:LU?N4#%6FJS$?8*Y.-$W\/-13E-Y'
M23)7KX3IFZ2$R:Z"G='NJ$$2CT'H.=L,T5B()H9!EBD;B"0'W$A[F[/ZK=2K
M*-ZGDJE>_C[,%VE;B">K;K2#-7L0FVX2PR@[A)&;=8D+NSMULZYS.Q5281,(
MF$3"+@K)9Z]3XA>?M,S'P$*V78-7$I*.4VC)%Q*/VT7'(J+JB4A5'LB\:,FY
M1'JJY<))%ZF. 9U3315XWEGD&*,7$7,WV%G,Q &W]<C(1;UW=E2W+M/'5RMW
MK,%2L!Q1G/8D&*(3GF""$',W86*6>6.*-M]RD,1;=W9ESN=JJE\4E(L8B/?R
MTH[081D6R=2,B^=*%2;,F+) [EV[<*F$"I(-FZ2BRRAA I$R&,(] SY,QC I
M#)A !(S(GV81%G(B=_49F9W=_677--%7AEL3R!#!!&<TTLA,$<440N<DAD^S
M"  +D1.^S"SN_4O7#R\78(F,G81^UE(:98-)2)DV2I5V<A'/T$W3)ZT7((D6
M;.FRJ:Z"I!$JB9RF*(@(9Q'($L82QDQQR )QF+[B0&S$),_JL[.SM]I?-:S!
M<KP6ZLT=BK:ACL5YX3:2*:"8&DBEC,7<3CD A,"9W8A=G9?#"6JN65>>:P$W
M&R[BKS2];L2+!TFY4A9YLV:O'$1(E3$1;/T6CYFX4;J=%"I.43B'0X9\Q3PS
M/*,4@R/!(\,K"^[QRBS.X%ZQ,Q,[MZSLNJK?I72MA4M063H6CI71AD&1ZMP(
MXY3K3L+ORYQBFBD*,MB8) )VV)M^?SM56F$3")A$PB81,(F$3")A$PBH2E_=
M#8/MVY^K-7PBKO")A%\C]H1^Q>L%#=Q-ZT<M#G%%LX[I'*)T3&\N\1<M%^Z!
MQ'P73==LKT[BZ*J1C$,18P.#79?4'A'N'<^W*Q=I*RO=GK&B8^,D:KKEFC#U
M/W+:E:)M8]U"T:%?4,A;91;3)CKW4KJB:0+"V"M1Z6LDY"BUZ4:D64K")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6(N@=FOL&F]H)8
M^8SOD))2]*E%4)9CJ)<U]5JS1\^E>09W\7$U1Q?%(RNNZ\QVC7YB$M[F<MT%
M(VFS[Z<M-0TD;Y%OXHBRZ81,(F$3")A$PB81,(F$6*NS[EWI5FW-[>"FRY23
MK/&RW7*MZ^U"C7*BG6I8PZZJ\@R=W"9]">ZIVR@IZR-I9!..FXLY&D>]2>NW
M*#P0;69+>R,39_(O<,H<58L0UJ7*AY1[P1\!3&P<TACDE$V82%]@=G-V-]M>
M<CJK5V,AZ7-7GG+%G'Z"R64HX/3$='%C0L\.G<5;CERUOM+Q3DBJ7L@-D>U[
MU5QABF&:24#9H[6[2OW(5AK*_P %:?V;[-3;YQWW:2\OMT5S1=590MFCM<2$
MU%3^M"ZT=MIE6%>N47,.^K,FC8 9,W\;)EEB*MGAWE)<L90*LX3=ORP6L9>[
M9>^&.B8)AK.8R4VJDTCQN[.)0NTC"+L?%U*W=0YO6L>G\[2R ZQR&+R^@]8C
MEY]68W1^+AI7Z^GK-NM<P7T/%%:.K-(,M2:A:&^\4<U6PUMBBG*>X-YVOL$K
M>5@-?[.W0=UK?2.MW[.IZ(UKKN1B*/8G=!"QC*;JOFV(60@':<HT&/>L:G!3
M,,X:ULAW;QLLZ?MG9.ZQ>M,!QUK=]RIXVI($&.JURCKR]J-+QY&S; @=I&=B
M&&,P;E!N[.3]=PYG4.:=[5'!ZAU4TN$TM@S'&Z/T_I^Q7Q%^;%%?[9U3F=4T
MK%"1K$#U9(<;2N5)8J#O//$13Q6([-1E[V3*1?(ODA^R/8FMU=]G+H[:*D*G
M$4%Q3QLDU6-R.DT?13^E.GRD/!3C)U8(9BK*G,:1FI)M-N)F%+&14=21V;1A
ME<GVS(TY:;QMEQX*Y0E++'=9V<"@?Q@$+R ._44AL;F'  V;6S.H9H-<Z_'/
MWX<M)T!Z2U,U,:F"/%#D;6*U=8 &KS8>6P56C>BDO589+9D\]N>*[)<IM7JP
M2VV%R+O>DY[83:R/SSK&[<?:ML#0#)1E%M0':#):+U_8*"T,U9-SR"DW:[=K
MRP-&[PSM5 DQ,$;^''MTT$)BQE;./DLM,;R#:Q=>UC!X0;]N"P5I:P;"SFYS
M2UYMBWV8SVV%MEE#/:WR^E+^=CNRM;AR>C*.9T5 \->-RU!!-!A+N%!XX@*=
M[>2RFG[< 3/*8]MW!C^D1, 6FD=I<EY'8NQM4)6;>KR1T)2M5PBUFT[1M'2;
M>W[-L^OV-SG[AL=#8B;?_-M9Y(I1<16*BU@62C-C*N%9<'@MBL*0K>7.S;IM
M-D"DQM:G&\M&''FTMR:LT\D]MK3!O$Y%PQPP\ N N3DQ/U6M8U)KN;/YW38W
MM9R3:-Q6FZ4F1TMA-'60RV?R&$ARU[*9L,X#<- Y+$=:MC\5%0CX(;A/;YO*
M[6R,Z/M=LO.H-;VZ]Q+2"ND_3X20M43'NFCR/9SZK-,)4K!RP>2#-5BH\*JN
MS\!\[(5LJD3S"HE$XW5CIIK-&I/8 8YY8(RF$"$@:1Q\<X$!$+B[[D.Q$VSM
MUNLXZ3R.2R^F<#D\S4CHY:[BZ<^2J0R1RPP7CA'MD(3BEFC*+G<;Q<,TK,#B
MW,-VXGQLSUDO^G=B<W+14-BV-:?MO(KC]JZ'-9XZER%6I[G;E/TZP0NZ[)E4
MHM^]=4*)EU*[6&C^8/$/(YG&)V=I/39W<ZYM*6:S1LZAFKV9>;-E<;3C>483
MBA*[6H;6"'E"Y%6 WBA%SY;@P-*,DG%(^"+5[-:7S_2SD,=GKTEO)ZWT-IZJ
MV2KX>7&XN34^/TQ6#+%'!BZMB:3"U;94\?#/<*M-#% V1BNW"ENG+&DS&Q]:
M<DX?2-EVG8-P52]:=L^QHU_=(JELKC3I^DVBIP,DD=[1JQ4HY_5[2C;BK1Z,
MC$G>Q4C#K-6T@X:KBDWFJ\EJGE@QTMR6]!8HR6@*<(6G@EAEC ]R@CB$H9N;
MXQB!W A81)VW62\59SN"US5TI?U%=U/C\QI?)YV"?+5L/!E,7<PN2P]">-SP
MF,Q-:;'Y(,R,D+3U2GK6*4H!/)%*P0_'M.3VC:N5E(TW6-N3FL:)(Z+ME^LA
M*K$TQU:I27B+K"04;Z%D[?6K.WBRD)* :35+&NP.S1\LBFV7=^=1^;I7)\U!
MCX;TM.L6-ELS<@8'G,QL-&/+.:*5@\D+D["[\+;,S<3DW3J"QJ'(=(N)TQC]
M2V<!AYM(9/-7QQ]3$S9*Q;JY:A3K]J6,KC\C%7 1LEVR[UI>*-F",8Y#YP14
MJNW+7.;>TY,[$M,*YG]-_M^->26RI",1C8.>9ZM/4F;&\S,1#^6:-2C'(-CV
M5G#>6:C(L90L<FT(9)!&$AO3R7J,EJ:,I:#ZEJE;,.".1J;1,-B2.-F9FX6;
MFC'U.XEP;;LRL#&:DR%O4>F[6<R-0[>EVZ9,)8STT 5ZER'3TV(BAR]NM6Y<
M43]K!&^2BJ\N%K,-IJXP@X1AP).3VY]>V#2ML&U;WV16+[$[#6M9MGZQUMKS
M7=V<5_4%MV'"OM/0T; P>TX)J,A7VX,_3Y)!H_@7:0R+M:14;K.>MLS?K24;
M#39&U%9CM%,]VK6K5+!15))XRI ,<=J*/B%C9S8F.,O'%OU*@'7NJ<+=TGDG
MR6L<_CLQ6SA9)L_IW3^#PF6.CI',:BJS:6JUZ-'4]1GLXP(X!R V(I:,K=L2
MG9*&:63.MIO<,'0]1[_N'(<MR:[!US(WFWZDG(2B14'//I76SV^0%;TBM!0$
M79V,I756O@KMYF9MZD[ -)-\[32?)%=)S%66]%6I92?*-.-FH=FQ2FC@C"4C
MJE9AAH<L!DC.)VX38CGY@"1.S$VZOO 6]45</IG664ULV6BS6#ER^3TU/2PM
M>E<FM8&;-5*.D)*=*MD@GI%$XL%VYEBN8^.Q-*PS THV"UKO#DY-PFDMC22.
MX[&QV\Y@1V'$6RMZ-K>DXZI7R">/FSW5,E"226Q2/:F+B/5C"34E/O[=%MI(
M\G'M9%5$64;7R&7.*C;/MV4+KAVT$\>/AH-#8C(@>D0'VRQP[CPL;F<XL3F+
M%W+-TUK#7]ZOH[-SQ:JO1:FEQY9RKD<;I"AI&KC<U4.<9M.6Z<S9YSQCR0%5
M>[:R$F4J1V'G@BL21O!\_'*3VQI[C-PUV2WV_+6FO7.T:PUM,ZB6K]*"I)U#
M8$VXK44E57C*OM[LC=*LJX:S,J_D+9*-999I,LU8QDP(R18<8P[M'%X.V-Z2
M:*Q:KU)*+Q0<GD6)9(Q&%QB&=K$3[&1%*7'L0N+"++KT'8U)IKH]Z*LZ.II\
MC2R=O2^!M::*CB!QC8S.V1Q=5L=-#1#,CE<6\L-RU-/E+4-EX;\;U88>0-:L
M%]P;S9\>$>: [@DU@5OC)P?0ZE>HQ==_L?R.VV^O"T,CTE7"_)WQM&N/-$LW
MNL.92S)^15A#1AC- [BO9(,7XO\ ;QO^VF=\=RH.U>U2NM5:LS\OG]L,SL33
M\W=S\8\;LI4]3:NCT5'TI?1/,8GEX97T<5+"M@O$6QJ2/"MAFL-C/%ULU%6D
MXFO^*KB65'E%2>L[P+*5*+J-XJ1<HF\-9&/=KI'Z%,)%$VRBB9NZ8!*/=, #
MT, E'IT$!#U9>4CN,<A-U.($[/ZSL+NW=6P<I.,4A"^Q#&9,_=V=A=V?KZN[
MZZQ4ZIV5R&;ZWX8;QMN\)VX.-Y[ IM$O6O7=2U^PI1Z]<(JR@PD88\/5F%K8
MVMDM#L95_(J65S'R#YP]:MXB.B?+,$+,J7,F-7 Y&;(2SOD;D-6Q6*&L,')F
M:5@*/@B&49A>-C(WD?C<G'A$&8%KOIO.ZW' =%6KLIJZWDY-7Y7#XO,X23%X
M*#$%3RU.\4-BJ57&096#)1%7KV9YGR4M2:<K$<5*O5**"*EZQR-Y.VJO1^\8
M..W._"1V@=HC0G-<T=%<??V-4]E'J#NN'LS]^UV>VN3.!2<.$K.XEB*+W5(D
M0:N&B%BM,ZHLIEYH1R,372XKFS5RCQX8SM3MKDE#S3(;;3L&_#.3[E,PAR^$
ME&8_7>O\E2@U73JZNGY^H7C#"GC=(5M%>(+:@\2I:1Y&64=1AE(: R2M?.Z/
M%FA:L6.>H7:Z_%?Y'\G;G7G6[JVPW*X$VU)B+BJ(%8T@RX__ +'D%LMU2G5<
MEK),2#/9Z5P/%1[ETYM!I9H*%M$L6UKRD.!$%T64R]B%\C$UU_VX0A78,>.,
M[5"T\!0G+(0VN>["[\]R9^9L Q\#LOFCKS7^6I2:KH5M6R.^H[=:MA6QFD(M
M%^(E+4$N'EI6LC9E#40Y1ZM>26;(/<B&'+?M:.@50.7+^-I2FV=S<7;+OF8W
M!+QL/,;RC(9/2QJ_24J5#TVF<E8ZB1<&H_\ <^%Z"]>8@&]@?32EL,V</W"D
M($&6.\ R?7>.[D,+-DY+T@QR7Q#Q/Y4#01UX,H->.)RY?/[8XXVE*7F^.=VB
M<.'K7WJ"SJ35&@+VL+&I[5>M:UA6J#I5Z.(;$5<5BND&#"05'G[0;-^+#]I#
M;GM'E7A>U(=9J(P,+-SEOW[R2MLYR/LFO0W-'GTWL2Y477-?J=2TJ]TV\/KU
MDU%Z?;\M>7S6]JEMCTRRS]Y!RE;0JU>=L)"),\=)+KN.^?(Y:<\K-5>Z#T+4
M]:J$,5 J'[6$>/MTK!A._.?K(@(&K@3$'$[/OW9/6NN\C<UU>PD>K(BTOG,K
MA\#0QF*TG/I:P>#ACYCZGMY>4<VXY2RYE/+1M8QL?C9*\]7FS,<DM;6^R[AW
MY!<M7[;:<SJ"(U)24:U$ZXC(:B2\3*2$WI&'V#:)#8<E.5^8F9&-D#6A6MQ)
MJO.UU)DRBU9EF\7>+=XG=-+?R<>;+MV2A'1KM$%4(ZQ@124!LSE9*2.0S ^:
M\4;QG&P"/,%R?=GG,G?U/J^ITE2Q:BM:8KZ9Q;8ZM@H*F%MU+%BUI"EGKUG.
M6+F/LW9Z\I9-Z%?Q,NXX8XJLEF.624V<)I<9?P<="?F;UI]38;+AQ'G5C/>%
M3P$:RAH+T#Z.^*^!_)=509EMM;NE[](4:I;%]QIIWGO9-.'F6E3J,@[CM<MM
M!O+BX9-&\A"K,W<TTD&AY*'F)A&263E$6!98DO"HN(9U;17L@=F2O!:[7>74
MLM'F#! 3C6:F\CLS'&XD;.+D!FQ/QL/%Q"W"L56]2:MM9<L1C<XV,>WTRWM*
M/:#&XV>6#3\>@;.;D@A">J<1W(K4+V:=NR%@ALC"-H;=(9:4TI>.E@OJ&P.0
M^I;M?)?9375%LI*=4MMFC:W'6I:$NU&CK,I$SIZE"5R#D58J0.Z(UDD(5BNL
MV7(DX(84"&&;Q4MEK>5HV+!VAI35N1-*,8S/'9@YO+D>((P-XR9]CX!=V?9V
M9F9FOW1-O,QY?6FG<MF;6?#3V2Q38[)Y"OCJ^1*GE</6OO6N/BJ6.HSE7L%,
MT4\=* RB,0D8G!B>6.3:R(F$3")A$PB81,(H#\46NQH3D+S/JVQ=L6;;#R)L
M&DY)@^FFS.&A8!*RZ^>RKF"IM4C!-'5FNM#F22;M2KR$H],D+^=F)>477>J$
M44-]<M'4SS9X_P!3:W^VZ]UUJ[D\QU-+TE*K7F-4W)9I[4FS7-AMDS)I0I8Z
M2UW3)U.K5"FQ:+IPC8+,[N-M?MSPE>JLL)<MMU[^L^WLK,U(NUF+)=VA'/99
M9$""2/CA8E>N1,H0@E0&2>QS(!(4PJG\=Z@'AD/W!,IW$SEPK9:[F7SV2O!5
MJM/QA7%Y=F44?JUP2,Q+6:WT(Z+'V!^J)C^&7N^53=%^W)]XQ?MOAD^Y]WJ_
M/O\ T*XZ#]RL[<ME(:3:I( J*;Y<\2+1X*:A2%*V*WE'#THKE$54O-,VP F4
MP+"BIW4S$^Y\GYUZF\F[6;.5U("8:J-P 4F;A2$%R]$0$1!L9M,N&A1+TZ#Y
MMTU#J(=!$.H@7'W'_H_.L&';<;_W7IFE\=I'4NP-@:C>V.R;':SQ*U83PCV4
M;QD=4CQY)%6!DG*#E%N=VY5:D,Y4%(7"HB4ACF#,T]#F%Q.9LYX<KCJ>0&"#
M'E"UN )VB>22VQN#&S\+FP"Q;=WA;?N+6;LDM3ZATUC]*28#,Y'#G;N94+)8
M^U)6*<(H:11#*\1-QL#F;BS[[.3[=UUKU?M_>;/^]/O+](=A_MN9V^@C2'V-
M8;^00?Y%J?\ LI](_P!FVI/QI:_SK9:[%7>.W=S<?]C3.V;;?=H3#+=4A#,K
M/:IU*;/$1)*/27I(L%Y:6+)IM4G;QV\!!HT72!5ZH<O50ZH%UXZ7\3C,1G\=
M7Q=&K0@DP\<TD52$(0.5[MP'D(09F<G  'B[NPLWJ,MR.QSU#G-1Z1S%O/96
M_E[4.HYJT5B_8.S+'7'&8R5H1.0G)HVDED-A;JXC)^Z[K,@B_<JOE6AX>2;H
M)]_N22QXH6*_=$H%!(J$FO(!X@")B>.P1  *;Q!(;N@;$ZV"^Y\GYUZFTD[7
M1>*J0,NT.U)WD6[E2%%:0'HH/ALQ:S#E I^I"E_RY9D3JJG[_H"HIEQ]Q_Z/
MSKP$F[%B+ST!, N"OAA&"I!^>,3U?;P.$R,=X7K'U&?@MZA^T_!U+G[GW.K\
M^W]*.)-V@V:KIP$P[4<%$56C=2$*Y9" %$"NA=3+9J8PB(@'DW+LO4INI@#N
MB8N-_M/_ $?G7M7?N47C=J2&DW**P)"I(('B09M14.8ABN"N)1!\(HE*"BOE
MF3@!(<OA"JIWB%+G[GR?G7DCYP=^=F,1))H$ 1+*'/%^04Z$*;H0A),\D B(
MBF'B1Y [Y3"(@3NG,3[GW?UZUZV\BZ6!X*D'+-!:D,9$'"D,89 2]_HFS\M+
MN0*<_<*!?/"R)]M)WCE %/#+C?[3_P!'YU^22;LS%5X,!,)KIJ@F6,.I!^>7
M(/A_;TCDF3QP)!WS=06?I+?:5.B(]4O$)]Q_8ZOS[(M)O$FC=R2OS"ZJXF!1
M@BK!@[: 43=#.#+32+(P'Z )?*O')NAB]\"CW@*3[C_T?G7L<2#E%=HDG"RC
MHCD$Q5<MU(@J#$3G I@=@YE6[@PH@/B*>30=@) $$A5/T()/N/\ T?G7Z\\X
M](BR]$20-P#KZ6[\7Z.'[2"O0"!)C)]>^/E_7&@'C (]? Z+"7/W/N]7Y]_Z
M%^6\@Z64=D4A)1J5L504E7"D0*;\2&,!2M ;2KA4IE0 #)^=39E IB^(9,W>
M*4N/N.WX/ZG7K2DWBC-PZ-7YA%9$Q2IQZJD&+QT!A( G;F1FE6(%)WA$WF7K
M<_1,_=(81(!R;_:?^C\Z*2;LC%!V6 F%5U5#)GC$U(,'S8H"J ++G4F4X\4S
M F42@W?KJ]%DN\D405!(GW']CJ_/LOVXD72 M 3@Y5V#DI#+&;J0X P$PD 2
M._,RS83&3[PB?R(/""!#]PYQ$@')]Q_Z/SK]F?.0D"L@B)(S<P=1E2GBO1Y/
MM8J=#$-)ED^O> $?>QQ@\0P#U\+JJ!<_<^[^O6O"$@Y6=.FZD+)M4FX+"D]7
M/$BU>^$H!" U*WE7#PHKE'Q4?-M&H F @L**O1,2?<^3\Z]2$F[6:N7!X"8:
MJH=/#9+J0@NGG4/6#8S>9<-"]WX!\VZ:AU^ 1#UX7'W'_H_.AI-V#$CP("8,
MN944QC"J0GGDR^^^WG.:9+'"D/= 0 C\ZWOR]4@'O@0GW']CJ_/LOTXDG:";
M(Z<%+.S.DP.LDW4A2J1QA*F(I/1=3#9,RA14,418*/4^\BIT4$HI&5+G[GR=
M7]/R;KV*OW*;Y-F6'DED%.[WI-(\4#%'O /4%"+2:4B/<Z !O"8*AU,'<$X=
MX2D^Y\GYT0?.57JS0\/)-D4@.)))<\4+)QW#%*4$2MY->0 5 ,)R>.Q1Z%*;
MQ/#-W2F)]SY/SJV=]WKJ_4T<WD]N7&JZG:R*J[:!/LBZT2HDLCMJEX[IG!.)
M:TH,W;ILD9$[A)1RW\(CA$YQ!,QC$D*&)RF5*0,9CKV1.$1*4:-2>T40D[L)
M2-!&;@).SL+ELSNSLW6HC+:@P6 CAESN9Q>&CL&4=>3*Y"GCPGD 6(PA.U-$
M,AB+L1"+NXL[.^S.K3_M[>(/D1>?MD-#^/XOA^C/V<=-^>$G_OP/[O?1WA?\
M!?@MZO\ 0_!UDOH/U9W/H9U!^)\A\O:^R@OV1^C[[.-(^Q]$F&_\W;^E7=HF
M[=<;6A5+!J6TUO:\8T>#'2[K7-QHUM;04F#9!V$9+OHJT+1K=^9LY27!LD]<
M*>"<JP@"2B1U(N_C,EBY AR>/NX^60.9'%=JS59#CXG'C )P B#B$AXA9VXF
M=M]V=3V)SV%ST,EC!Y;&YF"&3DS38N_4OQ13<(GRI)*LTH!)P$)\!$Q<)"6V
MSLKCKOW*+Q!J2'DG**P)B>00/% S;=\YBF!<KB40?B*0%!13R[)P D.7PA4/
MWB%H5+?<^3\Z)OG!WZC,T1))($ 1+**'BQ8*]"E, )D3DU)(!,(B0/$CTP[Q
M3=1 O=,8GW/N_KUKRQ?.'9W!%XB1C"HB4$U7QXLY'743@(MPCY-^H % H&-Y
ME-N/10G= QN^4A<?<=OP?U.N1PN4PB81,(F$5N&&I->1S79+!*M,W$?MZ8DY
MW8L?(J.9-C9Y"9A&-<E!>-'ZSANFU>PL:S8+,6J:#,R:9C> "BJIST@T:H#;
M!H6<+TAR6@-R,92EC&,]Q-W9A(!87$68>Z^V[NH6+3V%ACS<(T(2AU)9GMYN
M&;BGAR,UJG!C[#SQ3$8<$M.M# <0",3@'D.(B=[1Q?#?0L8A)M5H"S6%L_IL
M[KQFWM^Q+];TJQ2;*S)'SE;IA;%8Y'W(L9%BFFR7/ BQ>>3219E=%:HI(DH0
MP&-!C9XII6*"2J+36K,K0UY1X)(J_'*_(8A\:Y1\)\/C6+AZE;5;HQT?7&Q&
M=*_>CFQ5W"1QY7-YK*A0Q&0B&"[0Q8Y"_8;&06(0"*3M+DR/$ 1,;1 (-]LY
MQ'T=8)F5F7L!8&X6.&@("X0<1?+O!U:]1=6B$H" ;W>LQ%@90MJ&/@T4H?OS
M#-T9W&D(S?B[033(3ZDP6.E,C**5FDCBBFCCM68XK 0 T<33Q!*(2\$;,&YL
M[D/4?$R[;G1QI*]<M7)J5P'R%6I3RM2MF,O4QV9KT*HT:@9C'5;L-+)\FF(U
M&*Y#*YUP"&5S !%O4XX?Z#<,F<:-4E4(UIJ<='J1S.ZW5E'RFL",92.:5F>9
M-)]%M/$BVLU)A#R$ND\E8E5V=PP>MW $4+P^!QCL(\F1A:GVAPC9L"QU6$Q&
M.1FE;F\#&7 <G$8.^XDS]:^3Z--''%%!XFV K1Z9?1Q5HLKE8:UG3G(L5HL;
M=@BNA'=&M%:L-4GLC+9JE,<D,P&[$UR+CI765_<:W=V^JM)IQJ2P,+10%7+A
MZ0T%-1K8K5FY#P7*0/TTB)MU19R(.V:CMFR>J('=,VRR57/CJ=EZCSPC(]&0
M9:KNY-RS!F$7ZB;C;J%W$^(7<1)V=Q9VG<II? YJ3"39/'16Y-.7HLEACD*5
MGIW( Y<4H\!BTK"S ?*G:2)Y8H9G!Y88C"E=B\9]3;.LCJW6&.LD;896%;UJ
MQR5,O5TH:MNK;0S@S6!MY*A.PR-EC6OFW:;5.63<JM4'3ELW62;KJI'Z;6(H
MW)2GE"499(VAF*"Q/7Y\3=R.=H9 :469W9N-G=A=Q9V%]E&YO0FG,_>DR5V&
M_!>L5(Z%ZQBLQEL,63H1%(45+)MBKM0<A7B>:9HPM-(\832@!"$AB]Y*[7H.
MI0,-5JS%,H.NUV,90T'#QR)6[",BHUNFT8L6B!/>I-VS=)-),H? 4H=1$>HC
M7Q11P11PP@,<40#'& ML( #,PBWVF9O9]=7/2I5,;3JX^A7AJ4:->&I4JP T
M<%>M7C&*&&(!V8(XXQ$!%NXS,K0V+C5INV6#8=DL%7<R3S:T'&0-_8+6.RDK
MUB1A21B4+*+UI*73@FMFAT8:,1B[4P8-;$P29HD:R20 /6AEQ%":6U-+"YE=
MC".RSRS-'*T; T9O$QM&,H-&##,(M*+"VQMUJV[NA=,9&[F[UW'R3R:CI04<
MU 5Z^U&\%5H&JV#H#9&G'D*HUH K9*&&._ ,0-'8'9E]^M- ZWU3-2]GK;6Q
M2=KG(QG!/[9=[G;+]9_<]'KG=,*ZTF[C,3+^/@FKE0SDL6Q6;M5G71VZ(NZ*
M"P?53&5*4DDT0RG/(+1E/8GFLS<IGXAA&28S(8F?K8!=F=V9RW?K7=@M'8/3
MUJS?HQWK&1MUXJDV2R^5R>;R':4!E)#1CN9:W<GAIQR&4C5H3"(I'YL@G)L:
MM+M/C.7;'(^I;+L"TBRJ5:TS9::TE*I=;-2KM&6V8M\-)I+1DE5G<7()QKB"
M;R;1^(R7@K"L1!9DL E43H+N([>RT-N5R&O%0D@$X;$L%@+!3L3.!0N!<+Q.
M8EX[A??9Q?J5NY_08ZBUOCM073FBH4-+9#$PV,=E<EB<Q7R%S*4[/'6LXV2M
M,%>2I#-%/^VF8W(0*$V\<-S&7&?2$=%U.%:4*/3B:56KS48*/.[E%FP0>S$4
MD;ZC*%6>J#..[5X7CR\I,F?2;EVJY>&=@Y<KJJ5HX?'"$ -6'@KPV8(AXI''
MEVV9K+&W%],>5F\<<G$6[N[.SN[J=AT+I2"MCZ46&KM5QE#+XRI YSG&U//L
M/BS'.QREVW)DB'F6[%IYK$TI22E*\DLA%2M?X>:)KTM2YQ.$M,Y*:X<"I0'-
MOV-L"WA3F9HEY!*PE?;6.R2+1A7W,0].P>PR: L)!!NP\\BY/',CH=$>!QL9
MUY.7/(=5V[7>:W9F:$6$@Y0!)*0-$XDXD'#L;,/%Q.(NT=0Z,](4+.)N#3R%
MNS@9"+"2Y3.9O*OB8SJ24)*E <A?L1UZ4E.4H):@!R)@&+F@900N',4CBQI?
M7MEB;16X"9!U6DY9&F1$Q<K?8:I0DIUNLSETZ)4IR;D*[4B/F+A>..6$C6@(
M1BZT:T\NQ54;F[*^&Q]68)HHCXHN8T '/-+#6YK.TG:\,DA1P\0DXOP"VP.X
M#L/4JG$]'VEL+?K9"A3M-)CQLCB:MG*Y2[C<*-L"BLCA<7<N3T,6TT)G [4J
M\/!7,J\?! 11OQU;XAZ)JDY$3,36IH6]:?OY:GU22N]TF*%29:2([2=RE-HL
MI/.ZM6GWA/WJ3->*BVXQ:;IP6*!D"ZO?^(L%C89 ,(9':(C."$[%@ZT!GOQ'
M#7*1XHRV)V%Q'Z7N_+X5TX_HVTCC+E6Y5HVN''SS6L7CI\ME;6&Q%J<90DL8
MK#6;LN-Q\W!/,$9U:T;UQFE&ORFD+?\ -$X?Z%UO*522JM7F$&]#5,\I%=D[
MO=9ZG5*85:KM'5BK]/FY]_7(ZQO$73HSF<1C@D3N7CYZ1<CR0?+N%;!8VH<)
MPPR,U=W.".2Q8EAAD=G$IHX993C&4F=]Y.'BW<B9V(B)^,1T::.P<^-FQV.L
M1QX9WDQ%";*Y6WBL79*,XI+M'%6KLV/KWY0EEYET*[6".:>7F-+-*9^\O$C1
M9;46TA6I@Q"V\=@EIQ[G<5-:%O8OAE/=>76JDX:E%G2RPC+D<A" 0DN/I0J(
M2  Y#Z\0\;SN=R3VYSV>0\\SU.V'+CYW:KR<CF<?C_(</%X[AXNM?3=&^D1R
M+9%J%K9LH^;;%OE<J6 ;-//VUXJMI\KCX=KS6G>V,S4O&VW[;9FLLTK2/713
M<H+-UB]]%PDHBJ3J)>\FJ02'+WBB!@[Q3"'4H@(=>H" Y*NS$SB_6Q,[.WKL
M[;/W%?)"Q"XDVXDSB[=S=G;9VZNON>LK3,=$:NC:CK*BLZUX-7T]-P5BUY&^
ME)<_H&8K23U"&=^9.^,[D/)I2+LO@R:[Q!;Q>JZ:@D():$<92&"G6:'Z30EC
MFJCS)'Y<D7%P%Q.?$?#QEU&Y,^_6S[*W8=):?@QN!Q$5 0Q^F;-*WA*_.L.U
M*QCPDCIF)O*\DO)"606&<Y1+BW-B=F=J'-Q'T6>T'LYJU,"DK;PV"M3?=I<?
MV,UKT5^$L6VJZU].>XD\T67*68!<T(*7I@I9441D"%<A3^(>-YSR\D]GL=M/
M!VQ/VH]GBXN<]3F=KN?%X_ROAXO'./%LZB'Z-])/D'R#T+7"63;-EB_%;*_0
M^68:QVVV3+3_ &YXCO<:XS7.:]+S8S6N'MAFD1WQ&T4]L[JS+UJ8\*0MA+[)
M4U*Z7)#6LE>"/$Y(MLD-;(SI*4[FC2:2<FJX6A3)N9,I9)RBL^*1<HL'C3F>
M4H3V*=K)0-/.U4[#%Q-,=5I&@(^+QS[APN7CB%RZTDZ-](RY"3('0M<,^2',
MV,6.6RH8"QEQF&PV2GP 7&Q$MSMD LE*=-^.R V)!*86-OEL'#K0=HG)B:EZ
MQ-J(SUG;WB3J[6\W:.HKB[MWC:0"Y!1X^?;59*RK/FB#QS*I19%W+PIWBW?=
MK+KJ?,N!QD\DDDD,CM+-VP<0V;(5WL;L[S\@)1B:4G;<B8>M]W?K=W7Q<Z,]
M'W[=JW9Q]HPNY"++V<<&7RT6&DS$4\=D<MXC170Q@Y$IX8YI+0U6DDF%YC<I
M2,R^ZZ\3-(7ZQ6"QV"OSA5+FJR7OD%"W>YUVG;!6CT46S56]4Z#G6%;M*@-6
MS=FY/*QK@T@S129R(NVI"I!]V,'CK,LLLL4F]AQ>S''8GB@LN&W"]B&.08Y7
MV9F=R'QS,S%NS+LRO1SI/,W;MZ[2N;Y4HBS-*KE\M1Q6;*&,88RS.*IW8,?D
MWY,<<,CVZ\CSP1A!/S8A8%]%]XJZ4V1.R5@L=>F$'4]!,JQ:V5:N5OJ$'=*_
M&(J-HN*N4#5YN)B;.TC&RRC5D27:.119F\CWC,@!N'-K"X^W(4DL4@O)&,4P
MPV)Z\<\8=483QPR $K S[#QL^P^-?<>I=F8Z/=*YRY8NWJ5D9;U./'Y**CE,
MIC:>6I0@<<%;+4L?<K5<C%!'(<40VXI>"(GB9^5XQ7NK%<AZ=7("I5YIY" K
M$-&5^$8^,NX\G$P[-&/CVOF'*BSE?P&C=)+Q7"JJRG=[ZJASB8PR,,,=>&*"
M(>&*&,(HQW<N$(Q81;B)W)]A9FW=W=^Z[[JZZ-*MC:5/'4HN33H58*=2%B,V
MBK5HAA@CXY"(RX(P$>(R(RVW(G=W=6Y0T)JMO8"6A&L]V<3V@^W(1[Z5F#=-
MBR547I#R?\ S\6X^+67*T;Z.%+T80#^939E= "X4;8NBTO.:%^9VX60XN9+Y
MJ*)X2DVX^'9XW=N#;@W?=AWZU#!I+3X7!OCCQ:V&?FU0,O.L.[9RQBI,++>X
M7F<.(L9+)5Y7#R&$N,8VE9C:LX.B5:N6>Z7&'C?*6+83F#=VU_YIXMZ47KD2
M2#AS^6774:M/*1:9&W=9(MRK=WQ5P55ZGRHBJPPSV;$8.TMMXGG+B)V-X0Y<
M>PN[B/"'5XQFW[K[OUJ2JXJA2O9/)5H&CNYB2K)D9N.0GL'2K#4K.X$9!'RJ
MX#&S1"#%MQ$Q$[NJORH4BF$3")A$PB81,(J#>ZPH$BI>UG=4B5%]G-(YAL!P
M5$R+FUM(F-/#QB$NY0.DNN5A&'.Q:B"A#(MS"0A@PBY:9IE5L2U4<3D#'2J]
M&GD;14%7J +J5ZQ-X:7KR$S&'.(BWD$H.>F8LK@HB<&<D[2Z]%3815-A%0E+
M^Z&P?;MS]6:OA%7>$3"+7+^R&/B7Q>]J-H_1-*S/G05YJU)[WQGA+JU)[*[S
MMT9[^S/S?'K5[S8Q:6K;;^Q__P %G;GY_P"5_JZUYFK_ $X>B7%_ <7S^^M[
MNQ9]!&=^-5C\D8A9W<PNMFDPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81<+/62NU9DA)6>>A:Y'.I:$@&S^>E&,0R<3MFF&5>K<*@ZD%VZ"TM8)
M^2CH.$CDSF>2TQ(,HQ@BX>ND$%"+7Y^R$_O8\;O;R]?5^%S._07YXZ@]Y4O#
MS+5#LK/.32/PKD?FD*U9\V16DRVNNP+D&<1QCWW+2*Y6T?&;>7D'[DQ3G*W9
MLM?5MRZ7,1(IU3E202.H)4R'.8"]"%,80 =8^G'S_P 1\#__ -VRMY^Q7]".
MH_C&WY,I+*MH#FGQKY/6*YU32FSZ_=Y^BN%O2["(?LGYUH4C> 7:VQD>.=/4
MQK,HK8FC&*?/C,7+Z093+5)EWX=^*.$UM"I481,(F$3")A$PB818_P#D58N0
MFM:ANW=S[;\1K^+HKD0TKK2+K==LL'L,B#*/3@X>\N)2)-;G=HV+:G*]<CXJ
MH3$*,*DM'KHGD%@<*FMC*292K%?R!Y *D=<]J%0(89H[(LP\L;!&'/>6S([Q
ML$)Q\IMG9RV<EAO7.0UI@,3J_5DFHZN'AP[N^DL#!1I7ZF<<(*[4J>7.Q6\4
MI,CG\K(>-KUL7:J/5 ZQ1O/*YD\S)&Z1U5U\ZV!?%$:M&052-:K:9R<QTH%N
MQB?2<R14Q $ZOH\".$^B93*+&2 J9#'.4HSY6!AJO:L[0C'!SY]^Y$PQ\<C>
MN_#UMZ[NVW=64+&4@QV&ES.8(<=7I8XLCDBE+<:4<%?MBTQ$V[ER&$V\:SN;
MCL+.[LRBU-<S8UG NE#:FVU5;)8Z%:[IJ&/ND'68M/9:-8A#SCY&),2X*IQ<
MG&P_^<K^MVM:MSZE>;/7+-BX<-U&Q(674 !"3]I7899:L]FBUB.(!M-#%S7X
M7:=V @#Z:<4KQR\H2<1<N$7L"STH5XZI<6F]38^]?Q&1RFFJ^4IX^N^H&Q]5
M[DT51O%5VKVH:G[?EH90L==>D$TD<)G#+''5W#"P;"N?'ZC7W9T_=9ZTWZ'B
M+@X4N<=08L&B,]!Q<@1"JLZ @DT3IBBBZKFO>Z!5Q:O*+=)HR*X%;I56"DM3
M8Z"Q<EL2S6!"9WL!6#9I(P)N2-9F%H'=W>/F[S;/X_;J9J[HJO9K+:(PF:S]
MS+7,EFZ=3+2EE8,-7Y37J=>=H\;%A0&(<2[F4F/[=.7)/";=N$,GTL+"[0VK
MNK5FQZ$VFMQ5Q_L79.Z8B JG&R&@H5S5G6EI2UKPZLXYLKN'8W!I:XFI-7=K
MDI]S/H0!IYHO78^!>(&1%2)MW<C2MUFER$)6K=^.*'$1Q1E"]"29XVD>9XQL
M-,,0E*4CR-%QL\;1.VSM:FH=0ZIT]G,+'8U-1L9S/:KKT\;H6M4J%0FTI/DC
MJR6SORU8LI%DJF*CDRMFZ=T:+W8I,?7I3@\;G-_:>SH#4-3]VUJ0DCUU">J\
M'*/8U!%QZ%2M5AC:TVG)(BSEL*<)&OI5HM,.D1659,/&>>74204[MQW;D5"#
MMB9C>)I88Y"!F?E--*,32'N0_2Q,QXW'=Q%^+A=F?;*NH,]2TUCO%7(C.]$+
MF.J6)8 &3M4<E?KX^.W.Q&#C3KS6HY+<H\90UVDFX"&,E;W8?)6E:[MLK1UX
M&[VNS1,-3))2+I<$C-KN)'85C?UJFUI$3R#--&:F5XF6D^_(*,8B/A(UU)R<
MJS1\(%*6WEZ]2<JSQ6)IA" N"O&TCN=J4HH(6W,=I#X#/QVP#&!$1MLS/#9K
M7.+PN1M8HJ>6R5^K5Q-@JV)IC;,YL[D)\=BJ([S1"%NU+6LSN]@H:M>G =FU
M9ABX7*C%N95!AV=Y1NM-V31KK1)*C1#K6LU"PTC<;'([-=/&- ;4XM7L$_!6
M$UF?1[]FW,WFTRL5F3L986"3=14*=\_5C&PUB"U7L5BK@]0XP.>4[;NU<8.5
M))'*\CB3=1["XOQ;,VZBCZ3\-5BS Y7&9[$93#3X>M)@K=2K-E+\VH9IJ^##
M%CCKMZI=\4K%>Q!$XVQY)P2O;[7 "-<@;EO28JOWR2N]+V70;)KV0IL3*:^G
MZ\Q>VV;DMC.08T%G31K4S.UZUKVF1[\:T)$SRHL'[=TA,A&E;J*!]^+E<(K)
MV*]RM-5* #JR1"4\AVGVKC7Y1R13E*[.S,$C\+L[2<.SNN]^DC$UJ68L9;%Y
M[#7<)/BJUC#7:,,N3MSYV5H,+'B_$^W=HY(LG9=ZL+5KI/%8CECM]KM&1*E[
M;R>CW%4L*4K$;:T=;JE>=(QDS%3-5J,M/*1NSMA0=?@31RR<W/TZ5@+*LH\K
M\\^CIE:8KC<TBL1JWE6S$%.BQF!*"9B&[C;%>Q0&0#@@DD<+5@ #@?CD@..5
MN*.0A-Y(O'>-8V9GH[^OJQ4+@VZNI-)Y''YC2%6S6MX_&6+I0ZCS]''4"@..
MW?Q5BCD)3EH79J]L[="/MDVCBLQP<7MF.;E!B'5X6'7NW']1U?L-_K796PH^
MLQ*E0IDXPE&D4HZ?+K6)"7DXLJCYD\=NH"(EC14>Z0<RR3(RA4A^I-0UHRLO
MVK>*"G:*I;M#"#P02#(T>[N\K&8\3BY/&!. D+FS<3,OFUTK8:K)ER\1=2SX
MW3V;GP.?S<&/K%C,3<@GA@*28CO1V[%9GL0RRRT*EOM: VDLC#Y%5;=N5E0J
M%@O,.QI.RKU%ZH08N-M6^D0,9)5O7A)"';V(B$DH_G8R5GI!E77;2?EXRG15
MB?Q,2Z;+O$$UETFYN^QFH(); #7MV0I,+W9Z\8'#68@:38G*0#E(8R:208 E
M*,7W)F?J4EE>D/&8R[F*L6*SV6@TV$)ZER6)IUYZ&#::J%_EV2FN5K-NQ#CY
M8;]FMBJV0GKU9HCE 3D",I'PTQ%V*'BK!"/F\G"SD:QF(B2:'!5K(1DFU2>L
M'K90/4HW=-5TET3AZC)J%,'PY*QR!+&$L9,<<@#)&8]P@,6(2;[1"[.WVG5[
MU;->[6KW*DP6*MN"*S6GB+BCGKSQC+#-&3=1!)&8F!-W1)G4;JERKJUTGXAG
M"T#:2]+L=VGM>5W:B=>C'M'E+56WTM%R;=8D7.O[9!Q?I*#E6+6P6&L14*X<
M-0 7J2;EHHXB(,W!8DC8*MSM>:P=6&[R@*O)-&1@3.P2%-&#E&;-++$$;[-N
M3,ZLC&](./RMRM%4PVH9,7>RU["4M1!1@FP\^0QTMJO9 ^U[DV2J5NV:5NO%
M>O8ZM3.6';GB,U<I;(T[G ]CJUL&R[9U=L2.*QY+3VBZ'%UZ#K4K*33\[R99
M5RKMX^(N4LX=V5FK @SL3Q4Z$6K+ST=Z'<NHT'9XR@@U"00V9KM2RVV6FQU8
M((XI#,F.4(X6 )B(I1Y/#*3^,>24>6[AOP6?BNEN6*CG+VI-.YVLT&OK.C\-
M7IT\?8LW)S.>.ACPAJY:T4E^,ZO*NRF4=9Y[E?M:22%IGKWGEN4@1R9T6>B=
M[3LU$4^,NMX@(RNU5%_0HR5"04:Q\TO+W*+C)6Q&;1;U[Z!J;^PR!6I$3JII
M*NFZ*M<>:86=AQV1D.. ;%F,8H6.J!L;L,G'.+'*X@YM%"\A\+L[LSOLKMM:
M_P"0SA%I#6%VW7Q=;+92E5HXUI\1!:>;E5[1V<M7K6;[C7GD>GBY[\HQ@+DP
MO+",E ..9.L(12\[+6L]YL&O66LN/MW9P#"H1:C:,B=RSLS#0$U#G152L\I+
M2BQFX6*$?D-Z*2C$"PZ#EXY<H'IGSU2,K-MYK,U8:F-G&$((]HQN2& G&[$T
MIR%N/-C+J#@V#B)W91$G2AIRJ&6SY9#*W,)#@-#YF.M!C(2CAJ:NO7*>/MU>
M%QR%BQ9+EO>J2B[U@KQ]JQG-)*!5H7F'1(M+9(; I6S=6R.M*(SV<_A+M 11
M)6?HLC(N(9C-5LE?GYYH\45FD"Q#F+>/&$G'2#IHA(MFOB',G4>+U8&M]M5[
ME,ZE8;A1V(@:22L9O&,D31R&SOS&8" B$@,F$MG8N&2_9,Q%8<\V:Q6?T]-@
M,1%GYZV6I5FGNXB>>6K%;Q_:%Z]%,16HNUCK2RP6H)I(1GAC:1G:YNM-R?L@
MS<Q69/6VRM;6"(B(JP RO4/$E8RL',JN6[-]$6*K3MFK3Q9-=HLB_B1ETIB/
M-X9W# J"J:QJNGD&M220G4MU)0C"9ALQAPR1&[B)QRPR2Q.^[;$'&T@]6X]W
M:?P6IO%FU:HV,%GL%<JUJMSE9BK6&*Q5MO($<E6]CKF0Q\QA)"<<];MH;4#\
M)20M')'(=O\ D-NRZ:IO/'&MU6DS%JC]J;2?U2SK1:-?563BF="MU@3C8X\W
M9H$&LPN]BFLQYDR+AGZ @Y]OXZ4HO%-7W1D[]BG9Q<4,!RC<MG%*X<IWX0KS
M2, <R6/8W<6-W=N'EQR,Q,;@)0.N-797366T)1QV(MY*'4FI)<9D#K!2,@K1
M87*WF@@>WD:7+MR358K+2$$D/:5.\'&-DZT<OP27,:@1KR9D5*ALAQJZN717
M7U@W>U@XI7643:6LR2NR*:S@T\2SN(&(L)Q@I>V,:RZK4?*).$%I,$FSE='K
M+/51(RY%LJ<5AZLN0&(7J!,QM&6[\?->()'Y9SC$\0FSMQ>JOF?I.PL$EJ=\
M;G#T_1RI86[JZ.I5+3U;(1VVH6&.5[K9$Z=3(;T;>2AQTE"O9&03L-'#-)'>
MG<>V:MH[6EHVO<PD3U6H-6+V7&(:E?/RMGTJPB2*MVIED 7!)>0155*53Q/
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MS[/LV[=:R'H[$V<!I+2^"N%$=S#:=PN*M' 1' 5G'8VM4G*$S$"*)Y82>,B
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M=N2[:QS^PFD42,BKG(:J0BO-2[1)L9TZG"NG)R=S[OZ^K_4LN'$]UIEYQQU
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ME^H#X:U^$IP(LD51,3$ 2F*0X 4P!TSF'8_:U,!-K^F]C$2;>]D=]B9G;?\
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M21\3PTR%#!W2E##+EL<\L44CMCG9G.,#=F[9FZF<F?9ENWV,!$.E-0\)$/\
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M^C?^9>HO]YI[E^>GXY>+?Z!=F_X\8Y6H/K[$_BZU^D4\3NFO[*^C?^9>HO\
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MED-Q".,!9R,S)A$6=W=F9;97[9+CM^/O2WZ4J-_^]SS]^A_/?O)E_P 6W/\
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M)"0(,0[<.'$- (2,XAZ,E%@B@8((.G%Q4^CW(78<1:/*Z?Q@ZAFLP86O>OV
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M9W%M]VZEC5_91OO^T;K_ )=C_9<PAXKY'ZZ+_LB_TUNQVG6_<F_[C_S+:/\
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MA#"4Q1*(AGT!G&8R1F4<@$Q@8$X&!"^XD)"[$)"[,[.SL[/ULZ^3 9!(#$3
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M_='':AN9<,CJ2M0RFJ<1A<7/;B;2V3.?#G7J79;.0J1VVK$$D]8J]1Y)ZC3
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M?!T(\10,80,!0$2F ";^S^!_D[JTAI<>LK)CZ_7(/1]8" ^MRK\(#T$!_P"
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M7,C;'F>?W&7O"4R'DQ]L/RLNXRS&JEDPBQO=JM^"1,^W-)^?.,S)T$^C^O\
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MZ=5_,\'N,7>"O%BYYLM^^9_"DJ*N7Q1M/L[-?1KG.+7F:Q[A+X,E\5_+X?=
M^5E O+.5Q*.W*K[R-I^5USZQ1F6=KWT+9'V]+Y]769.@/TT<#[WS/Y&O+$AF
MO"]#%N3?8@OWP>=/L;H3Z;VKELZD\A4]M-\D:K*GU3[S^TMXK+558F$6M/VN
MOX44%^9^J?66[9N?V/\ Z![7QAO_ #+&KSH[*[TRZ/Q2Q?Y1S*Q;YG%:S*$F
MS_CY8OE+;Y@TRU,CYLG]D/!@I^GYFB]@N_)4%E$JE8)[9\:K-[03/TBYS5/(
M^>%[WY9\,:]6=/\ G#A/@C&_,X5=[BA^%+QK_/\ :<_K$KF1MCS//[C+WA*9
M#R8^V'Y67<99C52R818WNU6_!(F?;FD_/G&9DZ"?1_7^"\GX,%KSV3_I4W?A
MK#>'-:P&;N+S55@=]_<VN_+GOS='(?,>50^Z/WKJ3QO=F]@/E)1ERWU*K&OS
M8^/-1]DS?3$AF$^D_P ]<=\'O\YF6[/8P^A34/QA_P -I*%^8S6RZ[/'[',_
MB?N+/Y3WW_U%[7RQ,UYY6/8A\#&I*OY2'WW?$LW^12[DPB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB818P^TIUM
MMJZ:HN,F;E'JWCYQW@JU6INY+6[2,OL.U1=QJMU:66MVZM62)V%7'+>2;V!E
M4$J[7VU=EW+V=9)M@3DRROH["?KZO4J:UGL#E74MS<>JANWF%K>Q5_<,*6PU
MV!6X87?5SO8:!(%W*C3D=B2&Q)"NTW9IF#=6PJTR7BD+$I'1LGY:! $500+G
M[C?T_G61S;-SL.O=>V.XU2@RFSY^%18*1U$AINO5R3GS.Y5A'N$VLU:GT; ,
M18M':\HJ:1?($609*MT!.Z602.7"Q(;8>+H,>0.AC=G+L_>6J=D;FO&S)"W&
MW[Q_C6L[;+))MI#W=4,9.ZPUKI*C5\Q:R=66 K*?@5R%.#DJ@F 2YZO8]AO_
M &LA_"BA(ZPXLZ;HC>LW2FI5ZN.T/<SL6T5JZW>).[GY>160LEKIYU*U.R2B
MSP[@[^*.=%5-9,%3&<E7$2X5[=G(V5SK;83>EG53N*]'MB-340-W%T[*K R!
M((Z)^\3N*EE#-3)F[Y.Z< 'O%Z=0(L.G#.TZ/A+[QPL&KY>CU6N:N[/][#<O
M9A)W#UQ"D7EG,ZJ4KT)OJ0<BQ"%V3$6&/W"^?M+JNA9HPREID) B#>347=$_
M7]65JK2DJWY'[@EKE:M?V;<G[?S44[JGCQ,U**/M'8FK%R:DC*ELZD; ;2".
MSVE8HU,5G)B,DJ*Y;:T@#4^YQFQ&$XA/69DF3J_7]?7_ *%L%R*DBDR74B6K
M)[(E GEFLC(+Q;)4PJ$ X+OVT;,+MP*D*AR"G&NA.H4B0E3*<54R*VFNUK,K
M(W@92-@F0&O+OSB<?-R$F*)@K5;!,&RSBOQ .BF*")CBJ@T$@G4(!5 3*HJ3
MY/U^U_6H+]JT>5'BT[*Z0CTV(;(J/EE6[MRJ[/T"8!+QT%&2**7>2[QE/#<+
M=Q0"D+WRB)PS3T"^CQO@;(]]66N'92[_ +%Q;[>B+$=Y=^U_6M9_-UUYO*/F
M_/X'6OE,G^J99#9GRN#VY=ZRE,;]6_@_[Q1JR 4HL9W-;[XM8]BFWT[.9A#I
M.\^:/P8'SJTMW^QC]!F<^,\_Y*Q2AQF-ELBNU5[$LTG^Y4<,OM##H73J7HW_
M "IQU6-[I+)U!]_D?^3%[_A@ M_-CW1./0!*4IL?93SPM>ZO\C*4B\J#VK?K
M^O\ Z648#SGDA,+6*](^+T*B#YWY+P?5[X7/H[QP5^'W@-1)\'VSUCTH%V=?
MW?9_KV_J1<\V#=L+5K%'="4?.$7?.TFZ9N@= ;*IQRRBQ>O>ZBJB@(  #T$1
M$ +CK^U^'_TM(27Z^EI/K\/I![UZ?!U\RKUZ9Z=5_,\'N,7>"O%FYYLM^^9_
M"DJ+N7Q1M/L[-?1KG.+7F:Q[A+X,E\5_+X?= ^5E O+.5Q*.W*K[R-I^5USZ
MQ1F6=KWT+9'V]+Y]769.@/TT<#[WS/Y&O+$AFO"]#%N-?8AYI NQ>< ,DF:B
M0U'08/#.G"R"B:/IW:7OFQ$FK@JRG=\0>XJ= O4"!W^AA$MLZD\A4]M-\D:K
M*GU3[S^U]I;PW>E?/B44(_T9T]2_FW/G^OA /K:^3\OT\?J7KYS_ $713IW_
M +7EJJL^3]?M?UK\H'F!4= Y;QI$BE/Y(R#QTJHH8##X8.BJ,4BH%$O=$XI'
M<"4PB!0.  (D_7]>I:UO:T&?FY.P8R*3-%Q^Q%50 C)PLY1\/W1W3NB*B[9J
M<#B;O=XH)"4  H@<1$0#<_L?_0/:^,-_YEC5YT=E;Z9='?[$L7^4<S]IEC#S
M.*UF4)-G_'RQ?*6WS!IEJ9'S9/[(>#!3]/S-%[!=^2H+*)5*P3VSXU6;V@F?
MI%SFJ>1\\+WORSX8UZLZ?\X<)\$8WYG"KN<5.^'*+C=X8%%3]GS3WA@<PE()
M_P!D.N]T#F*4YBE$W0#&*4P@'40*(^H8VQYGG]QE[PE,AY,?;#\K+N'S'G/)
M$,5K%#(^*(*(F?.P9 C[[H8CD(X5S*_O.I#-2D]9OMGO0[V-5+=?W?9_KV_J
M7E<\T!&@M6T6=0Q \^5=Z[2(DIT3[P-#)QZQG!.\*H 98C8P@5,1* G,!"XZ
M_M?A_P#2QS=JL:0_:J3)029^CO=I21%;S"WG?&\\X]Z#;RW@>'UZ>_\ -=[X
M?M>9DZ"?1_7^"\GX,%KUV3_I57?6\6L-X<_M?UK6,S=Q>:JL#OO[FUWY<]^;
MHY#YCRJ'W1^]=2>-[LWL!\I*,N6^I58U^;'QYJ/LF;Z8D,PGTG^>N.^#W^<S
M+=GL8?0IJ'XP_P"&TE"_,9K9==G']CE&DOW(SBV4R+$(WTAOON+ Z<"^$_[8
MC:HB!FHM ;E+XG?+U!V8>X!3=WO")"V)FO/*Q[$/@8U)5]^4/K>.[YUF]9GE
M#'7]((1Z*8"'EA9NW#DYPZF[WCE79-2IB!>X(>&97J(F 1   312[OU_7J7(
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(K!<G='!R+TI;-5(VEU1Y>4=56Q5:XLX]M,'K%TH5N@KY39I>&>'
M2:3+!E9ZW%*2<0X51))1WFF8.&RBI'"1%!C4E<Y/<IMI1X<@]M<<9*B\-N0X
MC-5[0.NMLUNS6K>=,H,?)P#.US>T9M]'1M:AX/:,5:7C6CMI9M*RJS>%&P^4
M9R" $62S9.M:'N"D3VM]FU>+NE%M"#9M8*Q-I'7BY9!F_:2C5)VD0Z9SE0D&
M+1VGW3E$%FZ9NOJZ"1:P6Q>,L=;MSEJ6C>+'9\T*@6'DYN?B[1#;*UOM2WV_
MW8Z@U[-W)&3OLA![1@HR)C;\XJD\G7&T365'L9&K1#YX:7(_1$Q%GH[/61;2
M7#?1IT(FKU]PPK\Q!S5=I4$>MU*N6>OVVP0EJKU>B%)JQ*)1,'8V$I&,G:DR
M]4E46I)4XH&>BV1(IFX1?,#)F ."@T; 5V8QG1002 ')C=>\9P $Z+&-U'O"
MIWA'J/7X<(OT+9L*Q'(MT!<)$%)-P*28K)ICUZID5$OB$(/>'J0I@*/4?5ZQ
MPB]^$5"4O[H;!]NW/U9J^$4"NUB_!05_.13?U4UF:>@7T>-\#9'OJRUQ[*7T
MKG^,6([RXM8_-UUYNJ/F_/X'6OE,G^J99#9GRN#VY=ZRE,;]6_@_[Q1JR 4H
ML9W-;[XM8]BFWT[.9A#I.\^:/P8'SJTMW^QC]!F<^,\_Y*Q2AQF-ELBNUD[$
MO^*HX2?F?3^LUBS'V4\\+7NK_(RE(O*P]JRRF90+L3"+1PF/NM*?E%[\Y5ST
MZK^9X/<8N\%>+%SS9;]\S^%)45<OBC:?9V:^C7.<6O,UCW"7P9+XK^7P^Z!\
MK*!>6<KB4=N57WD;3\KKGUBC,L[7OH6R/MZ7SZNLR= ?IHX'WOF?R->6)#->
M%Z&+<F^Q!?O@\Z?8W0GTWM7+9U)Y"I[:;Y(U65/JGWG]I;Q66JJQ,(M:?M=?
MPHH+\S]4^LMVS<_L?_0/:^,-_P"98U>='97>F71^*6+_ "CF5BWS.*UF4)-G
M_'RQ?*6WS!IEJ9'S9/[(>#!3]/S-%[!=^2H+*)5*P3VSXU6;V@F?I%SFJ>1\
M\+WORSX8UZLZ?\X<)\$8WYG"KO<4/PI>-?Y_M.?UB5S(VQYGG]QE[PE,AY,?
M;#\K+N,LQJI9,(L;W:K?@D3/MS2?GSC,R=!/H_K_  7D_!@M>>R?]*F[\-8;
MPYK6 S=Q>:JL#OO[FUWY<]^;HY#YCRJ'W1^]=2>-[LWL!\I*,N6^I58U^;'Q
MYJ/LF;Z8D,PGTG^>N.^#W^<S+=GL8?0IJ'XP_P"&TE"_,9K9==GC]CF?Q/W%
MG\I[[_ZB]KY8F:\\K'L0^!C4E7\I#[[OB6;_ "*7<F$3"+C(F;AI]LJ\@I>,
MFF;=_(Q2[N)?M9%LC)P[U>-EHY5=FJLDF_BY%JYCY%F<P.&3UNNU<II+I*)E
M(N(M=[I%#;1[R\W*JTQI+2*,/%.K788BNMI.7<E.=O%QZ\N\9I/)%<B:AT6+
M8RCE4J9S$2,!#"!%S,1+Q,_%Q\W!2D=-0LLS;R$5+Q#UM)1<FP=IE6:OH^09
MJK-'K-RB<BK=RV54163,4Z9S%, B1<CA$PB81,(F$3")A$PBXN.FX:77EFT3
M+Q<FY@9(8><;QS]H]7AI<&;.1&*EDFRJJD=)!'R#!\+%X5%R#-\S="EX#E$Y
MR+E,(F$3"+\D.10I3IG*H0P=2G(8#%,'\Y3%$0$/_P"APB_6$7%0D["66+9S
ME<F(JP0D@0ZK"8A)!I*Q;Y--51!11G(,%EVCDA%DE43G16.4JJ:B8B!R& "+
ME<(F$3")A$PB81,(F$3")A$PB810+YL;YY0\=:T\V5J;7.AKWKN*:5*)=,K]
ML>_538DQL"Z75G2J_6:S#P.NK#5UVDK*3U9:-9.;MD*F@Z>2"LD#&.8@]5(K
M!T2Y\J>-.U:(EM70_&FD47F-R,!39=KUSO+:E\L$)N*W:W:QT3XT#;=:UQB7
MW01NKX2LM"5QZX@&DHV\=WY)%\>3<$67#"+ ML[4NWN7UWY:PFJ^-O"J$I#?
M>[2BWV4W%L'>-7W'=+]IB*9A6]JB.G(YJG35G<59SA5IAI)HV2<J;ML:6<N8
MQPT3.3J]7Y=OZG673C+KB3U%H75^M)BLZYI\G3*PA".ZWJ5U9'VO8P[9PY$A
M*Y(7 A+3((KI'3=OI"?[\H^E5WSMVLNJL*RA%?7")A$PB814)2_NAL'V[<_5
MFKX10*[6+\%!7\Y%-_5369IZ!?1XWP-D>^K+7'LI?2N?XQ8CO+BUC\W77FZH
M^;\_@=:^4R?ZIED-F?*X/;EWK*4QOU;^#_O%&K(!2BQG<UOOBUCV*;?3LYF$
M.D[SYH_!@?.K2W?[&/T&9SXSS_DK%*'&8V6R*[63L2_XJCA)^9]/ZS6+,?93
MSPM>ZO\ (RE(O*P]JRRF90+L3"+1PF/NM*?E%[\Y5STZK^9X/<8N\%>+%SS9
M;]\S^%)45<OBC:?9V:^C7.<6O,UCW"7P9+XK^7P^Z!\K*!>6<KB4=N57WD;3
M\KKGUBC,L[7OH6R/MZ7SZNLR= ?IHX'WOF?R->6)#->%Z&+<F^Q!?O@\Z?8W
M0GTWM7+9U)Y"I[:;Y(U65/JGWG]I;Q66JJQ,(M:?M=?PHH+\S]4^LMVS<_L?
M_0/:^,-_YEC5YT=E=Z9='XI8O\HYE8M\SBM9E"39_P ?+%\I;?,&F6ID?-D_
MLAX,%/T_,T7L%WY*@LHE4K!/;/C59O:"9^D7.:IY'SPO>_+/AC7JSI_SAPGP
M1C?F<*N]Q0_"EXU_G^TY_6)7,C;'F>?W&7O"4R'DQ]L/RLNXRS&JEDPBQO=J
MM^"1,^W-)^?.,S)T$^C^O\%Y/P8+7GLG_2IN_#6&\.:U@,W<7FJK [[^YM=^
M7/?FZ.0^8\JA]T?O74GC>[-[ ?*2C+EOJ56-?FQ\>:C[)F^F)#,)])_GKCO@
M]_G,RW9[&'T*:A^,/^&TE"_,9K9==GC]CF?Q/W%G\I[[_P"HO:^6)FO/*Q[$
M/@8U)5_*0^^[XEF_R*7<F$3"+!3HJZ[H4NNE-&:RVDMJNK[7Y"]J;8-@S494
M:=:+*JGK;D4^=5LE;5NL)88>*?%D+&Y2=+/(F29+QCEZ11@=\2.>,B*BHBP[
M/Y&7WA;L#9>R79['"ZZ[1:LSC6$IVO$:[8I/0VST-8K60(V9J<V\A)#8<%",
M1L80TFT-"'2,%*5K1G3]1X7.VV_VGV^7\RNGPVW[>:II> I V*-C*9K'LF..
MV\:LB]81!/1EU?MMQ1<Y/N9%TW\R]8$94JJI*L'JZT4T,W[X-TU'[@RY<_\
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MEJEH-7N-%@23<=)W:1O#=%%,_BI>\Z"0!)[TQPZ^OU6SJ3R%3VTWR1JLJ?\
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M\F:1?"]<+B[<>(1<W :QUK5%:\O5M>T>M+U*&F:Y5%H"IP$.K6:]8Y"-EK#
MUY2.CVQX6&GI2&AY*9BXT6S&4D(J->/D%W#%JHD14G-<=./EDKT[4;%HG3<_
M5+1:YR^66L36L*3*UZQ7FSE4)9+G.PKZ#7C9:UV$BJI9RQ/VSB7EBJ*%?O'
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M]6_@_P"\4:L@%*+&=S6^^+6/8IM].SF80Z3O/FC\&!\ZM+=_L8_09G/C//\
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M]$(*?O/]&/?_ 'OKRU56+PE(QZQER(OF:IVP&,Y(DZ04,W @B!Q7*4XBD!!
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MC>[-[ ?*2C+EOJ56-?FQ\>:C[)F^F)#,)])_GKCO@]_G,RW9[&'T*:A^,/\
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MCV4OI7/\8L1WEQ:Q^;KKS=4?-^?P.M?*9/\ 5,LALSY7![<N]92F-^K?P?\
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M= :>R6*S<^,FLV\S)D(BQUBQ/"T!T:59A,IZE4FDYE:1W%@(>%Q?CW=V:/\
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M=.ZH;WO0>O7U!!V^G'1\]B24*F>X3<=N*G29^H!'K;Q2?U6]=2E?L7.D6*$
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M*N]=;6UGM^(E;!JN_5'8L#"6>?I4M-4N?C;'$L+;57HQMDKKB1BG#IH66@Y
MIF4HS!856;HID%BE4*8H$5?X10KIG/+A]:[!<(2G;,6?V)@AL&R2C%'7&UFK
MNW!J%="H;'<:_!]2&Y=K/:2XAVT-.,-8C;'[0[5 @M3>(F=0BXJ%[2;AQ/UN
M]V^-V7:1K6M';2+NLN_T;O\ AVL///KS7-:-:H3TQJY@K*W1:]VZO5D*5"IR
M-L+(2)0/#%0;/%FY%7*7.?B6.E+YR(?;PJ5=T_JZ8D*WLBU7%.:I#BBV>-38
M+.*K:JM;XJ$N$':UDI6)5C:O(5]"?F$I>)4B8YZ248"X(N9VQS#XW:/AJ3/;
M-V?'P##8M??VZG)LX.UV>5F*=$1\;*SET& J4#.ST=2J['S,.YLMPE8UC6JV
M66C"3LI'J/VA%2+GG?*+CPSV-IW41]Q41QLOD#!2MJTU3(Z<;RTUL"K0U9?7
M)_:(-O%^<*-:"M1DA*-)]XHUB))-HLA&O';LO@81<KMGD+I+13S7<;MW9E4H
M4IMN^5_66LHB=D2I3%YO=IDFD1"5VMQ"!5Y*3=.9!^S1<+MVIF481RDXE'3)
ML;QL(J)O_,CC-JW:$;IJ_;:@JYL22<4]F>'<,+ ZCH-]L.25AM?,+E:XZ'>5
M"AO[Y+(GC:4QNL] .[6^[C6!1D%E$R'(I-81?(JQ9KNVC]5NFH\8$<ILW!@'
MQ&Y'A4BNBICUZ "Q44@/U >H$+TZ81?7A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M4(^TEUY==M<"N66M=<0$S:KW==(W6 JM=KOEAGYB9>QQBM&,,#U1)J:36.'1
MD5=0J9G )E-UZ]!+A_ZV_H?=8W]H4KD\SU;K7:_%^K\R=C[HKTEMOC98D.4:
M=1K.PF6M.3>O*_'(;"8IQC>J0<I1]&[HH>H[T*HL7$XPKQ-FDC3/%W96RA<J
MCZ_P@W!0^<L$5RAO%.CZWV9QK4XX;+I.N:A<8Z.X^:OU1KFK6S65AW7/;I@I
MO6-2GI^N;,)MZ@.J&]6OB%J]U-?:7>WS<2G'$7V5WAA-:VT3PD<[#XSW[;E#
M+.;'L?.33T.9M=K_ '^ZRE8L$?I"S;%JMBM#53;5-U=+O7,5#4;TE,,*.26I
M\Y"ULD51TEX4BM8?B%S+:TUFC)ZZV(ZF@XW:HJM=:/+2RM-FIU?8=ITIN.H:
M>GK8A89,DQ9]3<:'%=B;,X9S<S&&;UUZU83<RB1)=S\NV_\ VNWX=D5ZT.SY
MD[9LO6=YO>I+I(REM[3SE^_W?(O+?94T+#PNME9Y03]"IUM9MK.FTD>/MIV*
MTTI,+ZJ.W5ID[/RWGI^K.E9^QJO/K_U_[_H1?#%ZGY0Z,KM;3C= ;KV1!!QL
M[1GBM1:I29BMR4O1S6+E:^F^*#:>]V=X@BQ%!<:*K\-'5BW*R+Y&LPD?%1,A
MY1=[&M'1%<K26DMMT;E_QONI=)7ZS2BFF]04O<=UVS3X(D-I>"J_&((.2?Z+
MWA#[/+,IQ<CL%*.J-\X]6;74^:?V%,VC:T<K 1T<A9Y,BR^W>NV^6<"K!RWA
M-#3FG'1(\%C-S(M*KLP+!>5?$$2$$)>KF;LQ1*83.BQQFAB&!<A3$_\ ?]*Q
M5;<<6^A]J':+E(7#F7KW7-WT'Q3J[1/07#JW<@M3;>E:SM+D2K9J9L_9U?XR
M[L_8J;0+"V0(R;^/OFJ)%C"VM6:7F2(M&TE&$4/;/0^TBF-5<@J3&!ORO/N&
M-3@^,^M;<='8\S+<F=:6[E!#W39>Z:E'5J[T.V[AMU>X3T/5=6C92I7J)V(X
MV9;MU4JF6J%O)E'BQ%<W0O'[;E[LG%>NVS97*F[:"=;LY.7&P,@U=S;X:QU4
MK+;4- )2-=V^%W[MZ[\C#Z]5VNPL5KJ:NRKW&M)RP/7T)56"M(:-&<B14:RI
M7(.<L+N-:4_FJIR0+)\ZD>8TK=T-_K<<+MJ.SZ^WJRTK7]3.+4HMQYOB+^T/
M-#CIRMZ!))WBFP;*6C[FV@W@6EH](OLC]-\G[&WT]K:4B.4E4UZYV]V8\!:V
M]/?;<H Q.KH3AQ;(G><4$W6E8E_5*FWNR<97=I.8M[$EB[&X:MI9[&V/R*Z/
M#=QO7V9%<?4/&[>>L+UQ_LE<E.7#^3>\W.=6FK:&Q=I[ZNM5@^(;37/+970"
M,W!W*P2U=B]?(7"G:*>Z^V-*L#2<E-3,(#*UR)K0T;NN45H:A+\B]DZDU]KZ
MWLN?^F7&I^RW@-+;SV0GH/DE.S?[:2K;'X\Q5S/4X&%2A+QR"EW3&$N"DO>-
M,2LA)W_6TW;7VI-CR,H24?PY%E\[/21N4CQ:IPW?6EOU9(LK+LF,BH2\2&Z'
M$Y.U=CL*R(UF^%@^1CEWO>@Q-[B ;6>#UGM18ULU[$R+.JN!491C)90BFUA%
M ;GOK_:VQ&?$]AIY](P%I@N8.O[,[NK.B*[%84&"8ZVV^R?VNQ5PKN.:&@45
MY)E$.'LG)QK!L]F& '=@NJW16(H Q^D=QQO9_/=63FL=C2N^(+M-M?W/<3UE
M294C#:DT?M!]?[:N/(76T%$0Z$>QTS;:(_;[%9-H))]#:WB$IRJ6.P2L]2K3
M.."*T_:+:[VY8N37,&)JC?EDY)M;C=Q:8:MUCK3B79]N\=.3&RM9V[<UE8ZT
MW9O&.TY-,-05IM8752B[9*(<@M#GCJU:7LK)6#RS8B[<BEO;9>J5[M8=%6J.
MT!N6(L<GQZW)KC=FWJ-Q"Y!S&M7>TMD2G&5WK5E9N0E>U"XUU88F-KE(LD>-
MN?79S6*,A"+1%EEZX]5(R5)ZOZ_KZRL3Q3H]E<1G9Z:9MG'O<]1L'!+6.^8C
MEY8;GH78,51[:26T]8]5V&N:YNZ]7&L<CS;ZV%,,-PI-=-RVQ22;&O$=W D=
M;G,9%+$4M>RQGJJC <G:-4M-[FTO7&W*+:NP:'7-E<5-[<9ZRIJV]2+4E&5H
M[3;6K=<0KUN5I!NRNZS7 7EJJW!AZ?B8=.2C/-$65G"+ OPXXH<EM/;6XJW_
M &R[V1L37;*^<\(^/U3/0VNX=EQ+MFU=L;%MM$VM$O*5 5VR7&G[$UTWGZ;(
M'V--[ F*S+;-KSF"6B8V0E4H\BJS;6@]S+\).85.:TC:"%KMG:-$W-6(_6J,
M2OLU]K%ISDU#LY:]:\0?B[C5I=K0Z],VNOD?H+=]6-3!9@N80:J$5N(/4.T*
MSQ/[1YK+:.Y);=C]ZS%G?\? W11M;V;E9:=C7;C@75TQ<KFTJSI@C$UBO6)D
MTJU&GK RKMI@*BD[9I1WN3+ .GI%<./+N6E7?1_(Q+BKOR_0$UV>\SQ.D-<,
M:[4F>QZ#MVL76OR\<RM56LUQB4(FC[5;Q\BC[N$'[F C4ZM7G%L/'M)>*6(1
M45$:=V)QUG.QRHKKCSM/8ELXLUZ*C>0FV-7Z_C;%7V;%?B!NC1D-$+W+THQD
M9]M5=@WIL060$70AX"2=3S8A$%G"0D4M^TXCI>4INE$*7Q]V9N2]1'(WC1?P
MG=9Z^C;5)5+7VI>2^G-I;(:.YUT_CGD0$K7*BN^CX5JN8EDD(5!N8GF&[8P$
M48]\:NWO;7G.S3E<X];3GAYY[3XV[.U;MGRU0:4C6598:>XZZUO"6TI&2MK6
M=I5FTM(:6LEX;UXD0[>6)W8(1A1SR<XXE21I%1T9V>TC:-C:>NM_U%<Y*2M_
M::<XWW(!^_MUE!O9.&=PB^7]JU93[FR0LY6DEQ^LNQV?'^PHZJ,W6IDI8YDL
MG-599S8K0L]?^O\ W_0B@!R>U)<$X&OZ.W'0;M+:CX\\;-Y6?8K9:LZSVO8^
M/O'X.8FZBZ\V30D-R<L^/"%)N3'0&N*_!T2W5F$Y*VA_3&9JV[U<T!BP8VXB
MVZJDXA7=5K+NMI>!775?AG$"AY)2-\&%6CFRD6EZ/61;K,/#8F0)Y)5!!1KT
M\ Z*1B"0I%4&$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HLV[FKQDHFY(_0=IV>
MC';-?SE1JRK!*IWJ4JU?MNP? ]P%.NVRXBL/]9T"Y7L7D<2E5&\6^O62V*2T
M*E7XR14FHHKPBK??')+17&.KQ5RWULVM:TK\]982G5]Q.KN57]BM%AD&T;%0
M5>@XQL_G9Z06<.DU7*$1&O!CHY-U+R0M(EB]>MR*]^$3")A$PB81,(N'L5B@
M*C S5JM4W$UJLUN+?SEAL,](-(F$@X6+:JO9.6EY1^J@RCHV/9HK.GKUVNDV
M;-TE%EE")D,8"*V>F>0NC^0\/,3VD-I4W9T77I-*&L"U3F6\BM!2CEBWE&C*
M:8E$C^*6?Q;QI*1P/VS<)&-<MW[(7#19-8Q%P%$Y6\=MG;(L6H=?[:JMMV14
MI&UQ%DJD,L[=/H>5HTRK7K?'.UP:%8%>5V<07B95N1V=5J_06;'+XB2A2D4@
M\(F$3")A$PB816WG-PZJK6R*1IV?V)3HC:^R6%@E:%KA]8(U"ZVV*JK(\C9)
M6#K9G'I5]%PC-,RTE))-19->@)J+@J8I!(J+B>4_'&>W&_X^0V[-;R6ZXQ23
M;O-:M+3&+6DCZ$CVTM.1*3$JW^53L'$NT)6:@6JBTS$QAC2$BQ;-$EEDR*_F
M$3")A$PB^)[)1T:5L:1?LH\KUZUC69GKI!J5W(O5/"9L&PKJ)@N]=J_:VK5+
MOKKJ>\23.;U816FWKR U3QLI+?86X)Z6@:R]M%;I4:: I-[V+/S%LM\B2*K5
M>@Z;K:M6ZY3DI,2!RMFK6(@7JG>$3J FF4QP(JFU?LZJ;AI45L"E$MA*Y-&>
MD8ENVO-@ZLL@&CWJ\>Y\_2-HU>G76)*+ELJ+8TM7F17S;PGS(7#)PW<*D5P,
M(F$4?FG)C6<CL^Q:BBB7.8N-1V77M4VLD-1;/+0U8M%IU,ONF&<V&>CXYQ%P
ME9<TQ)!,UIDW#6#2LLE$591X$W*,FBQ%('")A%:'8W'W0NX9RI6;;>D=0[2L
ME!=@_HM@V-K6F7><I;X'39\#VI2UFA9-_7'8/6;-X#B'<,U@=-6S@#^,@D<I
M%=X     #H >H #U  !\  &$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6#?;^
MG.0+ZW\N.-L/H38$]$\KN8_'??U.Y&Q3ZACJFD:XK"'&@U^>W9W(7&/ND5=M
M<GT19R5>KQ]5DE[.Z?4L8:1:H/I!S#$5W^TBEMB;>X?7FKTSB5O:Y;*G=EGI
M53A(BMZXE;!&PNM-VUB2?;"-(*[ 1;0M%V96:4:?IRJ4AZ>DXY]"-K) 03XS
MAFR+CUO4?J^YUMNRC'S#X;V;EQL'F!O1]QYO;B?ENSCXQ-^)X6EZG7KSK[DW
M4MC<P;G(A56L+;U&=(WC0T[7K-%.]13]*:KS*S2$'6K@2)G[4U?%RHY\V>.,
MMQ\>7;3VG-+5>-TMO[EAQ+>:YTY886G7'36X+G7^.?("R;M3MFK-E;KT10-B
MI3DCKND6#9L9L+>.J"V^PP[>_*6:VW]BA!6WAOM]W9MT67?LH(3556X-:IJ6
MH:^XK,#3YO:52L\4XJE'IQ4=HUK:5PAMJECXG6ELV!0%(%O?V<^RK3ZI[#V#
M$.*XTBBI7>SJI+2SGE%D:PB81,(H5=HGK6\[;X9[OHVN(%Y;;<\B*U.,:9''
M:$D+RPIEYJ]TL%$C_/N6<>J^NU=K\K5F;:0=(,';F62:O52-5E1 BC]HRW3T
MIRSY"\J6VC^0%9U5N"K\/.-U2B[+IJV4N\S-RJ5BW(^N&U;'KNTLX*W5C65-
M9[7J]7FKS9(9FW!I5)B0BO25>91[UT16&4JVU:]NVYU3B>SYI1FL[ ES9M/)
M2E;FHDK Z6CK;L.,V#<:A)<?+'<*=$3DY<K1OZQ%EJX;3%RM53/2Y:=4M!47
M)*H9L11M_:)[/:T&7508<P%K KV5-0V5Y1;>W)!95[VA5<8SAHZPJ,?=\!#[
MJBE'*+-O5DDTXMNT+&L25@K>*ATF!%3Q7D_=^TJA-@;P=;@A->:XYA:4H]>V
M:R9;/L%3=[)<\:=?5:K\;I%Y7]V,-=5&HS&^+R:XV!L^T',/8[8""D989ML$
MJ[LT&1;06$3")A$PBQ0<J'M6K?/?A3=(?1&W9VP5BTWE?;6VM;\8=KWB*;U*
MU:3V=KS7+"T;6I.OY>'>LHBX6@R2L,ZL#@:4SF7,_+-(>(=.) Q%%"FZLW&Y
M3XY\9ATOMV(V3Q^[1'DUR<V!N63U_-QNJE=5V>5Y76RN6NG[<.@%8NMAVW#;
MKI=#"GUF:D;E#+3%F3N41$L:T\\<BLMJ7@5L]SIS1;*ZQ?,1"?LW9,O+7N:/
M?;XY*QSQUSEJ<%K9#79K(W1V"V58;4J9YV\-*G4R>49L"Q+(B4"H>HP9HHBH
MZ=D+=>^:M!MG(UQNB#H^GMR<&Z?9]ILF6T;!%5[:LOQ]TO*_L#SR=2W57:?1
MX_8F[=LQRNP&-CT7<I^+DY,9J3L*,//0;K7Y%M481,(L=_/#B5N;DTYT6[U7
MR8V]IEMKS>&H[K8:S1F?'=2!4BZA</3DIL)JXVWQ[VY8W&PZVQ$ JT02>;4)
M^JDD2Q5&8ZJG4(J1[1O4>S+1QJT;7JB3>VX9_67)7C'=[C8=8'H<9OV8J^O;
M@S=V^]PA6#*@4-"Y>534F'"$#"5R%([57"(@X]F5%DB11.V1Q_WOM&]Z=B*#
MK??2>B.7M3HFHN8TOOR4K+3;-"K/&?;SK:<=.;';Q,^^2F4]^ZVD]@Z#.[K:
M[U^2-G*@L_(P;M%%FQ%$RL\$.3C&T\SY:UU+=[[?EKUKV@$(XO\  ZVT5#:]
MY!P&W4+P71,!*;XC=CCMN^M8V&E=;EUSKZS5)D734O7W-1B"5RJPCE:1(I&<
MC^"U?J+VN5.+X+3G(;3:W$)_2])T?71Z*0=)<TYNQSLI==X6J0O=WJKRM[+V
M8UE*$L3E$U?S]_JLEKZTO7M@CWEF.M8"*H=6\5.558Y ZYL6QH&:N3Z#Y8<<
M;EL+:"3YFO'VYG2NRCN6B=@['\1P]2DG,:]W@^1@SF<LR2"TG)HN19BV!1RF
M^TBC_I[LFH-'6O%R+V!Q;*YEG_97[%@.1\?/2;B2+9.95?:<?VVDG.R45;,Y
M;W'9FNV\ENB.T[9)7TP35$8R)&4"4JL? 5-O'D5Q;-JCF-$5F]T>4X[[<V;:
MN2&INS'E'VQ(F=H*L#3+=H5W46O(*/VD]G;M%V%I9X<8):<:)P,'927 \N1)
MBZ S.878$4J>'6D[KK'GCRBM<=H&R0FN=D+[.L]HWWN"B:WK>VI:]3.TF,G7
MZ+6-HZ^V+/RF^]'N84\W,ZV2V-0Z]:-'5F+A*8G9I-"=/7X0BS#X1,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3"*B-A:SUOMRL.J3M?7U(V=3'Z[1T^J.
MPJI W2L/'+!8KEBX=0%D8244X79."%7:++-#J-UBE51,0X 8"+FZS6*U2Z_#
M5*G5Z#J=5KL<UB*_6:S$L(&OP42Q2*@RBX:&BV[6.C(YHB4J+5DR;(-FZ12I
MI)$( !A%SF$3")A$PB81,(F$5@%N*?&9QMXN_P!?0.H%]W%?H2Q=K+:^K"E\
M+,-HLD&VF@LIXT90)IO"IDB$)@''I-*-(1BFZ*V*5("*_P#A$PB81,(F$3")
MA%8&8XI\9K#MMION=T%J"8W6P>14BTVG)Z^K#V](2<$Q)&0<L6R.(U23&7A8
MY)!A$2IG!I"-9MFK9DY01:MR)$5_L(F$3")A%&O?/*G6O'V7IM5L<3LJ\W_8
M#&U353UMI[7%IVC>Y*M45"-7N=L5@ZNQ=>BZS7!FX-D\EI=RP1=S$["P$0$E
M.2C*.6(JJ:<BM+O="1?)Y"^1G[!<SK^(V?&7U1M)I-'=,GXUI*PS].)48EL
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G1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g475892g21d19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g21d19.jpg
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M0N1Q&O)-415@'@Q!<Y++BBH64A )LIL>U35"#Y67?&23T@!=$T;7Q;N9]?\
M[G[_  [^_P >]3%)OB)7#$[-DM"F:8CJ]KL[.>Q9H1KYA?%W0^+18#1U375,
MW,D!U13T@L>0R*):O&J(EOH3&0,9,*SII('1B-(B50Y,FGCX?B;Q?U^3>WU=
M5QZ^(W<I^-;F<4H&*#P$6@?C\[/6LTF\K%2![9?J>TS=>,*=K\3_ "?MW;Q_
MV-5KV61B63!M%NW;&Q(PV*0ULX(.^0I-O737Q?V,VNO>K&3][^D()!)%94E
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M ,;4M2!LA2:[DJ](I!LVL92*8;-ZM'RC=I8(R:41W0M(SMK67B/%0SM7EEF
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MKXJL?5ZB_P!%0?\ V]A_^'RW_1?G?]E?]:N_EGE6]LOZD^KU%_HJ#_[>P_\
MP^/]%^=_V5_UI_+/*M[9?U)]7J+_ $5!_P#;V'_X?'^B_._[*_ZT_EGE6]LO
MZD^KU%_HJ#_[>P__  ^/]%^=_P!E?]:?RSRK>V7]2?5ZB_T5!_\ ;V'_ .'Q
M_HOSO^RO^M/Y9Y5O;+^I/J]1?Z*@_P#M[#_\/C_1?G?]E?\ 6G\L\JWME_4G
MU>HO]%0?_;V'_P"'Q_HOSO\ LK_K3^6>5;VR_J3ZO47^BH/_ +>P_P#P^/\
M1?G?]E?]:?RSRK>V7]2?5ZB_T5!_]O8?_A\?Z+\[_LK_ *T_EGE6]LOZD^KU
M%_HJ#_[>P_\ P^/]%^=_V5_UI_+/*M[9?U*JT]-YM+'=K I^.BS$]6=D-(1I
MQ#W19R(+,7]65E9#<A]!I!!XU=)]6"L*6;_-9'KD8FZX5UMSTBE9;A@B:J=<
MI2CLUWFTF8&,2&S9KN/H.XNWVAB9^C^D[:=-7N@DD-YAD8&**5H_0<G%V>&*
M5G])F=G^VZ.WJU\5,^0UG3"+H.1@]XI]LZ:(KJ;XX3^M3CZNOH3TXYXY_P#1
MSIVYUK7^32RG^?"+BT$$ZZUWH>VUUKKGO6])_OUWPJBMQUK_ *>56Z'>O^LE
MQO\ R81?.@0?6N>=#FNM<\\<\ZTGK]W*:;1)/6O^CE-BSXU_FY;IZ_XN$T;Z
M_7Z]%2#_ %"8N&('I0ZCT=CXUOM0J://F0@./:J:4:;5?DB"[=DT0[^^J-_M
M'"R?&]N/L_J^KO6MY889K$H05XI9YI'VQPPQG+*;Z.^@1@Q&3Z,[Z"SOHSNL
M9G'"!22&$48-J1R$P #>9&3LPMU[W=N]5;@2%<\<N$VC-=-QS]OPLGKE1-;A
M?IRX^UX4XZWSWPMT_=*Z[YWOGO[RIUK>]=YC=G9W8F=G9]'9^CL[='9V?JSM
MW:>"OZ/UZ.S^/1]6?K_FOOD()YZY[Y8-M=<=<]\[UQ^_7?"B"W'6O^GE5JW[
MUO\ Y2/&_P#)E$T;Z_7HOG0$/SKG6AS76N>>.>=?9_NURFFV2XUK7^;E-FUX
MU_FY03U_Q<*J_-@0V];YV.:[YZY[YZUM/]V^>TW"/>M_O_FZ2=N>-_Y^5E-?
MY<(OOH()ZZZ[Z'MM]===]];VGKY]==J.5N^M_P"??2KQUWO_ *RZF_\ C81.
M0HGGKGKE@VUUSUQWSO7'[]=)J-EN.M?]/*K-KWK_ #=()[_XN%31O)NB^= 0
M^N=<Z'-=<\\\\<Z^S_=KGA)NCQSK]_\ -RDU;)ZU_P E'C7^3"KHS=S)L$'W
MKK6QS7>NN>^.M?9Z^6^5$W27?._^CI-Z[XW_ -5=37_&PFC?/\_54:1.8-$Q
M;F0RQ_'(T%;+-^'AN1$6 84W<$B'W5IPX)$G#9FBJ_*$]-6O"BW/3EZ^3;HZ
M[673XZRP03V91AK0RV)C8G&*",Y928!<S<8XV(G80$C+1GVB+D^C,[K'))%"
M#R2R!%&SMJ<AC&#.1,(LY$[#Z1$PLSOU)V9M7=E6^0@GCKGKD>VUUQUQUSO2
M?[^>DU&JO&]?]/*C)IWK_-MNG_R<Q+(OG0$/SSKG0YKKGGGGCGG2?[M<\)HH
M\\ZU_FY2;H<:_P"JEQK_ "85'9G[V^OU9DV"$=:ZYV.:[UWSWSUK:>O\;E1-
MVEWK?^?ZDWSSC?\ GY<*Z_XV$T;R^OU_2_FOK803OK?>V#??6^NN][^C]^^^
MU55NNM_O_GZ576[W_P!93K?^7":-Y-U[TY"">-ZWRP;<[YWQUSO2?R^72?;-
M3C>O^GGM@RZY_P VVR6_^+A57QH"&USKC0YKKG7//&M?9_NUQRDDCSS_ #_S
M:212XUK_ )*?.O\ )A%^[!".M=:Z'-=Z[Y[Y[UM/7RZY4X>)]ZW_ .MP0>\[
M_P"ARKK_ (V$7UL()WUOO;!M]6^M][Z^C]^^NE5%NNO_ $[5654W_P!;OK?^
M7":,G(03QOG?+!MK?&^-\[UQ_P";M/IGWQO7^;Z>Q[+K7^;;5+?_ !<*FC>3
M>Q</(8%OKIOPR8[[13XY[1YUSOM-/I+E%/7?&NM]<<](I<\<;ZUKZN.-?+Y_
M+*Z/HSZ/H^NC^#Z=^GGIXITZLVGK9O7\RY=@Q'6NM=#VV]=Z[UUK[/\ \[2G
M+WGO6_\ UN2+[6_\^G2W_*RBJOW\$$[Z^O[@V^K?>U-[^C]^^]J]K;Z_G_GV
MKWWW\_\ E=;WA%^<A!''T_2/;:^G?&^?DGK]VT^F77&]?^KT.8[U_P!+5'_D
MX31?GX"'^G7'X<U^G7.N-<_9_N^C26D=<_S_ ,VDN>4_E_R=:UA-&\OK]69=
MQLR:--J;;-TT=J__ %FT^?E]?S677_?_ )_]^<KJ?^LKWO\ RX1=K")A%:#.
MP(&1)C0H^;1)\8,.I@Q$"6<C#N211[7I;\ GS0<Q1>=NGKF$'?D%ER#9)12-
MEMZ'&.6;S>D=D5WX1,(J2)/!3W)#L(5'EN!)8@!)]#W2+OD>:%*Z0)BG>T>^
M]($&"V]).VJGTK(*?XBG'/7[L(JMA%2RYL-'VB3\Z5'AV3@H#"(.R;QNQ;+&
M9,:'QN.BDEG*B:?9 [("HP((9\];<$"I!DP:IJNG**79%5,(K193V&$C\OBS
M&2B'1^ (BEYL-2>)]+1;@V.V9%<G._GI <N[#_9E^6SA7ARF*=,2*R2;,@R7
M<$5LQB\Z6FL$-6C$+:KB3UM&^2?<AGP*:1TI#@/ 9BB4*J&9&S(JB1:8\4Y:
MEG2CUVAPD*=M"777W%VW75(KE5L"!H%^(^M-HDD>4E/$&3"JR,/P6[FO<2;S
M_B(<#NGFGG4GZ@CIK->0/*.RNXFX0D>FOX.KP\Z(KOPBMZ4RV+0<*O))G(P<
M3CS9V)8.3DC*L@HE!\>+L0 1FL1(KMVB;DN<)C0XQ#M72CXF_9L6W*CERBEW
MDAAFL2-%!%)-(XF31Q 1FXQ@4DA,(L[NP1@1D^F@@)$^C,[K#/8@JQ/-9FBK
MPB48%+-(,<;%+(,40N9NPL4DIA'&VNIR&("SD3,]PYC69,(K<BTOBLX%JFX=
M(@TH#H&9#'5R8(@V)L4CT3.D(Q)PZCEHHJEP2 2(24!EV?76EV!0>[9.>$W"
M"G'.6:&:N;1SQ21&X1R,$@N!/'-&,L1LQ,SN,D1A(!=Q 3$VK.RP5[->U&\M
M::.>-I9H7.(Q,6FKRG!/$[B[LQPS1R12#WA(! 3,3.RN/,2SIA$PB81,(F$3
M")A$PB81,(F$3")A%#KNXQQ!\Z$5Q'3UIDV+A5F0=Q?\/:P\0\1[Z37;%)V;
M>#HWVZ9J\](D14?=2&0CU.?H=!4^M\ZW73SZ?/\ 7\ZIKY-KW_F];J/_ #-(
M?0IUK8:-Y PXQD"G4@ 04BATIR<-B!1@BS5<ON$V;!B_$M])-F@*0IL!+H\@
MBL^<C?I[1?/*DPMIM\69W]3NW=X_CU[E0=>NOGT^O1919:KE =/?\(?JS_7Y
M'?\ NN^;<G6_Z/C/[#)_Q+(*-!_.W/[2/^YU%/F05)3")A%#M_"K,-5)+AM/
MF.0=@N.0G0AUHBR"O'H]M(P[N41X.?(BCC"-2.5Q- Y%XS*'@<FVC$A,##ZS
M)?@=M/<NB5<+416PWP-OWMM<V8GC-HY# 2 I(XI7"62)C%Y(P*/5MRP66E*$
MV@+;+Z.U]6%W9B%S$2=B8",-P ;B^PB8M.BPA.>C9:WK&HH)4#7T#9,H,E;%
M.6Z8+CZJYO.HJKH^<)#;7CIMB;+P:%GK#8R(D I..+AWD@+' ;HQ:T??V.]!
MMR$JW08^)[-J>V]"O$ UXZ@ 5KL5NS<A<JL@$ 3S! 48G<D8QC$#8:LC5F-Q
MB@':/E0QP=IE,BE*<G:'M$,5>1FF F(H@>5B(:X.+D[CNE%Y7%G/NU!Z#EUT
M>LK=KE*R.H[3\>F%?V)4;A ;PB5NR-&O,GGR>$*^C9<D%2:"HI!RTUW8T\&(
M+N[&D.[(CS7AQ%H0$,M93;;HPT\74L=GYEN2&>O:9RU"G(&2OP#8D$3=SEG&
M'L\!=*\?9Y'TEF,'B069+%R:+F[( .*6%V9MU@"J5I'B%W'00C*3FR-J\A\T
M6U",7W[,\YQ;9,(F$3"* Z>_X0_5G^OR._\ ==\VY.M_T?&?V&3_ (ED%&@_
MG;G]I'_<ZBGS(*DIA$PB81,(M;/Q;#@1M\/KU,'<&!:!=U6[;ML*6(-$B+CC
MN4@OI[08]K<N5N>OLE?IZ32ZUO[-3Y;_ ,3KY=[\&<,I<;\.2M%(\0Y!V*1@
M)P%^SS='-FVMWMWOXMYKFN+S!N'<J#F+$]9M!<F8GUEC[FUU?V+.FM#@0U"H
MOH.8%EMM(S'$W>AI!H^^Z]]B6_T<./NJROV/??V:GT\J?3OK[/OY:W]/7RXZ
M_#+%:L<V*2/=8G<>8!!N9I"U<=S-KIJW=YLM]6,#@BV&):11Z[28M/0;OT=]
M%?N0UG3")A$PB81,(F$6JWXQYX&GX,MX,H9$IF-RR@%="NR+/DEM+GT%5KCI
M73'I;3K:?+?CM???V7TZ1XZ5WOZ.=]:]&^"R&9^,\7*T4CQ=FS;<Q@)X]?B/
M)#IOTVZ[G8>_O=F[URO&9@V N YBQO-CO1W-N_[1J/\ <ZZ]S._=W-JMGXLV
M&-I*+A2PPN@BI]DLL+?M2"22OTZ[^R44:*J\<*?1USU]'6]=?3O77R^6];SS
MV2*6)V:6.2)W;5FD @=V[M68F9W;7Q74"8'JX$)LW1W$F+3Y]'=5/,:N3")A
M$PB81,(F$3"+6)07_P#%'^(-_JB\??\ _.3W/0LU_P#XZX(_\TXH_P#STER^
M/_\ W5Q%_8\-_P#CLK9WGGJZA,(F$3")A$PB81:B _F_T37\1]L,HY%2!&4^
MH/SF/Z[G@&91T+9M,&9!-+?+TY'@Y]_)V[1A6TZ;R$38T1U'G3$W7%P2R5D9
MH)[;REV6@Y7.[=/5I\S]&_Z?-HI+L&C;*BM@+CHQ&;?GGF/1JOI/)Z\C5T$^
MYK*3J\.MR/2IPR-3BT@<A?1P8>0J*332%.I>#83 HX=RMHE*#:$I"2(J:_-[
M/\G_ $?F5JBJJNMLW&:N*L_1-I0_]C)&UJJ%P+T&R#3VI"KFY[@/ Q]F2_\
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M(5I6FA>$#%B'5[-(Q(3%P,# Y2"2,P(@.,Q(#%W$A=G=E9)/5E!PDWD+Z/\
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M,H?.H<7PDYL29Y:N.E#7J+16(RT\A-K),WSN!?,MOWD?X]OEZ^RHN%7,'?\
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MU,%.7..WF0%C*D4;S'D)+9RS5(9BYI5J;268'M!.5?G6X[$L8@321 \8D[.
MZ7P4"=V:PQ-&-4(!".>2-M@S6'&&3DE&TO+@.(#<AV&6]V;0B69CB &N/1L*
MGK :T;PF/T18, 55069M],S1N=589"#6PSCOA?338F+%NM+((?<VOW5)OWVG
MVLAQWJ&G#XOF@(G>:2]7G9G9WU (+0&3EW:[Y0Z.^KZN_@ZG<LNU!(S,T8UY
M(_!M"*2(A9F\MH/ZFTT4[Y!4A,(H#I[_ (0_5G^OR._]UWS;DZW_ $?&?V&3
M_B604:#^=N?VD?\ <ZBGS(*DIA$PB81,(M2!;X*/B(T5)F'@RS=.RQ%Z3=:2
MG>N4M.7[E5VO]ESV&4[Y3^U6[^CGKOOKGGY:WUUO7SWZE!\,/&M:"&O%8Q[1
M011PQL^.@)VCB!@!G)^KNPBVKOU=^KKC)> ^'I9))3BM.<IG(;M:-F<C)R)V
M9FT;J[]/!2#2GPG?)-!6I#;B@ ^?IS*"/GI$ H7F&B U-T_#$@2_3IEP+;?>
M>?N!9YSQQTMSSRKM-3>NOHUK<#,_"AQ9GL9:Q.1GI'3N#&,XQ48HI':.6.8=
ML@]1].,7?3O;5O%2<?P=A,9<AO58[ V(')XW.P9CJ8%&6HOT?T3?O\='\%LN
MSSQ=4F$3")A$PB81,(M=WQ5H)-;)\.VE#J\B,DG,L)2JD'(^,Q((1D)Y\W#W
MM6QDLNT$BF[I\X1&"![XH_420[X:#V;IVOOA!!53GN?@XN5*'%^.M7K->G6C
MK9@3L690@A I<-D(HF*20A 7DE,(P9WU(S$1U(F9<YQ7!/9P5N&O#+/,4M!Q
MBA I)"8,A5,W8 9R=A 2,M&Z"+N_1G6Q'.&71IA$PB81,(F$3")A$PBUK42&
M,-?B:>]S3D42;ARM3^24!99=BZ1&$EV$>G/#Y%@_42Y:O%67:J?+M-NJIVVZ
M4XY6UQOOG6^^S,L1?!]P7$,D92QY/B8I(V,7DC8YJ>QS!GW"QZ/M<F9BT?37
M1<S0 VXGX@-P)@.IAV$W%V$G&.QN82TT=QU;5F=]-6U6RG.!73)A$PB81,(F
M$3")A$PBAJ_[YKGS/4\GN:U2;@9#8ML0W==,D$W)$@5D1L=&X\%&-UW#1MV0
M,GBPX<W4?/6 QGMQT_+D1PIJ]?MIV.Q]G*W(J-,&.>;>[;G=A$(HRED,W9B?
M:$8$3L(D1:;0$C(1?6Y?+4L'CY\G?,@K5^6);68C.2:4((8@8B$=\LT@ SF8
M1CNW2&$8D8X=MOBJ>8W5<#;/296<[ /K#D%..FT?BX6;OQ%SC8X-E,8JIXO
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MG?N;1E#8K,DMA@EA (I1C%B@*0GU@AE=W)IP;[J1V9F%M&9N]^JN7]E/2?\
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M+KLKTQ:7E?B*1L;#JBD)HQ7<=G=6$C[F?M@RDN/1$R'Z 5,YDRO<<T33U_\
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M9>'+%LV5QZN:Q#"YZ/B+*WYFYD%,%X/S&@[.YB:P=Z6>RJ/"6\7*%+7K%U9
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M>T]H9\G!$\$02,'VS:Y5 DEB>46"5Z\\D)35GD%F8WKR1N6GI:NAQTY).89
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M4O#UZVM"_P#!N?,XL@BYG=[71,&2*G*G0T$TAL,3<_3OY_8N72XB5NOL._\
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M$8$$(E#VTAE^V@)R5-/K\W>J%7_M"BK!CT@F[27 0->QX8%>.YI(9A!&S#9
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M!BJA20R!=A(N'06/QLJZ]_KU\?4[?XNOIIXM/QZ1AYY%;."\36'/H@:ANI%
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MKZMQ]I2T.:#2BY&+29?MR:XE QT%EY908[FCNN!\FEXA^28R&2!X$.+N>R1
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MXU?G\-*@_7"9_P!WO'*PWX?D_=-7]])S^(ODS"^_+W\/)^-7Y_#2H/UPF?\
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M/IPPN40D-,8.T!88^6P2/MB<W$2E-\B2^O>#Q[: [\9N$1,EY=&Q\4)1"/\
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MQ@6KR1A5M"+BYCLV&7Y_P-V'_P#EUS_^JCG#X;_M2C_\\?T.MIQ%_P!AY/\
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M?IT_,+07\<:?_4N%_P!=8^(\U\CY3W?;^A3[).'?E_"^]*/TZ?F%H+^.-/\
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?C-JLL,YM=@F$3")A$PB81,(F$3")A$PB81,(F$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g475892g74c97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g74c97.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[14B4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!I="D         "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 \     !  $#P     $  3A"24T$)@      #@
M   _@   .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #-0    8
M =4   4$          $                          0             %
M!    =4                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   =4     4F=H=&QO;F<   4$    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   %!     -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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M:USR"XM>WD;0(W5O;]%GO4W]$R7NNW=2R37:UK6-D LAYL<YCF;?TFNVM_\
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ML(V6MAQ&[VO]Z?!?@BAF-@FLTXS6UMKJ<UP8UHV5L]A.WVM1KL;'R &WU,M
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %*34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    0
ML(=I  0    !    P    .P 'Q),   G$  ?$DP  "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ,#HR-" Q,3HT-SHQ,0!(87)I<')A
M<V%D(%)A:G4   .@ 0 #     ?__  "@ @ $     0  !02@ P $     0
M =4         !@$#  ,    !  8   $:  4    !   !.@$;  4    !   !
M0@$H  ,    !  (   (!  0    !   !2@("  0    !              !(
M     0   $@    !.$))30/]       (          #_X0%,34T *@    @
M" $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    0    L(=I  0
M   !    P    .P   /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q-SHQ,#HR-" Q,3HT-SHQ,0!(87)I<')A<V%D(%)A
M:G4   .@ 0 #     ?__  "@ @ $     0  !02@ P $     0   =4
M    !@$#  ,    !  8   $:  4    !   !.@$;  4    !   !0@$H  ,
M   !  (   (!  0    !   !2@("  0    !              /      0
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M%&1B<0/L(W,7#J3@-M@*S<DBO@'+/?B@52 '=H3>BO55=V00D]=12"TI-:L
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M#8\TV<Q>4]$>(X>268+K\="S?8@KP-=_J^DZ[&ON$M]=-5M< 9U@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M$SSYSZFV'! P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# -.?Q<;6%B(!7L)3L$(-$L;/C9*[H
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M0<:F![!R'E#58"22-14BDVD #M)#\R.9:>L]K@3-@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&FWXUY1"-
M><JYFJC*5CUX5;74B8V1&;)OVL.:R=M*WGW.G[\]YTFU>3CE:=-^W%5A%B,K
M&14>:G#)Z8_(=I- I0/?O\RX/P]R3LMY)K)ZZ7F))/[^QV8F2SJ;6W89R=1L
M9:,T&1:R$)1>QV36PYCED1QF+G,0'S$\4>@XK( X1F]<"A[!7L"Z. , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M4RD56\&6:/ELJ>>8[7XF?#EI=)B8GE>UFW%Y8#*!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MWF;%B& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P#55\669$X34%4EX]9,[J62)VZV=,)W4X=[++4!B L.E9^8NHA"7\AC=82A
MNC$19A>4)7,X-007'$7Y5I$I1-&T4&* 6!^'NH\[\I0! P9)224!SUIQB:R$
M]J8)RDS.8E;,XC,U?3%G.9',3@>8+2D47ZE !K*Y%%0!S[X1!2SN%,P'>"9]
M??OWZ1Z%U,$# & , 8 P!@&L'XD'B*8>KA,&DE;%1+:<0+@N/_"GWBK :>"F
M>VCE1-N_X0<ILRC)VRYZ0^YX3:ND'*W"SE'M%']>C^LW3#4-_P"-I>7HV117
MJFD_$51CY=DU496-DS6[0ML(\5WUV51*=\16ZNT,RRJ\[(Z>[SQ-KVYN/J%5
MK8>=-3^-0L/91=5#+$LDRLO6ZO\ -VS++*QPLPT\<'\-SPG-_+"\VGEHE _4
MTF MK&V,>C[[LDQ# F[Y,DY6($-MVZ+DF_>MVNDT6>EFS-JV^?W2RKM1)M3=
M&.E>I[#G4]4UR_';4]1IKPZ\3$MFZK&Q4MBYVMME$5[[;$KX6ON2M$_WLUC*
MG=U"WMA[FC#PM-JMC#Q+&O?(O2*WNN9)K6*Z^69:T1FYE^UG9O\ 9$)$MM:S
M?)K$8 P!@# -8'L2WK'"6,E#@1TQ%P(X.-(([$.EQJQAR^Y446>K/&VTG"R#
M=3GIBDWTK]OPJU64ZXVKU\^?D/\ ;KZY=5MM]4<;8NVMQZYL_;FFZ!I6J5-H
M>7?I>1KN7J$WV7YM^?C-5DW8V*]?P%6*MT8Z78N18Z/:\2GK3H?LK:^H;8LU
MS4=/PM6U')SLK&>,VI,E,*JB55*$IMAJTLL68O:SM\1EM18:%B(FS'D6P9;8
M59.GDP<+DGH60.@K0RYY_P#F";))DP=\;<J_+6G+EJH[4;]N?E^M7CE+ZV^U
M^55._6GV(^IV]NJ'2+*U#?.5?JNHZ#N;-T##U[*2%RM7T^G TW.KLR[855RL
MK$MSK<.S+A8>ZNJKQYLR5NNLU3UIVUHNV=V54:)6F+CYVG4Y]V#5/-6)>]^1
M2T5+S,U57+2MJU>B-+=G%<JJVGSV(:A& , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8!KL^)<>\B"Z*'C/8U?2BRH"8-R%X# P=S(A$P;EX?6DZF
MQLB$D\2EL%D4=[[A("3A%U14I'K'>#?,552?M3J[14";?%QFK37G&"[IVMI%
M3\*!D9]#NJRF"[1]+X;,8/8LLB%D")6892>;-I')N;#"2AP>E?,QE*DJ*+NI
M$X/E7)-9XJ!.EA2UW!8:>E;"'2RP'X=JFJQA<&9L'TKD3QPZ;LFHX.B6)!Q*
M:JB[E/MP\*EAHL<SX<D"+YJR:KK< 4=B_P 2"N)1*!<52JFVV#AO,0<!LDLM
M_P ;/@%3RF6WC+_.T,92(H'L0DG)FTIM&$&Q+0A7/$Q:C6?*+T_V*W]R@V Y
MFY/B&U924KLL#)X)9Y$#5G1\%()\$90]6+N;(C]&/?1JU8CD2$Q'2/9]S5+'
MLTD<? F,(;/%41A&4,W'U?I!Q[_0D;S#[,J;U<U=+5YHF/=CXY'SQ(3('D7_
M "3=<U]WT[%-4 4B-\&>0*'(=V0D850A$'C241U8)("NGJNFX%M< 8 P"EOK
M^ZIE6#&+!(6X_$O9)HDZ=G=-D'"S=L/Z:I<LV6G2:S?A9?MUOM97I+I1---/
M26^>E-]\^"/MQ=?]]]'],V?H.P<B-&U'=DZKE9FXIQ,;+NQ,32IPJXPM/3,J
MOQ:\C(LS8LOO>FRRJFM%I[&MFQ-[=$]AZ'NW)U;.UVOXS'TOX6JG3_%LJKMM
MR8M:;KYJ9+62M:NU$AU5F9N_F%B#C/']XS>REY-&)JZV;<!63<LQ.]MF[=S]
M%=SIHJ/>;:)((+=:[ZY6:J[2TOOCEQRKVIKE/]%I^PW]H?J#U:MW=M+J!E_M
M_*V]@X>LZ=N1L3%Q,J<?*RFQ+M,U",*C&Q;G5Y2_"N\%<AJURDN>V*ZY6KZV
M]/\ 0-JII.K:#3&!5GWVX>1IT6V6U^)75XR9-$7/98B]L37<G?-<--4JJRS=
MUY<^AIY^& , 8 P#KC?%E],ST;>;"H8PDTC8J$QT,47/<"F"QX^_D;71+KA(
MJ\;KK( 6"':#5-DT^CPL32(*N^U_T-TV_@7[5>+H.\-SZ=M[7=M:5G5Z!AU7
MX^H96(LZC8^H)XUE5.<O9D)IZ1V+.*EGA/E+;99#.E?9Z6Z-XU^FZ-D:KC9^
M2MFHY%E;XU=TQC5KC--:L]'FC9+3$MXK1W13-:KQ$MW;%?A<7K([O\Z./\I%
MC696O)<\A>R@@:V%,I UY%"C;8BNS9)(LTR_.BW;8GTV133<])(/>^.5G2NM
M>@/LYY^+=TZQ](PM'T[1L/;F;;I.-1I6)5A8=U7A4YD7S12J5_%.^2_Q=D1+
M7V_]18TV7.:TZJZ>V)NA\ILO(RWU3&3-><JY[[JG[[*)KBRQF?P8BJ)I69X2
M.ZM8A4@V29OHUH, 8 P!@%9O0OL7S9Y5?5L,ORV(Q7+^V94WB,):FW?Z%B#]
M?>N52+OA+2G0J-#U5&R!:3DM-@8MP]9(O7R/;I'759BX&9FQ=.+19=%"39;*
M1S"K]WXM/GVI'+-$3,1Q$E%F:E@Z?-$9F35CSDVQ31%C0O?9/TC[ECR[G;A5
MF8B9B6B)LLDJFLFFLBIPLBMQPJDJEWRHFJFISKOA1/OC>^>^.^=ZZX[YWOGK
MG>MZWO6];RC*T\\ 8 P!@# (>.W[4,;DO^)&IN*9G.%N6SA#>G2K9DXZWK6D
M'Y!%!1@R5UO>M*<.'">T=[_ZWT_]_+1VXOM)=$-J;M_^#Z_U"T73]QK>F+DX
MKQEVXV!E6<0N/J6IT8UNFZ==$S$6UYF72U$S'Q'A1/)FVG].=Z:II7[:P= S
M+]/E&LKMB:DLOK7SFS'QGL7(O28Y[6JJ:'X^3N\B7DU.%4^%4N^5$E..5$U.
M.M=\*<=ZUUQWQUSO?/7/7.]=<]:WO6];UO6_EO-W5V):B6U.EE=B+9796T.E
MB/$,CHZS*LC+,,K+,PT3$Q,Q)A3*R,RLLJRS*LK1,,K1/$JT3Q,3$QQ,3YQ/
ME)YYS(& , 8 P"LD=]D>:)9Z+EGE"/6Y%"=]PH$V/GX"W>ZZ?(-U_J]N1[5U
MO6F) Z&;\H/3P)BY7*A63UFY(-4$U%-I5CZ?F5XB9SX]BXMC2B6S'E,Q]>/6
M%F>85IB%:8F(F>"A34L&S-LTY,JELVFM;;,>&B756]/+TEHCB66)EE65EHB&
MCFS>497# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# -1GQ-:ZG%@SKR !9W#!HA"Y+>#88VAMB>>*FN&-HV'&8/
M8$\!V4I(K-E<6YC;V+#XZ\V-&!UG)<P0Y;M!R*R3HDAT!9/X<B[=7Q_63=%_
M^07#F;7C9CI.'5Y!!["21BX)['I2$!1^J7I2 [C8&1C"@:.'0)@UJ5!&+&3D
MC!,N7?O%1,^LEDKFK/\ YDJV;5;U/+!K)&<!%P#J<U47$@+! LG:B7WRL7-G
M ,F'"G[QGRN.[?=A7;ELU>.%!_;,ARV>MA!5>/\ P]ZS DJX??\ )=L/F=?,
M*R$NHXDTI*)Q2>B*2GYBSJ8%R^.5Y2\,&,&M93,X_*@^J[0@3HSKM-K-W,K;
M<;2Z S<=XQ@#:X&EREYO94K*\&VDX+Q*0.8#_@LFMAK4>Z*4MTV("5\%)\3!
M_5O:L8?!PAL-6RG*FR:,!0,<(OT@,=J;X?\ 1]-7@SO^)D9TM.$(B;C#U$L2
MC2H8V1DIA^:D$T*)CHD,,?Y"4<$G:&Q(XR/KX<UVAH-!QKADR<-Q/,EX<$#
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M:9D3^O*]<3B4NJ9B4\:T*\<5H%G0RI^HBSEC2+)-PJLC:EU1^W2?ZW2H%^,
M8 P!@# & , 8 P!@# & , 8!6GU-Y"\^^SJ[2J_T/ &,YB[0PQ/"N^EW PX!
M+,5D^_O ,@'*-RHCMZWX['$^63E+@B-<+LW7*B?>OTUF%GY>GVS=B6S4\K*-
MY0RLL_1E:)5N)\UYCRF(F"AU#3<+5*/AL_'3(I[E>%;F)5EF)AE99AEGRXF5
MF.5F5GRF8)QAT-BE>Q4!!X-'A$3A\5%,PD<C8!@W&!PHE@ER@T8#V+7A-!NW
M13YUK7/'&M]=?J[[WUWUUUNFLL>UVLM=K+':6=VF69FGUF9GSF2KKKKJ1*JD
M6NNM81$185$58XA56(B(B(\HB(X,ES@<Q@# & , TJ^K/BROJ5N8]55<UJ'E
M3>"E-AY<<DI5^RV_+-])[)# ;4<EK[/@>IOMGT3>J/=+NN%?T#N44>5'/FG?
MO7^S;&Y,K0='T3'U!-+O^'U#*S,FVKQ<A8CQJ,5*5GP_!F?#FZV;.ZR&XIA5
MB7W#MCI:NLZ13J>H:C=BMFU^+B4X]5;]E3?]JV]K)^;Q(X?PTA)A9CFSNF87
M9YYTO*/^CJ>B%O1MBZ$L9.W><N0[U3A=T(+"W[D66&J.$^$TW7+9\T6T@ZX3
M2TY;;17VBCTIM+C>&S]T8>\=NZ=N'"J>BK.2SOQ[&AK,>^BUZ+Z6>(6'[+:V
MA7A5[T[7[5Y[8UON#1;]OZMEZ5D.MKXS+VVI$JMM5B+959"S,RLLC1W+S/:W
M*]S<<S-V9,688 P!@# -7]A?"9\T6#:+ZQU7LWCC,V64-R"$1XD,:QP@_<+]
M.7WV:BXEP4#M"+CKM5VU9/-<I[55Y&]CN=I:1T?K'0'9.L:[;K3OJ>&F3D-E
M9FF8E]->%=<[2]DURU#WXZ7/,M9779Q'<T4S3';"[)P.J6X\#34T]5PKVIJB
MFC,OJL;(KK5>U.^%M6JUJUB(5G3SXB;(LGF9V4@ (B+ P\:C[!N*! !C$.'&
MM>?T-F T<V3:,FB'.][WI-!NDFGS^K>^MZY^?76^M[WO=&+BX^#C8^'B5)1B
MXM-6/CTUQPE5-*1776L?<J+$1S,SY><S)KN^^W)NMR+W:VZ^Q[K;&GEGLL:7
M=FG[V:9F3E\J#J& , 8 P#YN'K-1QVT3=MNW:6OU*-N%TNG"?/\ ]>T==[4X
MU_O7^^N=:_WE*F;AV9%F'7EXMF74L-;BI?4V16L\<-90KS8BSS'$LL1/,';-
M%ZU+<U-JTM/"VS6\5-/W+9,=LSY>D2?3E4=0P!@# & 1O< 602*L)R$BRG?!
M\E'GS8=I-3Z2BZG7&MJLTU?GSI-1\WY69I][ZYUSVOSO?7.M;WK5G6[0=R[H
MZ1]0]O[/MLJW+JVUM3P])\*WP+;[[*?GPJKY9(IMS\>+L&NV72*WR%>72%EH
MRC96=INF;LV_J&KJK:=B:GCW97<O>J(K?+<R<3++19*7,L1,RM<Q$3/D:>J+
MA<W)73'A(0>28FX=)@3V5:Z25;KQACRY2>+=&D^]<=LN7PY-?35LZUQLFDI^
MA#A9-3>\^(?V?.DG5RWK=L1=.VKNG0LC;^[-*U'6=3SM)U'3,72M,TO4*;-8
M^+RLFFBF5MPTR,3X7Q&G-F[X94L6V8GVGO[=>TTV9KGQ&J:9G5YVE9./BXM&
M5CY%N3D96.ZXD555N[Q,6RED6]L>%"3;RO9S&\W/T'G@08 P!@# *(?$EM()
M2OD:Q;2DY)Z/C,.5#$CR0UJY>/R[)1]RR0"M$&W'7ZEGY-T/YYZ==MV/'T]]
MO7*#?7:FO/\ ]I?I?OKK%TOR-@=/LO'Q=8UK7] 7-C+RYP<7(T2O,_\ R->3
M?',_#X_=3J%]*K99D583T556V6)6V;; W?M_8NNON;<E5MN!IVFY[U>!1\1<
MN;-4?#^%7_\ TMX?'1YE4K:^'=D16=>O5\'7XEJ/I?UR-J^4 N*_DI-[*R4&
MY$[(DAQ^'M [YWW&CJ_*:ND) R;H\.E2:O+,,2WQO:*(]T@@@[T[M#[!6N]!
M.JW3'?\ L7>EVM;<P=,S,#J57J/A8.4^==I&539;IF-3\F1HFJ:A9C^#I][7
MYFEVX]5MF3F*WBX]P3[2N!U-V]NK;.X=!33M4ORDR]K-BR^13\'7EU.M69:_
MG5J&'1#M9DI%=&6MC(E5#+"6]P3/<1KD8 P!@# /!15-%/M593A))/G?2BBG
M?/"?'.O][Z[[ZWKGGG7_ ([WO6M?^.<++:Z:WMNL2JJM9:RRQU2M%CSEG=IA
M56/K,S$1]3DJL[*B*SNTQ"JL2S-,^D*L<S,S](B.3P0<-W27*[5=%RCW\_T+
M(*\+)=?+?RW^E1/KKCKY;_UOY;W\M_ZSACY&/EU+?BWTY-#\REV/:EU3\3Q/
M;96S(W$QQ/$SY^1-E5E+S7;6]3QZI8C(\?O5HB8_.#W9W' 8 P!@# -9/O/X
MA6O)!B,P.)0YA,I](0^I(ZV;?.F0( "[>N6#+M=)CQIV2?$W+%_RDW2=LDVB
M+;:ZRJNUDD=Z2ZK=7EZ>Y&%I>!IM>I:MF8\YCQDVO5BXF+-CTU,\51XEUEUE
M5L*BO6J+7+,T]T*;&V/L*=U59.;E9CX>#CV_#KX-:O???V*[PLO/96E:NDRT
MJ\M+=L0O'<2MX:]EC_8<%D9=:,ZB$R@Q$:-E85L\[(BE.#+=VN(+"7:R*#CE
MJ0V.))=,7/"B[)9EWQTY=)]I+]W[I=U(HZBZ5F9,X7[/U'2[J:,_&6R;J9C(
M2Q\?(HLE$;P[O!NB:WB6J:N8EWB5:;9O3:-FTLW'IC)^+Q,VNRS%N9(KLCPF
M5;:K5B966K\2N>]>%>'B>U9B8+P9L\PP8 P!@# -/WM3XH;KSE:SFH*\K\3+
MCD;0&.)B9DI%\U'-G!5@W*-PHID-Y376<)CWC1=T27>:1166^UX8K[345UYX
MZE]<VV9KS[=TC2*-1R\-*'U'(S+K:Z:VOJ2],>BNF(9[(IL1GM9X56;LBMIB
M9-L;.Z:KN'2UU;/S[<2G(:Q<2G'K1K&BIYK:ZU[.5A9=75:U3F8CNEXY[2]7
MDSTH"]54^,M .'7CKO\ )/H_(X\NZY??ASXSANJZ;H/N46WWC-=L\:/6;CIN
M@IM!SQPLEPJGWK-I; WIB;\V[1KN-COAO-UN+F8;OXLXV71"38BVPJ1;6R65
MV5OV),H\=RJT3$83NG;M^V-6LTRZU<A?#2_'R%7L\6BR6A69.YNQX9&1U[FC
ME>8F8F"R^9J8Z, 8!HL^,18$DC"57@#U5HCZ&-2\(YLVXVOI[SEYFDTRTRC-
MAZ#U7$YM:AD?- 1@$<6$2]R[CVF&S,?V; M#K%L\-HNQ,<_3WSY%I_A81N+/
M?+4'N!('!^YU/6\MCI2<Q>3U;8QJ1UU!;<LUI48*7VS3Z:<*LV00Z(DD11J5
ML>4W).1=''A9!N8<$$>!'G]?4V&2LR_CT:.G1<:,S$D)%/7["*1Y0.B<D3QL
MAVJW#"EI 4" T7Q!7GALW6+EQHY+M32CMZW1Y[4Y UJ0GXC<AFC*BSJ-$L1<
M<L&O?*\XM-=[:>U35:NO6]GG*CKX#%!;2OUF5D]@I6!<KRXD[,P)!J$51>"$
M2[K?;#@#FKL^(')JHGEI1T%0BU@QFNI)(*L8$A$Z?)3>676(\P/_ %0RBX^O
MV-?&]\0TA#6B0#N6-)&5D:4E<?185^5:)\KJA[]_V,O\A>_H/ZG.O80Z$"ZX
ML@9$Q1QU 2,I<D9$^(<+O49A^$&$XO%BKF+QS?0'AL<*#0QM^\)%AI2(QU]&
M2:&P_D; L 8 P!@# & , 8 P!@# & , 8 P!@# .LC[;\HJG_2ME29,BK%.I
M-(ES2S585V\:D$GO*?7!<:KIVU^>WW.OJNT][4X^_P"G/R42W\T>/B_]H'JS
MK^P.LG4#1=R[/L:N[7+\_;F71<V!7J.BY:5V8.3R^/D5Y/?$S%V1CMRN1%U-
MM475MS[=Z<:5A:MLK;]^!J2O-.#7CYR-$6MCY=4S%U3<.K5]D^2(\1_IPC+,
MJW)N\\05[_Q=YGKJ':8+C^6*1IWQIVGM)\\X*G2)'DD]XWKG]*[_ $Y^XUSK
MCCGE#M'GGG7.M9](/LO9.X\WHEL_4-TZ2NB:KJ/[8U!=/BFS'>O3LO6L^_2K
M+JKIFY;+M/?'M[K85W1DLE5[N(\R]5&P9WSK*Z=E?&8]7PE$W0ZNLWTX=%>2
MB,OR]M=RNO$3,*T,L3/!;+/0!KP8 P!@# & , 8 P!@# (]MJ1JQ"KK%E:#U
M$:M&X3)SB9!QO6D6/8L,\>Z=][ZUO7R;[1^KK6]=?/KG6OT]?/Y;POJ/F:WI
M_3[>^=MJRNG<.)M37\G0[K6K2NK5:=+RGP+6:V8JCP\E:WB;)\/F([_EY+WM
MJC$RMPZ'C:@C68-^K:?3EHL2S/CV952W)$+\T]R2T3"^?$SQYG5ZB/N'AA8;
M0RA_D0)?13ZJ$S6*_<O-K**__$Z+,MI==]-'&][^\X[=/?U(]]:614YWWSKX
M>Z=TSZH[5U;&W_MS?V5;O_%REU)K9MRENR\MG\2^J[5<O+LC4%OF63(KU#'3
M%RT9Z\C_ $VGGW9EYF@:E@6:)GZ-1^QK:?A_!A*^RNJ([:YKHKJCP9KB(FMJ
M6\2MHAJ_.(.UL'==O1(MZHHBJH[',G2BK;K7;=7MPV25Z40[YWOGM'OKO?27
M6M[UUQOG>M[UOYY]Z=,LR;M.T^W,\+XRW"Q+,KP)B:?B7HK:_P &8F8FKQ9;
MPYB9B4XGD^?^4E=>3DI3W14E]R50_,/X:V-"=\3YPW;$=W/GSR<CE:= P!@#
M ,+L=M/7E?S5I5A..A;+<Q8ZA 2TO'O"L6&R]4:YXCSV0C1[EF^>AVY3;54@
MW:.4UU&W*FD_U]?)/KLJFJ+:YNAVIAU\5:YA7FOF.^$:8F(;MYXF8F.3KMBV
M:K(H9%NFM_":Q9:M;.V>R7565F6&X[HAEF8YXF#I6_"ZIKXN(+XJMBE9@_EP
M$J)E2"WLN56?T0,U_-(D^5^Y8L1FVSEJ-DAHN+UI6IW,:72;1IGINX3^RC;9
M\+<;$UK(T%M#I6J*VADG]G5T\+;59'DTMS$LBJW_ 'X?F;)Y]6F'C4^W,3==
M>Y<JS*>Q5BR)U2R_E\>^N?.M:.)56;L__7:OB*5CM:(7FMN\-FMS;@P!@# &
M <')HS'9I'C<2EP,5)HO)!;T)((\<8MB8<T()-^VK\:3'O$U6KQD[;J*(N&Z
MZ?::B?>^>N=ZWG)'>MULK9D=&AD=9E65EGF&68\XF)\XF#BZ)8C5V*KHZRCH
M\0RNK1PRLL\PRM$S$Q,<3'E)1+Q7\,3R=X+.65)Z(ASU*366=?/G,BE3U ^;
MBT8<N/N65=Q$DHS0=BX8,6^??#=55V7*=\-E#Y8MVQ8=-KGJ.LYVIK2F59$I
M2L1")':KO$<3;9',PUC1ZSY1'GVJL3/-HTK0-,T5LE\"CPWR;)=W:>]E29Y6
MBMI\UI2>95.9\YY:6F(XV$Y:B\C & , 8!JM^*]Z "><J4!SN;R/L# >2)1N
M3:-7&N2<GD/#))>.QL:QY436)NWW*9/M)M\MM4ND?O'O:"#;:Z?BC[8O3OK+
MU:3ICTZZ7X^=9I&X]?U*O=V1CWV8NG8<48V)9IN7N')JF)KT7%HG5LFRNR+$
MORJ<:NNJ[-G#K;;O2W=NR-C4;IW3NZ^BJ_3,#&G2:[$6W)R7LLNB_'TVIH^?
M.NLC%K7MF)2IK+'>NA;GBO/P9O8L:]8B9F1A)-PQ8!Q#5695X8((K&8C)5GW
M"0Y=-OKKC3H<39</ND3(]#EF\Y230=?0?M>VB%G^S%T)ZU?9WZI[]V%NO*NU
MCIG=M_$U;0=?H>Z=!U+5GSZJ<:W3<:^VQ],U*,.-1IUG G_4CP,*VQ[\=L'(
MMY[WZF;%ZJ;0T/<6BUIA;FJU"S#U+2K>S]HX./%#NZY%E:*N5B-9X#8>3'R-
MWVHL5VK?4F]C/=YI\8 P!@# .LW\?*45E4;^#VK-BO Z1NH5W'H4!'<(.C,^
M>CBY-XX&=-MKIJ,68?9-NNXD"W.V;!N]Z0[3>.EF+7?C[JQT\ZI=1^O6T-N[
M:VSCW;*SMG+;K.\KV?'Q-O7X.L9WQTYERI9&9D-CYF NGZ0BUY.6]KV56UX]
M&;;3MS;74+:73[IYJ^IZQGV/JZ:RZZ?H-4JV5J<W85'@QCJW$44P]-LY68W=
M50JQ#*UKTUO:/X&9BLIE0L_L.LCZ<C9RHY%D3[E?A)F:#GQ(PIV[BY<1RNNL
M-Z#<D^.VW2O:B1#;YP^9N7#-5'?%_P#L[[1ZF[*U_JUH74+;%.@8>!K6@X>V
M,W'MG+Q]P8M.+J=N5JF)G=M?Q6'97DZ<]4112V+==D8ER1E49"K0[_W?M;>N
MF;0UG;.I-FS?@Y]FHXMBQ7=I>0]N*JX>33'/A9"/7?#3W-%U:575S--E;-O!
MSU$:Q& , 8 P#5![&^%Z%],6<K;43L7_ (]DAMJP:S!D0C_<A%%U1;)N-8E6
M/VY04X'/N1S5LU>(=[=-GFT$G'/31;Z^W&@^HW0W%WOK<Z_@ZQ^Q\W)2FO4*
M[</XNC(FBM::[Z^R^AZK8I1$L6?$2SLAXE&[N_:&TNI-^W-.C2\G3_C\:EK&
MQ&2_P+:HM=K'J?NKM5TFQF96CM9.Z8F'CMA;K>7/.,6\M5(*JV+D'AOZ+UX:
M/R!^BDV<GI"2Y0X?$/LT>U$V3;239LT8LM+..FS-L@FJZ<K:4<*;,V-L[ V+
MM_'T' MLR82RS)RLNU51\K+N[?%N\-9E:U[42NNON>4K189W;EYP[<NX,K<N
MJVZGE(M,LB4T4),LM&/7+2E??,1+MR[,[]JPSLTPJKPL6)S,"P# & :P/BIW
MEU1=+P4RVG]R5\5D4^*!0;RF->?4S<B-CJUG<L$PIVY]%4[=<7Z7F1*.M(U&
M!<=BB<M,2PH&:LGGX_1)NL!*7PUG#!SX\KQ1GT;7=ZEUWHR<D<F<7L3L_/$+
MVLE&PY,%FT(@=6PN1P^33A.0'H20B=;02.]1(@&3$Q4(S328H@7MP"JK#Q1Y
MK%D:K)CH ^8K4R!AL8@S5K/+%0$<@ZZ,O)'7[&6@DY9R%L74&D9!](8@O83"
M4.8V==N"X=9F05Z<; R -Y3H\%: RY6<:.N+$%(,OH&C%AV,?9NC ^&_\>-I
MH7CIR5D(T<LC4$WU#UK,,AWT^=1Q142YD:S-51+H#Y(+Y!\\UM9 ^W(9 -B+
M &QE_%$#O4IF1+A9B6)/"Q@J1$E9"^"%9D:?D2"IJ?$QSN;E^'SMN1D#ENX5
M2[ LK@# & , 8 P!@# & , 8 P!@# & , 8!Q1$"#+J-EBP84359]_4:*$![
M1ZHU[^>M_K;]N4E.D>OGK6_U)[YW\]:W\\L^J;=V_K=F)=K6AZ/J]V!9XV#;
MJ>FX>?9A6\\^+B695-KX]G/$]],HW,1/)68VH9^$MJ8>=F8B7QVW)C9-U"W+
MQQVVK4Z19''EP\3'!RNM:UK6M:^6M?ZUK7^M:UK_ +:UK+Q$1$1$1Q$>41'E
M$1'I$048P!@# & , Z0GQ'/<WQ7X+\5>$Q.'1V2PA[#Y0D(\VTK%NGLD@ESP
M^0NN&'9@_P MOL&D]4G""72![IQRR5@OTNAS/L(1"+%E=D:1IFA6Z';9:]=D
M.DMF9+\);C6)$S"KSS-7A3/*QY^-SS,-#0IJ77]9W1C[GQL?&I9%5^W Q*^7
MHSJGXAWNGY8>6X^?GM^&B.8E9CQ&[IM?DI>8@T/+6#'6,0G1*,A'TQBHPOR?
M'1R3.AS=8V$8F^$&W!5J-(]N&B#_ (03X=)I<J\ZWSUK>]=60BV.M;R]<.T(
M\KVRZ1,PK2O,]O='$\<^1M>N7:NMK$BNQD6;$AN^$>5B62'X7NA9YB&XCGCG
MB#+LX',8 P!@&'6'" ]E0.95[(-N- YO&3<5*]M>])NDV!T<X&N56RG7/7/#
MA))QTHAUUQWQI7GG?7/7/SYW;M7TS'UK2]1TC+[_ (74\+)P<B:Y[7BK*I>E
MY2?.(>%>969B8YB.8F/(J\#,MT[.Q,^CM\;#R:<FJ'CE9>FQ;%AH\IE9E>)X
MF)XF>)@T$1+X*L]XL9!*;6E%%:K:DOK.7T>1*\3,P)34_7RS1&OA^Q0=\Z2U
MI%9WV3*(,NNNU4D'WZ>4^_)VG?9GU-=:2-3UW!?0*[N]GQ%O74LFA6YBJ*K*
MIHQK7CA6L\>]:^995LXA9WEE]8L.=.;X/3,F-3>KM5;YJG$JMF.)>71_$M19
M\X6*ZV>(XF:^>8[#0P<U$#1XE@GM)B+8M!S-+?6^]IM62";9NGOKKY]=;X12
MXY_5O_>_E\]_[WGKVBFO'IIQZE[:J*JZ:EYF>VNI(1%YGSGA5B.9\S0MEC6V
M66O/+V.UCS][.TLT_G,S)]V=IP& , 8!7SU=,)M /.%RS*N4E%)I'H*7( U4
M4>7"[!7CCCAV800[X4X67"#U'9A%-1-1/M1CSSVFISO?'6);\U'4])V;N/4M
M&5IU+#TO(NQ65>]JFB(BS(5)B89L:F;,A5F)B6JB)B8Y@ONV,3#SMP:3B:A,
M1AY&;57=#3*J\3,RE33$Q,1=9"53,3$Q#\\G5M\D>@+_ !OI^L7H"=362EYO
M8D8"RD23.E3#:6"3)EJR,H&&[UPX26TD-<.W"3]7CZ@G:6GJ*J.F^]Z\+]/=
MX;PKWSH;XVJZIG7:EK&'C9V-?E9&37G8^3DHF4M]=KNL]M+6.MLQ$X\KXBLO
M;R>EMU:!H+[:U);<+#QJ\/3\BW&NKIJJ;&LII9Z6J9568Y=5B4B>+>>R8GN.
MXKGT5/)@P!@# & , 8 P!@# & , U+?&,KGR3:OEM>&>H42W!1\_>K4N:B#-
MN\GT:GZ0Y37!L#PZ<LF:H=!#M)*5,"KM 42'+),^^TB?8ERWQW<74W2^EV-5
MK.I67/\ $V3C4:=CI%E^H2L>)96JLR)6M:\,U[NL5S*Q'<SPC5F+L&_J%%VD
M5(BK6GCMFV3*I@M/*5VPT*\M8TS*K5"SXBP_=PD,RU,^ 507DZDZOER-=NR,
MD]/$6K?NXI9*A+<64ZCRKS]8D- VK=\30:0%DZ21^]ZY=[+E#NN'Y[A!#8%@
MPZ=N]9]%ZL_$_LM<K ?3>U[-'S82+ZZ[)E%RX>IWJR%>8[)96AJ9F$9%[U:S
MKLZ5Y?36FI,J:<U\[R?5,?O\.VQ([OAH6Q5>B$CYE28F+(Y?O9E94[#F904X
MP!@# & :MOBA_"[JKXD=6M!A5TW@UWP9N[[JFUTVO;G8O[GKZSN*REFCOE4Q
M"S"^N%G+9/>B A_PF5$JZ[^^8D[UHNM7Z/?++'BXULQX]$SQW<>CI/\ XV+'
MI/HT?*T>DQCVXMNXFX,6*K9\'*IYG%RECEJFGCN1X\N^E^([TYCSB&68:(DE
M[X??@*F_AZ4>SJ>KT%"L@,=,C%H6,22XX/V'+4&W2/1%YKC?7+ ,-TNY:1H
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MS_1P!^<:_M3/\"9_HX _.-?VIG^!,_T< ?G&O[4S_ F?Z. /SC7]J9_@3/\
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M\"9_HX _.-?VIG^!,_T< ?G&O[4S_ F?Z. /SC7]J9_@3/\ 1P!^<:_M3/\
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MFR:X@^WKUUYH4=.FXV\JF-I!C#\)+GX>S( Z8P-T. S*0N>YFKW)45 R7+.
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M 7YB(3=.53%98/<;D'&U&CN06G%Y].G*3%V^;/EI9V:=K\&BI5L@!:3 & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MWH8D[#&1KI!=-!X/*AC#!\)+BB#=J1%DF;I@_;-W2"J7(&:X P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8!&HZHX (FYBQAX+AO+3C==!^1TZ=]<=:=
M<I\NE46?:W31NNZTEQ]PLDCSVI\NM[WK:BF^]6:/T6Z;:#U%UGJMI6W*\7?&
MO46X^I:M&7G.ED9$4QEVTX%F0^#C9&7&/5\3D48]=MO#RS?ZMWB91E[SW'G;
M>P]K96H-9HF"Z/CXOA4JT>%+S4CWK7%UE=,V-X:.\JOR^4]B=M+7T7\-57'7
M996V L4!Q*O3GBJ;DQ\S']IG624<0DO^)S[0YDYY+3BMHWT;E XKV@B]@H0[
M-WY3IL$=F=(;3,7)#/\ B"IYF48G$YM932-$*TJ&M)!$@)N([BE@0:G'IPO
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M:;@F#T2X?M4X[P ;=/@KE1Q7<% VP_/7_P!=?^NL _-[U\M_[U_VW_XX!Y8
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P#6%.YO;@GVX/8_Y!:+((RF\!;@XDS82+JG2OGES2-B&[9F<@Z:"^XPX
MD06T1PUGR7($>I(%(#X-'QG#0=-'+4Z!E=OSGT+!+3M.3UQ(2<T!2"M/-W-9
MQ>00AV8K>%E)Q?7%?3$RFPBRD<DDF)-XB85F!W9"6(+LQS ;SSR($M'*KL""
M'_K;V7#>6;>P!U7L!DBE\\AFK(9^?K=Y U@SK?T>ZI;4^E,01MXN7FPRT(UP
M.E\<CX8[%?\ $6Y7DZ\D4MB0P@3Y V#^5+4D%W^=ZFMB4\".)!.HJ@;)_@ Y
MF/AE%U';M#E<:#D3TB=$-7**";A,:7?.B+/ZNT'2O2W'7R L%@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M#\^6O_/_ -=Z_P#^X ^6O_/_ -=__O ,/G=>02T(VZA]CP^.3J*O7#%VZCTK
M$,3HA9V,=I/QKOI@11<-_NQ[Y!!VR<\\:7:N4DUD%.%.==: YH!'P45!B(S&
M XR.QR/C608$!",6PH,&$#6Z;0>+%#6*:#-@/8M4DFS1FU12;MT$^$DD^..>
M>= <M\M?^?\ Z[__ '@#Y:_\_P#UW_\ O 'RU_Y_^N__ -X!^X P!@# & ,
E8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g475892g77j27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g77j27.jpg
M_]C_X0[E17AI9@  34T *@    @ #0$   ,    ! >P   $!  ,    ! 1\
M  $"  ,    #    J@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    L $;  4    !    N $H  ,    !  ,   $Q  (
M   >    P $R  (    4    W@$[  (    0    \H=I  0    !   !!
M 3P "  (  @ .:V@   G$  YK:   "<0061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q-SHQ,CHP,2 P-CHP-3HU,0!(87)I<')A<V%D(%)A:G4
M    !)    <    $,#(R,: !  ,    !__\  * "  0    !   ![* #  0
M   !   !)          & 0,  P    $ !@   1H !0    $   &* 1L !0
M  $   &2 2@  P    $  @   @$ !     $   &: @( !     $   U#
M     $@    !    2     '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 7P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M0\VS&^LE-+3^CS6/IL;V)8UV34_^LST[&?\ 7DS/BC*!D !*.NGAO:[%DD)
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M:7!R87-A9"!286IU' (%  9G-S=J,C<X0DE-!"4      !"3?=$?L$=EV6(
MZ&)OIIS8.$))300Z      #E    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #P!ZX  (  0/ 'K@  @ !.$))300F
M   .             #^    X0DE-! T       0    >.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      -!
M!@             !)    >P    & &< -P W &H ,@ W     0
M               !              'L   !)                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !)     !29VAT;&]N9P   >P
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    %.$))300,      U?
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P#U5))))2DDDDE*22224I))))2DDD-M]+VN<Q[7AGTBT@QW
MUA)3SGUM^N+>CG[#@M;=U%P#G;M:Z6GZ+[=L;[;/\%1_UVW_  ?K<#D=>Z[E
M/-E_4<DN/(98ZIORJQC57_T55R<RS.R+L^\S9E/=<\GMNU:W^K77LK9_(8BM
MZ;FDEKJS2Z YK;IK+@7-KW5[V[?8Y[?4]WZ-:6/%#'$6!Q=26G/)*9\.S=Z?
M]:_K!T^P/KS+,AGYU.4XW,</#=8?7K_ZW:O2?J_U_$Z[@_:: :[6'9D8[C+J
MWQ.V?SZW_2JM_P )_P 9ZE;/*'X-[,7[8"RS&+@UEK'2'$_N;FL_.]KV_P [
M_P 'Z?Z1;/U#S;,;ZR4TM/Z/-8^FQO8EC79-3_ZS/3L9_P!>3,^*,H&0 $HZ
MZ>&]KL620D =B^I)*'K5>IZ6]OJ<[)&[_-4U0;2DDDDE*22224__T/54DDDE
M*22224UNH=2P>F8SLK.N;12TQN=)))X8QC=S['N_<K]ZY#*_QG5"PC"Z<^RO
ML^^P5$_];K9D_P#5KF_K7UJSJ_6+K=WZIBN=3B-GVAK3LMO_ *^0]OTO]#Z2
MQ]S?$>/*O8N5CP@S%D].S6GGE=1T ZOH73_\973[; SJ.*_":?\ #,=ZU8_X
MS:VJYO\ VR]=3D=0QZ,$YX)OQPT/#J1ZFYCHBRL5SZK=KM_Z->*2)B1*[#_%
MWUJVC-/1;7$XV0UUF*T_F6M_275L_D75[[MO^DKL_P!,FYN6B(F4-*WCX)Q9
MB3PRZ]7N:J1DM;?DQ8'@.KJ_,:#JWV._G+/Y=G_6]BM;6ENV/;$1Y)TE3;#X
MAE8=F#D78%XBS%>ZEX/<-T:[^K;7LL9_(>I'-S"X.-[]P.X&8,[FVSI_PE5;
M_P"PO1OK9]3F=9(S<)S:.HL :[=(KN8/HLNV[G,LK_P5_P#UNS?^C]+@LGH'
M7<5YKOZ=D@CO76ZUORMQO5K6ECS0F ;'%U!:<\<HGK7=JV963:PUOL)K)!],
M!K6 CZ.RMC6LKV_\'_Z,L6Y]0L*S)^LE5[1^CP6/NL=VE[78U3/ZS_4L?_UE
M5>G?5/ZP]0L#:\-^,S\Z[*!J://TW_I[/^MU+TGZO] Q.A8/V:@FRUYWY&0X
M0ZQ\1NC\RMOT:JO\&S^7OL3,^6,8&((,I::+L6.1D"=AW=&RNNUNVQH>W]UP
M!'XJEE9 Z6T6.WVX[W!C:FAUE@>[1GI\_HW?\+_,_P"D])7TE0;3"VVJFI]U
MSVU55@N?8\AK6M&KG/<[VM:U<AG_ .,K JL+.G8K\QH_PSW>BP_\7N9;<[^U
M36LS_&'UJV_/'1JG$8V,&69#1^?:X>I4U_[U=%7IV_\ &V_\#6N0W-/<:^:N
M8>6B8B4];U \&OES$&H].KWF+_C.J-@&;T]]59Y?38+2/^MV,Q_^BNOZ?U'"
MZEC-R\&YM]#M YO8CECVNA];V_Z-_O7BFYOB.)Y[+:^J/6;>D]:IAWZKF/;1
MDLG3WGTZ;_Z]-COI?Z#U$<O*QX28"B.G=&/.;J6H/5__T?54DDDE*220KKVU
M%K0"^Q_T*V\F/I.UAK6-_?>DI\2H+Z+*RX$/H>-X[[F._2-]W]5:5/5<=EHM
MLJ=:-?T);6&M<?4W9++/INMN]3])6YOI_P#&;,?T];Z\_5R_ SK>K8["[ RG
M>I>6R?1M=_..L_X"]_Z3U?S+O4W_ .!7++4B8Y(B0Z_RIHD&!(;=F76X$-#M
MCJ75-I+&-962*_=4YI<YS7/J]7W?I/\ C/?8KGU18]_UHZ:&<BQ[C_5%5V]8
M[G!HEQ@>)7H?U#^K-^#OZMGL-61<ST\>APAS*R0Y]EK3]"V[:S]'_@JOY=ME
M=;<TA#'+Q! ^J['$RF/ V7L4D*O(:^QU1!KM;KL=R1^^R):]G^MB*LUN*222
M24I))))2DDDDE/D/UK8]GUFZDVSDVAW]EU=3F?\ 00F]2J(8;6.=M:UKV;:R
MVX-KKJ N<[:^OT;F69->S?ZGJ_X*S]*NP^OOU9OS"WK&!6;;ZF>GE4,$N?6"
M75VUM'N?;3N=N9].RK_B=C_/FN:X;FF0>X6EBE&<(^ X2T\@,9'Q-NH_J>-9
MDBX"W'J]4V/JJ94[=.N_U;"W].QOZ#?_ .A/Z*[U%0:'W9(%8 ?=:!6UHV@.
M>_\ 1M8SW;/>[V,0_/LNJ^HOU;NSLVKJ^2PMP<9V_'W:>M:/YM[!_H*/YSU/
M\)=Z?I_0L3I&..)D>@6Q!F0'_]+U5)5V99>QKVT6EK@'-,-X(D?GI_M+_P#N
M/;]S?_)HT56E<]K&ESR&M'))@(.(TEAO?_.7PXSR&_X*K_K;3_VYZG[ZC>YF
M12^B_%LLJM:66,<&D%IT<T^]2Q/L]>,&45^A33+!4 !MVZ1M:E2K3D @@B0>
M0N?ZA]3/JS8'7G"%;R1(H>^ENI#?YNES:N_^C6RS*>]C7MQK=K@"/YO@_P#7
M4/)-U]?IBJ^K4'<ST9TUC]*ZQJ,3*)TEP^16D [B_HU.G?53ZO\ 3+1?BX;?
M7;]&ZPNM>#XL?>ZST_\ K:UU7;?<&@''M<0(+B:I/G[; U.,D^HQCZ7U^H2U
MKG;") +X]CW_ )K$I&4C9-^9M( &PI6767U;V#]+5[ZC_*'YO]6S^;>BL>U[
M&O;]%P!'P.J#==+GT"NQ_M!<:R&P';@(>;*G[O9^8H4$T5BJO&OV-XW/:\_Y
MUESG(4JVVD@?:+?^XUOWU_\ I5(9)WL8^FROU#M:YVPB8<_\Q[W?F)4FTZ22
M2"E))))*4LCJ/U3^K_4K3?E8;?7=]*VHNJ>X_O6.H=7ZCO\ C%KI(QD8FXDC
MR00#N+<+$^I'U9Q7BQN&+GMU!O>^T?\ ;=SGU?\ 06YQH$Z24I2E\Q)\U"(&
MP \G_]/T_#_H='_%L_ZD+/=TWJ1+VUY'H,?ZNUS7%SF^I_A?TC?TMK?\!_W%
M_P"[:O\ V'"_[CU?YC?[DOL.%_W'J_S&_P!R<)5?\$4SH8ZNEC'QN:()!)!/
M[TV;G^[^4@T_S-_]>S\I4_L.%_W'J_S&_P!R+7776T,K:&,'#6@ :Z\!"PI'
MC3]EJC0^FV"=1PLT]*ZB0[?D"RPQ^EES3(MLOT:X7;/;8W_";/T7I?Z.Y:/V
M'!_[CU?YC?[DOL.%_P!QZO\ ,;_<B)5M^2B+0XF#9CV,>ZTV&+2^28W6.J?^
MC;^:QOI?Z^]&R/YW&_XT_P#GNY+[#A?]QZO\QO\ <I,Q<6MP?736QPX<UH!U
M\P$B>JJ8L_IEW]2O\MJ!F8>3==NKMV5N:T.&YP(+/4^B&_Z7UO?_ ,5_A/\
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M #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
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M(" @(" \/WAP86-K970@96YD/2)W(C\^_^X #D%D;V)E &1      ?_; (0
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M^'P/YG!J/-_LQE*(]6K[3_0UT3]O:]]&K_1F:K3;C_.WM^;^SG_6>]O--/W
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M4-^-5$#_ %M['5M[#\XS*&GO+&'Y&21C_P 9B*_\:Z"TWNIR[&:16UU)\PB
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M4C_$=*@K2=*?(V>E#6$U1B^LZ6<K?ZFFB[(K(P;?CRG_ %_8A7V!YH*U?=[
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M:<.MD/J;:LVQ>K>M]EU#R256U-B[3V[633.TL]16X?!4-!6U-3,[-)-4U-5
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M[C^7^[\MTKTSFLA@_B_M3*-3ZZ-ZB@K>Y\QC*@Z=T[A6T50NSZ:JB$F'QD@
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MWO?M/?F33$;-Z^VOFMW;DR# ,U/B,%03Y"K%/$60U-;,D/C@A4ZYYG2-068
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M,*:KEFG5*>.1@EYSW7;MVV>7ES:KR*YWB^TI$D3*Y3N5C.^DG0D0'B:VH*J
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M*K746^GM+=;9MM^\<E]M\$TB?"7C1R/L+ T_+I1!>WMJKI;7<L:-Q"NR@_:
M17\^DG09O,XJNER>+R^3QN2G@R%+-D*"OJJ.NFILO25%!E:>6KIY8ZB2#)T-
M7+#4(6*S0RNCAE8@JGABE01R1*T8(-" 152"IH<5! (]" 1TPLDB,71R&((J
M#0T(H?V@T/J.O'-YEL,FW&R^4;;T63DS4>!-?5G#1YB:EBHILLF+,OV*9.6B
MA2%IPGE:)%0MI 'O7@PB8W'A+XY73JH-6FM=->-*YI6E<]>\230(O$;P@:TJ
M:5I2M.%:>?2MC[:[5AV<_7</9O8,77\JLDFQ8]Y[C39TB.Q=T?;"Y(81U=S<
M@P6)Y]I3M>V&[%^=N@-]_OSPT\3_ 'NFK^?3XO;T0?2B\E%M_!K;3_O-:?RZ
M1V/RV5Q(KAB\GD,:,GCZG$Y(8^MJ:,9#%5AC:KQE=]O)']WCZIHE,D,FJ-RH
MN#8>U;Q1RZ/$C5M+!A4 T8<"*\"/(C/2=7=-6AR*BAH:5!\CZCY=-_MSJO7O
M?NO=#]\5.NZCMOY-?'_K.FIVJ/[\=R=<[=JD5-:Q8S([LQ468K)5 _X#4.+,
MT\IMQ'&Q_'LCYFOUVOE[?-P=J>#:2L/M"'2/M+4 ^9Z,]EM6O=XVNT KXEQ&
MOY%A4_D*GKZ<'OGEUEYU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T2[^8OUW4=J?!?Y4[+HJ=JO(U
M?3&\<WBZ.--<M;E]FT!WIB*.%0#>HJLEM^*./\:V'T^OL6\AWR[;SERW=NU$
M%W&I/HLA\-C^08GH/\U6AO>7-YMU%6,#$#U*#6!^94=?-S_WW^^_I[S\ZQ0Z
MZ]^Z]TX8K+97!9"FRV$R>0P^5HG:2CR>*K:G'Y"DD:-XF>FK*22&H@=HI&4E
M&!*L1]#[;EBBFC:*:-7B/$, 0?M!P>K([QNLD;E7' @T(^PCJ/2555055/74
M-3445;1SQ55)64DTE/54M33R++!44]1"R2P3PRJ&1U(96 ((/NS*KJR.H*$4
M(.00?(CK0)5E=20PX$>72SWIVEV;V0,>.Q.QM][]&)C:+%?WTW?N#=/\,B<*
MK1X_^.9"N^RC95 (CT@@#VCM-MVZP\3Z&PA@U_%X:*E?MT@5_/I1<7EY=Z/J
MKN673PULS4^RI-.'3!%N?<L,NWIX=PYR*?:10[4FBRU?'+MDQY*;,QG;TBU
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M)VMA.V,?MO IC\JB34D-#24\-&\:>!(]"V%=KSGOEE;P6L L_"C0*-5G:.U
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M[:WOL_H;Y1[@VGO' 8?=.V,]C^H'DH,UM[<&/I\MALM1.^>1WI,CCJN.:,D
ME'' ]BVZY1N+*YN+.ZWO;4NHG9'4SY5U.EE/;Q!!!Z((.8(KF&&X@VV\:"10
MRL(L%6%01W>8->E#_LU8_P"\;OE=_P"B=/\ ]D/MC^K7_AP;9_SG_P"A>G?W
MU_TB;W_G%_T-U[_9JQ_WC=\KO_1.G_[(??OZM?\ AP;9_P Y_P#H7KW[Z_Z1
M-[_SB_Z&Z]_LU8_[QN^5W_HG3_\ 9#[]_5K_ ,.#;/\ G/\ ]"]>_?7_ $B;
MW_G%_P!#=>_V:L?]XW?*[_T3I_\ LA]^_JU_X<&V?\Y_^A>O?OK_ *1-[_SB
M_P"ANO?[-6/^\;OE=_Z)T_\ V0^_?U:_\.#;/^<__0O7OWU_TB;W_G%_T-U[
M_9JQ_P!XW?*[_P!$Z?\ [(??OZM?^'!MG_.?_H7KW[Z_Z1-[_P XO^ANO?[-
M6/\ O&[Y7?\ HG3_ /9#[]_5K_PX-L_YS_\ 0O7OWU_TB;W_ )Q?]#=>_P!F
MK'_>-WRN_P#1.G_[(??OZM?^'!MG_.?_ *%Z]^^O^D3>_P#.+_H;ICW/\T,#
MLS;>X=X;IZ"^4N$VSM3!Y;<NXLS6]/NM'B<%@J"HRF7R=6R9]W6FH,?2R2R$
M D(AL#[>M^4IKNX@M;;>]M>XE=411/EF8@*!V\22 .FYM_CMX9;B;;+Q844L
MQ,6 JBI)[O("O1P:2IBKJ2EK8"Q@JZ>&IA++I8Q5$2RQEE-RK:'''X/L*NK1
MLZ,.Y20?M'1ZI# ,.!ZD^Z];Z*ON/Y/5V.[%W[UOLSXZ=^=MUW6M7MW';JW!
ML!NC*/;=+D]S;7Q.\,?CJ>3L?O#K_.54\>%S4#2LM#X5=BH=K'V)+?EU)+"R
MO[O?[&U2X#%%E^H+D([(2?"MY5 U*:=U?ET32[PZ75S:0;5<SM$5#,G@A:LH
M8#]29#P(\J?/J-_LR?97_>#_ ,L?_/A\2_\ [JGW;]P;?_TV&V?LO?\ MCZK
M^]KO_IG;W]MM_P!M/7O]F3[*_P"\'_EC_P"?#XE__=4^_?N#;_\ IL-L_9>_
M]L?7OWM=_P#3.WO[;;_MIZ]_LR?97_>#_P L?_/A\2__ +JGW[]P;?\ ]-AM
MG[+W_MCZ]^]KO_IG;W]MM_VT]>_V9/LK_O!_Y8_^?#XE_P#W5/OW[@V__IL-
ML_9>_P#;'U[][7?_ $SM[^VV_P"VGKK_ &9/LK_O!_Y8_P#GP^)?_P!U5[]^
MX-O_ .FPVS]E[_VQ]>_>UW_TSM[^VV_[:>N_]F3[*_[P?^6/_GP^)?\ ]U5[
M]^X-O_Z;#;/V7O\ VQ]>_>UW_P!,[>_MMO\ MIZ]_LR?97_>#_RQ_P#/A\2_
M_NJ??OW!M_\ TV&V?LO?^V/KW[VN_P#IG;W]MM_VT]>_V9/LK_O!_P"6/_GP
M^)?_ -U3[]^X-O\ ^FPVS]E[_P!L?7OWM=_],[>_MMO^VGKW^S)]E?\ >#_R
MQ_\ /A\2_P#[JGW[]P;?_P!-AMG[+W_MCZ]^]KO_ *9V]_;;?]M/7O\ 9D^R
MO^\'_EC_ .?#XE__ '5/OW[@V_\ Z;#;/V7O_;'U[][7?_3.WO[;;_MIZG[0
M^3-7G>R]I=7;O^/G>O4.8WSB]UY3:^7[$/2=7@,D-F4N.K,Y1";K3NKL3*TM
M9'392%H_-1QQ/<CR BWNEUR^D.WW6XVN^65U%"R!UB^H##Q"0I_5MXE(J#6C
M5^75X-W:6[@LY]KN8))%8J7\(J=%"1^G+(:Y'$4^?1HO8<Z..@O[D[5Q'2O7
M6<[(S>#W)N6APM7MO')M_:,.&GW'F<GNS=&%V?@\=BH]Q9O;>#\]3FL_3J6J
MJZEAC0LS.+6)CM6VR[O?PV$,T<;N'.I]6A0B,[%M*LU JG@I)].D=_>)M]K)
M=R1NZJ5&E::B68* -15>)'$@?/H'O]F3[*_[P?\ EC_Y\/B7_P#=4^S7]P;?
M_P!-AMG[+W_MCZ0?O:[_ .F=O?VVW_;3U[_9D^RO^\'_ )8_^?#XE_\ W57O
MW[@V_P#Z;#;/V7O_ &Q]>_>UW_TSM[^VV_[:>O?[,GV5_P!X/_+'_P ^'Q+_
M /NJ??OW!M__ $V&V?LO?^V/KW[VN_\ IG;W]MM_VT]>_P!F3[*_[P?^6/\
MY\/B7_\ =4^_?N#;_P#IL-L_9>_]L?7OWM=_],[>_MMO^VGKW^S)]E?]X/\
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M48A38[)N>X2V<5O;&MP)/#+=JOX*EY*,<'2!FGG0<3TQ=;E96B7#S3C]+1K
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MF[N^376>YNM<7USO2&$POM?<<>W9X:RLKL=CZF+-BOFEH8HVC#BFVCM;K?\
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M[I;[?!>A'DMH_#62A\0QCX4=J]PCX)4:E7MJ5  4VFW6]C-=RVQ94F?6R5[
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M?^M/7O\ 9U.C/^5;OG_TD?Y9_P#VDO?OZH[U_%9?]EME_P!M'7OZP[;Z7/\
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M^_JCO7\5E_V6V7_;1U[^L.V^ES_V37/_ %IZ]_LZ?1G_ "K=\_\ I(_RS_\
MM)>_?U1WK^*R_P"RVR_[:.O?UAVWTN?^R:Y_ZT]>_P!G4Z,_Y5N^?_21_EG_
M /:2]^_JAO/\5E_V6V7_ &T=>_K#MOI<_P#9-<_]:>O?[.GT9_RK=\_^DC_+
M/_[27OW]4-Y_BLO^RVR_[:.O?UAVWTN?^R:Y_P"M/7O]G3Z+_P"5;OG_ -)'
M^6?_ -I+W[^J&\^ME_V6V7_;1U[^L.V^ES_V37/_ %IZ]_LZG1G_ "K=\_\
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M5I:)<EE*'"T"OI!8O693(P0( .9)0/:[;-MO=XOK?;MO@,EY*2%4<30%C^P
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M_3'_  ]&R?"OV=./NG5NO>_=>ZIQ^?VZ.G._?D1T[\'^W>R-G[&Z>Q6U\_\
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MW_Q5_O[_ -]1NSV(N4/^5MY7_P"EC;?]7DZ)^8?^2!OG_/'-_P!6VZ,?A_\
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M_P P[_Z0O_9MU[_L1]_X*H_]E%]^_P"8P_\ AR_]GO7O^8=_](7_ +-NO?\
M8C[_ ,%4?^RB^_?\QA_\.7_L]Z]_S#O_ *0O_9MU[_L1]_X*H_\ 91??O^8P
M_P#AR_\ 9[U[_F'?_2%_[-NO?]B/O_!5'_LHOOW_ #&'_P .7_L]Z]_S#O\
MZ0O_ &;=>_[$??\ @JC_ -E%]^_YC#_X<O\ V>]>_P"8=_\ 2%_[-NO?]B/O
M_!5'_LHOOW_,8?\ PY?^SWKW_,._^D+_ -FW7O\ L1]_X*H_]E%]^_YC#_X<
MO_9[U[_F'?\ TA?^S;KW_8C[_P %4?\ LHOOW_,8?_#E_P"SWKW_ ##O_I"_
M]FW3WMG_ (9B_O)M_P#N=_PV'_>_^-XK^ZO]V?\ 95/[R?WD^_@_@?\ =_\
MA?\ N3_C?\3\7VGVW[_GT^/UV]LW'^NS]//]5_6+Z30VO7]9HT4.K57&FE=5
M<4K7IR'^H'BQ_3_N?Q]0TZ?IM6JHI2F:UI2F:TIU9Y[COH8=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
*?NO=>]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g475892g79t13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g79t13.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1M^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #H< 5H  QLE1QP"   "   < E  "D=R86-E("!496\< @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0DN>SIZX0HT7YR^N'1S&X
M6SA"24T$.@     !#0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    %0!A 'H
M,  Q #4 ,0 M '@ 90!R &\ >  M #$ .  @ $< 3P!/ $0       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q >/            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 ! \     !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _0
M     !( -0    $ +0    8       $X0DE- _<      !P  /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      S4    &              0S
M   )'0         !                          $             "1T
M  0S                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  0S     %)G:'1L;VYG   )'0    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M<VTTDC":! K:YNU[]?\ #.W/K_J?]MTWTDDE*22224__V3A"24T$(0
M50    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !,
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))
M300B      %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    +    L(=I  0    !    O    .@ /.'P   G$  \X?   "<0
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ,#HR-2 Q,SHU
M.3HT. !'<F%C92 @5&5O     Z !  ,    !__\  * "  0    !   )': #
M  0    !   $,P         & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
M         $@    !    2     $X0DE- _T       @      0   /_A 4A-
M30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    L
M  "PAVD !     $   "\    Z    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C$P.C(U(#$S.C4Y.C0X $=R86-E
M("!496\    #H $  P    '__P  H ( !     $   D=H , !     $   0S
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0             #P
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M.%%A)$)867&6UAHE,Y?5)B=2@9&5H:>Q_\0 % $!
M /_$ !01 0                    #_V@ , P$  A$#$0 _ /?QP' <!P'
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MPK=+)ZZO*KG-G0[!-E_><=:!Q0#'!LUYO,JJRD6IR*W:Y@;R. X#@. X#@.
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MA+9"Q)4&(\S#0XPVI(9@X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@.
MX#@.!@8CU;ZVEW=[/E-#ZD(O=H!PP1V-=FT&LR7-YBPE?>JH<?M9;HY2KU$%
MUN3(!CV+%F>W$&/NQ&$H9<4G(65L[HETNW2/U:)VWU5T!L@7I(- K>HQURU5
M3#\'7=8%LC8\"JU2*1$/LB*I&9#"&T5B,A(%6!0W*QZLP8N6@OR5UDZ[33)&
MPR](:LDG2^UJ?O0H7>H]><(D-S:]!CZU1=IRY:H&7G[[4*\*&!*Y:7%J,!Q8
M^'!@RV8\=IM(8QV!X^^C6U@X.O[+ZC=>+T$K5VO.QP(NT:FI9F$+O.SSR[3L
MJRQ6)HAU"2.P[(O)V]*5A35N*X1-L#1!]MM:0R43ZO\ 7$T_;91?1>J24B^W
MC7&R[J],HM<?7:MA:>9K\?5-U/Y<'J^U+/KF/4ZPQ2S4OY9];:KX=L4_%0/B
MX:#.W <!P' <!P' <!P' <!P' <!P' <!P' <!P' XW7,,M..Y2XO#3:W,H:
M0IQU6$)RK*6VTXRIQQ7IZ(0G&5*5G"<8]<\"!@KO5DFG8 I[K5O4!?*)5]3;
M!>H%JE:? %5ZXW-/V5 JEULIN7M+-4UO"&9U'>)-P%;!.5X_768@J,H9,+G(
M(M04ZL>176]Q?UM.K^L-LR:1>AO7=\_?Y,:BQ NM37:>S.4W3-8M Y=X78#)
M,S9<C8)B;115K!!(=CK1Q1:8")/$80; )$N+$2A<N3'BI<7AM"I#S;*5N9QG
M.$(RXI.%+SC&<X3C.<YQC/X<#L<!P' <!P' <!P' <!P' <!P' <!P' <!P'
M <!P' <!P.@4GH%#")1R-.F-C8$N>Y$&0WB!*4B''<D+C#X$9*Y$Z<^EO+42
M&PA3TF0IMEI*EK3C(:\H7D5'2X&PH[_6/L*'OFLX&M+-;]=G\Z:#$ZOK_:]4
MNESK5[O%IF[;;U_0!PX10;!#MP6WVL5::Z?4&&+"2V3X:?,"Y:MY!-<W*T:]
M' ];;851;W*TO7I>U"(ZH"ZS2-@]@-=PMG:RUY; <NX(O:#L^N&JG&,SPE5,
MUT*=N]4&.F'TOFY0()W2)D.)\?U<J-%^97L:^H?:9^5?X?HM_(I/O5^./T4^
MN?QQ^'X\#L\!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
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MJ'9:Z')6*Z;9TC4H%1I%E1?8LL=]V:OB-7Z9/)T:#5ID?,FEA(80R"#+*#"
M27[G@ 1;K#O8D5#"B1&N:@V25K\^>/B2Y@,HU4B3C1(/)D-./#9[3C++C<N&
MMF0A;3:TN84A.<!)V/\ N=C^1:_L)X'-P' <!P' <!P' <!P' <!P' <!P'
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MR4A0%!W_ &G8/7/?%2N'7ZDZXO\ 8M5C! 2^VZ0'VM5+#<:P()R:>4(@J3;
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MO9DS9;K<>,VZ\M*,A<_ <!P' <#SX=V^X&].[_86P>*GQJ6? (T$2U#\@O=
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M[K+B<^BD9X'GX#],_(IXG"UPD^,U-5[E]*K <>L\7H-OC8I2D[&T)F2_*F&
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M$P.X'<2L]0:%2+M8J>0MKE]MBZD)'LW;6.O T&3$I-JV 1EG;_M:X4NA"6D
M:<5C!XLBP?76,\^-$"(SZI;DB,%B:^\@5/V1M6M48-J7: RC64_2=>,[<LRJ
M2!##=Q7[KX"[/ M7E:1-MB=E1R2=3V4&]/.M55\#$MDU56S,7(AS94<)_P#
MU >9HA;8'7W6RJM4*Y=,N[8FMS0\JA:WVC?)DIS46T6*T'UC0MCXEMG2UJM;
MX6HW3-/!V2Z0M6G;Q(&BX@_!:Q @E?X^:0>UUU,UI4#^OTZPR-(['?KU-?JM
M>I!Z%0RVS[D9UV1N]2JKKP&O['L-%GUZP['&05XS'O!0\F6U'G?4QV@FAP'
MQINC_8_M7^CB[_X:)\"D77;^K=#::>VQNC8%3UAK:G5482LMUNQN#7Z\(BI@
MQT(^I($'F6<R)+RD1H,)G+DTA,=9A08\B4^TRL-#$SO1Y ?+>F;3/%54#73[
MJBLG]EVCR5=C*8EJSVX:VASZYCJEU_-1\SK.B8TY%<@[&MLL0,;0N9$2W63L
M-A]89-3^QQ.@>=6S(;\C<<KMO-L3&S,^0F1M"WN=MXN\(S*7&-HC[MDQ]+#P
MT63DCBE-0ONLKW8^6(X2:9+-!CVK=_\ N5XI#=:TIY=PT_>/70J<8JNJO*/I
MVL+=KS,)V3'AB8G<?7 YOZK5)U#<F*S(O8=9@&7D?)GV%E1#%B2'H7IEUIVQ
MJL#O&O[77+Q3+./9+5RVU$T-L5;/#)'K\! .;$298TE#=],X1)AR7F592K&%
M^J<XP%S\!P/AQQMI"W'7$-MMI4M:W%)0A"$XSE2UJ5G"4I3C&<J5G.,8QC.<
MY].!@*\]L>K6L<N8V3V3T'K]365)=3==P:]JRFU(QE2TN)-V&#E"D)3E2L*Q
MC*4XSG/IC&>!HB[Z]S WE)V13?$EX[=QA;P W:)<L_>WM-IVQB+=3M']4H))
MT7<=?![4'^U0LK:&YL-NT\5!:E^V(((.9D^Z&6D2Q@>@W2FFM;]>-2:ZT;J"
ML0:;K'551"TBDUH?A7TXH "AMPX;2W7%+?F3'L-JE$2$IQV:2(/RI\UYZ7)>
M=6&4. X#@. X#@.!U9\^"+@S"9.9%'#1T61.($)TAJ)"@PHC2Y$J9,E/K;8C
M18S#;CTB0\M#3+2%N.+2A.<X#7#L;NS:0Q\-LT(G25)Z,U>S:PG73MWLG98@
M]0=W:[VU7"P8*CK9(UB6L3C=NK^X2%%JQ*3L>$*K1P>2G.5^9)<S%?4&R?&<
M*QA2<^N%8QG&<?JSC./7&<?^..!^\!P' <!P' <!P(Y]O_\ =4['_P!".S?\
M'E^!(:/^YV/Y%K^PG@<W <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
M <"'7:3Q]=*^[$^HE.UW6W5^]B="B%(%.(7T(HC-K\$V]$D%80^4Q(C/HBS9
M$&*^['6M;6'F<.(0E:EY4$4?] KX<_\ N\^NG_EB=_\ 5> _T"OAS_[O/KI_
MY8G?_5> _P! KX<_^[SZZ?\ EB=_]5X&7:KXJ>CFI-+=A]+=;]#4'K>*[,4&
M90-D'=7U^)'*E(&19L<&?GM&,DH1B,#58";[8,HR^$)-S)D$I"E0YLEI88]C
M>.C9PZE7(4'[51 =RV[8+D_N<H(ZZZ_CZVL=2NVMZ5J>>&H.I7STJ#J^R0:?
M0P[L2VC[*<C%K&1L!2XUBTCIHP(&#)FX?'[7+6(I#FGKY.UI<Z(:=(#"^RAQ
M[LG29 Z?KJR:O*0%ZOV7>6J\&FYK5GFN"2]2DUQ8\@WA,V(7"S2@6<&/-?\
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M;[F5QX4& U%9]$X2SZ8].!= SPJ'J3$C0=4>6CRWT2%"3C$(>3[.5C8PV/\
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MDTH@C&9+S3DZ6I3K24QHJ77E*<1C",Y6GU"3T?\ <['\BU_83P.;@. X#@.
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MU2WPF'P' QINC_8_M7^CB[_X:)\"\*U^]RO_ ,R"O[@QP*WP' <!P' <!P'
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ML(4G,/6H2VRO];./:K#.4K3ZK1E2,95@(6W7]E7^)0.N1"U?9^PG9(VPZA&
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MO:3M==Q NUZOL^T%L/#ZWH <_)J-WC2AS9+,B$<D!AT@E.,PCDA#D(51I"K
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M#I8!M<:.SB7"&"8D ,ST/R:TW\]H]T"WWJ+;?7_<,Z811UYO5YK67-0]N0
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MCU1TGI_8F_-D;_U@$U!J:8/&;&O$"T0+0+J)<O*'0Q0,LS4W#A!H\3DEQ;4
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M@5EK-$E7VY1WNPHG=?6C4HO59:SZ/V]2I8N?&[*DXU5LDFYUHZ7K$-C#,-Z
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M[FK+K3I&,R^&]M@R 7.7.90K(Y<K,A.7>!.KMAMCL#IK5>+GUNZNS.W&P$6
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MZ1[L]C[ANC?.FM,QM=UK7A#LD/I-VW;&JL6.0LVQKCK.N$(A\Y:B#PPD6/'
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M=F_X/+\"0T?]SL?R+7]A/ YN X#@. X#@. X#@. X#@. X#@. X#@. X#@.
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MC.1$E$%PX+;FN4KERDP(,V:IAC"W<1(DF1E/Q,.K2'=_.(U]_%&X?ZO6^_\
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M2!\8VX#+?9RI*&U240G76TY:RVM85PL#$G40$%X+,] LJ/.#TO>_TBEA;WU
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MDH&;-U8NF"2A.PI61ECK! 18@4_$=U>(A<&4'%ASV&Y(^;%DM-/(#AIE,JU
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I32A0G/DR9Y(C,E3ILE^5(==6%T<!P' <!P' <!P' <!P' <!P' __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g475892g80i74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g80i74.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4M::'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^56YT:71L960M,3PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.GAM<$=)
M;6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+VEM9R\B/@H@(" @
M(" @(" \>&UP.DUE=&%D871A1&%T93XR,#$W+3$P+3(U5#$T.C(U.C,V+3 W
M.C P/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A
M=&4^,C Q-RTQ,"TR-50Q-#HR-3HS-BTP-SHP,#PO>&UP.DUO9&EF>41A=&4^
M"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#$W+3$P+3(U5#$T.C(U.C,U
M+3 W.C P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R
M5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E
M871O<E1O;VP^"B @(" @(" @(#QX;7 Z5&AU;6)N86EL<SX*(" @(" @(" @
M(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIW
M:61T:#XR-38\+WAM<$=);6<Z=VED=&@^"B @(" @(" @(" @(" @(" @(#QX
M;7!'26UG.FAE:6=H=#XQ-# \+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @
M(" @(" @(" \>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^
M"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:
M2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.
M02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K
M8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="
M9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%
M>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX
M.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!:D%%04%W15(F(WA!.T%!
M25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!
M2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C
M24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'
M13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4
M:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6
M=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U
M=EDS4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59
M;5HF(WA!.W%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1
M545"45E%0T%-1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B
M2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD
M56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U4
M53504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(
M,2MF,T]%:%EA2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ
M3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=&5TLO
M;48U9C%$5S=#>6<F(WA!.W,T5FTY1V1P6C%0<#AV5#E#4E-)>DPX26M02VE.
M*WDQ1S)P6$-&4V959DQF;4=W,4\V,4A13$EW4WEZ5'-P='9Q:7E/:VE7;$%X
M;E F(WA!.T%C;FEL<7A6:415,#-X5DXY8G503GHV-5!B85 V;U=/0S)E17-,
M8U=96C5*0DXV-T]0<D(K0D)X.4QV,7!I<EAL841Z,$QU238U9%,F(WA!.U-7
M<7)->D(T<E-*,F,K:TDQ8U%04#A)<DE62W-$=#A865EQ<%=B969J23EV9%)3
M3D9.3$AW=7!0<6%H255M:V%B;6MB1F@V:U!"54,F(WA!.SAY3W!967%X-5DO
M4#%T2G!E;#)R>5%8159G47!N:C V939J.4IO56TK<CA74U P=#!#*W$T62]&
M5W!#-'%Y:&]V3U0O049/2S1L=5 F(WA!.VET;VQN;7,Q<VM55&MS2FUU1FY-
M:D-I.$]0;S%&95AA;4MR6F)B>FAA-D9P1G1:3DTQ,41::$QK<6)6;2MT<6E#
M351T3G-90659:TTF(WA!.UAX.4M9<6A.4W0O>D\Y3"]!15<X0T9*5$5P:&ET
M6EAE2TUF=35M17I1279Q;&HV9T(K2&EV16)N1E=3-D9&<DM16$1A=$XV='<Y
M>$LF(WA!.UDP06I616A$:U)"3T$U54M!2#0R3%E&5$Q&6%EQ-T9867$W1EA9
M<3=&6%EQ=W98+T%#;&1A;#5T6%5*8E=/-# P47=W=4-S2FM*57HF(WA!.T4P
M85-R0TUC;$5I0VY-2'919VQ54#5E,%1Z4F\X*VYW5SEU,$9I>G<O<$-+23)O
M:DE7>70T,UHR674K,'E38E)R5FIU5TAD5G%A8C@F(WA!.WAB<4MD=$]K=5E6
M13EY:GE3>%=,2&=L>55I*W%2<S!*4#=T5'HY9&AT=71C5E13,V@X-VI39%)E
M-G588E541D-L9VM-9')S=VE1>4\F(WA!.T9:9W9->49G96-N2&(T4E-M2W!:
M8U%E9F(S5&)A,W4W961:8F0P=4HU63-S5$I)=W5O2EEX15-6:CE31TU30G53
M2VI(>$=+;U-E8C@F(WA!.W=*-RLT9S R8U)854-1+UA(5T=Y;'5V:65C=TI/
M5V5+1W9O.$1*=UDX4V%O2TA&53-U<DQZ:&526$YV4$QC>'DK=D5Y4U%M>5<Q
M16$F(WA!.UAC8D%W5C581E)!0U=%=%)7;T92:7%*,5)F3W)A<E K:C-:3&17
M-5%C=G$S,59O;&@U0D=Q1&-I6C=G8U-F<T--,4AX6493,F%(.# F(WA!.U)D
M1C0W<%-H=&YD659H=%1#2FYI9&=H;%HP;#52>6M);$5+;%%#>"LQ:%9M9&Y(
M3D9A>%)Z>71037%G4U1/141-,4YY46=69G5'0E8F(WA!.V)&6%EQ-T9867$W
M1EA9<3=&57,X>'!D='!Q9E905CED8FTP4#=K=4<T9E=9+U5R=S-+*VYY-4$W
M538T<6Q/=F$O=T-:8EA58G5X,'DF(WA!.WEI=5AG=#%V16M94TU04V8Y,$DR
M5TUL>DE*5F%4-%8K2D)X035B-%91:S-M4'IL2&]D=F-V6E)R975L>7I'2WIV
M8FA*2DEI0D)%25 F(WA!.S-5.%!Q9VXT-4YH5#-'2W-L,%<T,4LT=$I*8CE&
M:FQ-.#9X4G)',%)%56-R2D=71',U2EI6-6-T9V$Y34-O+T9867$W1EA9<3=&
M6%DF(WA!.W$W1EA9<3=&6%EQ-T9867$W1E9+-FHY4S%M:G%W-6]Y,5)M5G1W
M4CA,2U%W4&=1831Q>&)Y+V8K641Q=6U7=#=B6% Q9$Y,:%=785$F(WA!.U-G
M9E='4EAL:VQ,2G=:=5-H04,O3E1Y*T=J5D)646TX>&5F,5-D53!735-12WA7
M9&A)635$1"LV;%I5471)3U5R0U-.4E5T1T-".%8F(WA!.TU653E*.'@K9G)R
M56)A,W9D3W0T-U=25T4P<5$S,&)-2U!35TYP53129U5!.4]7:FLY3FE$:7%R
M-5DQ=GI7>C9,6F%J87E+<W-*4SDF(WA!.TPR='E:565/1W%'4S5:=E(K3VQ3
M,C4U2&IX0D)/2W,P=TLW1EA9<3=&6%EQ;#$Y93,X5W(V8F%W4F,W835-=C%T
M+U-K64EQ4FQL4'$F(WA!.W(K-U0T-D-J9F$W9$U64C5:9V%"0V9C52]I8U9D
M>F(K4G8X06AF-C1Q-VTS.&IF.$PO6$988S(O:V(O:&8V-'$W;3,X:F8X04,O
M,7@F(WA!.U9A2T)Y-&E03F=&6G9H<5%+:T-T93%4:7$W;3,X:F8X3"]81EAC
M,B]K8B]H9C8T<3=M,SAJ9CA!0R\Q>%8S3G8U1R\T6"MU2W4U="\F(WA!.TDS
M+T,O=T)C5F1Z8BM2=BM&+W)I<EE9:S=Q4C=M;CA$:7)E2W5X5C)+;U16<C)7
M># V93=H=#)U<%EL<71V1TA,3V%G54%26D<O-%@F(WA!.T955'EA9U!%;6\S
M<%1B-WE-5F1Z8BM2=BM&+W)I<G5B9GE.+W=V.$%81EAC,B]K8B]H9C8T<3=M
M,SAJ9CA,+UA&6&,R+VMB+T%)6"LF(WA!.W5+=35T+TDS+T,O,7A6,TYV-4<O
M-%@K=4MU-70O23,O04%V.6-69'IB*U)V*T8O<FER=6)F>4XO=W8X05A&6&,R
M+VMB+VAF-C1Q-VTF(WA!.S,X:F8X3"]81EAC,B]K8B]!25@K=4MR<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F0F(WA!.VER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U95-'!(
M95-:5W!33G=Q,$<O,E9B9F8O04-S5E9-5F1I<G-69&ER<U9D:7(F(WA!.W-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7%1,G5S87DQ+W!T<F-7<D)B9S-9=34F(WA!.U5T-65#0T9Y<T(U
M;'5-66M64V0K4D\Q0E$Q>%900WI!,$-%*S1P+T4T<7=N.'I0>DU0:VE,5#5$
M<&AV+T%+*S!Q,$TT:#1E:T906DHF(WA!.V$Q-2LR5U%H>$U:4W!G4V8X-4PK
M;7IV+T%)8W(V<F,V9EAE;$9#52\S;B]Y8W,X1'I994LY;#!,5FTQ6%$Y3S%4
M-G599G(Y=$1D96PF(WA!.WE$8U!7:D0X95AW,7!Y<%=G>6=I:E191&%/-70O
M23,O04%V.6-#6&,R+VMB+VAF-C1Q-VTS.&IF.$PO6$988S(O:V(O04E8*W5+
M=34F(WA!.W0O23,O0R\Q>%8S3G8U1R\T6"MU2V]#9GI$;W1V8G)C5#-T=D9B
M=5-%;65E1E5*5G5$55EV5%HO:%!V=&EQ<F%A=' Y-'A3,'5)<F@F(WA!.V=I
M4VQ9<$DS4'!Y:FQ'.499+T,T,U4Y.%9265EK-W%2-VUN.$1I<F5+=7A6,DMP
M6'%D>C5G:6IV4'%&<6QX24)(.5)Q5D%,1W9Q97 F(WA!.WEK5%ED<55X5DUQ
M>55'=W)497!P=CEX>%8Q6F8U5B\T22\P>%8Q6F8U5B\T22\P>%8Q6F8U5B\T
M22\P>%8Q6F8U5B\T22\P>%8Q6F8F(WA!.S56+S1)+S!X5C%:9C56+S1)+S!X
M5C%:9C56+S1)+S!X5C%:9C56+S1)+S!X5C%:9C56+S1)+S!X5C%:9C56+S1)
M+S!X5C%:9C56+S0F(WA!.TDO,'A6,5IF-58O-$DO,'A6,5IF-58O-$DO,'A6
M9&ER<U9E22]W1$]49CA!=DPU92]W0F4V+U9&;"M$<3%:6&A$145,5'%"42]F
M6$TF(WA!.VAP9EI(:U O04I18GDW+S)Z3% O04MH,'I#;GI,;%(U2C=K56]4
M5DY5=$Y-=$=U-W8Q4%)3=DEX4GE3='-#9G-X<7@W9&-696%.*V4F(WA!.W=K
M=%1C5V5G4$]5:$9X3D,Q,T%K<U-'47AF=D5!6F<S269:<%=G2BMZ>$Q';&5G
M84)R3C5Q<7EZ=EI#0WA:65I,0SA755-*8WAY>&@F(WA!.WDV<E)(44M4>"M.
M450T1$%Q8EEQ>&)Z>#5X,&)Y*W1V1G%P;FIT-3!A-65E,UEO>4Q$8S(P0496
M2VLX-7)Y2F%6<'@U5C)'2W9)-V<F(WA!.R]L8VQZ33!T,7)&.4).1&-X5$<U
M:6EG:&-O-UAJ1T]+5T]#:&Q#36EY;V]64U9&45--2TAO6#5E*UDO3'IZ,FUN
M,DYL4#E9;&=70G0F(WA!.U9U9E%A-&U%1G9&4$=S:VM7-W%Q5&Q64%0T9'1I
M1&EL-DAG5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8F(WA!.S)+=7A6,DMU>%8T:B]W035.+S=Y*UAV.64V+U9&;"M$<3%:6&<R
M6DQ3*WEV268X07EG,VPS+W1M5V8X03%$<&U$4&U82VIY5#-)<%DF(WA!.TYR
M+VU8>B]:*UI*<DA2=$,O4V1S>%%13DIY9V=64%15<S=82D)7<&0S0EAC+T%.
M=FER:%9,3&I74'IF1C%+,&9L=3!%,W%7-6EE<V(F(WA!.TEO350K<V=M.55/
M-$UP4F95-$M6575E3%5P:7%).'5E65!Z5&TQ-U-B5%=T1E<R,#):6$8W8V]Q
M9T-I,TQ":45K;45E-E<V:&57+THF(WA!.W9A:7(P5$%Q1W9D3# R*TU:=F)3
M1S9-3$)O5$Y':VY"9U%W2SAG84AK;T\S9TU66'II07E23$I%2$QK;W)%03 R
M-45B-S<X8U9C3$LF(WA!.WI%.&1W24DO<D53=$A&3G=8;7%0>#5+<E5Q03-P
M<E5E=SA-5E9S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&DF(WA!.W)S5F1I<G-646MW=B]W0DM7<&I0*V=E;$XY6DAW+S-L62]3-B]&
M,#4Y3G9(=&EQ2DIK<G-!4C=K:BM'2W9%=BMC;5,S,5AY+WE!2'@F(WA!.S-8
M43$W4F5W>2]",6%S<G=F36QP9EI(:U%Y9C1(.'4P554O4FQN,U O3$]N=&U$
M4&U82VIY5#)S=CAQ+SA%9C9:1DQQ>2]Y<B]W044F(WA!.V8V67%P3$QC1S9E
M3VEE;7%+,4MM=%=,1'(T9D0T67%Q,6PO;%@O9VHO5$985FPO;%@O9VHO5$96
M<VMJ;VI/>6EI:7 S4#E-:D]1:4,F(WA!.U0P4T):<$%4-FY'6F)F-&5K:%!8
M+VET+V)-56$V2&TR*T)*1U%84FY"2TM+1%DQ4#EM6%EC,&-G,EE49UDX,5E&
M-C=G065X<B]$3&TF(WA!.T1E2W5X5C)+<48X,31T<U=S,%8U*U-55BMN175/
M9F1F,DLP,RLO<&EQ<WAF.6M!+TTP+V=C5F%R3"]+=B]"2"MM2W5R3"]+=B]"
M2"LF(WA!.VU+=7),+TMV+T)(*VU+=7),+TMV+T)(*VU+=7),+TMV+T)(*VU+
M=7),+TMV+T)(*VU+=7),+TMV+T)(*VU+=7),+TMV+T)(*VU+=7(F(WA!.TPO
M2W8O0D@K;4MU<DPO2W8O0D@K;4MU<DPO2W8O0D@K;4MU<DPO2W8O0D@K;4MU
M<DPO2W8O0D@K;4MR<U9D:7)X2"]N2G8X03-L.'8F(WA!.V8V.3$K<4Q,.$A6
M<7EV0G-Y5VPY;&51+RM51SAU+SA!8DUS+RMO9$UW6CAY-55E4V4U1DM(=C5(
M:G1Y>4AI,5)U37AD6$UX:%EB8TDF(WA!.T)L=6LV,V1Z.6%K4'%'=D)0,79M
M<R]--4LU=50T8V(U2GI9=3<R>7,U<3%4=69N;3 P<WI+04IC6$M!2F)+*UI,
M5W!89BLX,'8K<6,F(WA!.W Q2#DR9F-Z>"]51U!Y<7AK:6]+:%=*63=B1&E2
M+TA.0T]R;FQ..4LO=350;5 Q6G1/>B]!2U,T=6\U:$A:<TA(9&ER<U9D:7)S
M5F0F(WA!.VER<U956C)C4S(T5FEO85%H=TMB:F=X<'5$,TAB1E9B1EA9<3=&
M56LQ+WIN-6,P1U,R:#%'.%),:3=U24Q32S-1:#5F575'-'AL:T@F(WA!.WA+
M;7AQ>#)X5DET3B].,WDW<4XQ2&)7,6YF;5-A0V$T="M52T0Q4F)H:3AC63E4
M:SAT54LK;6],8W1I0E)Q2W-Y<W)K6%9N0F1#2U,F(WA!.T54>'!+25IL2U-P
M>E5.>&M1+UI95F]2,D]+<3)+=7A6,DMU>%8R2W5X5C)+=D5F*V-M+SDU9DPS
M*W9D9G%I>2]",6%S<G=B36QP9EHF(WA!.UAK4"]!2E%B>3<O,GI,4"]!2V@P
M>D)N>DQL4C5*-VM5;UA5=CDU5#AX;4AR=C=T=7=F56LO1F582V<U57!Y-S X
M33 Q=5EN3VYF-WDF(WA!.W(X>BMV3C-O=C=S3T9M*W!%-6Q.4VQD+S=Z4R\V
M<'EN568S6CEZ4$@Y45-43D$U-EIA5B]D>69-9G%Z83EN+U-81C%(34DW3F<T
M-W,F(WA!.U9D:7)S5F1I<G-667HK6G8O:W9T9B\U9W!F,5I/2#%"1754-4%8
M-TPO3"M)>DUC65!94"MC868K56HQ9B]M1%@O:S9-<'HX;7I%*V@F(WA!.V-X
M;352=EI,:4]Z;FMT:T5T>6MB=$1%96I/1DI693-5-'$X=VPQ6#AX.5HP-E)8
M.&Y7;"MB6DEM9W4Y5$%T,V5622]5-7)B4W)Y-4PF(WA!.TM!47!+0W4S261C
M2V]33S$O36$Q=3E+8E0O2T]M=W)%3&9L2UE);$U*-3!K6F%804M&:$I-5T,Q
M-&UH*TQK4T9$3B])5V]E9$QU,G4F(WA!.S$X,3(P9'9E4DY&>$5+36M93'A"
M;E)'670V9U=O<7=.3U))-UE%<W!X5DIV36YM9E(Y16II5%5B>C9I8G-/<U9X
M>$1#36II9V,Q1$0F(WA!.RLX;%)61D16;4%P:7)Y2%4W5'EL9&5A-S(O8GIX
M2&5G<F-V93)Q4G1*145I9V%A4EIP-$A(0GI"8E-,468W<E8K0W%A-%946'ET
M<D@F(WA!.S5C955O24IR<2]N=3=M,&$U4S!U5W1,;4)O;UAI1GA/:W=Q56-X
M.$AQ-R]%2T92.6UM2W99<T-S63!B4G9.3G)C-F%B>3=383-T+U@F(WA!.RMT
M9S-.>$EZ1U)&0U4U2V=E:F]7+V5B3'E)03)"=W%Y56U3=7="2'534#191F5*
M9C@U36QV<79L+VM!4&IU=6AR,FDY:&PK1'$Q6E@F(WA!.V<K6DQ3*WE026AK
M+W=0-61O;W K:DQ0=68K5V108DU'9DUU5DAK;G1:9C56+W=#0U Y36EL0S9I
M6"MR1V]!1E(P3F8T6F@V-RLW8G,F(WA!.T@Q2EAM;6-X3F103"]65F]!4E4Y
M5%1V.',S96DO=7<T5V(V:U176"M69CA!9VHO5$UP<55R;WEF5C5+<4MC5#-0
M.4UP,4@Y,F9C>G@F(WA!.R]516UZ44]E;4]L;"]49FE!9'@Q3E T2$YR,F8Y
M2F-856-W:F=8<G5!0C='=CA-,D1J=#1Q-T9867%K,G R+VUH-6)V.4@S345C
M56LF(WA!.V%,83@Y;6IK0G$W;CDS2GEQ4$@X2V)Q<'934V<S1F%B,49D+W9'
M2W-:+TTP4V8X04MV.$%8-G-+9E5P97@X4&YK-&951TUU5#5!>DXF(WA!.V-:
M-T0O=T$T,3AV.%)A=GA)2"MH<C%&9CDR:C-'55HK5&)I9E%L2F8U;"\T12\Q
M>D=B;E5L+VU8+V=4+T%&>%8Q2F8U;"\T12]W0F,F(WA!.U95<EHW:5)'6C)3
M;V0Q1D9),E9I;R]A4&AI<7)36"M:9BM"4#EC5F136"M:9BM"4#EC5E-N>D(U
M5#!4>D1(0DAR3G)(95(R-VE32D<F(WA!.SE25G%'5C9-161E4SAO,5!&<6I9
M67%P,V9L4'ER23A*=4Y*<VYA<&IH+S!65%1K2VMB1%E55'9I<6QD95%02T8Q
M06M%,FM76FIJ:DTF(WA!.U5F1TQG>7AS=D)L1$M1,4=86G0Y>#%X5E V4R]Z
M3"]W2B]R:7$W1EA9<3A2+W=#8VTO.$%E6'DY+W(S6#9O<W9W9%=R2SA'>DIA
M6#(F(WA!.U8U1"]!3U5'.'4O.7-Y>B]!3V]D37=:.'DU5653935&2T8Q3"]E
M52]-6F@V-RLW8G-(,4I4;6UC>$XY3R]W0C56*UHO6&TW,%@Y,D@F(WA!.T-Z
M9E5I8WEM<%-U+SDU<&8Y5354<5 W<RLU;FHK;TI*;6=C.4UT2R]U-5!M4#%:
M=&5Z+W!,:39J;45D;7=C9#)+=7A6,DMU>%8R2W,F(WA!.UHO33,O=T%L.7(O
M+T%$0E,O<7EC4'%#2F-N>#EM831R,DPO;D=N+VQ).5@O04]93F8K5&]Y:E!Y
M8F-4-D9Z1V)N67%L97$O-S!,+W$F(WA!.T0Y6GI582\V>#=V,75:<"]P4RM"
M2%)#2'!8:WA&1%A:;4I(665/655I,T)K568X061P.&@K<D]I:#E)9&1,;75Y
M4T9K-T996D=";U$F(WA!.W!)4'5";&55:U%*2&-Y9TQ)4U-A-W9#.$I$1G5$
M,5!464975W4O>GI4:E9:3SEZ1&EJ,TDO5#=I85=6:$DS24)A:C<X>3E(;6Y/
M4D(F(WA!.U!2<7I104=Y4'I9=4TW1EA9<3A2+W=#8VTO.$%E6'DY+W(S6#9O
M<W9W9%=R2SA'>DIA6#)6-40O04]51SAU+SES>7HO04]O9$UW6C@F(WA!.WDU
M5653935&2T8Q3"]E52]-6F@V-RLW8G-(,4I4;6UC>$XY3R]W0C56*UHO6&TW
M,%@Y,DA#>F95:6-Y;7!3=2\Y-7!F.54U5'%0-W,F(WA!.RLU;FHK;TI*;6=C
M.4UT2R]U-5!M4#%:=&5Z+W!,:39J;45D;7=C9#)+=7A6,DMU>%8R2W-:+TTS
M+W=!;#ER+R]!1$)3+W%Y8U!Q0THF(WA!.V-N>#EM831R,DPO;D=N+VQ).5@O
M04]93F8K5&]Y:E!Y8F-4-D9Z1V)N67%L97$O-S!,+W%$.5IZ56$O-G@W=C%U
M6G O<%%E64QC;C F(WA!.V8Y,FYY2#9S-D](,&@Q,'5A-TI)53=N+T%(;FPO
M=T)2=C%:5FTK:5AU3$M(,4)).#4Y,D-.,'(K*V8X03%F-&I-+W,O-FHW;6I5
M8VLF(WA!.WIZ8D]);%8U<"MQ>38Y63-K3GIW,"M"5T9X0GID95)+=5 W<T1G
M.5-Y+V%0=SAD=75+<&U22EA99T0S0E X8U998BM9,S5A>&5D-'(F(WA!.T-/
M-'8R<W9Q3%-S<&II1#AV5D-G,7%W-F--;D-F0WAL1S)%9CE#>39F+S%F<'8X
M07!(6"]!2G)Y>GAZ,TU00T0Q>E).3&)3=$9S3DPF(WA!.U-54W!95S!.<7-P
M5VA947AH07A!8F%V2$M38DQ906IA4R]Z3"]W04-F-C1%<&9Q,2]P='-Q4F%H
M<49T6FU133A9;619>7=J,UEJ;7<F(WA!.W%&-S56;7AE2D=M54HX2G1!=S-7
M9WIX=$Q$<D9P3$5O9&UD2DDR54-,:C9H2D0O<V,Q-65&4C0U:69Y94\Y=2]-
M2'545%0U8F0T4W0F(WA!.W)D4EA#>&MC;6I)86Y.4DET94Q(<6IH:#=%2$UZ
M1&DT23A,5$]816)25DIF-6PO-$4O,7EX:71L:FMK:EI#-$%957)X4#EC:$](
M1D4F(WA!.VIV5$4P8E%8-DI0*R]V.$%H9C=C=W8U4&HS="\U9SEY2G1R5C1&
M64-13GE.9#$O='I*=UE":D)!3%AK>6-3=4$Y9'E#4%E5+VIL-U<F(WA!.S-I
M<G-69&EQ0S%I3%9*8D-23DQM4T,X2DA#4C9507)V,5=19% X:S1Q:39354AX
M3%=N>$=H;U0W8C1Q;'9M4%)$<F5H6#)K4U0K:6PF(WA!.SE#,$Q3<6Y)<4=&
M2V=&<TU44G1"1G9+4"MH6F10+S9V,#,O4T]V.$%Z6&PS:FYU82]#1$QF>3<O
M04-M="]*5V]85C5"<50S:EA546@F(WA!.TM0145#9TU'<G,U.$UH4$IX36]W
M<&YL2F8U;"\T12\Q>71M-FMV.$%-=CA!=THO<FEQ4S9N<6UG4C-,<&5A>%HR
M,#!.16QI:VQJ4FPF(WA!.TI"8T)G>F=G;&0O;&U,;C!O>4<W8EE:9455,'-M
M:G-9,5A63%IM;$UA>$%/:$Q'56-O=W9X-SAX=79J,GEN*U1X,W,O>D(W:S)T
M<%8F(WA!.VUT-'!R96%/84-243!5<69%<DM2<WES1V]18WIW2T9/3U-Q,&PO
M;5@O9U0O049W<71K:FME3FM,04)G4EAI92\P-4=C94E%9#9184XF(WA!.V],
M.45N+V8S+T,O,C5G+WEF2'9B+W=!=V4U5W1R1F](3$-13E55,U@K,TQS1VQ'
M33)#=VYL-&=I85,O>DPO=THO<FU5,4QS5F1I<D,F(WA!.V)B.'0U8D=-:E1T
M6&QT6DI"1V)H,%%P>6%0;%9G24I)3V]99F$U03E7-6LT8E9U-3AG-C5C;3-%
M=FU39C!94BLX='=*>6MR<3-*6&LF(WA!.TQ83%!Y<4(Y:&Q',W=H8V)63V1&
M.'8V;%E8-UA.>G$P=#=%,%AP:4(O5F]'<$=++TA,274S<&UN=SAV:5!*;7=+
M;FU+<U@X-S)':'4F(WA!.TQ7+S%16$1#2DQI0TU7+W!M9VMG95)Y>7EB5C1W
M+T-E>E4K64E62EE,4'E66D)P2G(V*VAM,48U<'=K<2MO65AK;$)B-&]O<$DP
M16(F(WA!.S)P<'E9<CA*-FI&1$IV2UDP5#9P2V1);6QM:"]C<3=4239(-$QE
M3EEY3V%2,4120E=Q3FI88D%L1&5F=$\P9E5D2W0W5%9B*T]W:&4F(WA!.S54
M,&UK04EK;$MS<4I1;&1U5%9.1#!(5F9T0D-S3V=J.&\R5W,V:3!U;W)9=S9C
M0D$Y=5E%-"]U.5).,WI8,%I*1T%6;R]4061&-G$F(WA!.U(Y<%%3:$YD1790
M2RMI,TYX<55E;TYE17AY3S-P5W-Q8VMM:F=M:DQ3;C1#>DML87-2>5IJ,$Y2
M:7%886)A*U@S36$R;7981F\P<5$F(WA!.W=2;4<S=6)C;&A#3&5.5VUJ64DY
M2%1K<6AQ0VI$9F5I<DEF2T9V<59Z<68V5&HQ539H;V%W9E8T5V0W<%I8;%)9
M;S):-%IA4F=";VTF(WA!.UE.=7A,2&9&3$UC0W5X5C)+=7A6,DMS8S$O>5I"
M<D=Q>&%K,3 P13EU:U,R+T)%8FDP8VI/5S5%8W9I1%5O0T(S4$MG;U912CAK
M95DF(WA!.V92;6I8>DQC23!Q8U5L6#9Y5VE02W19*V0P-#-'>#4X:B]+5GA6
M8F(K43E:9W140D@U:75!>DYZ95=K-$QU=V9K>D)B9T1L>69K3T@F(WA!.T56
M2'AH.&)6;65"6%EQ=U!Z4'!V;&E(5G(S-C1,,%A';T-.-7!91$120DI"4$1Y
M478X4SA)-&Y:9T]P-"]A3S)&0S,P4$DY<&57,7,F(WA!.S)O6%IU=$\K<C)Y
M:C!P2#E1,CAX-%(X;&<T=7I3:F8P.7IX,C9.:7)-3D17>5A2<DIB1C)K<VA#
M9W0U2D%68W@X4GA,06A31%1X07<F(WA!.TI795ET1VDQ;E)R:E1:<%1$1F-C
M4%5K54)I1E(Q8S!$9D1U1G!V.$%J:7)!=CA&*UAR3%9O;S$Q84="3'%Y:TAP
M<&%(,%=34WIK:$TF(WA!.W8Q;FMY<7)+<GEC5V8T-F0V5G=O5'94-T1Y-7 Q
M*TY1:S%Y>DI3-VYN*S%%;C)L9$A2;4UH*TI48TQY8C)157A3;'-M;&58-VTV
M.4LF(WA!.WDX>E$R1C!P93)I5TTK:&-+>'5P2D]%9C<R3BM"379#:6EJ14$Q
M-UEO5%!29$]V;#AZ4FTS,3E.43 V,6IE4U<S3C%,3F-F=BM44DLF(WA!.SAF
M3F\K05=137)T5FI153(V2U=:649D:7)S5F1I<G-69&EQ;F-7='1C<#9D>$-K
M>6(O1$EO8V)Q5D]X<C%6:5!K8U955'!/;&Q&:DXF(WA!.VY!63!14F]N<'!1
M26]:46]&3FQ!9&A4,T]+<4]I-D)P1VE7,&QT<&QV.5AH;&M-,&DX;F-L,D%"
M2EIY>F1&2&9&564V231!9%%W0D0F(WA!.T%%5C-"<40Y0GA6:E=P,G1R8C8Y
M16DV3&)Y,DXV:VIA;F-R6FU6,RM&;DE:,$(O86EJ*T9G4S5)<'5-2V]+.&QU
M3&93=$]U0C56=#<F(WA!.RLX3G0V;'A%<U)I.4IY231J2$=V<%1K5E4P-&MJ
M-%8W,'A65SAT,U=H95E0,&AA=&]T<DAB5TUI>$941W-I1C9U4VI+,%-+2%-T
M4T8F(WA!.TQ$-'1J=FER2TQ7>G1,4TUX,G-%9'9'>DTW2D5Q;T,W1W)-46]'
M-5!5-$968U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<4AU3E!S3&DF(WA!.U):
M3&DR:6UK47%Y4$EI<W=-6DI19VM(9%-X<#16>%9$86PU8S!057)A5S)V3$M+
M4TM9,6LT:C S2C5&-C@P-'5$>5IJ<V4U.%1I<4TF(WA!.W,W4S)S-U-','1K
M159T8F]S54U9<E)545558C<Y0FER9'AB=UA-16QV8U)R3D)+<%-72G='5FQ/
M>$1!-T59<7A0>EAO,VQB4W)3>C$F(WA!.UHY2FIN:S S:$9:2C9J=U)X<6I'
M5E%E3E8K,'4Q5E!*:4(S=W%G>EDK4V1,,'956C1D3%IB1WEM5#!M<W U1$I*
M.6%J9VM,>'0V:V8F(WA!.TAQ;S)F;U!E;4M(85,O:V$T,6%(5&]D2FUT-W4T
M;6%F:$LV:FI.8D=48V]*,F%G-'11<7!4=%=U=U9:5'!8;'92=$IM96%W9V%+
M4U(F(WA!.T9I9&UL;&MQ:V1E02]E33,R83!(='0P1T)+6C1Q-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T8F(WA!.UA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T951"]!3&<O,'HO>#8O<'(P=CA!:78V
M,39.4B]Z,#16*VI&561I<B]!4"]:/"]X;7!'26UG.FEM86=E/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E
M240^>&UP+FEI9#I$1# T,CA",D,Y0CE%-S$Q0C-&-$-&-S<V,T8W,#)%.3PO
M>&UP34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^
M>&UP+F1I9#I$1# T,CA",D,Y0CE%-S$Q0C-&-$-&-S<V,T8W,#)%.3PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD
M:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @
M(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#I$
M0S T,CA",D,Y0CE%-S$Q0C-&-$-&-S<V,T8W,#)%.3PO<W12968Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#I$
M0S T,CA",D,Y0CE%-S$Q0C-&-$-&-S<V,T8W,#)%.3PO<W12968Z9&]C=6UE
M;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU
M=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I
M;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @
M(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O
M<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D1#,#0R.$(R
M0SE".44W,3%",T8T0T8W-S8S1C<P,D4Y/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$W+3$P+3(U5#$T.C(U
M.C,P+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#I$1# T,CA",D,Y0CE%-S$Q0C-&-$-&
M-S<V,T8W,#)%.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C Q-RTQ,"TR-50Q-#HR-3HS-BTP-SHP,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T
M;W(](FAT=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @
M(" @(" @(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL
M=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @
M(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(
M87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N
M8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @
M(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @
M(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*
M(" @(" @(" @(" @/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @
M(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @
M(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&
M;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$YA;64^0V5N='5R>4=O=&AI8SPO<W1&;G0Z9F]N
M=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D-E
M;G1U<GD@1V]T:&EC/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T
M1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO
M;E-T<FEN9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP
M;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^
M0T5.5%5264<N4$9".R!#14Y455)91RYP9FT\+W-T1FYT.F9O;G1&:6QE3F%M
M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$YA;64^0V5N='5R>4=O=&AI8RU";VQD/"]S=$9N
M=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI
M;'D^0V5N='5R>2!';W1H:6,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF;VYT1F%C
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@5'EP
M93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV
M97)S:6]N4W1R:6YG/E9E<G-I;VX@,BXS-3PO<W1&;G0Z=F5R<VEO;E-T<FEN
M9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO
M<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=$9I;&5.86UE/D=/5$A)0T(N5%1&/"]S=$9N=#IF;VYT1FEL94YA;64^"B @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^
M"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L
M871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L
M;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%10
M9SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O
M=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO
M>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R
M;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z
M4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E
M<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N
M9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_  !$( 2X"-0,!$0 "$0$#$0'_Q  ?  $  @(" P$!
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ML)XC08W5>AL!>&V.(&=[.U2!V""&AHU"F&QY!$G(H2Z7G,T;+G(=K:$MLUC
MYBK<C)1C1V7<9# F9AVW>985JV*Y)-K/*^Y7MA.Q9[.GKVVEB#^)36JL$F<Z
M/WDD)MKHLVCD\ATK .D)[&I.2L+N!C><;#Y&5#Q65]N@L8;W2<R%C+U#(Y&-
MO2:SCH\9)S2OG=(3LF[-??J/"+;]6.R$;'#^D=Z:Z<2!N26BI":1>,+AI&L,
M&N"ZHWM.$S29H1,JX&LW3EB/V)W-</,FZK1'')]A=K26E=^OHF)Z'L[RZ9=1
M%^%;<,TVZ&V:YFD4F4?<1C<6T8Z(=RD?#!Z.8$5/Y.(#1AKC$3Q>[@M"Q@MF
M(D3I^AA9P]S16:EY!TCA]B:E+4NKM"<\S6LD4MXBQ0*6R&%Q'6FV-P&(5BQO
M/\]7@XV^&PA<D/0,,19<C+9=#VQ61+!G;(QE%(AG)I2W&$!CMR&1P*C>MI:4
ML-/?3)%[]^\S/1C?^MYB0UBTC[\@\9[>CTM.P<TH.68C'KN#.!Z$FB)!-]DV
M+!9N+Q=O5W,9*BVCY!.-RI%Q9%['R#5))VO"6_LTZL1.9CC7$?KD$-GI1Q:1
M/&T$V$/U-@D("J%G\WV41'AGB4-UZ-8K+/Y*7;NSC<(0OBW:,1IAB=1?/$&D
M?-/6*5VG=;*T&(&\3,=LK(QTY@&SM326/P:2;(;1;8(J+V)2J'1%%%:1DX@6
MADPF,0,N@_6QR90'WF;'QERHQ8D+:-':;FDKI-.V7>PD^J>;CF)SI[;;'=$7
M0FP*'3F-Q0LU&$XF9FHT,'M,P99@F09GP0MF?*G6HI1-7#%/*3BXZ\=XY)O!
M[-X,7;/UC4LZ>H)S[]^]Q;-0HH!0"@% * 4 H!0"@% 4!Q,Z\-[1U:A#P(IF
M:=*;5T!(B U^LQ19N(U"-]:VFTONX[1S3:.$T(I'C+CJ.=\U"-TK,&Z*[ARD
MBI58^A]3(^U=:(_H[51_0\IENM8T#'JZ!)W=377+]HL-:$M=&"9"^4CU:18=
M(B0+QBSEQ<]KTN@B[S!"E"<,**-V 6+J/3MUY].GC_<*S5FT=\V&Q%6E=&[(
M=<-VZ==(AFV4KF7$/LN?@&%RXO%%W%Y)Q,.-D"7RC[)W9FU5<1%3 AFR<K).
MT%K]161P>VNA532B3S275(1*::1('4,V*KQ-!Y;#]4FM;L;R5UGMC9C38,8=
MZ[W)KQI"B@N/-"FO&A?O$ZV<S/Y1A)D?)0H0YC80&Y'H[ /!,TH^^3LE.>B5
MJ>O"6GH&?#M4L-?3+.?IQ./IF,VUPDDH''Q,K/L-C;)<WCA4FF$N8%XZ6F^!
M=F),KH.&@T_<=FX5"J$,4!;M^DD,*/Q0]\Y*,XKHM7:@\VOL9C91K78?$Q*<
MR$]@9K1L( ZGV_KP,S/GX5(-C'9!N8"/BI4VJCKV32^*A8Q& 3)RJ/;7EKTO
M(39!FZ=L 2(!'M.SE9?.6*N[]\R4]%C69WRUE(">&XR^C47U:;X5E;&&UH]'
MYKL:0;Y-F-#O@(M9FA(#L<B8S;.&SBKHP,:.5H_#3<!BPT:3>-&A*1Y#QZKI
MU>=_[IK"5NIV2UF*AP4GC.S3GGMZ3=32$$D4)+[]=GV*+)&>[ZD$[CN:3MJZ
MR?QU_"-? VKY:S957)JMF]CQ!O=J[LD[P3;)J9I6251RSQ>;5VLSQW;%VS*H
MWK#-BR#:L0-:UU4:%S08]@S<=Q"@=@Q@*!9PE"6)$I["-JPYV7'R28 +A+F;
M1N.HQ6<L,S)OM0:5@I?!8PC5*5KLMLZ+).3[XD<]EUN-\UHO(J0C>^=>A]^Z
MJA>F%=@L-M3/9\K@FR4)Y!P,1C_UX.G(%&^RA9TVQG#"\3D)4K?"\'BTXL<!
M(#\TKCR2[EJV633G*4IK5AKTW"4IRSN<]?#-W9[+77VY=([6B4D@VN\=N:[C
M/"]J_2AAL)DD4C<_?FX/(96X0)1=M,#(2/.$D&#ULH7&G9#'&KO NW<#C3AX
M#6%OEC5]LV]LKY=B%URL2_M+^NTKS;L5GCX//-W['C;?7Q38>V^ ;7\7UUVT
M*/F0T0UKQ=1$TS*2\K'W#R.N9>?-[%D.:HZ/DCHP*!'!6J)T@Z5(="LN5MD5
MNN'^A--UL.Y_U#CAV)0"2;2;9<.\PW;A-]E3W9,/FD.WICKX8VRV/(7\O?1_
M9(8WLV'N@=XZ?+D1K,Y!(S/,R<81%.W(Q(TF\9JWG7?&E<FI89U)=><G-5MD
M\+<<=6-KZBSQ.GM@Z2?Z;GT U[&Y>M%-3'-6['U9!3UPG5^\DD$3Q<_J<ML\
MZFU?=0E;0NT(")M*P69\238D^V&#T&D(>R<YIO/-3V6RT2S&4I2T*4ET73U9
MR=SC#<>Y]&<146(ZFOKIW+]43>':TCD@FD5+S,T;D,*D8O-256BI W XPT6)
MOA+,5BPG4CYV&)!Z6<#$[-T+Q235N>W;W9;;<,Q>+^(8R+6;R!%EEV&)V"N(
M@3<,E,+NF6)./YAGBS17&]T[KMK+J9H*8Y7PZ3##*U[V]>HK+0:8EH_Q'2?0
MKGA3(:68C'I?766ECV\,)C!U]1)0UR [FEIN BV!S/:"LA7C>3@D'@I*"LA#
M*0*MA;V8JB&^99QE9/G3TRE;.=V'3N)+-*Q6)SWZ&NLF^]^&D]L28Z_=1$RW
M%P^1"1NJ.(X>^S4S=S?2T<)VG(0<DICEAU@HH;'&->O,E+9<Z';?G"W-LNW:
MJ($Y)Z+5KN_KK2&$NGLMW=)A=X:'<O=X8[HPU9(-T #FL8[K<W$(7L7'7DWC
M+N&2272$$=CW:T[US$9"&,I3<L/D0TS+!;T2N("/PB)#KQ9%(G)2G+/BNID:
M3S3Z?[=^F<9 \.\ILA")"/U,$UT\4XGM?[(,1N\[(S25#M=PB)G@;$A.Y0=D
MQP28ER1$DX<8"84Z=#!0EZ,%MGQUP-=E53;>><EUWYNLJ4EAHF[._>9R(UB4
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * _E_M7_W7H#CBX?.&B<\/ ;A]E\2
MAP-.6.M::ZU9Q.P9L[CZ&3_(*&;CV>S8X=LNF-6E\)?=(QDJ"+^Z,]A:G1X*
M.CT9C*3G)N<YZ6GV=.[48PII+?V;%WSFTP^#21OQ.R_92K-/&(%M#ZY@S$A9
MVUR65DD>V#M(^59Y,+*W>IIH#).&7P=J(8M5\G&:**N:K=?!/$R-.B>EMM@]
M"ZNA O2QPMN")!-A7@FU8/M*&Q UIV<R&5%'PE<Z](FQBI?791HN((RX0&PV
M U/(#,0YK79:Z33/#-M3=MCE-2O2[<+K[S%)I)2Z5FMZ.G$V-XQT2N/!SO5!
MVX8N3>.H3J+IW=I?LU<K89C@LXZCGE>_457?.4ZIEG>_09=#?*_KWK%6-.VQ
MJZ_HTE=W01?8;;?&](LTTS(-*YZ[:%SD3SV3L]W.80=@Z8"-201(S%]5L QQ
MYL,R:/=C]FQY6:PJ I1^[_$V^5=N!28PA5).<YX*6>6?5H;&O1W[YF5:5X>7
M\'G.VG:W#],]XL=B[!D&QXI*(-NQ+7UA+J8=7>EHSL,'(-G01(>W#GL7UQ<D
MA0N:.7L;<CV[L&@2&9IO:HK%\:69V3Z<_88N%3=D\+9;>^?66SIW0\EUULK4
MII2+1./ 8QP\[,B,B;PXJ5? !.P-@;7@FPR L+G*R3^7EF+MPPD+U<\1YN+Y
MVC=TNW%YOFHQ"-SGI:W)X6&24I:G.^]R_J69Q'QY640\2+OI<]N=LF?2(6:0
MN= ->[ A15FP?6"S6$2*02.$ICC+!VMDP5("YK'S+(:1>9-,2Z"KL4YBURZN
MG^S*^_?1>4?'HGQ#ZR/:NVR>A3_>4O>:#%:FVR&B\K@PF8#3X.2.)6!/L7LT
M*0.%2I'.QLT&ESM,Q'G"A%JQ,AA;UJ]<LV=LM4Y*<UIS:UWF8VWRF[;G=MZ)
M[D1DEIG?MHA'IH#A\4ML\OQB9\2)_7YB5M,@T=B]H<9B#>+O)8V:N6[B0*QY
MB!;/"@0<79"908<.QZ!H.(ZTZ36I<V6MSGO[R+;)XMSOEWDK[^DME9EM;<^R
MM32*8:I)Z4@NDI(?V&LK,)7 CTLF4Q?:_F.N!8H&VUW)I>*%0QB+G1\R8,'#
M8TT3=LP8Q&-(LUB3E*6).V;>ZYYT.CO+^KSYL&:@ZCT4[+:HX1=U8ZR/[F"O
MN"O1>LY!#(AL/ZWDW!*QT-E*8_)(TJ4F^O8G(6!*\N-C),*/2P.Z:=2CQ /D
M^OB1:UFW\:-)R^-$YWIVZGT&/-32FIV)8<-.<O(?PWRQW 91(8QK2+ZIV#]=
MK5VTH1#9'.Y'-2!UEIPF/* X_MV9YFYD+:%9 IG*&C)2$V,"82B4!/>MRIZ)
M<64Q<5M\[&KL<._65*6BU.]O#KSRWFRT1V'N6528,.*</QK6D:13>JR^1SN?
M:Z(K9J)L5L1[.!"-;R2=N3G62V3;)R_EV<$LU$).54V#D@JBSPDEC/"4]\TB
MVX2[Z#]=!PF104#L%C)6:;)R?WGNZ;#,$G;9Y9>.S39,@D4>>99M55<45'8E
M^U74:*WP<M<\[H.4DEL,\+'V+J12K!S7<.BIAME"+::*[HA^SY^_V=&R\2F.
MOXV9C9V1!0@X_')XSV%)(K;,,V*!<B 22Q5:4/\ $*02#.8RDL#0<%;8Y6RE
M9GVV;^\I=//-SS:.ZWXD><\.^R&W#PHU%/8RUXC ^T9EQ*P]=LLZ4A0/;LHG
M$GG;J$-7BR(]\O"RHF5&]5'2RK=B]+Q\X:-YMF+U]9%NG;HE+HQ[=PE8Y7W]
MYZ+#U]A\*3M316E(6$12G\DTOL$?M8\-)2(G#,MP2DJ&FPO:#UQ* ZS9W'Y+
M+"&QY7- Y#)1(>G*<!HXFJT!N7RZ!16MW34K$G+#J2U"4U;?QOW6+/ISD.9Z
M#)R=2;% G#D3U3BTT]M",1=SM';%YSL,O.9Q'%8^T;QUE'=L;$@$8BEARA!N
M9+'#2YHJY>B<$!(1L,=O'-YUTW.U9K)+H3_MJ,>;?)2L:OG/AWNMEO-JX$_B
M^L]=1DJ@FU*1V"Q$$2:I*)+)-GXB/CQ[Q!-9#+-!5-%PW43P41SR2SQQMDGE
MEA>U[XNUMZ3)6)+03JH44 H!0"@% * 4 H!0"@% * 4 H#&NPXA^^%$WPH:]
M) EW3D&0=L6KE\&<OF2XUZX%.UDLUQR[P<Y<L'2K11%1PR<+M5<LT%5$\@,E
M0"@*YVQM*+Z8@A[8\T1D:D7C+1<D=<1B+'I<]&"F;=9X1,/!T=8$'C8.*8MG
M+\J5<)),!S1!19TX3MS+95*=BZTNLC<K2?-'*+UJV>-\KY(.VZ+E#*^-\;Y(
MKIXJIY7QRM;+&]\,\;WQRM:]K^M>W+4*>Q0"@(G(X%!YB_C!66P^,2<G"C&$
MAAY ^"&%WL6/)VQLF9C[I^V76#DT^C3R3?,,T'.&:**F*EE$4LL$P2R@% *
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M$;]'6#<RI2+*J%% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M$NU&JRS1=P.=ME5VBRS1;)1NLHGE4VKF&IDAB,0BL!C@J(0F/!XI%P;>[40
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M4.]$9\1 O*X_TBDG@]C$UBMJ'>B,^(@7E<?Z123P>QB:Q6U#O1&?$0+RN/\
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M2!8= * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@(D$G<.D9L[&P4B&%#L8<9M)"*:+
M](\#N4\\4\T'Z7):[=6V6>%[89WY<L,\%,;73SQRN!+: 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%407V?;M_
M]WQ7_EE#*KN6KM9%>]?8BUZA10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M-*R=^E3Y,OL\>4#(4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MUA%\WT <C!M22EKNM[]\3D>H04 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% <#/U13^ 7
M&?UC-??$S9E;%R8\HQ^JTGO*$XC+7S2#T\'L4AT?:WXU8]]RZ;K-62":"R:C
M1/)/-7-S@K@KTBF:V=\4L6J.27]9GES;755YN')C>^67+G?XP4<<-)2QQ1PQ
M*DB34*@<+AYL*A2<3I(E%8E/XL-MMBL/I%%"X8(5#$G"FFW$FG-MV+FJ5K>=
MV6:3T*^Q\SZDVH_O4ZQ_1["_BV-KJ.F\;2^DC]IF^T?BZ/S(?9185?,S% *
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M $AC(L\'B<UW67-[)[[.[-\J$% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M>!0GBS[8*I,FC9^958-L6C5<DNV12S=*(-\;(M^EOEBV1Y$&]DT;6PL,3)4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MX%Q HIBFGECAB1&#WUL;.6395.JZ+5VHCS:^QE[5"B@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * KN&R<P:D^T@16PS)"&2\6'#+#VCIHLJ+*0>*2G#$GUDB0P<D&[LZZ;9/
M&N+!NNW2;\@]!3%3-6X:5VM$3M:PEO)XZ=-V2"CITKB@W2M:ZBN?+;'"V66.
M&-[\EKW]?++''[7V[VJ%,-WKCGNNT]]E_)0#O7'/==I[[+^2@."7ZH<."2/
MC&6[%^@Y6MQ$Z_4NFG?*^5D\8=LO'++U\;>M:^6-K_[[5L7)CRC'ZK2>\H3B
M,M?-(/3P>Q2'22K?C5A0"@/J#:EE4>PU7K/'(LUMECKZ&8Y6OEGRVRM'!MKV
MO]A]NU[<E=1TWCJ7TD?M,WVC\71^9#[*+![UQSW7:>^R_DKYF8[UQSW7:>^R
M_DH!WKCGNNT]]E_)0#O7'/==I[[+^2@'>N.>Z[3WV7\E .]<<]UVGOLOY* K
M5UMEVAM(1",!D44BQ.,FY&I*\ID43.-L0BX1@HRQB-H.H/74<$CS/!)6\R0Q
MQ'HNWN>'6$T1SBRLGIEW9)VRT3O[.TLKO7'/==I[[+^2H4=ZXY[KM/?9?R4
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M_%T?F0^RBPJ^9F* 4 H!0"@*H(??RB7Z*-A_&_6%7,]:ZF3.M3ZT6O4** 4
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M-$B"#^V2EU70T$Y,NQ+7/&^=TK8,G,@,JIY8)XJ99/E;*YYXX)63 RE * 4
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M%:ORU^BF7OL^EZX3E,B^5JAZQ!VFI]>1SMP4 H#:F!>Q$+_@+_OCBO5_P?\
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MF@^^]Q2?HW@/QG,UJG*KQ%4]+2>Q"<[D/QE8\R#VHCM^5I1L8H!0"@% * 4
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MG/\ (Y_M85J_+7Z*9>^SZ7KA.4R+Y6J'K$'::GUY'.W!0"@-J8%[$0O^ O\
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M3&O1/P0?1[*'VS3?@:B==<K_ "C5_4H/?U@M2NUS5!0"@% * 4 H!0"@% *
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MV_+:W53US%.#N2["#G&  'PEY00@HI%3Q=:-S@F!T@[P!%PXL60*CBAP;%Y
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M&1X(O(@[(6@XYCEZ4)!VKEZS%MTE"#G%!5-!LHKCT=23MT7E/PCNYM42XNQ
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MV59M+3Q9N%$R,1FL\=P.&:K&"10&.7D*ZAK6NR8U-6)!:,]J@U3D;:6#Y*$
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-C-9G.3RL#(4 H#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g475892g92q50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g92q50.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( $P!/ ,!$0 "$0$#$0'_Q  =   # 0$! 0$! 0          "0H(!P4&
M @,$_\0 21   00" 0," @0("@<) 0  ! $" P4&!P ($1()$Q0A%2(QMA89
M,C<X05=W%R,Y475VE9;6US5"6'&TM;<8)"4F,S125&%B_\0 '0$  00# 0$
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M[R1K6BU@CD:^1L<;C39#+(AJEFD/?*[9^UL?LW;]# XY1X=6,&Q8[0LEV[(
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M^ N>7]CA@O\ >#'_ %=3_7&O=^S)W/\ [I9/ZYR']W]'XWW9O^RD3_>[(/\
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M/6V53<UWQ9LKUBI9V5I);8*PVPL QQR/+U'P_P /S?3I2GCU]#\>/CJF"OL
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M\C=1%R6=R+1SY2\J'N6'Q(XXHJM-'^<E2K%%&6"23F>=1,=/\X33J:7QU>]
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#-?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g475892g99k81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g475892g99k81.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1P84&AO=&]S:&]P(#,N,  X0DE-! 0
M     #H< 5H  QLE1QP"   "   < E  "D=R86-E("!496\< @4 %U!O=V5R
M4&]I;G0@4')E<V5N=&%T:6]N.$))300E       0DN>SIZX0HT7YR^N'1S&X
M6SA"24T$.@     !#0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4    %0!A 'H
M,  Q #4 ,0 M '@ 90!R &\ >  M #$ .  @ $< 3P!/ $0       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q >/            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 ! \     !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _0
M     !( -0    $ +0    8       $X0DE- _<      !P  /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      S4    &              6)
M   (ZP         !                          $             ".L
M  6)                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  6)     %)G:'1L;VYG   (ZP    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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MTE-M0KIJJW>DQK-[B]^T ;G'Z3W1])[OWE7/2\4N+BZ^223&1<!KKP+56?\
M5OIC^H5=1<<C[314^ECOM-\;+"'/D>M_K_UJGTDIU$E3_96+^]?_ .Q%_P#Z
M61L?%JQ]WIEYW1/J6/LX_=]9]FW^RDI,DDDDI22222E*%W\R_P#JG\BFH7?S
M+_ZI_(DI#FW =/R+:LAM!;6\MR2 ]M9#3^E<W\[T_IK*!RA:V.MTAL?I!%9)
M!)U9N+MGOLV_]M_Z+TK=C*/I8EKF5>L6,<YM('TB!.S0.^DL=]%OJMW]#K+
M'.#F6,D$F!3&UGML_P ,S=Z.Q_\ A?TJ2F3,JX,J]/JF/[/4<_<&D/K&UM)N
M?['56>S>]_\ +L_G-B&S(RV.!/6*K*:MK7$-8XN+WMI9OL:'MI_2[F?^?/\
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #
M 0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    "P   +"':0 $     0   +P
M  #H #SA\   )Q  /.'P   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3<Z,3 Z,C4@,30Z,#0Z,3@ 1W)A8V4@(%1E;P    .@ 0 #
M ?__  "@ @ $     0  ".N@ P $     0  !8D         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
M   !   !1@("  0    !              !(     0   $@    !.$))30/]
M       (      $   #_X0%(34T *@    @ " $2  ,    !      $:  4
M   !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R
M  (    4    G $[  (    +    L(=I  0    !    O    .@   /
M 0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHQ
M,#HR-2 Q-#HP-#HQ. !'<F%C92 @5&5O     Z !  ,    !__\  * "  0
M   !   (ZZ #  0    !   %B0         & 0,  P    $ !@   1H !0
M  $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @(
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M(" @(" @(" @(" @(" @(" @"B */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M\0_^ 9PXNN63'R=T]_\ RC<(X?+.?_P<,^!ZQ^[ZP# R19E.(5('K8Q*8B*
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M+0(8=P?IR&'Q3#-S-1=G.1J":@L>_%X#PTG425<'%QK7L@L'U[?Z/-"?N_\
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M X#@. X#@. X#@. X$&U5_*)LS_3%&/[O-&\"<N X#@. X#@. X#@. X#@.
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MM26GL69A>O\ N68&.:S@51D4:,0H'7K6Q@G=[$_83J!/D;.F-I7A@^AU9U-
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M@. X#@. X#@. X#@. X#@. X#@.!!M5?RB;,_P!,48_N\T;P)RX#@. X#@.
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M: Y9RY:X8'(R4QQ(!GO2K57O)F[QZ5QP[PS[Z],^N!,_ <!P' <!P' <!P'
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MP3333QRS4SS[ZQPQQ[RR[ZZZ[[X'S5P+\*P\7%A;>#=3Q#^X6;8]8&-91S8
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M(]3MSB.Z>I?+]8H.4L%%L5 Z)<!P' <!P' <!P' <!P' <!P' <!P' <!P'
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M X#@. X#@.!!M5?RB;,_TQ1C^[S1O G+@. X#@. X#@. X#@. X#@. X#@.
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M;(CWZ#.1L40N#X[!]@BML;I'VO"GU<V2U\;/B[3FT$)6 <M-]$Y%W:7DDS)
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M=6=4IGG6&-<4Y(_HT@C\2^9F("O0]M68#J8-*30VH %B3DZRA;;L3DKV:=@
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M5B0BQOKF9&,Q+8O8*+0^*.9++F4]/OZLB &S!\:J,@5F(]M(7;ZM1<7<]O\
MI;V*8-W3I!8*ES?Q(Z^2>\->PP=V2%TC4E1[2M;%@32_;O%W59,KV9G54'WT
MQFLY$3%.>6'&I:Y@,V'V/W8$T?,Y6J4:CG3$P@@M@/"T[[3O1P';D:8*1N+Q
M>TY:5IVTX1!F,[+1YZ4ZTE%M(Q7!>&0%H?:-LXQ4@R<B!9MD$$?0.\#X-.4-
MW*CD;WD'L?FX].A]L2N^5*\+H3>2FK.EAQVYM.T>H>S*W!#LX5;A09!%YI]@
MHYW8$=Q2[F2@B/C\"Y!@.-ON\R@QB\;AH [Q1:!$(K5@IA5Y4Q$8#!P$*CZ>
M%T7 5$3^L \A<3F)PBU%OQ@.&UY5R$D1%S((O%;.SF$7$JO%>P[!LS<9HYAL
M&P>A48LRE[#H&L7(6O*]V1V 8VMM1T70,RLE-HJ4)AC-F1Z%)$B*X^+%Y_U$
M8Y%\E^D.PD=CKL\[#BD3/;%=,/2IUHV8>47=5BR02:LV6CGC<:-&R&&*:+=L
MVMWR2HH((IX]=8X)(I88)IX8]=8XX8]8]====<#HSP(!V4DFR,4K)<MJI5E9
MW#;&)L2W;PVVK/+5%$50"V:_1HDI, L'L)ZF0888M\F0[J.YI/NU%,5'C7X?
M7>8<\OQY^<C]7WHA^WS8W^4_@/QY^<C]7WHA^WS8W^4_@/QY^<C]7WHA^WQ8
MW^4_@/QY^<C]7WHA^WS8W^4_@?YOGD6W[\OH[RG6V3LBU+YIS9"O[N)Q^OZ>
MK&=SI6'09BU.=HP>(5@!:(AQ\VA9<,J,S%EU8KCU9XXGT=,#W"I]RAD'^BG7
ME_\ GA(P"#D)%X_M(E) ^B$;>'%#.[<_BQ?,PY#,EB696,MM833:.DLGF:^3
MX&W,%4!+KM5@B1>IM\7*H;A^//SD?J^]$/V^;&_RG\!^//SD?J^]$/V^+&_R
MG\!^//SD?J^]$/V^;&_RG\!^//SD?J^]$/V^;&_RG\#?ZKN#R_F;(A(JXM)=
M-H/5A"2"VL_E\,W1G<UE<;BJSG# N7CT2?ZUQEE(BS)KVHLS$NI '1>JXXHJ
M$&V.7:G0=3. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X$&U5_*)LS_3%
M&/[O-&\"<N X'+?R=5SL+8C[Q^_DT/5(]84+WU 35S.WU;&K4A$!CK/5?:X&
M[.6E& 9F,O,:V-E#X> 2(CA*XHY0SF;% -(ADB=!EN!4NY/$!=UVQ1U,K)O>
M@[6V GVT3;9.^8/:- S8KI+;+ )13+7VNZ?*48&NT5-',1I^+APLOA964V7*
MW)>QT"\BDPARB7'L8Z&4J#Q#6W05>0 36=W:]CYQ77D>PWYCXZ/ZO.JLH@:,
MDFM1'6V=TG&JD@EK]+Q0$P#2:2GJ\.M)60=L%6X!E+FLH?\ UR0E M$'\<Q
M5K[3U']VVS66JSR&$-YU9)U"ETTC;)]N?8&V75:)BOM1GFP=)M9OA!>Y9D0>
M)9.!N4B^SV*;KH*W"%H1XQ-@P#6F]<9%M!79S077O8B+;$UK7C"C2XS8\O\
MBUM=6[:@IB>V\XM,C 'U>UW8J0!\M(P-1!YG,0$6$QXBX%9N"AEZ'-6FZSV;
M-W7HUIO W>R*.M.H6X*EAY5+<?C_ )Y3+^GZ8K05;:<9%65NX_L.0Z^WZ#"=
M& L2I1O0@;*0SP8:"2.;.L<XX6SZ"]^KGAND&L]F4P-"R32]37W7F>D)E 9
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M <!P' <!P' <!P' <!P' <!P' <!P' <!P' <"#:J_E$V9_IBC']WFC>!.7
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MV^8027^7=H^[X+I#XF.7P7"7OR^$NG[54_=E[<NO7OU##]Q**]R3J8]QF/\
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MVMC9U 6T0!B:HGH,4Q2=R)\G86)S*/DV(=M/&]_J[]"O^"_5S_D=!N!=#@.
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M X#@. X#@. X#@. X#@.!!M5?RB;,_TQ1C^[S1O G+@. X#@. X#@. X#@.
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MA/'\QGQD?U^67^\O ?CU_">/YC/C(_K\LO\ >7@/QZ_A/'\QGQD?U^67^\O
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M]=8XX]=8XXX]==8XX]=>G77777W====?=UUU]W77W=<#^\!P' <!P' <!P'
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M'??TMB^9)J/&;M]\!NZ:X9N$%,TL<L^@]+NRJYQ!L)-E/X5C&RH]X7&2#N5
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MX:/DKKT2+9*3"XK(BM2U\+[:!]JGSO!,U/)K&PZI!1#$>*2?9DRSED+9O'B
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M9M*HJU-\^47CTFF';8+$P4.E'V^E3:0R& Q\X'4K'R*U0CH1UY"WT/F.50L
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M"=#+KDA35G]33=$ T>(!PRK?P\:9M)^<L!LSN+!<L\VF?C8<O=D_(UK"G.Z
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1P' <!P' <!P' <!P' <#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
